Content type:,Orphan designation,Output automatically generated from content on www.ema.europa.eu on:,21/03/2025 - 09:31,,,,,,
,,,,,,,,,
,,,,,,,,,
,,,,,,,,,
,,,,,,,,,
,,,,,,,,,
,,,,,,,,,
,,,,,,,,,
Medicine name,Related EMA product number,Active substance,Date of designation / refusal,Intended use,EU designation number,Status,First published date,Last updated date,Orphan designation URL
,,Trehalose,19/10/2020,Treatment of neuronal ceroid lipofuscinosis,EU/3/20/2347,Withdrawn,16/02/2021,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2347
,,Humanised IgG4 monoclonal antibody against C1q,10/02/2025,Treatment of Guillain-Barré syndrome,EU/3/23/2836,Positive,24/01/2024,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2836
Enjaymo,EMEA/H/C/005776,sutimlimab,11/02/2025,Treatment of autoimmune haemolytic anaemia,EU/3/16/1609,Positive,06/04/2016,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1609
,,Upifitamab rilsodotin,09/12/2022,Treatment of ovarian cancer,EU/3/22/2723,Withdrawn,13/03/2023,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2723
,,pelabresib monohydrate,17/02/2025,Treatment of myelofibrosis,EU/3/20/2247,Positive,05/05/2020,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2247
,,Adeno-associated viral vector serotype rh10 containing the human cholesterol 24-hydroxylase gene,01/04/2019,Treatment of Huntington’s disease,EU/3/19/2149,Withdrawn,07/05/2019,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2149
,,Ornithine phenylacetate,20/02/2025,Treatment of acute liver failure,EU/3/11/945,Positive,01/02/2012,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-945
Hetronifly,EMEA/H/C/006170,Serplulimab,20/02/2025,Treatment of small cell lung cancer,EU/3/22/2731,Positive,13/03/2023,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2731
,,autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,20/02/2025,Treatment of myasthenia gravis,EU/3/24/3011,Positive,13/01/2025,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3011
Seladelpar Gilead,EMEA/H/C/004692,Seladelpar,20/02/2025,Treatment of primary biliary cholangitis,EU/3/17/1930,Positive,10/01/2018,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1930
,,Magrolimab,26/06/2020,Treatment of myelodysplastic syndromes,EU/3/20/2288,Withdrawn,22/09/2020,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2288
,,Magrolimab,11/11/2015,Treatment of acute myeloid leukaemia,EU/3/15/1582,Withdrawn,06/01/2016,12/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1582
,,Tafasitamab,26/02/2025,Treatment of follicular lymphoma,EU/3/25/3027,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3027
,,Rimeporide,26/02/2025,Treatment of Duchenne muscular dystrophy,EU/3/15/1478,Positive,21/05/2015,11/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1478
,,hydroxocobalamin acetate,26/02/2025,Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing,EU/3/25/3030,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3030
,,Venetoclax,12/12/2017,Treatment of mantle cell lymphoma,EU/3/17/1954,Withdrawn,23/01/2018,11/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1954
,,adeno-associated virus serotype rh.10 containing the human PKP2 gene,26/02/2025,Treatment of arrhythmogenic cardiomyopathy caused by pathogenic mutations in the PKP2 gene,EU/3/25/3033,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3033
,,"(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-hydroxy-6-methylpyridin-2-yl)methanone",26/02/2025,Treatment of Olmsted syndrome,EU/3/25/3032,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3032
,,Venetoclax,14/10/2016,Treatment of diffuse large B-cell lymphoma,EU/3/16/1766,Withdrawn,15/11/2016,11/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1766
,,,26/02/2025,Treatment of  X-linked hypohidrotic ectodermal dysplasia (Christ-Siemens-Touraine Syndrome),EU/3/05/334,Positive,04/12/2007,11/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-334
,,paltusotine,26/02/2025,Treatment of acromegaly,EU/3/25/3035,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3035
,,adeno-associated virus vector serotype SNY001 containing the human PAH gene,26/02/2025,Treatment of hyperphenylalaninaemia,EU/3/25/3026,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3026
,,volixibat potassium,26/02/2025,Treatment of primary sclerosing cholangitis,EU/3/25/3029,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3029
,,epertinib,26/02/2025,Treatment of amyotrophic lateral sclerosis,EU/3/25/3028,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3028
,,Autologous CD34+ cell enriched population containing haematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding the human ADA2 gene,27/02/2025,Treatment of adenosine deaminase 2 deficiency (DADA2),EU/3/25/3034,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3034
,,adeno-associated virus sector serotype rh74 containing the human SGCG gene,27/02/2025,Treatment of limb-girdle muscular dystrophy,EU/3/25/3031,Positive,11/03/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3031
,,Ex-vivo-expanded autologous human corneal epithelium-containing stem cells,07/11/2008,"Corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns",EU/3/08/579,Expired,24/04/2009,07/03/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-579
,,Adeno-associated virus serotype 9 containing the human RPE65 gene,16/01/2025,inherited retinal dystrophy due to defects in the RPE65 gene,EU/3/24/3020,Positive,24/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3020
,,"N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride",10/11/2022,Treatment of biliary tract cancer,EU/3/22/2721,Positive,23/01/2023,24/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2721
,,Arsenic trioxide,13/12/2024,Treatment of acute promyelocytic leukaemia,EU/3/24/3014,Positive,14/01/2025,24/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3014
,,human anti-promyostatin monoclonal antibody (apitegromab),14/12/2018,Treatment of spinal muscular atrophy,EU/3/18/2115,Positive,07/03/2019,24/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2115
,,Lomitapide,17/12/2010,Treatment of familial chylomicronaemia,EU/3/10/823,Positive,20/01/2011,24/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-823
,,Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues,19/07/2021,Treatment of familial chylomicronaemia syndrome,EU/3/21/2459,Positive,12/11/2021,24/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2459
,,Rilzabrutinib,16/01/2025,Treatment of autoimmune haemolytic anaemia,EU/3/24/3019,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3019
,,Clofutriben,16/01/2025,Treatment of Cushing's syndrome of endogenous origin,EU/3/24/3024,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3024
,,xevinapant,11/11/2015,Treatment of ovarian cancer,EU/3/15/1576,Withdrawn,06/01/2016,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1576
,,Adeno-associated virus serotype 5 vector encoding C1-esterase inhibitor,10/11/2022,Treatment of hereditary angioedema,EU/3/22/2722,Withdrawn,23/01/2023,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2722
,,Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel),07/10/2013,Treatment of Wiskott-Aldrich syndrome,EU/3/13/1196,Withdrawn,31/10/2013,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1196
,,amitriptyline,21/06/2022,Treatment of erythromelalgia,EU/3/22/2626,Withdrawn,15/09/2022,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2626
,,Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene,10/08/2015,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/15/1540,Withdrawn,10/08/2015,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1540
,,Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase-alpha gene,24/01/2013,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),EU/3/12/1095,Withdrawn,01/03/2013,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1095
,,Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene,26/03/2014,Treatment of recombination-activating gene 1 deficient severe combined immunodeficiency,EU/3/14/1257,Positive,07/05/2014,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1257
,,zopapogene imadenovec,12/01/2024,Treatment of recurrent respiratory papillomatosis,EU/3/23/2887,Positive,11/04/2024,20/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2887
,,"N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide",16/01/2025,Treatment of glycogen storage disease type IV,EU/3/24/3023,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3023
,,volixibat potassium,16/01/2025,Treatment of primary biliary cholangitis,EU/3/24/3017,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3017
,,Allogenic umbilical cord-derived osteoblast cells,16/01/2025,Treatment of non-traumatic osteonecrosis,EU/3/24/3022,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3022
,,Elraglusib,16/01/2025,Treatment of soft tissue sarcoma,EU/3/24/3016,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3016
,,"[4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl]-amine",16/01/2025,Treatment of gastrointestinal stromal tumours,EU/3/24/3025,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3025
,,Elraglusib,16/01/2025,Treatment of pancreatic cancer,EU/3/24/3015,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3015
,,Alvelestat,16/01/2025,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/24/3018,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3018
,,Camostat mesilate,16/01/2025,Treatment of chronic pancreatitis,EU/3/24/3021,Positive,20/02/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3021
Blenrep,EMEA/H/C/004935,Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F,16/10/2017,Treatment of multiple myeloma,EU/3/17/1925,Positive,08/01/2018,19/02/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1925
,,Colistimethate sodium,13/12/2024,Treatment of cystic fibrosis,EU/3/24/2997,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2997
,,tobevibart,13/12/2024,Treatment of hepatitis delta virus infection,EU/3/24/3012,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3012
,,mitapivat sulfate,13/12/2024,Treatment of sickle cell disease,EU/3/24/2999,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2999
,,"4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid ",22/08/2014,Treatment of acute myeloid leukaemia,EU/3/14/1328,Withdrawn,02/10/2014,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1328
,,Losmapimod,24/03/2020,treatment of facioscapulohumeral muscular dystrophy,EU/3/20/2263,Withdrawn,12/08/2020,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2263
,,"3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid",19/11/2018,Treatment of ATTR amyloidosis,EU/3/18/2081,Withdrawn,19/02/2019,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2081
,,,15/02/2023,Treatment of Huntington's disease,EU/3/23/2754,Withdrawn,24/01/2024,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2754
,,isotretinoin,11/10/2022,Treatment of autosomal recessive congenital ichthyosis,EU/3/22/2701,Withdrawn,24/01/2023,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2701
,,isotretinoin,15/02/2023,Treatment of recessive X-linked ichthyosis,EU/3/23/2760,Withdrawn,24/01/2024,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2760
,,Omigapil maleate,08/05/2008,Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency,EU/3/08/544,Withdrawn,29/07/2008,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-544
,,Omigapil maleate,08/05/2008,Treatment of congenital muscular dystrophy with collagen VI deficiency,EU/3/08/540,Withdrawn,29/07/2008,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-540
,,propagermanium,19/11/2018,Treatment of focal segmental glomerulosclerosis,EU/3/18/2100,Withdrawn,19/02/2019,15/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2100
,,2'-O-4'-C-(S)-Ethyl-P-thioadenylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-P-thioguanylyl-(3'-O->5'-O)-2'-O-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-fluoro-P-thioadenylyl-(3'-O->5'-O)-2'-fluoro-P-thiocytidylyl-(3'-O->5'-O)-2'-fluoro-P-thiouridylyl-(3'-O->5'-O)-2'-O-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-adenosine,13/12/2025,Treatment of autosomal dominant polycystic kidney disease,EU/3/24/3009,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3009
,,monepantel,13/12/2024,Treatment of amyotrophic lateral sclerosis,EU/3/24/3004,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3004
,,allogeneic cardiosphere-derived cells,13/12/2025,Treatment of Duchenne muscular dystrophy,EU/3/24/3003,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3003
,,diazoxide choline,13/12/2024,Treatment of glycogen storage disease type I,EU/3/24/3008,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3008-0
,,"4-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazol-5-amine",13/12/2024,Treatment of neurofibromatosis type 2,EU/3/24/3005,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3005
,,divesiran,13/12/2024,Treatment of polycythaemia vera,EU/3/24/2996,Positive,15/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2996
,,Davunetide,13/12/2024,Treatment of activity-dependent neuroprotective protein (ADNP) syndrome,EU/3/24/3007,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3007
,,roginolisib,13/12/2024,Treatment of uveal melanoma,EU/3/24/3000,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3000
,,Vosoritide,13/12/2024,Treatment of hypochondroplasia,EU/3/24/2998,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2998
,,Felzartamab,13/12/2024,Treatment of in solid organ transplantation,EU/3/24/3002,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3002
,,votoplam,13/12/2024,Treatment of Huntington's disease,EU/3/24/3001,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3001
,,"mRNA encoding Cas9-deaminase, single guide RNA against the human TGM1 gene",13/12/2024,Treatment of autosomal recessive congenital ichthyosis,EU/3/24/3013,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3013
,,elebsiran,13/12/2024,Treatment of hepatitis delta virus infection,EU/3/24/3010,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3010
,,adeno-associated virus serotype 5 containing the human RORA gene,13/12/2024,Treatment of inherited retinal dystrophies due to dysfunction in the ABCA4 gene,EU/3/24/3006,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3006
,,diazoxide choline,13/12/2024,Treatment of glycogen storage disease type I,EU/3/24/3008,Positive,13/01/2025,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3008
,,"[Nle4, D-Phe7]-alfa-melanocyte stimulating hormone (afamelanotide)",08/05/2008,Treatment of erythropoietic protoporphyria,EU/3/08/541,Expired,17/09/2009,09/01/2025,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-541
Emcitate,EMEA/H/C/005220,tiratricol,12/10/2017,Treatment of Allan-Herndon-Dudley syndrome,EU/3/17/1945,Positive,15/01/2018,13/12/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1945
Rytelo,EMEA/H/C/006105,imetelstat sodium,27/07/2020,Treatment of myelodysplastic syndromes,EU/3/20/2305,Positive,19/11/2020,13/12/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2305
,,garadacimab,10/12/2021,Treatment of hereditary angioedema,EU/3/21/2532,Positive,13/04/2022,13/12/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2532
Wainzua,EMEA/H/C/006295,Eplontersen,13/10/2023,Treatment of transthyretin-mediated amyloidosis,EU/3/23/2828,Withdrawn,24/01/2024,03/12/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2828
,,Human monoclonal IgG1 antibody against tissue factor pathway inhibitor,14/10/2016,Treatment of haemophilia A,EU/3/16/1752,Withdrawn,14/11/2016,03/12/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1752
,,pasireotide,08/10/2009,Treatment of acromegaly,EU/3/09/670,Expired,20/10/2009,28/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-670
,,Ketoconazole,23/04/2012,Treatment of Cushing's syndrome,EU/3/12/965,Expired,03/05/2012,28/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-965
,,Avenciguat,11/11/2024,Treatment of systemic sclerosis,EU/3/24/2989,Positive,21/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2989
,,"Curcumin E100, Resveratrol",11/11/2024,Treatment of Dercum disease,EU/3/24/2995,Positive,21/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2995
,,"4-[[(4-Methoxyphenyl)thio]methyl]-N,N-dimethyl-1H-1,2,3-triazole-1-ethanamine",11/11/2024,Treatment of non-syndromic inherited retinal dystrophies with a rod-dominant phenotype,EU/3/24/2993,Positive,21/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2993
,,3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1yl)methanone,11/11/2024,Treatment of fragile X syndrome,EU/3/24/2992,Positive,21/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2992
,,Felzartamab,11/11/2024,Treatment of primary IgA nephropathy,EU/3/24/2994,Positive,21/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2994
,,"H-L-Tryptophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond), acetate salt",10/11/2024,Treatment of amyotrophic lateral sclerosis,EU/3/24/2986,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2986
,,Navenibart,10/11/2024,Treatment of hereditary angioedema,EU/3/24/2979,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2979
,,Genetically modified human adenovirus encoding human PH20 hyaluronidase,10/11/2024,Treatment of retinoblastoma,EU/3/24/2982,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2982
,,Sodium selenate,10/11/2024,Treatment of frontotemporal dementia,EU/3/24/2981,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2981
,,Ivosidenib,10/11/2024,Treatment of chondrosarcoma,EU/3/24/2978,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2978
,,Atacicept,10/11/2024,Treatment of primary IgA nephropathy,EU/3/24/2985,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2985
,,3-(5-(2-Hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1H-indole-7-carbonitrile,10/11/2024,Treatment of X-linked spinal and bulbar muscular atrophy (Kennedy's disease),EU/3/24/2987,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2987
,,"4,9-Dimethyl-6-(4'-aminophenyl)-2H-furo[2,3-h]-1-benzopyran-2-one",10/11/2024,Treatment of cystic fibrosis,EU/3/24/2976,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2976
,,"Interleukin-12, human, recombinant",10/11/2024,Treatment of cutaneous T-cell lymphoma,EU/3/24/2983,Positive,20/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2983
,,A combination of H-Lys-Lys-Gly-Pro-Arg-Cys(SH)-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys-OH and H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH,19/11/2014,Treatment of haemophilia A,EU/3/14/1360,Withdrawn,15/01/2015,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1360
,,7-Ethyl-10-hydroxycamptothecin,11/11/2024,Treatment of glioma,EU/3/24/2988,Positive,19/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2988
,,Coramitug,11/11/2024,Treatment of ATTR amyloidosis,EU/3/24/2991,Positive,19/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2991
,,Mesenchymal stem cells-derived small extracellular vesicles loaded with siRNA against phosphatase and tensin homolog,11/11/2024,Treatment of spinal cord injury,EU/3/24/2990,Positive,19/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2990
,,,26/06/2020,Treatment of Becker muscular dystrophy,EU/3/20/2293,Withdrawn,23/09/2020,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2293
,,Autologous bone marrow derived CD34+ cells transduced ex vivo with a self-inactivating lentiviral vector containing a normal version of the coding region of the IL2RG gene,13/11/2020,Treatment of X-linked severe combined immunodeficiency,EU/3/20/2362,Withdrawn,15/02/2021,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2362
,,Autologous mobilised peripheral blood-derived CD34+ cells transduced ex vivo with a self-inactivating lentiviral vector containing a normal version of the coding region of the IL2RG gene,20/05/2021,Treatment of X-linked severe combined immunodeficiency,EU/3/21/2440,Withdrawn,18/03/2022,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2440
,,6-(4-(tert-butyl)phenoxy)pyridin-3-amine,10/12/2021,Treatment of acute lymphoblastic leukaemia,EU/3/21/2546,Withdrawn,28/04/2022,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2546
,,marstacimab,13/12/2023,Treatment of haemophilia B,EU/3/23/2866,Withdrawn,01/02/2024,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2866
,,H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH,10/08/2022,Treatment of  haemophilia A,EU/3/22/2677,Withdrawn,15/12/2022,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2677
,,glecirasib,10/11/2024,Treatment of pancreatic cancer,EU/3/24/2977,Positive,19/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2977
,,octreotide hydrochloride,10/11/2024,Treatment of autosomal dominant polycystic liver disease,EU/3/24/2984,Positive,19/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2984
,,"N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine",20/04/2017,Treatment of fragile X syndrome,EU/3/17/1868,Withdrawn,15/05/2017,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1868
,,Live attenuated Listeria monocytogenes transfected with plasmids encoding the HPV-16E7 protein fused to a truncated fragment of the Lm protein listeriolysin O,11/01/2016,Treatment of anal cancer,EU/3/15/1602,Withdrawn,05/02/2016,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1602
,,Pamrevlumab,16/12/2019,Treatment of Duchenne muscular dystrophy,EU/3/19/2234,Withdrawn,25/02/2020,19/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2234
Kizfizo,EMEA/H/C/006169,temozolomide,21/08/2019,Treatment of neuroblastoma,EU/3/19/2188,Positive,14/01/2020,15/11/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2188
,,adeno-associated virus vector serotype SAN011 encoding a microRNA against DMPK mRNA,11/10/2024,Treatment of dystrophic myotonia type 1,EU/3/24/2980,Positive,14/11/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2980
,,"Adeno-associated viral vector serotype 1 containing the 3' portion of human OTOF gene, Adeno-associated viral vector serotype 1 containing the 5' portion of human OTOF gene",20/03/2023,Treatment of otoferlin gene-mediated hearing loss,EU/3/23/2771,Positive,01/02/2024,31/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2771
,,Cemdisiran,20/08/2021,Treatment of primary IgA nephropathy,EU/3/21/2489,Positive,01/03/2022,31/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2489
,,edaravone,16/12/2014,Treatment of amyotrophic lateral sclerosis,EU/3/14/1399,Positive,26/02/2015,31/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1399
,,6-Amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl)-4-pyrimidinecarboxamide,20/05/2021,Treatment of glioma,EU/3/21/2434,Positive,18/03/2022,31/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2434
,,efineptakin alfa,24/05/2024,Treatment of acute radiation syndrome,EU/3/24/2925,Positive,22/08/2024,31/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2925
,,Rivoceranib (mesilate),25/07/2024,Treatment of hepatocellular carcinoma,EU/3/24/2950,Positive,13/09/2024,31/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2950
,,Heterologous human adult liver-derived progenitor cells,17/07/2013,Treatment of argininosuccinic aciduria,EU/3/13/1163,Positive,21/08/2013,28/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1163
Elahere,EMEA/H/C/005036,Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4,19/03/2015,Treatment of ovarian cancer,EU/3/15/1458,Positive,11/05/2015,28/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1458
,,Heterologous human adult liver-derived progenitor cells,17/07/2013,Treatment of ornithine-translocase deficiency,EU/3/13/1167,Positive,22/08/2013,28/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1167
,,milademetan tosilate monohydrate,20/03/2017,Treatment of soft tissue sarcoma,EU/3/17/1847,Positive,05/05/2017,23/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1847
,,Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene,12/01/2017,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),EU/3/16/1825,Positive,14/07/2017,23/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1825
,,ganglioside GM1,13/04/2021,Treatment of amyotrophic lateral sclerosis,EU/3/21/2426,Positive,24/01/2022,23/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2426
Rilonacept FGK Representative Service GmbH,EMEA/H/C/006537,Rilonacept,06/01/2021,Treatment of idiopathic pericarditis,EU/3/20/2390,Positive,18/05/2021,23/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2390
,,Soticlestat,12/11/2021,Treatment of Lennox-Gastaut syndrome,EU/3/21/2529,Positive,09/06/2022,23/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2529
,,"(S)-N-(1-(3-Fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide",13/12/2023,Treatment of soft-tissue sarcoma,EU/3/23/2861,Positive,01/02/2024,23/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2861
,,Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene,21/08/2019,Treatment of neuronal ceroid lipofuscinosis,EU/3/19/2196,Positive,16/01/2020,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2196
,,Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene,21/08/2019,Treatment of neuronal ceroid lipofuscinosis,EU/3/19/2197,Positive,16/01/2020,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2197
Enpaxiq; Epjevy,EMEA/H/C/004193; EMEA/H/C/004793,"11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",25/08/2010,Treatment of primary myelofibrosis,EU/3/10/768,Positive,18/10/2010,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-768
Enpaxiq; Epjevy,EMEA/H/C/004193; EMEA/H/C/004793,"11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",25/08/2010,Treatment of post-polycythaemia vera myelofibrosis,EU/3/10/769,Positive,18/10/2010,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-769
,,Treprostinil sodium,16/03/2022,Treatment of idiopathic pulmonary fibrosis,EU/3/22/2588,Positive,16/06/2022,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2588
Enpaxiq; Epjevy,EMEA/H/C/004193; EMEA/H/C/004793,"11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",25/08/2010,Treatment of post-essential thrombocythaemia myelofibrosis,EU/3/10/767,Positive,18/10/2010,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-767
,,Relacorilant,25/07/2023,Treatment of ovarian cancer,EU/3/23/2811,Positive,01/02/2024,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2811
Skyclarys,EMEA/H/C/006084,Omaveloxolone,27/06/2018,Treatment of Friedreich’s ataxia,EU/3/18/2037,Positive,22/08/2018,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2037
,,Atrasentan,10/12/2021,Treatment of primary IgA nephropathy,EU/3/21/2542,Positive,19/04/2022,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2542
,,humanised IgG1 monoclonal antibody against annexin-A1,15/02/2023,Treatment of pancreatic cancer,EU/3/23/2752,Positive,24/01/2024,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2752
Filsuvez,EMEA/H/C/005035,"dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w) (birch bark extract)",23/02/2011,Treatment of epidermolysis bullosa,EU/3/10/845,Positive,04/03/2011,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-845
Sovrima,EMEA/H/C/000908,idebenone,08/03/2004,Treatment of Friedreich's ataxia,EU/3/04/189,Positive,10/02/2009,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-189
Puldysa,EMEA/H/C/005123,idebenone,20/03/2007,Treatment of Duchenne muscular dystrophy,EU/3/07/437,Positive,19/07/2007,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-437
,,Cyclo-L-glycyl-L-2-allylproline,06/01/2021,Treatment of Angelman syndrome,EU/3/20/2389,Positive,18/05/2021,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2389
,,Cyclo-L-glycyl-L-2-allylproline,06/01/2021,Treatment of Phelan-McDermid syndrome,EU/3/20/2394,Positive,18/05/2021,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2394
,,Cyclo-L-glycyl-L-2-allylproline,06/01/2021,Treatment of Pitt-Hopkins syndrome,EU/3/20/2393,Positive,18/05/2021,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2393
Myalepta,EMEA/H/C/004218,Metreleptin,17/07/2012,Treatment of Lawrence syndrome,EU/3/12/1024,Positive,31/08/2012,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1024
Myalepta,EMEA/H/C/004218,Metreleptin,17/07/2012,Treatment of Berardinelli-Seip syndrome,EU/3/12/1025,Positive,31/08/2012,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1025
Myalepta,EMEA/H/C/004218,Metreleptin,17/07/2012,Treatment of Barraquer-Simons syndrome,EU/3/12/1023,Positive,31/08/2012,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1023
Myalepta,EMEA/H/C/004218,Metreleptin,17/07/2012,Treatment of familial partial lipodystrophy,EU/3/12/1022,Positive,31/08/2012,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1022
,,Humanised IgG4 monoclonal antibody against A proliferation-inducing ligand,21/06/2022,Treatment of primary IgA nephropathy,EU/3/22/2623,Positive,22/09/2022,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2623
,,Adeno-associated virus serotype 5 containing the human RDH12 gene,19/10/2020,Treatment of RDH12 mutation associated retinal dystrophy,EU/3/20/2351,Positive,18/02/2021,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2351
,,adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene (entacingene turiparvovec),31/07/2018,Treatment of achromatopsia,EU/3/18/2042,Positive,11/10/2018,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2042
,,Adenovirus associated viral vector serotype 5 containing the human RPE65 gene,11/11/2015,Treatment of Leber's congenital amaurosis,EU/3/15/1577,Positive,22/01/2016,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1577
,,Adenovirus associated viral vector serotype 8 containing the human AIPL1 gene,12/12/2017,Treatment of Leber's congenital amaurosis,EU/3/17/1950,Positive,24/01/2018,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1950
,,Relacorilant,29/05/2019,Treatment of Cushing's syndrome,EU/3/19/2164,Positive,09/08/2019,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2164
,,Relacorilant,21/08/2019,Treatment of pancreatic cancer,EU/3/19/2191,Positive,14/01/2020,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2191
,,Adenovirus associated viral vector serotype 8 containing the human CNGB3 gene,11/11/2015,Treatment of achromatopsia caused by mutations in the CNGB3 gene,EU/3/15/1578,Positive,22/01/2016,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1578
,,Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7);talfirastide,19/02/2014,Treatment of Duchenne muscular dystrophy,EU/3/14/1241,Positive,01/04/2014,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1241
,,Entospletinib,16/10/2017,Treatment of acute myeloid leukaemia,EU/3/17/1922,Positive,08/01/2018,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1922
,,2-Hydroxypropyl-β-cyclodextrin,26/04/2013,"Treatment of Niemann-Pick's disease, type C",EU/3/13/1124,Positive,14/05/2013,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124
,,Donidalorsen,19/02/2024,Treatment of hereditary angioedema,EU/3/24/2898,Positive,11/04/2024,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2898
,,"5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1,3'-indol]-5'-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine;crozbaciclib",26/03/2021,Treatment of glioma,EU/3/21/2416,Positive,19/01/2022,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2416
,,Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7);talfirastide,20/06/2017,Treatment of epidermolysis bullosa,EU/3/17/1879,Positive,17/07/2017,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1879
,,Humanised monoclonal antibody targeting interleukin-15,27/06/2016,Treatment of eosinophilic oesophagitis,EU/3/16/1681,Positive,26/07/2016,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1681
,,"Anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide;pivekimab sunirine",26/06/2020,Treatment of blastic plasmacytoid dendritic cell neoplasm,EU/3/20/2292,Positive,23/09/2020,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2292
,,"[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-pyridin-2-ylhepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl]4-methylpiperazine-1-carboxylate",20/06/2023,Treatment of myelodysplastic syndromes,EU/3/23/2796,Positive,02/02/2024,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2796
,,camrelizumab,25/07/2024,Treatment of hepatocellular carcinoma,EU/3/24/2943,Positive,13/09/2024,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2943
,,Glycyl-L-2-methylprolyl-L-glutamic acid;trofinetide,10/08/2015,Treatment of Rett syndrome,EU/3/15/1534,Positive,02/10/2015,22/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1534
,,Enzastaurin hydrochloride,27/05/2024,Treatment of glioma,EU/3/05/343,Withdrawn,08/08/2006,16/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-343
,,Fosmanogepix,15/02/2023,Treatment of fusariosis,EU/3/23/2748,Positive,25/01/2024,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2748
,,Heterologous human adult liver derived  stem cells,04/02/2008,Treatment of ornithinine transcarbamylase deficiency,EU/3/08/530,Positive,10/07/2008,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-530
,,Heterologous human adult liver-derived progenitor cells,17/07/2013,Treatment of citrullinaemia type 1,EU/3/13/1162,Positive,21/08/2013,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1162
,,Mecasermin rinfabate,28/08/2006,Prevention of retinopathy of prematurity in neonates of less than 32 weeks of gestational age,EU/3/06/399,Positive,24/04/2009,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-399
,,Heterologous human adult liver-derived stem cells,29/11/2007,Treatment of Crigler-Najjar syndrome,EU/3/07/506,Positive,02/07/2008,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-506
,,Heterologous human adult liver-derived progenitor cells,17/07/2013,Treatment of hyperargininaemia,EU/3/13/1164,Positive,21/08/2013,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1164
,,Heterologous human adult liver-derived progenitor cells,17/07/2013,Treatment of carbamoyl-phosphate synthase-1 deficiency,EU/3/13/1161,Positive,21/08/2013,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1161
,,Adeno-associated viral vector serotype rh.10 encoding the CLN2 gene,11/10/2022,Treatment of neuronal ceroid lipofuscinosis,EU/3/22/2700,Positive,24/01/2023,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2700
,,Heterologous human adult liver-derived progenitor cells,17/08/2013,Treatment of citrullinaemia type 2,EU/3/13/1166,Positive,22/08/2013,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1166
,,Heterologous human adult liver-derived progenitor cells,17/07/2013,Treatment of N-acetylglutamate synthetase (NAGS) deficiency,EU/3/13/1165,Positive,22/08/2013,15/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1165
,,adenovirus associated viral vector serotype 5 containing the human pde6β gene,19/06/2013,Treatment of retinitis pigmentosa,EU/3/13/1142,Positive,11/07/2013,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1142
,,"Allogeneic umbilical cord-derived mesenchymal stromal cells, pooled",13/12/2023,Treatment of perinatal asphyxia,EU/3/23/2862,Positive,01/02/2024,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2862
,,Humanised IgG1 kappa antibody against serum amyloid A and AL amyloid,08/02/2013,Treatment of amyloid light-chain amyloidosis,EU/3/13/1100,Positive,04/03/2013,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1100
,,"6-Ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one (tirasemtiv)",05/03/2012,Treatment of amyotrophic lateral sclerosis,EU/3/12/970,Positive,19/04/2012,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-970
,,Autologous haematopoietic cells genetically modified with a lentiviral vector containing the human gp91(phox) gene,09/02/2012,Treatment of X-linked chronic granulomatous disease,EU/3/12/957,Positive,01/03/2012,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-957
Bylvay,EMEA/H/C/004691,,17/07/2012,Treatment of progressive familial intrahepatic cholestasis,EU/3/12/1028,Positive,30/08/2012,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1028
,,"2S, 4R ketoconazole",04/07/2012,Treatment of Cushing's syndrome,EU/3/12/1012,Positive,24/07/2012,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1012
,,Flucytosine,22/02/2018,Treatment of glioma,EU/3/18/1978,Positive,10/04/2018,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1978
,,Vocimagene amiretrorepvec,22/02/2018,Treatment of glioma,EU/3/18/1987,Positive,11/04/2018,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1987
,,Reldesemtiv,28/06/2019,Treatment of spinal muscular atrophy,EU/3/19/2169,Positive,02/10/2019,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2169
,,Reldesemtiv,28/02/2020,Treatment of amyotrophic lateral sclerosis,EU/3/20/2256,Positive,06/05/2020,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2256
,,Enzastaurin hydrochloride,24/02/2022,Treatment of Ehlers-Danlos syndrome,EU/3/22/2582,Positive,13/05/2022,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2582
,,"Cyclo(-gamma-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt",06/12/2012,Treatment of acromegaly,EU/3/12/1075,Positive,24/01/2013,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1075
,,Brincidofovir,28/04/2016,Prevention of cytomegalovirus disease,EU/3/16/1644,Positive,30/05/2016,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1644
,,Brincidofovir,14/07/2016,Treatment of adenovirus infection in immunocompromised patients,EU/3/16/1697,Positive,06/09/2016,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1697
,,autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1,14/07/2016,Treatment of soft tissue sarcoma,EU/3/16/1694,Positive,06/09/2016,11/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1694
,,Antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA,28/04/2016,Treatment of Leber's congenital amaurosis,EU/3/16/1641,Positive,31/05/2016,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1641
,,ultevursen,22/02/2018,Treatment of retinitis pigmentosa,EU/3/18/1973,Positive,10/04/2018,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1973
,,erlotinib,09/12/2020,Treatment of patients with Olmsted syndrome,EU/3/20/2382,Positive,27/05/2021,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2382
,,Elamipretide,20/05/2021,Treatment of Barth syndrome,EU/3/21/2430,Positive,17/03/2022,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2430
,,Ibrexafungerp,12/11/2021,Treatment of invasive candidiasis,EU/3/21/2525,Positive,09/06/2022,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2525
,,Epetraborole,10/08/2022,Treatment of nontuberculous mycobacterial lung disease,EU/3/22/2680,Positive,15/12/2022,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2680
,,Fosmanogepix,18/07/2022,Treatment of invasive aspergillosis,EU/3/22/2645,Positive,23/01/2023,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2645
,,Fosmanogepix,18/07/2022,Treatment of invasive candidiasis,EU/3/22/2644,Positive,23/01/2023,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2644
,,erlotinib,18/07/2022,Treatment of pachyonychia congenita,EU/3/22/2668,Positive,23/01/2023,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2668
,,Fosmanogepix,15/02/2023,Treatment of mucormycosis,EU/3/23/2749,Positive,19/01/2024,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2749
,,Fosmanogepix,15/02/2023,Treatment of lomentosporiosis,EU/3/23/2750,Positive,25/01/2024,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2750
,,Fosmanogepix,20/03/2023,Treatment of scedosporiosis,EU/3/23/2763,Positive,01/02/2024,02/10/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2763
,,Adeno-associated virus vector serotype 9 containing the human GCDH gene,21/08/2024,Treatment of glutaric aciduria,EU/3/24/2967,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2967
,,gallium (68Ga) boclatixafortide,21/08/2024,Diagnosis of marginal zone lymphoma,EU/3/24/2959,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2959
,,Sodium valproate,21/08/2024,Treatment of pulmonary arterial hypertension,EU/3/24/2972,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2972
,,Olezarsen sodium,21/08/2024,Treatment of familial chylomicronaemia syndrome,EU/3/24/2973,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2973
,,Adeno-associated viral vector serotype 3B encoding human CYP27A1,,Treatment of inborn errors in primary bile acid synthesis,EU/3/24/2971,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2971
,,"(E)-2-((4-((4-Benzyl(ethyl)amino)phenyl)diazinyl)phenyl)amino-N,N,N-triethyl-2-oxoethan-1-aminium chloride",21/08/2024,Treatment of syndromic inherited retinal dystrophies of the rod-dominant phenotype,EU/3/24/2975,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2975
,,"4-(1H-Pyrrolo[2,3-b]pyridin-2-yl)phenol hydrochloride",21/08/2024,Prevention of acute liver failure,EU/3/24/2965,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2965
,,"4-Benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginine acetate",21/08/2024,Treatment of pancreatic cancer,EU/3/24/2974,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2974
,,Interleukin 4 - interleukin 10 fusion protein,,Treatment of complex regional pain syndrome,EU/3/24/2960,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2960
,,"Humanised IgG1 monoclonal antibody against misfolded immunoglobulin G, fused with pan-amyloid-reactive peptide p5R",,Treatment of AL amyloidosis,EU/3/24/2969,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2969
,,Obrixtamig,21/08/2024,Treatment of pulmonary neuroendocrine carcinoma,EU/3/24/2961,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2961
,,Bemarituzumab,21/08/2024,Treatment of gastric cancer,EU/3/24/2966,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2966
,,"Humanised IgG1 monoclonal antibody against misfolded immunoglobulin G, fused with pan-amyloid-reactive peptide p5R",21/08/2024,Treatment of ATTR amyloidosis,EU/3/24/2970,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2970
,,"(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone",21/08/2024,Treatment of punctate palmoplantar keratoderma,EU/3/24/2968,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2968
,,Autologous CD34+ cells edited with a CRISPR/Cas9 system and transduced with an adeno-associated vector containing a codon-optimized version of WAS gene,21/08/2024,Treatment of Wiskott-Aldrich syndrome,EU/3/24/2964,Positive,19/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2964
,,octreotide hydrochloride,12/06/2009,Treatment of acromegaly,EU/3/09/645,Positive,17/09/2009,18/09/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-645
,,Obrixtamig,21/08/2024,Treatment of extrapulmonary neuroendocrine carcinoma,EU/3/24/2962,Positive,18/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2962
,,Polihexanide,21/08/2024,Treatment of fungal keratitis,EU/3/24/2963,Positive,18/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2963
,,"N-[(1R)-1-[(S)-(2-Chloro-3-fluorophenyl)hydroxymethyl]butyl]-7-fluoro-2,3-dihydro-2-oxo-1H-indole-4-carboxamide",25/07/2024,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/24/2952,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2952
,,"N,N'-([Cyclohexylmethylene]di-4,1-phenylene)bis(2-[1-pyrrolidinyl]acetamide)",25/07/2024,Treatment of Creutzfeldt-Jakob disease,EU/3/24/2958,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2958
,,emavusertib,25/07/2024,Treatment of primary large B-cell lymphoma of immune-privileged sites,EU/3/24/2945,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2945
,,Sodium phenylacetate;Ursodoxicoltaurine,25/07/2024,Treatment of Wolfram syndrome,EU/3/24/2954,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2954
,,Adeno-associated virus vector serotype rh.10 containing the human FXN gene,25/07/2024,Treatment of Friedreich's ataxia,EU/3/24/2957,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2957
,,4-[[[4-[5-Chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl-ethyl]amino]cyclohexyl]amino]-4-pyridinyl]-2-thiazolyl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile,25/07/2024,Treatment of peripheral T-cell lymphoma,EU/3/24/2949,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2949
,,befiradol fumarate,25/07/2024,Treatment of spinocerebellar ataxia,EU/3/24/2951,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2951
,,Adeno-associated virus serotype A101 containing the codon-optimized human CFTRdeltaR,25/07/2024,Treatment of cystic fibrosis,EU/3/24/2956,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2956
,,afamelanotide,25/07/2024,Treatment of variegate porphyria,EU/3/24/2947,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2947
,,"Urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor",25/07/2024,Treatment of thrombotic thrombocytopenic purpura,EU/3/24/2946,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2946
,,Adeno-associated virus vector serotype 8 containing the human TYMP gene (CpG-depleted),25/07/2024,Treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE),EU/3/24/2948,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2948
,,"(E)-2-((4-((4-Benzyl(ethyl)amino)phenyl)diazinyl)phenyl)amino-N,N,N-triethyl-2-oxoethan-1-aminium chloride",25/07/2024,Treatment of non-syndromic inherited retinal dystrophies of the rod-dominant phenotype,EU/3/24/2944,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2944
,,Heterologous swine glyco-humanised polyclonal antibody against T lymphocytes,25/07/2024,Treatment of peripheral T-cell lymphoma,EU/3/24/2955,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2955
,,Cannabidiol acid methyl ester,25/07/2024,Treatment of Prader-Willi syndrome,EU/3/24/2953,Positive,13/09/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2953
,,uridine triacetate,28/06/2024,Treatment of hereditary orotic aciduria,EU/3/24/2938,Positive,22/08/2024,23/08/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2938
,,nizubaglustat,28/06/2024,Treatment of GM1 gangliosidosis,EU/3/24/2940,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2940
,,afatinib,28/06/2024,Treatment of complex regional pain syndrome,EU/3/24/2929,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2929
,,Topiramate,28/06/2024,Treatment of neonatal encephalopathy,EU/3/24/2932,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2932
,,Complement factor H,28/06/2024,Treatment of C3 glomerulopathy,EU/3/24/2936,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2936
,,nerandomilast,28/06/2024,Treatment of idiopathic pulmonary fibrosis,EU/3/24/2931,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2931
,,L-methionine,28/06/2024,Treatment of pulmonary alveolar proteinosis,EU/3/24/2934,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2934
,,sargramostim,28/06/2024,Treatment of pulmonary alveolar proteinosis,EU/3/24/2928,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2928
,,(R)-3-(1-Cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide,28/06/2024,Treatment of hyperphenylalaninaemia,EU/3/24/2930,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2930
,,apilimod,28/06/2024,Treatment of amyotrophic lateral sclerosis,EU/3/24/2942,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2942
,,"Ethyl(2E,4S)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate, Pocapavir",28/06/2024,Treatment of poliovirus infection,EU/3/24/2941,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2941
,,"(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone",28/06/2024,Treatment of pachyonychia congenita,EU/3/24/2935,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2935
,,Autologous induced pluripotent stem cells-derived thymic epithelial cells transduced with a lentiviral vector encoding forkhead box protein N1,24/05/2024,Treatment of DiGeorge syndrome,EU/3/24/2924,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2924
,,Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene,24/05/2024,Treatment of recombination-activating gene 1 (RAG1) deficiency,EU/3/24/2918,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2918
,,"N-(1,3-Benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxyphenyl)methylamino]benzenesulfonamide",24/05/2024,Treatment of Platelet-activating anti-Platelet factor 4 (PF4) disorders,EU/3/24/2917,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2917
,,"7-Ethyl-10-hydroxycamptothecin, Irinotecan hydrochloride trihydrate",24/05/2024,Treatment of small cell lung cancer,EU/3/24/2923,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2923
,,Allogeneic non-alloreactive T cells edited with mRNA to disrupt TRAC and CD52 genes and transduced with lentiviral vector expressing a chimeric antigen receptor against CD22 and RQR8 depletion mechanism,24/05/2024,Treatment of acute lymphoblastic leukaemia,EU/3/24/2920,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2920
,,quabodepistat,24/05/2024,Treatment of tuberculosis,EU/3/24/2916,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2916
,,Adeno-associated virus serotype rh.74 vector containing the human PKP2 gene isoform,24/05/2024,Treatment of arrhythmogenic cardiomyopathy caused by pathogenic mutations in the PKP2 gene,EU/3/24/2927,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2927
,,afamelanotide,24/05/2024,Treatment of xeroderma pigmentosum,EU/3/24/2926,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2926
,,"2,4-Diamino-5-[[5-(1H-pyrazol-5-yl)-2-thienyl]methyl]-1H-pyrimidin-6-one",24/05/2024,Treatment of hyperphenylalaninaemia,EU/3/24/2921,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2921
,,DNA plasmid containing the COL7A1 gene,24/05/2024,Treatment of epidermolysis bullosa,EU/3/24/2919,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2919
,,serdexmethylphenidate,24/05/2024,Treatment of idiopathic hypersomnia,EU/3/24/2915,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2915
,,Adeno-associated virus serotype 9 containing CRISPR/Cas13Y and guide RNA against the human MECP2 gene,24/05/2024,Treatment of MECP2 duplication syndrome,EU/3/24/2922,Positive,22/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2922
,,2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid,28/06/2024,Treatment of systemic sclerosis,EU/3/24/2939,Positive,05/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2939
,,4-[[[4-[5-Chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl-ethyl]amino]cyclohexyl]amino]-4-pyridinyl]-2-thiazolyl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile,28/06/2024,Treatment of acute myeloid leukaemia,EU/3/24/2937,Positive,05/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2937
,,"Human IgG1 monoclonal antibody against hepatitis B virus, surface antigen",28/06/2024,Treatment of hepatitis D virus infection,EU/3/24/2933,Positive,05/08/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2933
Adzynma,EMEA/H/C/006198,Recombinant human ADAMTS-13,03/12/2008,Treatment of thrombotic thrombocytopenic purpura,EU/3/08/588,Positive,29/06/2009,01/08/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-588
,,acetylleucine,16/04/2024,Treatment of ataxia-oculomotor apraxia,EU/3/24/2913,Positive,26/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2913
,,annamycin,16/04/2024,Treatment of acute myeloid leukaemia,EU/3/24/2910,Positive,26/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2910
,,Humanised IgG1 (K322A) monoclonal antibody against disialoganglioside GD2,16/04/2024,Treatment of neuroblastoma,EU/3/24/2914,Positive,26/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2914
,,Autologous adipose-derived mesenchymal stem cells embedded in an extracellular matrix with hydroxyapatite/beta-tricalcium phosphate particles,16/04/2024,Treatment of congenital pseudarthrosis of long bones,EU/3/24/2912,Positive,26/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2912
,,Autologous adipose-derived stem cells,16/04/2024,Treatment of spinal cord injury,EU/3/24/2909,Positive,26/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2909
,,Sevasemten,16/04/2024,Treatment of Duchenne muscular dystrophy,EU/3/24/2911,Positive,26/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2911
,,4-(4-Methyl-piperazin-1-yl)-N-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1H-indazol-3-yl}-benzamide hemioxalate,21/03/2024,Treatment of acute myeloid leukaemia,EU/3/24/2908,Positive,23/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2908
,,Mibavademab,21/03/2024,Treatment of Lawrence syndrome,EU/3/24/2904,Positive,23/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2904
,,Sevasemten,21/03/2024,Treatment of Becker muscular dystrophy,EU/3/24/2907,Positive,23/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2907
,,zatolmilast,21/03/2024,Treatment of fragile X syndrome,EU/3/24/2906,Positive,23/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2906
,,Mibavademab,21/03/2024,Treatment of Berardinelli-Seip syndrome (congenital generalised lipodystrophy),EU/3/24/2903,Positive,23/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2903
,,Alrefimotide acetate;riletamotide acetate;tapderimotide acetate,21/03/2024,Treatment of mesothelioma,EU/3/24/2902,Positive,23/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2902
,,Autologous CD3-positive T-cells expressing a chimeric antigen receptor against B cell maturation agent,21/03/2024,Treatment of multiple myeloma,EU/3/24/2905,Positive,23/07/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2905
Alsitek; Masitinib AB Science,EMEA/H/C/004398; EMEA/H/C/005897,Masitinib mesilate,29/08/2016,Treatment of amyotrophic lateral sclerosis,EU/3/16/1722,Positive,03/10/2016,28/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1722
Winrevair,EMEA/H/C/005647,sotatercept,09/12/2020,Treatment of  pulmonary arterial hypertension,EU/3/20/2369,Positive,21/05/2021,28/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2369
Ordspono,EMEA/H/C/006215,Odronextamab,18/07/2022,Treatment of diffuse large B-cell lymphoma,EU/3/22/2656,Positive,25/01/2023,28/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2656
Ordspono,EMEA/H/C/006215,Odronextamab,18/07/2022,Treatment of follicular lymphoma,EU/3/22/2649,Positive,25/01/2023,28/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2649
,,Brentuximab vedotin,11/01/2012,Treatment of cutaneous T-cell lymphoma,EU/3/11/939,Withdrawn,01/02/2012,26/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-939
Adcetris,EMEA/H/C/002455,monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin),15/01/2009,Treatment of Hodgkin's lymphoma,EU/3/08/596,Withdrawn,15/05/2009,26/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-596
,,monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E,21/08/2019,Treatment of peripheral T-cell lymphoma,EU/3/08/595,Withdrawn,15/05/2009,26/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-595
,,Sorafenib tosilate,13/11/2013,Treatment of papillary thyroid cancer,EU/3/13/1200,Expired,02/12/2013,07/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1200
,,Sorafenib tosilate,13/11/2013,Treatment of follicular thyroid cancer,EU/3/13/1199,Expired,02/12/2013,07/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1199
,,Chimeric anti-interleukin-6 monoclonal antibody (siltuximab),30/11/2007,Treatment of Castleman's disease,EU/3/07/508,Expired,29/07/2008,07/06/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-508
,,"6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate",22/09/2016,Treatment of mucopolysaccharidosis type I,EU/3/16/1714,Positive,11/10/2016,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1714
,,Diacerein,20/02/2014,Treatment of epidermolysis bullosa,EU/3/14/1236,Positive,31/03/2014,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1236
,,"3,3-Dimethyl-N-(6-methyl-5-{[2-(1-methyl-1H-pyrazol-4-yl)pyridine-4-yl]oxy}pyridine-2-yl)-2-oxopyrrolidine-1-carboxamide hydrochloride hydrate",13/12/2023,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",EU/3/23/2873,Positive,01/02/2024,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2873
,,Batoclimab,10/08/2022,Treatment of myasthenia gravis,EU/3/22/2684,Positive,15/12/2022,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2684
,,"(S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester",20/04/2017,Treatment of pulmonary arterial hypertension,EU/3/17/1861,Positive,15/05/2017,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1861
,,cusatuzumab,22/04/2020,Treatment of acute myeloid leukaemia,EU/3/20/2265,Positive,11/08/2020,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2265
,,Synthetic hypericin,28/07/2015,Treatment of cutaneous T-cell lymphoma,EU/3/15/1515,Positive,18/08/2015,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1515
,,"N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide",25/07/2019,Treatment of neurofibromatosis type 1,EU/3/19/2184,Positive,24/09/2019,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2184
,,anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein;anti-CD7 mAb (WT1)-ricin A chain fusion protein,26/08/2005,Treatment of graft-versus-host disease,EU/3/05/317,Positive,27/10/2005,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-317
,,Tranilast,27/07/2010,Prevention of scarring post glaucoma filtration surgery,EU/3/10/756,Positive,06/08/2010,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-756
,,Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate,21/08/2020,"Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes",EU/3/20/2311,Withdrawn,25/11/2020,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2311
,,Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate,21/08/2020,Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency,EU/3/20/2319,Withdrawn,25/11/2020,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2319
,,Interferon beta,29/11/2007,Treatment of acute respiratory distress syndrome (ARDS),EU/3/07/505,Withdrawn,02/07/2008,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-505
,,,16/01/2014,Treatment of acute lymphoblastic leukaemia,EU/3/13/1231,Positive,24/03/2014,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1231
,,,16/01/2014,Treatment of acute myeloid leukaemia,EU/3/13/1230,Withdrawn,24/03/2014,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1230
,,branaplam,16/04/2018,Treatment of spinal muscular atrophy,EU/3/18/2010,Withdrawn,17/05/2018,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2010
,,antisense oligonucleotide targeting exon 73 in the COL7A1 gene,12/10/2017,Treatment of epidermolysis bullosa,EU/3/17/1938,Withdrawn,15/01/2018,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1938
,,Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant,26/10/2018,Treatment of haemophilia B,EU/3/18/2080,Withdrawn,11/01/2019,11/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2080
,,Repagermanium,19/02/2024,Treatment of focal segmental glomerulosclerosis,EU/3/24/2897,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2897
,,Andecaliximab,19/02/2024,Treatment of fibrodysplasia ossificans progressiva,EU/3/24/2901,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2901
,,Raludotatug deruxtecan,19/02/2024,Treatment of ovarian cancer,EU/3/24/2890,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2890
,,,19/02/2024,Treatment of small cell lung cancer,EU/3/24/2892,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2892
,,carboplatin,19/02/2024,Treatment of glioma,EU/3/24/2891,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2891
,,Plerixafor,19/02/2024,Treatment of acute respiratory distress syndrome (ARDS),EU/3/24/2899,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2899
,,Autologous CD3-positive T-cells expressing a chimeric antigen receptor against B cell maturation agent,19/02/2024,Treatment of AL amyloidosis,EU/3/24/2900,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2900
,,Human IgG1 monoclonal antibody targeting amyloid transthyretin,19/02/2024,Treatment of ATTR amyloidosis,EU/3/24/2896,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2896
,,paclitaxel,19/02/2024,Treatment of gastric cancer,EU/3/24/2893,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2893
,,Adenine,12/01/2024,Treatment of epidermolysis bullosa,EU/3/23/2880,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2880
,,Recombinant human heparan-N-sulfatase,12/01/2024,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),EU/3/23/2888,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2888
,,Ziftomenib,12/01/2024,Treatment of acute myeloid leukaemia,EU/3/23/2881,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2881
,,Apilimod dimesilate,12/01/2024,Treatment of amyotrophic lateral sclerosis,EU/3/23/2877,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2877
,,"Adeno-associated viral vector serotype 9 containing the human MECP2 gene, an intron encoding a miRNA generating sequence, and complementary miRNA binding sites",12/01/2024,Treatment of Rett syndrome,EU/3/23/2884,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2884
,,cutamesine,12/01/2024,alpha-thalassaemia X-linked intellectual disability syndrome (due to mutations in the ATRX gene),EU/3/23/2883,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2883
,,Tarlatamab,12/01/2024,Treatment of small cell lung cancer,EU/3/23/2876,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2876
,,motixafortide,12/01/2024,Treatment of patients undergoing haematopoietic stem cell transplantation,EU/3/23/2885,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2885
,,mitapivat sulfate,12/01/2024,Treatment of thalassaemia intermedia and major,EU/3/23/2889,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2889
,,Thiophene methylimidazole pentahydrogen,12/01/2024,Diagnosis of glioma,EU/3/23/2875,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2875
,,Ersodetug,12/01/2024,Treatment of insulinoma,EU/3/23/2879,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879
,,"Methyl-(1-{[6-{[(1S)-1-cyclopropylethyl]amino}-2-(pyrazolo[5,1-b][1,3]thiazol-7-yl)-pyrimidin-4-yl]carbonyl}piperidin-4-yl)carbamate mono(4-methylbenzenesulfonate)",12/01/2024,Treatment of eosinophilic granulomatosis with polyangiitis,EU/3/23/2882,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2882
,,golcadomide hydrochloride,12/01/2024,Treatment of diffuse large B-cell lymphoma,EU/3/23/2878,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2878
,,Human coagulation factor X,12/01/2024,Treatment of acquired factor X deficiency,EU/3/23/2886,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2886
,,"(4R)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-1-carboximidamide hydrochloride",12/01/2024,Treatment of systemic sclerosis,EU/3/23/2874,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2874
,,mRNA encoding the human CFTR gene,19/02/2024,Treatment of cystic fibrosis,EU/3/24/2894,Positive,11/04/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2894
,,fidanacogene elaparvovec,19/11/2018,Treatment of haemophilia B,EU/3/18/2090,Withdrawn,19/02/2019,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2090
,,Veliparib,17/12/2010,Treatment of ovarian cancer,EU/3/10/830,Withdrawn,20/01/2011,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-830
,,Eflornithine,27/09/2011,Treatment of neuroblastoma,EU/3/11/902,Withdrawn,17/10/2011,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-902
,,Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer,29/04/2014,Treatment of ovarian cancer,EU/3/14/1265,Withdrawn,04/06/2014,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1265
,,"(6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic acid",12/01/2017,Treatment of systemic sclerosis,EU/3/16/1808,Withdrawn,14/07/2017,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1808
,,Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene,19/10/2020,Treatment of aspartylglucosaminuria,EU/3/20/2334,Withdrawn,12/02/2021,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2334
,,"(6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid-",14/10/2016,Treatment of cystic fibrosis,EU/3/16/1736,Withdrawn,15/11/2016,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1736
,,"(6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid",,Treatment of dermatomyositis,EU/3/18/2070,Withdrawn,10/01/2019,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2070
,,"3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile",21/08/2020,Treatment of von Hippel-Lindau disease,EU/3/20/2324,Withdrawn,25/11/2020,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2324
,,"Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl) sulfane",21/08/2020,Treatment of idiopathic pulmonary fibrosis,EU/3/20/2309,Withdrawn,25/11/2020,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2309
,,Adeno-associated viral vector containing porphobilinogen deaminase gene,29/04/2009,Treatment of acute intermittent porphyria,EU/3/09/632,Withdrawn,12/05/2009,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-632
,,Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene,21/03/2012,Treatment of primary hyperoxaluria type 1,EU/3/12/974,Withdrawn,19/04/2012,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-974
,,Adeno-associated viral vector containing modified U1 snRNA,08/10/2009,Treatment of Duchenne muscular dystrophy,EU/3/09/663,Positive,20/10/2009,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-663
,,Florilglutamic acid (18F),21/03/2016,Diagnosis of glioma,EU/3/16/1631,Withdrawn,02/05/2016,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1631
,,Florilglutamic acid (18F),21/03/2016,Diagnosis of hepatocellular carcinoma,EU/3/16/1632,Withdrawn,02/05/2016,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1632
,,Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha,19/10/2020,Treatment of Fabry disease,EU/3/20/2341,Withdrawn,16/02/2021,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2341
,,"Adeno-associated virus serotype HSC15, containing human homology arms, expressing human phenylalanine hydroxylase",16/03/2022,Treatment of phenylalanine hydroxylase deficiency,EU/3/22/2593,Withdrawn,20/06/2022,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2593
,,Adeno-associated viral vector serotype 8 containing a functional copy of the codon-optimised F8 cDNA encoding the B-domain deleted human coagulation factor VIII,25/05/2018,Treatment of haemophilia A,EU/3/18/2015,Withdrawn,18/07/2018,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2015
,,Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta,21/08/2020,Treatment of Gaucher disease,EU/3/20/2326,Positive,25/11/2020,09/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2326
,,Allogeneic cultured postnatal thymus-derived tissue,26/02/2019,Treatment of DiGeorge syndrome,EU/3/19/2135,Positive,09/04/2019,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2135
,,Allogeneic cultured postnatal thymus-derived tissue,26/02/2019,Treatment of CHARGE syndrome,EU/3/19/2136,Positive,09/04/2019,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2136
,,Azithromycin dihydrate,14/01/2022,Prevention of bronchopulmonary dysplasia,EU/3/21/2568,Positive,15/06/2022,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2568
,,Mavorixafor,25/07/2019,Treatment of WHIM syndrome,EU/3/19/2183,Positive,24/09/2019,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2183
,,"haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",20/04/2020,Treatment in haematopoietic stem cell transplantation,EU/3/20/2271,Positive,12/08/2020,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2271
,,Glycyl-L-2-methylprolyl-L-glutamic acid,28/07/2015,Treatment of fragile X syndrome,EU/3/15/1529,Positive,18/08/2015,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1529
,,"(S)-2-isobutyrylamino-pentanedioic acid 5-amide 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-bis-((S)-sec-butyl)-21-hydroxy-5-(4-hydroxy-benzyl)-15-isobutyl-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-10-oxa-1,4,7,14,17-pentaaza-bicyclo[16.3.1]docos-12-yl]-amide}",17/10/2019,Treatment of Netherton syndrome,EU/3/19/2203,Positive,21/01/2020,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2203
,,Nirogacestat,17/10/2019,Treatment of soft tissue sarcoma,EU/3/19/2214,Positive,23/01/2020,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2214
,,Adeno-associated virus serotype rh10 containing the human GALC gene,15/10/2021,Treatment of Krabbe disease,EU/3/21/2511,Positive,21/01/2022,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2511
,,"Oxygen, sodium chloride solution 0.9%",11/10/2022,Treatment of amyotrophic lateral sclerosis,EU/3/22/2692,Positive,24/01/2023,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2692
,,Recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter,14/10/2016,Treatment of Duchenne muscular dystrophy,EU/3/16/1759,Positive,15/11/2016,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1759
,,Olorofim,14/01/2022,Treatment of invasive Scopulariopsis,EU/3/21/2563,Positive,09/06/2022,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2563
,,"2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide (also known as F901318) (olorofim)",29/08/2016,Treatment of scedosporiosis,EU/3/16/1713,Positive,03/10/2016,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1713
,,melatonin,02/04/2012,Treatment of perinatal asphyxia,EU/3/12/978,Positive,30/04/2012,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-978
,,Autologous CD34+ cells transduced with a lentiviral RNA vector that results in integrated cDNA encoding for functional cystinosin,19/02/2021,Treatment of cystinosis,EU/3/21/2407,Positive,23/02/2022,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2407
,,Aglatimagene besadenovec,11/10/2022,Treatment of glioma,EU/3/22/2699,Positive,24/01/2023,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2699
,,imatinib,21/06/2021,Treatment of  pulmonary arterial hypertension,EU/3/21/2449,Positive,11/05/2022,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2449
Raxone,EMEA/H/C/003834,idebenone,16/02/2007,Treatment of Leber's hereditary optic neuropathy,EU/3/07/434,Positive,10/07/2008,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-434
,,"Alisitol, retinol palmitate, zinc gluconate",13/11/2020,Treatment of microvillus inclusion disease,EU/3/20/2354,Positive,15/02/2021,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2354
,,"Adeno-associated viral vector serotype 8 encoding B-domain deleted liver specific codon optimized bioengineered chimeric human porcine factor VIII, under a synthetic hepatic combinatorial bundle promoter",13/04/2022,Treatment of  haemophilia A,EU/3/22/2606,Positive,19/07/2022,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2606
,,Allogeneic placenta-derived decidual stromal cells,10/08/2022,Treatment of graft-versus-host-disease,EU/3/22/2679,Positive,15/12/2022,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2679
,,Lactobacillus plantarum,16/12/2019,Treatment of amyotrophic lateral sclerosis,EU/3/19/2232,Positive,25/02/2020,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2232
,,rovatirelin,11/11/2022,Treatment of spinocerebellar ataxia,EU/3/22/2715,Positive,23/01/2023,08/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2715
,,"Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib)",06/02/2009,Treatment of medullary thyroid carcinoma,EU/3/08/610,Positive,29/06/2009,02/04/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-610
,,Tislelizumab,06/03/2024,Treatment of hepatocellular carcinoma,EU/3/20/2269,Withdrawn,15/03/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2269
,,"(1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline",26/08/2005,Treatment of tuberculosis,EU/3/05/314,Withdrawn,17/09/2009,13/03/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-314
,,Selumetinib,13/12/2023,Treatment of amyotrophic lateral sclerosis,EU/3/23/2870,Positive,08/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2870
,,Autologous T lymphocytes containing a T-cell receptor against Epstein–Barr virus,13/12/2023,Treatment of peripheral T-cell lymphoma,EU/3/23/2868,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2868
,,"2'-O, 4'-C-Methylene-P-thio-adenylyl-(3'->5')-2'-O, 4'-C-methylene-P-thioguanylyl-(3'->5')-2'-O, 4'-C-methylene-P-thio-adenylyl-(3'->5')-2'-deoxy-P-thioadenylyl-(3'->5')-2'-deoxy-P-thio-thymidylyl-(3'->5')-2'-deoxy-P-thio-guanylyl-(3'->5')-2'-deoxy-P-thio-guanylyl-(3'->5')-2'-deoxy-P-thio-cytidylyl-(3'->5')-2'-deoxy-P-thio-adenylyl-(3'->5')-2'-deoxy-P-thio-cytidylyl-(3'->5')-2'-deoxy-P-thio-adenylyl-(3'->5')-2'-deoxy-P-thio-thymidylyl-(3'->5')-2'-deoxy-P-thio-cytidylyl-(3'->5')-2'-deoxy-P-thio-thymidylyl-(3'->5')-2'-O, 4'-C-methylene-5-methyl-P-thio-cytidylyl-(3'->5')-2'-O, 4'-C-methylene-5-methyl-P-thio-uridylyl-(3'->5')-2'-O, 4'-C-methylene-5-methyl-P-thio-uridylyl-(3'->5')-2'-O, 4'-C-methyleneguanosine",13/12/2023,Treatment of Angelman syndrome,EU/3/23/2869,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2869
,,brogidirsen,13/12/2023,Treatment of Duchenne muscular dystrophy,EU/3/23/2863,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2863
,,Humanised IgG1 kappa fragment antibody targeting TfR1 conjugated to P125 oligonucleotide,22/05/2023,Treatment of myotonic disorders,EU/3/23/2781,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2781
,,govorestat,22/05/2023,Treatment of Charcot-Marie-Tooth disease,EU/3/23/2783,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2783
,,"2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",22/05/2023,Treatment of neurofibromatosis type 1,EU/3/23/2779,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2779
,,Aspacytarabine,22/05/2023,Treatment of myelodysplastic syndromes,EU/3/23/2782,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2782
,,Fingolimod,22/05/2023,Treatment of hypomyelinating leukodystrophy-18,EU/3/23/2776,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2776
,,Efzofitimod,20/06/2023,Treatment of systemic sclerosis,EU/3/23/2795,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2795
,,Fasudil hydrochloride,20/06/2023,Treatment of amyotrophic lateral sclerosis,EU/3/23/2789,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2789
,,"Adeno-associated virus vector serotype 8 encoding the ABCA4 protein, C-region, adeno-associated virus vector serotype 8 encoding the ABCA4 protein, N-region",20/06/2023,Treatment of inherited retinal dystrophies,EU/3/23/2788,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2788
,,"(3S,3'S,3a'S,10a'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-1'-(cyclopropylmethyl)-6'-methyl-2-oxo-1,2,3',3a',10',10a'-hexahydro-1'H-spiro[indole-3,2'-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazole]-7'-carboxylic acid",20/06/2023,Treatment of soft tissue sarcoma,EU/3/23/2792,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2792
,,Evorpacept,20/06/2023,Treatment of gastric cancer,EU/3/23/2787,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2787
,,Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene,20/06/2023,Treatment of glioma,EU/3/23/2794,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2794
,,Autologous dendritic cells pulsed with allogeneic tumour cell lysate,20/06/2023,Treatment of pancreatic cancer,EU/3/23/2790,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2790
,,exenatide,20/06/2023,Treatment of moderate and severe closed traumatic brain injury,EU/3/23/2793,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2793
,,Adeno-associated virus vector serotype 9 containing the PKP2 gene,16/08/2023,Treatment of arrhythmogenic right ventricular cardiomyopathy due to plakophilin-2 gene mutations,EU/3/23/2824,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2824
,,2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting PLP1 pre-mRNA,16/08/2023,Treatment of Pelizaeus-Merzbacher disease,EU/3/23/2823,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2823
,,"Herpes simplex virus-1, derived from strain F, with deletions on genes gamma (1) 34.5 and UL39",16/08/2023,Treatment of glioma,EU/3/23/2820,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2820
,,Virus-like particle containing Cas9/gRNA ribonucleoprotein targeting the human HTT gene,16/08/2023,Treatment of Huntington’s disease,EU/3/23/2819,Positive,02/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2819
,,Cedazuridine / decitabine,16/08/2023,Treatment of myelodysplastic syndromes,EU/3/23/2825,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2825
,,Mitazalimab,16/08/2023,Treatment of pancreatic cancer,EU/3/23/2821,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2821
,,"Allogeneic faecal microbiota, pooled",16/08/2023,Treatment in haematopoietic stem cell transplantation,EU/3/23/2818,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2818
,,alprostadil,16/08/2023,Treatment of in solid organ transplantation,EU/3/23/2817,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2817
,,Adeno-associated viral vector serotype rh10 encoding miRNA against SOD1 mRNA,08/11/2023,Treatment of amyotrophic lateral sclerosis,EU/3/23/2859,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2859
,,Oregovomab,08/11/2023,Treatment of ovarian cancer,EU/3/23/2857,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2857
,,rucosopasem manganese,08/11/2023,Treatment of pancreatic cancer,EU/3/23/2852,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2852
,,"5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidine-4,6-diamine",08/11/2023,Treatment of Prader-Willi syndrome,EU/3/23/2855,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2855
,,Ambroxol hydrochloride,08/11/2023,Treatment of Gaucher disease,EU/3/23/2849,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2849
,,bortezomib,08/11/2023,Treatment of patients with light chain (AL) amyloidosis,EU/3/23/2848,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2848
,,setanaxib,08/11/2023,Treatment of Alport syndrome,EU/3/23/2850,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2850
,,bersiporocin,13/12/2023,Treatment of idiopathic pulmonary fibrosis,EU/3/23/2871,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2871
,,Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate,13/12/2023,Treatment of Leigh syndrome,EU/3/23/2867,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2867
,,Allogeneic amniotic fluid-derived mesenchymal stem cells with lung specificity,13/12/2023,Prevention of primary graft dysfunction following lung transplantation,EU/3/23/2860,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2860
,,golcadomide hydrochloride,13/12/2023,Treatment of follicular lymphoma,EU/3/23/2864,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2864
,,Selumetinib,13/12/2023,Treatment of glioma,EU/3/23/2865,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2865
,,cutamesine,13/12/2023,Treatment of amyotrophic lateral sclerosis,EMA/OD/0000149115,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/ema-od-0000149115
,,Ovine polyclonal fragment antigen-binding against ricin,13/12/2023,Treatment of ricin poisoning,EU/3/23/2872,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2872
,,vactosertib,25/07/2023,Treatment of osteosarcoma,EU/3/23/2797,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2797
,,Ulefnersen,,Treatment of amyotrophic lateral sclerosis,EU/3/23/2839,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2839
,,Humanised IgG1 monoclonal antibody against TfR1 conjugated to exon 44 specific phosphorodiamidate morpholino oligonucleotide via a non-cleavable linker,13/10/2023,Treatment of Duchenne muscular dystrophy,EU/3/23/2838,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2838
,,"2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol",13/10/2023,Treatment of myelofibrosis,EU/3/23/2844,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2844
,,zedenoleucel,25/02/2023,Treatment of acute myeloid leukaemia,EU/3/23/2806,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2806
,,Autologous adipose-derived mesenchymal stem cells,21/04/2023,Treatment of oesophageal atresia,EU/3/23/2772,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2772
,,Setmelanotide,13/10/2023,Treatment of acquired hypothalamic obesity,EU/3/23/2833,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2833
,,"Human IgG1 (296-cysteine,301-glycine,306-cysteine) monoclonal antibody against TREM2",13/10/2023,Treatment of CSF1R-related leukoencephalopathy,EU/3/23/2847,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2847
,,"(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone",13/10/2023,Treatment of Olmsted syndrome,EU/3/23/2840,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2840
,,sodium oxybate,13/10/2023,Treatment of narcolepsy,EU/3/23/2846,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2846
,,chimeric human-murine IgG1 kappa monoclonal antibody against TNF alfa,25/07/2023,Treatment of sarcoidosis,EU/3/23/2809,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2809
,,tarperprumig,25/07/2023,Treatment of sickle cell disease,EU/3/23/2814,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2814
,,mitapivat sulfate,13/10/2023,Treatment of thalassaemia intermedia and major,EU/3/23/2827,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2827
,,Alpelisib,13/10/2023,Treatment of lymphatic malformations,EU/3/23/2841,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2841
,,paclitaxel obaluronate,25/07/2023,Treatment of malignant mesothelioma,EU/3/23/2807,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2807
,,Anagrelide hydrochloride monohydrate,20/03/2023,Treatment of gastrointestinal stromal tumours,EU/3/23/2765,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2765
,,"6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, L-tartrate salt",20/03/2023,Treatment of hereditary haemorrhagic telangiectasia,EU/3/23/2766,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2766
,,Sodium selenate,13/10/2023,Treatment of progressive supranuclear palsy,EU/3/23/2829,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2829
,,messenger ribonucleic acid coding for coiled-coil domain-containing protein 40,25/07/2023,Treatment of primary ciliary dyskinesia,EU/3/23/2812,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2812
,,Nomacopan,25/07/2023,Treatment in haematopoietic stem cell transplantation,EU/3/23/2810,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2810
,,bezuclastinib,20/03/2023,Treatment of gastrointestinal stromal tumours,EU/3/23/2767,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2767
,,rhizobium rhizogenes;lipopolysaccharide,25/07/2023,Treatment of congenital diaphragmatic hernia,EU/3/23/2801,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2801
,,vonafexor,25/07/2023,Treatment of Alport syndrome,EU/3/23/2808,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2808
,,Certepetide,13/10/2023,Treatment of pancreatic cancer,EU/3/23/2834,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2834
,,taldefgrobep alfa,25/07/2023,Treatment of spinal muscular atrophy,EU/3/23/2813,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2813
,,Indole-3-carboxaldehyde,20/03/2023,Treatment of primary CTLA-4 checkpoint related immunodeficiencies,EU/3/23/2769,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2769
,,sildenafil citrate,13/10/2023,Treatment of Leigh syndrome,EU/3/23/2831,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2831
,,"Allogeneic peripheral blood-derived haematopoietic stem and progenitor cells, regulatory T cells and conventional T cells",25/07/2023,Treatment in haematopoietic stem cell transplantation,EU/3/23/2815,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2815
,,Omadacycline,25/07/2024,Treatment of nontuberculous mycobacterial lung disease,EU/3/23/2804,Positive,01/02/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2804
,,rituximab,25/07/2023,Treatment of primary membranous nephropathy,EU/3/23/2816,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2816
,,humanised IgG1 monoclonal antibody against muscle specific kinase,25/07/2023,Treatment of congenital myasthenic syndromes,EU/3/23/2799,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2799
,,Ilginatinib maleate,25/07/2023,Treatment of myelofibrosis,EU/3/23/2803,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2803
,,tasimelteon,13/10/2023,Treatment of Smith-Magenis syndrome,EU/3/23/2832,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2832
Fintepla,EMEA/H/C/003933,Fenfluramine hydrochloride,20/03/2023,Treatment of CDKL5 deficiency disorder,EU/3/23/2768,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2768
,,guanabenz acetate,20/03/2023,Treatment of vanishing white matter disease,EU/3/23/2764,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2764
,,"5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",20/03/2023,Treatment of fragile X syndrome,EU/3/23/2770,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2770
,,Lurbinectedin,21/04/2023,Treatment of soft tissue sarcoma,EU/3/23/2774,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2774
,,Riboflavin,08/11/2023,Treatment of medium-chain acyl-coenzyme A dehydrogenase deficiency,EU/3/23/2853,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2853
,,Elesclomol-copper,08/11/2023,Treatment of Menkes disease,EU/3/23/2858,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2858
,,"N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-trifluoro[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide",08/11/2023,Treatment of narcolepsy,EU/3/23/2851,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2851
,,Humanised IgG1 monoclonal antibody against CLDN6 conjugated to monomethyl auristatin E via a cathepsin hydrolysable dipeptide VC linker,08/11/2023,Treatment of ovarian cancer,EU/3/23/2854,Positive,31/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2854
,,"5-(3,4-Dichloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide",20/06/2023,Treatment of Alport syndrome,EU/3/23/2791,Positive,30/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2791
,,nicotinamide mononucleotide,20/06/2023,Treatment of sickle cell disease,EU/3/23/2786,Positive,30/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2786
,,Cannabidiol,25/07/2023,Treatment of Leigh syndrome,EU/3/23/2800,Positive,30/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2800
,,Pemafibrate,25/07/2023,Treatment of primary biliary cholangitis,EU/3/23/2798,Positive,30/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2798
,,ulviprubart,25/07/2023,Treatment of inclusion body myositis,EU/3/23/2805,Positive,30/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2805
,,Adeno-associated virus serotype 9 vector containing the human LAMP2 isoform B transgene,16/08/2023,Treatment of Danon disease,EU/3/23/2826,Positive,30/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2826
,,lusvertikimab,25/07/2023,Treatment of acute lymphoblastic leukaemia,EU/3/23/2802,Positive,26/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2802
Nezglyal,EMEA/H/C/005757,"5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride",18/11/2016,Treatment of adrenoleukodystrophy,EU/3/16/1770,Positive,13/12/2016,26/01/2024,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1770
,,Lithium carbonate,16/08/2023,Treatment of Kleine Levin syndrome,EU/3/23/2822,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2822
,,"2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol",21/04/2023,Treatment of mastocytosis,EU/3/23/2775,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2775
,,"Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase",21/04/2023,Treatment of hyperphenylalaninaemia,EU/3/23/2773,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2773
,,Autologous blood-derived tumour and hypoxia educated macrophages,22/05/2023,Treatment of spinal cord injury,EU/3/23/2777,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2777
,,doruxapapogene ralaplasmid,22/05/2023,Treatment of recurrent respiratory papillomatosis,EU/3/23/2785,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2785
,,"H-L-tryphophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond), acetate salt",15/02/2023,Treatment of spinal cord injury,EU/3/23/2758,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2758
,,adeno-associated viral vector serotype 9 expressing fukutin-related protein,15/02/2023,Treatment of limb girdle muscular dystrophy,EU/3/23/2755,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2755
,,patidistrogene bexoparvovec,15/02/2023,Treatment of limb girdle muscular dystrophy,EU/3/23/2753,Positive,25/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2753
,,Glycerol phenylbutyrate,13/10/2023,Treatment of STXBP1 developmental and epileptic encephalopathy,EU/3/23/2842,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2842
,,Adeno-associated viral vector serotype 9 containing the human PLA2G6 gene,10/12/2023,Treatment of infantile neuroaxonal dystrophy,EU/3/23/2845,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2845
,,Adeno-associated virus vector serotype 9/rh74 containing the human CAPN3 gene and a target sequence of cardiac-specific microRNA,13/10/2023,Treatment of limb-girdle muscular dystrophy,EU/3/23/2837,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2837
,,"1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl) ethanone oxime",13/10/2024,Treatment of pancreatic cancer,EU/3/23/2830,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2830
,,Resminostat,13/10/2024,Treatment of cutaneous T-cell lymphoma,EU/3/23/2835,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2835
,,melatonin,15/02/2023,Treatment of perinatal asphyxia,EU/3/23/2757,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2757
,,"Messenger RNA encoding Cas9, Single guide RNA targeting the human KLKB1 gene",08/11/2023,Treatment of hereditary angioedema,EU/3/23/2856,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2856
,,Idronoxil,22/05/2023,Treatment of soft tissue sarcoma,EU/3/23/2778,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2778
,,"Humanised IgG4 monoclonal antibody against active complement component 1, subcomponent s",22/05/2023,Treatment of chronic inflammatory demyelinating polyneuropathy,EU/3/23/2784,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2784
,,Adeno-associated virus serotype 9 expressing a transcription factor for the SCN1A gene,22/05/2023,Treatment of Dravet syndrome,EU/3/23/2780,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2780
,,Adeno-associated viral vector serotype 9 containing the human NPC1 gene,13/10/2023,"Treatment of Niemann-Pick's disease, type C",EU/3/23/2843,Positive,24/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2843
,,Bitopertin,15/02/2023,Treatment of erythropoietic protoporphyria,EU/3/23/2761,Positive,19/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2761
,,,15/02/2023,Treatment of GM2 gangliosidosis,EU/3/23/2762,Positive,19/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2762
,,autologous CD34+ cells transduced with a lentiviral vector containing the human GAA gene,15/02/2024,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/23/2751,Positive,19/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2751
,,crisdesalazine,15/02/2023,Treatment of amyotrophic lateral sclerosis,EU/3/23/2759,Positive,19/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2759
,,humanised IgG1 monoclonal antibody against TfR1 conjugated to double stranded siRNA oligonucleotide against DUX4 mRNA via a non-cleavable linker,15/02/2023,treatment of facioscapulohumeral muscular dystrophy,EU/3/23/2756,Positive,19/01/2024,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2756
,,Dersimelagon,16/03/2022,Treatment of erythropoietic protoporphyria,EU/3/22/2585,Positive,16/06/2022,07/12/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2585
Finlee,EMEA/H/C/005885,Dabrafenib mesylate,09/12/2020,Treatment of glioma,EU/3/20/2372,Positive,25/05/2021,05/12/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2372
,,cholic acid,18/12/2002,Treatment of inborn errors in primary bile acid synthesis,EU/3/02/127,Positive,18/08/2008,25/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-127
,,7-Beta-hydroxy cholesteryl-3-beta-oleate,17/12/2010,Treatment of glioma,EU/3/10/816,Positive,19/01/2011,22/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-816
,,"(S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one",19/10/2020,Treatment of sickle cell disease,EU/3/20/2335,Positive,15/02/2021,22/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2335
Talvey,EMEA/H/C/005864,Talquetamab,20/08/2021,Treatment of multiple myeloma,EU/3/21/2486,Positive,25/02/2022,21/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2486
,,Belzupacap sarotalocan,13/04/2022,Treatment of uveal melanoma,EU/3/22/2599,Positive,19/07/2022,20/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2599
,,Celecoxib;Ciprofloxacin,06/01/2021,Treatment of amyotrophic lateral sclerosis,EU/3/20/2395,Positive,18/05/2021,19/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2395
,,"3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid",19/06/2015,Treatment of non-infectious uveitis,EU/3/15/1507,Positive,27/07/2015,18/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1507
,,"N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt",23/03/2009,Treatment of acute myeloid leukaemia,EU/3/09/622,Positive,08/04/2009,15/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-622
Yorvipath,EMEA/H/C/005934,"Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1)",19/10/2020,Treatment of hypoparathyroidism,EU/3/20/2350,Positive,18/02/2021,15/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2350
,,everolimus,04/08/2010,Treatment of tuberous sclerosis,EU/3/10/764,Expired,11/08/2010,15/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-764
,,zilucoplan,18/07/2022,Treatment of myasthenia gravis,EU/3/22/2650,Positive,25/01/2023,15/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2650
,,Asunercept,23/08/2017,Treatment of myelodysplastic syndromes,EU/3/17/1900,Positive,17/10/2017,15/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1900
,,Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule,28/01/2010,Treatment of glioma,EU/3/09/709,Positive,25/02/2010,15/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-709
,,Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule,31/10/2006,Prevention of graft-versus-host disease,EU/3/06/411,Positive,02/04/2009,15/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-411
,,"2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide (zeteletinib)",19/02/2021,Treatment of medullary thyroid carcinoma,EU/3/21/2410,Positive,23/02/2022,13/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2410
,,Entinostat,10/06/2010,Treatment of Hodgkin's lymphoma,EU/3/10/732,Positive,24/06/2010,13/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-732
,,Mixture of seven synthetic fragments consisting of p21 RAS peptides,05/08/2011,Treatment of pancreatic cancer,EU/3/11/885,Positive,16/08/2011,13/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-885
,,Pomalidomide,08/10/2009,Treatment of multiple myeloma,EU/3/09/672,Expired,20/10/2009,13/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-672
,,Enzastaurin hydrochloride,20/03/2007,Treatment of diffuse large B-cell lymphoma,EU/3/07/442,Withdrawn,10/07/2008,12/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-442
,,Risdiplam,26/02/2019,Treatment of spinal muscular atrophy,EU/3/19/2145,Withdrawn,09/04/2019,12/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2145
,,Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene,17/01/2018,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/17/1956,Withdrawn,13/03/2018,12/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1956
,,Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene (devafidugene civaparvovec),17/01/2018,Treatment of mucopolysaccharidosis type I,EU/3/17/1955,Withdrawn,12/03/2018,12/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1955
,,Lentiviral vector carrying the Fanconi anaemia-A (FANCA) gene,17/12/2010,Treatment of Fanconi anaemia type A,EU/3/10/822,Positive,20/01/2011,11/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-822
,,"2',3',5'-Tri-O-acetyluridine",15/05/2009,Treatment of 5-fluorouracil overdose,EU/3/09/637,Positive,09/06/2009,11/09/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-637
,,"4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride (ronopterin)",28/08/2006,Treatment of moderate and severe traumatic brain injury,EU/3/06/390,Positive,24/02/2009,11/08/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-390
,,Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase (Bevufenogene nofeparvovec),16/03/2022,Treatment of mucopolysaccharidosis type II (Hunter Syndrome),EU/3/22/2592,Withdrawn,20/06/2022,08/08/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2592
,,Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase,14/12/2018,Treatment of phenylalanine hydroxylase deficiency,EU/3/18/2109,Withdrawn,08/03/2019,08/08/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2109
,,Human telomerase reverse transcriptase peptide (611-626) (tertomotide),25/07/2006,Treatment of pancreatic cancer,EU/3/06/384,Withdrawn,21/09/2009,08/08/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-384
,,Recombinant human factor IX protein modified with three point mutations (dalcinonacog alfa),20/06/2017,Treatment of haemophilia B,EU/3/17/1884,Positive,17/07/2017,03/08/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1884
,,Marzeptacog alfa (activated),01/04/2019,Treatment of haemophilia B,EU/3/19/2151,Positive,07/05/2019,03/08/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2151
Ztalmy,EMEA/H/C/005825,Ganaxolone,13/11/2019,Treatment of CDKL5 deficiency disorder,EU/3/19/2224,Positive,13/02/2020,31/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2224
,,Humanised IgG1 monoclonal antibody against SEZ6 linked to N-acetyl-calicheamicin,15/10/2021,Treatment of small cell lung cancer,EU/3/21/2502,Withdrawn,20/01/2022,31/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2502
,,Tobramycin,17/03/2003,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,EU/3/03/140,Expired,07/03/2007,31/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-140
,,Itraconazole,23/08/2017,Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome),EU/3/17/1901,Withdrawn,17/10/2017,27/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1901
,,Fusion protein composed of the first 2 immunoglobulin-like domains of the human Roundabout guidance receptor 2 fused to a human IgG1 crystallised fragment,16/05/2022,Treatment of focal segmental glomerulosclerosis,EU/3/22/2611,Withdrawn,14/12/2022,27/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2611
,,Iodine (124I) evuzamitide,09/12/2022,Diagnosis of ATTR amyloidosis,EU/3/22/2725,Positive,13/03/2023,25/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2725
,,Iodine (124I) evuzamitide,11/11/2022,Diagnosis of AL amyloidosis,EU/3/22/2712,Positive,23/01/2023,25/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2712
,,Codon-optimised human cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid complexed with lipid-based nanoparticles;pomulmeran,01/04/2019,Treatment of cystic fibrosis,EU/3/19/2150,Withdrawn,07/05/2019,21/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2150
,,Adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene,26/06/2020,treatment of metachromatic leukodystrophy,EU/3/20/2297,Withdrawn,24/09/2020,21/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2297
Radicava,EMEA/H/C/004938,edaravone,19/06/2015,Treatment of amyotrophic lateral sclerosis,EU/3/15/1510,Positive,27/07/2015,21/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1510
,,"Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] (ponatinib)",02/02/2010,Treatment of acute lymphoblastic leukaemia,EU/3/09/715,Expired,04/03/2010,20/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-715
,,"Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] (ponatinib)",02/02/2010,Treatment of chronic myeloid leukaemia,EU/3/09/716,Expired,04/03/2010,20/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-716
,,Human embryonic stem-cell-derived retinal pigment epithelial cells,21/06/2011,Treatment of Stargardt's disease,EU/3/11/874,Withdrawn,12/07/2011,19/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-874
,,"1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one (futibatinib)",01/04/2019,Treatment of biliary tract cancer,EU/3/19/2146,Positive,07/05/2019,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2146
Columvi,EMEA/H/C/005751,Glofitamab,15/10/2021,Treatment of diffuse large B-cell lymphoma,EU/3/21/2497,Positive,20/01/2022,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2497
Xenpozyme,EMEA/H/C/004850,Recombinant human acid sphingomyelinase (also known as olipudase alfa),24/06/2022,Treatment of Niemann-Pick disease,EU/3/01/056,Positive,15/06/2009,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-056
Cerdelga,EMEA/H/C/003724,,04/12/2007,Treatment of Gaucher disease,EU/3/07/514,Positive,02/07/2008,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-514
,,Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran),29/07/2014,Treatment of haemophilia A,EU/3/14/1297,Positive,01/09/2014,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1297
,,Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran),29/07/2014,Treatment of haemophilia B,EU/3/14/1298,Positive,01/09/2014,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1298
,,,22/08/2014,Treatment of Fabry disease,EU/3/14/1310,Positive,30/09/2014,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1310
,,"(3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbaNmate (venglustat)",19/11/2014,Treatment of Gaucher disease,EU/3/14/1374,Positive,15/01/2015,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1374
,,sutimlimab,28/02/2020,Treatment of immune thrombocytopenia,EU/3/20/2258,Positive,06/05/2020,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2258
,,Rilzabrutinib,04/06/2020,Treatment of immune thrombocytopenia,EU/3/20/2278,Positive,19/08/2020,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2278
,,Venglustat,21/08/2020,Treatment of GM2 gangliosidosis,EU/3/20/2325,Positive,25/11/2020,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2325
,,Humanised monoclonal antibody derivative against fibroblast growth factor receptor 3,21/06/2021,Treatment of achondroplasia,EU/3/21/2454,Positive,11/05/2022,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2454
,,"Humanised IgG4 monoclonal antibody against active complement component 1, subcomponent s",18/07/2022,Treatment of autoimmune haemolytic anaemia,EU/3/22/2643,Positive,25/01/2023,18/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2643
Nulibry,EMEA/H/C/005378,Cyclic pyranopterin monophosphate (fosdenopterin),20/09/2010,Treatment of molybdenum-cofactor deficiency type A,EU/3/10/777,Positive,18/10/2010,17/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-777
,,"Cedazuridine, decitabine",10/12/2021,Treatment of acute myeloid leukaemia,EU/3/21/2548,Withdrawn,28/04/2022,06/07/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2548
Hetlioz,EMEA/H/C/003870,tasimelteon,23/02/2011,Treatment of non-24-hour sleep-wake disorders in blind people with no light perception,EU/3/10/841,Positive,07/03/2011,30/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-841
Strimvelis,EMEA/H/C/003854,Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene,26/08/2005,Treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency,EU/3/05/313,Positive,04/01/2006,27/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-313
,,"(S)-N-(5-(4-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, hydrochloride salt",09/12/2020,Treatment of progressive supranuclear palsy,EU/3/20/2381,Positive,27/05/2021,27/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2381
,,Recombinant adeno-associated viral vector expressing the human CNGA3 gene,09/10/2015,Treatment of achromatopsia caused by mutations in the CNGA3 gene,EU/3/15/1556,Positive,16/11/2015,27/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1556
,,Zanidatamab,13/11/2020,Treatment of gastric cancer,EU/3/20/2353,Positive,15/02/2021,27/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2353
,,Zanidatamab,19/07/2021,Treatment of biliary tract cancer,EU/3/21/2458,Positive,12/11/2021,27/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2458
,,Modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles,25/05/2018,Treatment of methylmalonic acidaemia,EU/3/18/2025,Withdrawn,23/07/2018,26/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2025
,,Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene,08/10/2009,Treatment of neuronal ceroid lipofuscinosis,EU/3/16/1806,Withdrawn,09/01/2017,20/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1806
,,Recombinant human elafin,28/01/2010,Treatment of oesophagus carcinoma,EU/3/09/710,Positive,25/02/2010,20/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-710
,,Elafin,20/03/2007,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/07/443,Positive,02/07/2008,20/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-443
,,Cannabidiol,13/04/2022,Treatment of epilepsy with myoclonic-atonic seizures,EU/3/22/2600,Positive,19/07/2022,16/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2600
,,Recombinant adeno-associated viral vector containing the human CNGB3 gene,08/02/2013,Treatment of achromatopsia caused by mutations in the CNGB3 gene,EU/3/13/1099,Positive,04/03/2013,16/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1099
,,imetelstat sodium,14/12/2015,Treatment of myelofibrosis,EU/3/15/1593,Positive,03/02/2016,16/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1593
,,Cannabidivarin,22/02/2018,Treatment of fragile X syndrome,EU/3/18/1977,Positive,11/04/2018,15/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1977
Epidyolex,EMEA/H/C/004675,Cannabidiol,17/01/2018,Treatment of tuberous sclerosis,EU/3/17/1959,Positive,12/03/2018,15/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1959
,,Cannabidivarin,16/10/2017,Treatment of Rett syndrome,EU/3/17/1921,Positive,08/01/2018,15/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1921
,,Delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant,17/02/2016,Treatment of glioma,EU/3/16/1621,Positive,07/04/2016,15/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1621
,,Cannabidiol,16/10/2017,Treatment of West syndrome,EU/3/17/1920,Positive,08/01/2018,15/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1920
Epidyolex,EMEA/H/C/004675,Cannabidiol,20/03/2017,Treatment of Lennox-Gastaut syndrome,EU/3/17/1855,Positive,05/05/2017,14/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1855
Epidyolex,EMEA/H/C/004675,Cannabidiol,15/10/2014,Treatment of Dravet syndrome,EU/3/14/1339,Positive,12/11/2014,14/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1339
,,Cannabidiol,28/07/2015,Treatment of perinatal asphyxia,EU/3/15/1520,Positive,18/08/2015,14/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1520
,,Rifapentine,09/06/2010,Treatment of tuberculosis,EU/3/10/750,Positive,23/06/2010,12/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-750
,,7-ethyl-10-hydroxy-camptothecin,25/07/2019,Treatment of soft tissue sarcoma,EU/3/19/2181,Positive,24/09/2019,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2181
,,Sirolimus,13/11/2013,Prevention of arteriovenous access dysfunction in haemodialysis patients,EU/3/13/1204,Positive,02/12/2013,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1204
,,Glucagon,19/11/2018,Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome,EU/3/18/2091,Positive,19/02/2019,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2091
,,Sulfonated monophosphorylated mannose oligosaccharide,21/06/2011,Treatment of hepatocellular carcinoma,EU/3/11/872,Positive,12/07/2011,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-872
,,Glucagon,08/10/2009,Treatment of congenital hyperinsulinism,EU/3/14/1342,Positive,12/11/2014,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1342
,,Triamcinolone acetonide,21/05/2015,Treatment of non-infectious uveitis,EU/3/15/1490,Positive,30/06/2015,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1490
,,26 base synthetic single-stranded fully phosphorothioated 2'-O-methyl-RNA and DNA mixmer oligonucleotide-based compound,27/02/2017,Treatment of Dravet syndrome,EU/3/17/1829,Positive,31/03/2017,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1829
Hyftor,EMEA/H/C/005896,Sirolimus,23/08/2017,Treatment of tuberous sclerosis,EU/3/17/1910,Positive,17/10/2017,09/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1910
,,"Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",24/03/2020,Treatment in haematopoietic stem cell transplantation,EU/3/20/2260,Positive,12/08/2020,08/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2260
,,Doxorubicin(6-maleimidocaproyl)hydrazone (aldoxorubicin),26/03/2014,Treatment of soft tissue sarcoma,EU/3/14/1258,Withdrawn,07/05/2014,06/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1258
,,Citric acid monohydrate,27/06/2016,Treatment of acute liver failure,EU/3/16/1675,Positive,26/07/2016,05/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1675
,,"4,7,10,13,16,19-docosahexaenoic acid",04/11/2006,Treatment of retinitis pigmentosa,EU/3/06/412,Positive,02/04/2009,05/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-412
,,5'-ASCSASTSCSASGSTSCSTSGSASUSASASGSCSTSA-3' (lademirsen),19/03/2015,Treatment of Alport syndrome,EU/3/15/1451,Withdrawn,11/05/2015,05/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1451
,,Viltolarsen,04/06/2020,Treatment of Duchenne muscular dystrophy,EU/3/20/2282,Positive,19/08/2020,01/06/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2282
,,Recombinant human acid alpha-glucosidase,21/03/2018,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/18/2000,Withdrawn,15/05/2018,30/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2000
Tibsovo,EMEA/H/C/005936,Ivosidenib,21/03/2018,Treatment of biliary tract cancer,EU/3/18/1994,Positive,08/05/2018,12/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1994
Tibsovo; Tidhesco,EMEA/H/C/005936; EMEA/H/C/006174,Ivosidenib,12/12/2016,Treatment of acute myeloid leukaemia,EU/3/16/1802,Positive,09/01/2017,12/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1802
Nugalviq,EMEA/H/C/006270,govorestat,21/06/2022,Treatment of galactosaemia,EU/3/22/2642,Positive,22/09/2022,10/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2642
,,Pegunigalsidase alfa,12/12/2017,Treatment of Fabry disease,EU/3/17/1953,Withdrawn,23/01/2018,08/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1953
,,"N-[(2S)-5-{[(1R, 2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosilate salt (Bomedemstat ditosilate)",14/10/2016,Treatment of myelofibrosis,EU/3/16/1757,Positive,15/11/2016,08/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1757
,,Nimorazole,23/02/2011,Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy,EU/3/10/842,Positive,04/03/2011,08/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-842
,,Troriluzole hydrochloride,10/12/2021,Treatment of spinocerebellar ataxia,EU/3/21/2553,Positive,05/05/2022,08/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2553
,,Rozanolixizumab,11/01/2019,Treatment of immune thrombocytopenia,EU/3/18/2131,Withdrawn,27/03/2019,08/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2131
Oxbryta,EMEA/H/C/004869,2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor),18/11/2016,Treatment of sickle cell disease,EU/3/16/1769,Positive,14/12/2016,04/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1769
SomaKit TOC,EMEA/H/C/004140,Gallium (68Ga)-edotreotide,19/03/2015,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,EU/3/15/1450,Positive,11/05/2015,03/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1450
,,68Ga-DOTA-pABzA-DIG-dPhe-Gln-Trp-Ala-Val-Gly-His-NHCH[(CH2-CH(CH3)2]2,12/12/2016,Diagnosis of gastrointestinal stromal tumours,EU/3/16/1794,Positive,09/01/2017,03/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1794
,,"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-Lcysteinyl-L-threonine-cyclic(2-7)disulfide",19/02/2014,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,EU/3/14/1237,Positive,01/04/2014,03/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1237
Lutathera,EMEA/H/C/004123,"Lutetium (177Lu)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide (lutetium (177Lu) oxodotreotide)",31/01/2008,Treatment of gastro-entero-pancreatic neuroendocrine tumours,EU/3/07/523,Positive,10/07/2008,03/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-523
,,Bomedemstat ditosilate,21/06/2021,Treatment of essential thrombocythaemia,EU/3/21/2451,Positive,11/05/2022,02/05/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2451
,,Ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast,31/07/2018,Treatment of Duchenne muscular dystrophy,EU/3/18/2045,Positive,10/10/2018,28/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2045
,,Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast,19/11/2018,Treatment of Duchenne muscular dystrophy,EU/3/18/2088,Positive,25/02/2019,28/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2088
,,Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp,19/11/2018,Treatment of multiple system atrophy,EU/3/18/2095,Positive,25/02/2019,28/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2095
,,Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor,19/11/2019,Treatment of Duchenne muscular dystrophy,EU/3/18/2089,Positive,25/02/2019,28/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2089
,,Tazemetostat,21/03/2018,Treatment of follicular lymphoma,EU/3/18/2005,Positive,15/05/2018,28/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2005
,,Tazemetostat,21/03/2018,Treatment of diffuse large B-cell lymphoma,EU/3/18/2004,Positive,08/05/2018,28/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2004
,,Tazemetostat,21/03/2018,Treatment of malignant mesothelioma,EU/3/18/2006,Positive,17/05/2018,28/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2006
,,thymidine;deoxycytidine,20/04/2017,"Treatment of mitochondrial DNA depletion syndrome, myopathic form",EU/3/17/1870,Positive,15/05/2017,25/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1870
Fintepla,EMEA/H/C/003933,Fenfluramine hydrochloride,27/02/2017,Treatment of Lennox-Gastaut syndrome,EU/3/17/1836,Positive,31/03/2017,25/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1836
Fintepla,EMEA/H/C/003933,Fenfluramine hydrochloride,18/12/2013,Treatment of Dravet syndrome,EU/3/13/1219,Positive,23/01/2014,25/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1219
,,"3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-pyrazol-1-yl)propanoic acid",24/04/2019,Treatment of Stargardt's disease,EU/3/19/2152,Withdrawn,14/06/2019,13/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2152
,,tripotassium citrate monohydrate;Potassium hydrogen carbonate,09/01/2020,Treatment of cystinuria,EU/3/19/2239,Positive,19/05/2020,13/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2239
Miplyffa,EMEA/H/C/005203,arimoclomol citrate,19/11/2014,"Treatment of Niemann-Pick's disease, type C",EU/3/14/1376,Positive,16/01/2015,11/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1376
,,"(R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea (ceclazepide)",14/12/2015,Treatment of gastro-entero-pancreatic neuroendocrine tumours,EU/3/15/1588,Withdrawn,02/02/2016,04/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1588
,,"Streptococcus pyogenes, group A, type 3, strain Su, inactivated",16/05/2022,Treatment of lymphatic malformations,EU/3/22/2613,Positive,14/12/2022,04/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2613
Qalsody,EMEA/H/C/005493,Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid (tofersen),29/08/2016,Treatment of amyotrophic lateral sclerosis,EU/3/16/1732,Positive,03/10/2016,03/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1732
,,Humanised anti-alpha ν beta 6 monoclonal antibody,29/07/2014,Treatment of idiopathic pulmonary fibrosis,EU/3/14/1301,Positive,01/09/2014,03/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1301
,,2-(3-(4-(1H-Indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt,17/10/2019,Treatment of graft-versus-host disease,EU/3/19/2205,Positive,21/01/2020,03/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2205
,,Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene,07/06/2013,Treatment of adenosine-deaminase-deficient severe combined immunodeficiency,EU/3/13/1134,Positive,25/06/2013,03/04/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1134
,,Iodine (131I) iobenguane,31/01/2008,Treatment of neuroblastoma,EU/3/07/525,Positive,10/07/2008,29/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-525
,,Recombinant adeno-associated viral vector containing the human RPGR gene,30/05/2016,Treatment of retinitis pigmentosa caused by mutations in the RPGR gene,EU/3/16/1665,Positive,22/06/2016,27/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1665
,,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride",28/06/2019,Treatment of maternally-inherited diabetes and deafness,EU/3/19/2168,Positive,02/10/2019,27/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2168
,,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",10/08/2015,"Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes",EU/3/15/1543,Positive,02/10/2015,27/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1543
,,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",15/10/2014,Treatment of Leigh syndrome,EU/3/14/1336,Positive,12/11/2014,27/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1336
,,Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel),06/06/2012,Treatment of Wiskott-Aldrich syndrome,EU/3/12/998,Positive,04/07/2012,27/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-998
,,Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase,20/03/2017,Treatment of ornithine transcarbamylase deficiency,EU/3/17/1850,Positive,05/05/2017,27/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1850
,,Soluble recombinant human fibroblast growth factor receptor 3,27/02/2017,Treatment of achondroplasia,EU/3/17/1843,Withdrawn,31/03/2017,24/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1843
,,miglustat,11/01/2019,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/18/2129,Withdrawn,27/03/2019,24/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2129
,,Autologous haematopoietic stem cells transduced with lentiviral vector encoding the human beta-globin gene,29/04/2009,Treatment of beta thalassaemia intermedia and major,EU/3/09/623,Positive,12/05/2009,24/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-623
,,Adeno-associated viral vector serotype 2 containing the human SLC6A3 gene,13/01/2023,Treatment of dopamine transporter deficiency syndrome,EU/3/22/2746,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2746
,,Autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene,13/01/2023,Treatment of chronic granulomatous disease,EU/3/22/2747,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2747
,,Efzofitimod,13/01/2023,Treatment of sarcoidosis,EU/3/22/2744,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2744
,,Opelconazole,13/01/2023,Treatment of invasive aspergillosis,EU/3/22/2745,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2745
,,Autologous hematopoietic cells genetically modified with a lentiviral vector containing the human RAG2 gene,13/01/2023,Treatment of recombination-activating gene 2 deficient severe combined immunodeficiency,EU/3/22/2741,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2741
,,Nanatinostat;Valganciclovir,13/01/2023,Treatment of diffuse large B-cell lymphoma,EU/3/22/2742,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2742
Zynyz,EMEA/H/C/006194,Retifanlimab,13/01/2023,Treatment of Merkel cell carcinoma,EU/3/22/2743,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2743
,,"N1,N14-diethyl-3S,12S-dihydroxyhomospermine tetrahydrochloride",13/01/2023,Treatment of pancreatic cancer,EU/3/22/2740,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2740
,,Octreotide acetate,13/01/2023,Treatment of carcinoid syndrome,EU/3/22/2738,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2738
,,"3-(1-(2',3'-dimethoxy-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-4-yl)benzoic acid",13/01/2023,Treatment of Duchenne muscular dystrophy,EU/3/22/2739,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2739
,,Vorasidenib hemicitrate hemihydrate,13/01/2023,Treatment of glioma,EU/3/22/2737,Positive,23/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2737
Reblozyl,EMEA/H/C/004444,Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept),29/07/2014,Treatment of beta thalassaemia intermedia and major,EU/3/14/1300,Positive,01/09/2014,21/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1300
,,Autologous T-cells transduced with a lentiviral vector encoding a chimeric antigen receptor against CD7,09/12/2022,Treatment of acute lymphoblastic leukaemia,EU/3/22/2732,Positive,13/03/2023,14/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2732
,,Briquilimab,09/12/2022,Treatment in haematopoietic stem cell transplantation,EU/3/22/2733,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2733
,,"(2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid",09/12/2022,Treatment of idiopathic pulmonary fibrosis,EU/3/22/2735,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2735
,,"Adeno-associated virus serotype rh79 containing the human OTC gene, adeno-associated virus serotype rh79 encoding a meganuclease for targeted editing of the human PCSK9 gene",09/12/2022,Treatment of ornithine transcarbamylase deficiency,EU/3/22/2736,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2736
,,"Potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo-5-phenyl-6,7-dihydrothieno[2,3-b]pyridin-4-olate monohydrate",09/12/2022,Treatment of adrenoleukodystrophy,EU/3/22/2734,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2734
,,Duvelisib,09/12/2022,Treatment of peripheral T-cell lymphoma,EU/3/22/2730,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2730
,,Utreloxastat,09/12/2022,Treatment of amyotrophic lateral sclerosis,EU/3/22/2728,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2728
,,Recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA,09/12/2022,Treatment of Canavan disease,EU/3/22/2729,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2729
,,Copper (64Cu) oxodotreotide,09/12/2022,Diagnosis of neuroendocrine neoplasms,EU/3/22/2727,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2727
,,Mebendazole,09/12/2022,Treatment of autosomal dominant polycystic kidney disease,EU/3/22/2726,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2726
,,16-base single stranded RNA targeting miR-23b linked to oleic acid,09/12/2022,Treatment of myotonic disorders,EU/3/22/2724,Positive,13/03/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2724
Farydak,EMEA/H/C/003725,Panobinostat,08/11/2012,Treatment of multiple myeloma,EU/3/12/1063,Positive,13/12/2012,13/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1063
,,Lentiviral vector containing the human MYO7A gene,23/03/2010,Treatment of retinitis pigmentosa in Usher syndrome 1B,EU/3/10/727,Positive,26/03/2010,13/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-727
,,Lentiviral vector containing the human ABCA4 gene,02/02/2010,Treatment of Stargardt's disease,EU/3/09/720,Positive,04/03/2010,13/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-720
,,clofazimine,21/08/2019,Treatment of nontuberculous mycobacterial lung disease,EU/3/19/2200,Positive,16/01/2020,13/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2200
,,5-aminolevulinic acid,12/01/2017,Treatment of glioma,EU/3/16/1811,Positive,13/07/2017,10/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1811
,,Cannabidiol,11/11/2022,Treatment of 22q11.2 deletion syndrome,EU/3/22/2718,Positive,23/01/2023,07/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2718
,,Cannabidiol,25/02/2022,Treatment of fragile X syndrome (FXS),EU/3/22/2583,Positive,13/05/2022,07/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2583
,,"3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide, Sodium chloride solution 4.2% (w/v)",16/11/2020,Treatment of primary ciliary dyskinesia,EU/3/20/2363,Positive,15/02/2021,07/03/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2363
,,apomorphine hydrochloride,16/02/2006,Treatment of off-periods in Parkinson's disease not responding to oral treatment,EU/3/06/349,Positive,24/08/2006,28/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-349
,,Ribitol,19/10/2020,Treatment of limb-girdle muscular dystrophy,EU/3/20/2337,Positive,25/05/2021,27/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2337
,,Synthetic double-stranded siRNA oligonucleotide directed against SERPINA1 mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues,16/12/2019,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/19/2235,Positive,25/02/2020,24/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2235
,,Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues,31/07/2018,Treatment of primary hyperoxaluria,EU/3/18/2052,Positive,11/10/2018,24/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2052-0
,,Patidegib,21/03/2018,Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome),EU/3/18/1998,Positive,08/05/2017,24/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1998
,,"2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate",24/03/2020,Treatment of pancreatic cancer,EU/3/20/2259,Withdrawn,12/08/2020,16/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2259
,,proteolytic enzymes enriched in bromelain,30/07/2002,Treatment of partial deep dermal and full-thickness burns,EU/3/02/107,Expired,08/01/2003,15/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-107
Tyvaso; Tyvaso,EMEA/H/C/001115; EMEA/H/C/001115,Treprostinil sodium,14/04/2004,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/04/197,Positive,23/09/2009,13/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-197
,,Treprostinil diethanolamine,15/05/2009,Treatment of systemic sclerosis,EU/3/09/635,Positive,09/06/2009,13/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-635
,,Ralinepag,11/01/2019,Treatment of pulmonary arterial hypertension,EU/3/18/2130,Positive,27/03/2019,13/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2130
,,Berzosertib,18/07/2022,Treatment of small cell lung cancer,EU/3/22/2655,Withdrawn,23/01/2023,07/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2655
,,Rebastinib,12/11/2021,Treatment of ovarian cancer,EU/3/21/2524,Positive,09/06/2022,07/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2524
,,"Dodecyl creatine ester, dodecyl creatine ester hydrochloride",19/02/2021,Treatment of creatine deficiency syndromes,EU/3/21/2409,Positive,23/02/2022,06/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2409
,,polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase (pegtibatinase),30/05/2016,Treatment of homocystinuria,EU/3/16/1664,Positive,23/06/2016,06/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1664
,,Volanesorsen sodium,14/07/2016,Treatment of familial partial lipodystrophy,EU/3/16/1711,Positive,06/09/2016,02/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1711
Waylivra,EMEA/H/C/004538,Phosphorothioate oligonucleotide targeted to apolipoprotein C-III (volanesorsen),19/02/2014,Treatment of familial chylomicronaemia syndrome,EU/3/14/1249,Positive,03/04/2014,02/02/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1249
Ebvallo,EMEA/H/C/004577,Allogeneic Epstein-Barr virus specific cytotoxic T lymphocytes (Tabelecleucel),21/03/2016,Treatment of post-transplantation lymphoproliferative disorders,EU/3/16/1627,Positive,03/05/2016,30/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1627
,,Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene (prademagene zamikeracel),27/02/2017,Treatment of epidermolysis bullosa,EU/3/17/1835,Positive,31/03/2017,30/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1835
,,Bardoxolone methyl,20/08/2021,Treatment of autosomal dominant polycystic kidney disease,EU/3/21/2480,Positive,25/02/2022,30/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2480
Imbarkyd,EMEA/H/C/005869,Bardoxolone methyl,25/05/2018,Treatment of Alport syndrome,EU/3/18/2019,Positive,23/07/2018,30/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2019
,,idursulfase,06/01/2021,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/20/2391,Withdrawn,18/10/2021,27/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2391
,,Loncastuximab tesirine,20/08/2021,Treatment of diffuse large B-cell lymphoma,EU/3/21/2481,Withdrawn,25/02/2022,26/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2481
,,"2,4,6,7,8,9-hexahydro-4-((2-methylphenyl)methyl)-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-one",18/07/2022,Treatment of glioma,EU/3/22/2661,Positive,25/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2661
,,Adeno-associated viral vector serotype 9 containing the human ABCD1 gene,11/11/2022,Treatment of adrenoleukodystrophy,EU/3/22/2719,Positive,25/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2719
,,Autologous naive regulatory T cells transduced with a lentiviral vector encoding for a chimeric antigen receptor to recognise the HLA-A*02 antigen,18/07/2022,Treatment in solid organ transplantation,EU/3/22/2647,Positive,25/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2647
,,Crofelemer,11/10/2022,Treatment of microvillus inclusion disease,EU/3/22/2693,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2693
,,Autologous T cells transduced with a lentiviral vector expressing a chimeric antigen receptor against CLL-1,11/10/2022,Treatment of acute myeloid leukaemia,EU/3/22/2694,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2694
,,Epeleuton,11/10/2022,Treatment of sickle cell disease,EU/3/22/2695,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2695
,,Velusetrag,11/10/2022,Treatment of intestinal pseudo-obstruction,EU/3/22/2696,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2696
,,Inaxaplin,11/10/2022,Treatment of apolipoprotein L1-mediated kidney disease,EU/3/22/2697,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697
,,"Adeno?associated viral vector serotype 8 containing the 3' human otoferlin coding sequence, adeno?associated viral vector serotype 8 containing the 5' human otoferlin coding sequenceAdeno‐associated viral vector serotype 8 containing the 3' human otoferlin coding sequence, adeno‐associated viral vector serotype 8 containing the 5' human otoferlin coding sequence",11/10/2022,Treatment of otoferlin gene-mediated hearing loss,EU/3/22/2698,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2698
,,Human IgG4k monoclonal antibody against CD89,11/10/2022,Treatment of linear IgA bullous dermatosis,EU/3/22/2702,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2702
,,Etidronate disodium,11/10/2022,Treatment of pseudoxanthoma elasticum,EU/3/22/2703,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2703
,,"Sodium ({(2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1)",11/10/2022,Treatment of vanishing white matter disease,EU/3/22/2704,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2704
,,Selinexor,11/10/2022,Treatment of myelofibrosis,EU/3/22/2705,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2705
,,"Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate",11/10/2022,Treatment of Rett syndrome,EU/3/22/2706,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2706
,,Eculizumab,11/10/2022,Treatment of Guillain-Barré syndrome,EU/3/22/2707,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2707
,,acetylleucine,11/10/2022,Treatment of GM1 gangliosidosis,EU/3/22/2708,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2708
,,ropeginterferon alfa-2b,11/10/2022,Treatment of essential thrombocythaemia,EU/3/22/2709,Positive,24/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2709
,,Recombinant human mesencephalic astrocyte-derived neurotrophic factor,24/04/2015,Treatment of retinitis pigmentosa,EU/3/15/1486,Positive,22/05/2015,24/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1486
,,(R)-deuteropioglitazone hydrochloride,11/11/2022,Treatment of adrenoleukodystrophy,EU/3/22/2720,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2720
,,"(S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile (olutasidenib)",29/05/2019,Treatment of acute myeloid leukaemia,EU/3/19/2159,Positive,09/08/2019,23/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2159
,,tricaprilin,11/11/2022,Treatment of West syndrome,EU/3/22/2717,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2717
,,melatonin,28/11/2022,Treatment of retinopathy of prematurity,-,Negative,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-retinopathy-prematurity
,,Pegcetacoplan,11/11/2022,Treatment of C3 glomerulopathy with or without immune complexes,EU/3/22/2716,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2716
,,"Copper nanocluster conjugated to acetate, histidinate and ascorbate",11/11/2022,Treatment of Menkes disease,EU/3/22/2711,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2711
,,Delpazolid,10/11/2022,Treatment of tuberculosis,EU/3/22/2710,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2710
,,atorvastatin,11/11/2022,Treatment of familial cerebral cavernous malformations,EU/3/22/2714,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2714
,,Thiostrepton,18/07/2022,Treatment of  malignant mesothelioma,EU/3/22/2648,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2648
,,Propranolol,11/11/2022,Treatment of familial cerebral cavernous malformations,EU/3/22/2713,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2713
,,"(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione",18/07/2022,Treatment of familial adenomatous polyposis (FAP),EU/3/22/2670,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2670
,,Toripalimab,18/07/2022,Treatment of nasopharyngeal cancer,EU/3/22/2669,Withdrawn,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2669
,,liraglutide,18/07/2022,Treatment of Wolfram syndrome,EU/3/22/2667,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2667
,,mRNA encoding modified human ornithine transcarbamylase,18/07/2022,Treatment of ornithine transcarbamylase deficiency,EU/3/22/2646,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2646
,,W253R/R275S tissue plasminogen activator,18/07/2022,Treatment of non-traumatic spontaneous intracerebral haemorrhage,EU/3/22/2666,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2666
,,Pyridoxal 5'-phosphate,18/07/2022,Treatment of pyridoxal 5'‐phosphate homeostasis protein deficiency,EU/3/22/2665,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2665
,,Hydroquinidine hydrochloride,18/07/2022,Treatment of Brugada syndrome,EU/3/22/2651,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2651
,,"3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole",18/07/2022,Treatment of multiple system atrophy,EU/3/22/2652,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2652
,,Human decorin fused to the truncated homing peptide CRK,18/07/2022,Treatment of epidermolysis bullosa,EU/3/22/2664,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2664
,,melatonin,14/10/2022,Prevention of spaceflight-related radiation and microgravity,N/A,Negative,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-prevention-spaceflight-related-radiation-and-microgravity
,,Sodium phenylbutyrate,18/07/2022,Treatment of maple syrup urine disease,EU/3/22/2663,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2663
,,"(S)-1-(4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide",18/07/2022,Treatment of fibrodysplasia ossificans progressiva,EU/3/22/2654,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2654
,,vilobelimab,18/07/2022,Treatment of pyoderma gangrenosum,EU/3/22/2662,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2662
,,Efgartigimod alfa,18/07/2022,Treatment of pemphigus,EU/3/22/2653,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2653
,,Panobinostat,18/07/2022,Treatment of glioma,EU/3/22/2660,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2660
,,Parsaclisib,18/07/2022,Treatment of autoimmune haemolytic anaemia,EU/3/22/2659,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2659
,,Heterologous swine glyco-humanised polyclonal antibody against T lymphocytes,18/07/2022,Treatment in solid organ transplantation,EU/3/22/2658,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2658
,,"Salmonella enterica, subsp. enterica, serovar Typhimurium, strain YS1646, live",18/07/2022,Treatment of schwannoma,EU/3/22/2657,Positive,23/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2657
,,Ramiprilat,12/03/2013,Treatment of Stargardt's disease,EU/3/13/1117,Positive,05/04/2013,17/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1117
,,Herpes simplex virus 1 expressing the human CFTR gene,26/03/2021,Treatment of cystic fibrosis,EU/3/21/2421,Positive,19/01/2022,17/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2421
,,"Replication-incompetent, non-integrating, herpes simplex virus 1 vector expressing the human transglutaminase-1 enzyme (Inetagugene geperpavec)",13/11/2019,Treatment of autosomal recessive congenital ichthyosis,EU/3/19/2225,Positive,13/02/2020,13/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2225
,,Humanised IgG1 monoclonal antibody against TfR1 conjugated to double stranded siRNA oligonucleotide against DMPK via a non-cleavable linker,20/08/2021,Treatment of myotonic disorders,EU/3/21/2485,Positive,09/01/2023,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2485
,,zanubrutinib,20/05/2021,Treatment of marginal zone lymphoma,EU/3/21/2438,Withdrawn,18/03/2022,05/01/2023,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2438
,,Pegylated adrenomedullin,27/07/2020,Treatment of acute respiratory distress syndrome (ARDS),EU/3/20/2301,Positive,19/11/2020,22/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2301
,,Human allogeneic bone-marrow-derived osteoblastic-like cells,05/08/2013,Treatment of non-traumatic osteonecrosis,EU/3/13/1176,Positive,13/09/2013,22/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1176
,,Human allogeneic bone-marrow-derived osteoblastic cells,10/08/2015,Treatment of osteogenesis imperfecta,EU/3/15/1533,Positive,02/10/2015,22/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1533
,,regorafenib,28/06/2019,Treatment of glioma,EU/3/19/2177,Withdrawn,14/10/2019,20/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2177
,,Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase,15/10/2021,Treatment of mucopolysaccharidosis type I,EU/3/21/2505,Withdrawn,20/01/2022,20/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2505
,,bevacizumab,16/12/2014,Treatment of hereditary haemorrhagic telangiectasia,EU/3/14/1390,Positive,26/02/2015,19/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1390
,,4-[131I] Iodo-L-phenylalanine,11/04/2006,Treatment of glioma,EU/3/06/363,Positive,24/04/2009,19/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-363
Yescarta,EMEA/H/C/004480,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor (axicabtagene ciloleucel),16/12/2014,Treatment of diffuse large B-cell lymphoma,EU/3/14/1393,Positive,26/02/2015,16/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1393
,,Amphotericin B,10/08/2022,Treatment of cryptococcosis,EU/3/22/2691,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2691
,,Tamibarotene,10/08/2022,Treatment of myelodysplastic syndromes,EU/3/22/2688,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2688
,,"(7S)-8,8-dimethyl-7-{[(2E)-3-phenyl-2-propen-1-yl]oxy}-7,8-dihydro-2H,6H-pyrano[3,2-g]chromen-2-one",10/08/2022,Treatment of Hutchinson-Gilford progeria syndrome,EU/3/22/2689,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2689
,,Humanised IgG1 tetravalent monoclonal antibody against death receptor 5,10/08/2022,Treatment of chondrosarcoma,EU/3/22/2690,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2690
,,Allogeneic adult liver-derived stem cells,10/08/2022,Treatment of urea cycle disorders,EU/3/22/2685,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2685
,,Gold,10/08/2022,Treatment of amyotrophic lateral sclerosis,EU/3/22/2686,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2686
,,clarithromycin;clofazimine;rifabutin,10/08/2022,Treatment of nontuberculous mycobacterial lung disease,EU/3/22/2687,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2687
,,Vutrisiran,10/08/2022,Treatment of Stargardt's disease,EU/3/22/2682,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2682
,,Sotuletinib,10/08/2022,Treatment of amyotrophic lateral sclerosis,EU/3/22/2683,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2683
,,"Autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes",10/08/2022,Treatment of frontotemporal dementia,EU/3/22/2681,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2681
,,Mazindol,10/08/2022,Treatment of idiopathic hypersomnia,EU/3/22/2676,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2676
,,Calmangafodipir,10/08/2022,Prevention of acute liver failure,EU/3/22/2678,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2678
,,Lithium carbonate,10/08/2022,Treatment of familial adenomatous polyposis (FAP),EU/3/22/2674,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2674
,,Bezafibrate,10/08/2022,Treatment of primary sclerosing cholangitis,EU/3/22/2675,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2675
,,Toll-like receptor 4 agonist,10/08/2022,Treatment of osteosarcoma,EU/3/22/2672,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2672
,,Nanatinostat;Valganciclovir,10/08/2022,Treatment of peripheral T-cell lymphoma,EU/3/22/2673,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2673
,,Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA,10/08/2022,Treatment of mucopolysaccharidosis type IV A (Morquio A syndrome),EU/3/22/2671,Positive,15/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2671
,,pentosan polysulfate sodium,21/08/2020,Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome),EU/3/20/2315,Positive,25/11/2020,15/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2315
,,pentosan polysulfate sodium,19/11/2014,Treatment of mucopolysaccharidosis type I,EU/3/14/1359,Positive,15/01/2015,15/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1359
,,concizumab,12/10/2017,Treatment of haemophilia B,EU/3/17/1940,Withdrawn,15/01/2018,14/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1940
,,Humanised monoclonal IgG4 antibody against tissue-factor-pathway inhibitor (concizumab),10/10/2012,Treatment of haemophilia A,EU/3/12/1052,Withdrawn,16/11/2012,14/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1052
,,Alisporivir,16/03/2022,Treatment of collagen VI-related myopathies,EU/3/22/2590,Positive,20/06/2022,14/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2590
,,besilesomab,17/10/2019,Treatment in haematopoietic stem cell transplantation,EU/3/19/2211,Positive,22/01/2020,14/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2211
Livmarli,EMEA/H/C/005857,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",18/12/2013,Treatment of Alagille syndrome,EU/3/13/1214,Positive,22/01/2014,14/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1214
,,"Chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment",16/05/2022,Treatment of idiopathic pulmonary fibrosis,EU/3/22/2619,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2619
,,pasireotide,16/05/2022,Treatment of noninsulinoma pancreatogenous hypoglycemia syndrome,EU/3/22/2620,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2620
,,Autologous peripheral blood-derived CD4 T-cells CRISPR-edited at the CD40LG locus,16/05/2022,Treatment of hyper IgM syndromes,EU/3/22/2617,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2617
,,Icerguastat acetate,16/05/2022,Treatment of amyotrophic lateral sclerosis,EU/3/22/2618,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2618
,,Ibudilast,16/05/2022,Treatment of fragile X syndrome,EU/3/22/2615,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2615
,,Adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene,16/05/2022,Treatment of limb-girdle muscular dystrophy,EU/3/22/2616,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2616
,,Elamipretide,16/05/2022,Treatment of myopathic mitochondrial DNA depletion syndrome,EU/3/22/2614,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2614
,,Elezanumab,16/05/2022,Treatment of spinal cord injury,EU/3/22/2612,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2612
,,Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD123,16/05/2022,Treatment of blastic plasmacytoid dendritic cell neoplasm,EU/3/22/2610,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2610
,,Cannabidiol,16/05/2022,Treatment of epidermolysis bullosa,EU/3/22/2609,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2609
,,Adeno-associated virus serotype R100 containing the human RPGRorf15 gene isoform,16/05/2022,Treatment of inherited retinal dystrophies due to defects in the RPGR gene,EU/3/22/2608,Positive,14/12/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2608
,,Parsaclisib,25/07/2019,Treatment of marginal zone lymphoma,EU/3/19/2185,Withdrawn,24/09/2019,13/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2185
,,Tremelimumab,09/12/2020,Treatment of hepatocellular carcinoma,EU/3/20/2370,Withdrawn,21/05/2021,09/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2370
,,3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt,14/07/2016,Treatment of idiopathic pulmonary fibrosis,EU/3/16/1692,Positive,06/09/2016,08/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1692
Pyrukynd,EMEA/H/C/005540,mitapivat sulfate,22/04/2020,Treatment of pyruvate kinase deficiency,EU/3/20/2270,Positive,12/08/2020,07/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2270
,,Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express beta-domain deleted human factor VIII,09/12/2020,Treatment of  haemophilia A,EU/3/20/2380,Withdrawn,27/05/2021,05/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2380
,,Lentiviral vector encoding human coagulation factor IX,26/02/2019,Treatment of haemophilia B,EU/3/19/2141,Positive,09/04/2019,02/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2141
Tecartus,EMEA/H/C/005102,Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel),19/10/2020,Treatment of acute lymphoblastic leukaemia,EU/3/20/2344,Positive,16/02/2021,02/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2344
,,"1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4- c]pyridin-6-yl)ethan-1-one (Tinlarebant)",25/05/2018,Treatment of Stargardt's disease,EU/3/18/2014,Positive,23/07/2018,01/12/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2014
,,Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene (betibeglogene autotemcel),24/01/2013,Treatment of beta thalassaemia intermedia and major,EU/3/12/1091,Withdrawn,01/03/2013,30/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1091
,,Linerixibat,12/11/2021,Treatment of primary biliary cholangitis,EU/3/21/2515,Positive,07/06/2022,29/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2515
Livtencity,EMEA/H/C/005787,Maribavir,07/06/2013,Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity,EU/3/13/1133,Positive,25/06/2013,24/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1133
Livtencity,EMEA/H/C/005787,Maribavir,18/12/2007,Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity,EU/3/07/519,Positive,23/09/2009,24/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-519
,,"1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt (onvansertib)",24/08/2018,Treatment of acute myeloid leukaemia,EU/3/18/2057,Withdrawn,19/12/2018,22/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2057
,,"5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride",19/11/2018,Treatment of Kabuki syndrome,EU/3/18/2082,Withdrawn,19/02/2019,22/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2082
,,Hexasodium phytate,17/07/2012,Treatment of calciphylaxis,EU/3/12/1026,Positive,31/08/2012,22/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1026
,,Recombinant chimeric monoclonal antibody against CD20 (ublituximab),26/11/2009,Treatment of chronic lymphocytic leukaemia,EU/3/09/699,Positive,09/12/2009,22/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-699
,,6alpha-ethyl-chenodeoxycholic acid,27/07/2010,Treatment of primary biliary cirrhosis,EU/3/10/753,Positive,05/08/2010,21/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-753
Loargys,EMEA/H/C/005484,"poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with arginase 1 [cobalt cofactor] (synthetic human) (1:10), trimer (pegzilarginase)",14/07/2016,Treatment of hyperargininaemia,EU/3/16/1701,Positive,06/09/2016,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1701
,,Glyceryl tri-(4-phenylbutyrate),10/06/2010,Treatment of citrullinaemia type 2,EU/3/10/739,Positive,24/06/2010,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-739
Ravicti,EMEA/H/C/003822,Glyceryl tri-(4-phenylbutyrate),10/06/2010,Ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria (HHH) syndrom,EU/3/10/738,Positive,24/06/2010,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-738
Ravicti,EMEA/H/C/003822,Glyceryl tri-(4-phenylbutyrate),10/06/2010,Treatment of hyperargininaemia,EU/3/10/737,Positive,24/06/2010,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-737
Ravicti,EMEA/H/C/003822,Glyceryl tri-(4-phenylbutyrate),10/06/2010,Treatment of argininosuccinic aciduria,EU/3/10/736,Positive,24/06/2010,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-736
Ravicti,EMEA/H/C/003822,Glyceryl tri-(4-phenylbutyrate),10/06/2010,Treatment of citrullinaemia type 1,EU/3/10/735,Positive,28/06/2010,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-735
Ravicti,EMEA/H/C/003822,Glyceryl tri-(4-phenylbutyrate),10/06/2010,Treatment of ornithine carbamoyltransferase deficiency,EU/3/10/734,Positive,24/06/2010,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-734
Ravicti,EMEA/H/C/003822,Glyceryl tri-(4-phenylbutyrate),03/02/2010,Treatment of carbamoyl-phosphate synthase-1 deficiency,EU/3/10/733,Positive,24/06/2010,18/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-733
,,gefinitib,26/10/2018,Treatment of Fanconi anaemia type A,EU/3/18/2075,Positive,10/01/2019,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2075
,,Metformin,12/12/2016,Treatment of progressive myoclonic epilepsy type 2 (Lafora disease),EU/3/16/1803,Positive,09/01/2017,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1803
,,Temsirolimus,30/05/2016,Treatment of adrenoleukodystrophy,EU/3/16/1669,Positive,24/06/2016,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1669
,,Ubiquinol,20/09/2016,Treatment of primary coenzyme Q10 deficiency syndrome,EU/3/16/1765,Positive,15/11/2016,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1765
,,Haematopoietic stem cells modified with a lentiviral vector containing the CD18 gene,20/09/2016,Treatment of leukocyte adhesion deficiency type I,EU/3/16/1753,Positive,15/11/2016,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1753
,,Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene,22/08/2014,Treatment of pyruvate kinase deficiency,EU/3/14/1330,Positive,02/10/2014,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1330
,,afatinib,14/12/2018,Treatment of Fanconi anaemia,EU/3/18/2110,Positive,08/03/2019,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2110
,,dimethyl fumarate,09/01/2020,Treatment of adrenoleukodystrophy,EU/3/19/2236,Positive,14/05/2020,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2236
,,Autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by CRISPR/Cas9-mediated excision of mutation-carrying COL7A1 exon 80,28/02/2020,Treatment of epidermolysis bullosa,EU/3/20/2253,Positive,06/05/2020,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2253
,,Adeno-associated virus of serotype rh10 encoding Human MLC1 under the control of GFAP promoter,15/10/2021,Treatment of megalencephalic leukoencephalopathy with subcortical cysts,EU/3/21/2500,Positive,20/01/2022,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2500
,,Autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene,12/11/2021,Treatment of Diamond-Blackfan anaemia,EU/3/21/2519,Positive,08/06/2022,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2519
,,Fingolimod,12/11/2021,Treatment of adrenoleukodystrophy,EU/3/21/2520,Positive,08/06/2022,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2520
,,Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene,24/02/2022,Treatment of pyruvate kinase deficiency,EU/3/22/2580,Positive,13/05/2022,11/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2580
Vyjuvek,EMEA/H/C/006330,genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (beremagene geperpavec),16/04/2018,Treatment of epidermolysis bullosa,EU/3/18/2012,Positive,17/05/2018,10/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2012
Crysvita,EMEA/H/C/004275,Burosumab,16/04/2018,Treatment of phosphaturic mesenchymal tumour,EU/3/18/2011,Positive,17/05/2018,08/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2011
,,"6-((3S,4S)-4-methyl-1-(pyrimidin-2-yl-methyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7H-imidazo(1,5-a)pyrazin-8-one (Tovinontrine)",21/08/2020,Treatment of sickle cell disease,EU/3/20/2322,Withdrawn,25/11/2020,08/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2322
Febseltiq,EMEA/H/C/005361,Infigratinib,21/08/2020,Treatment of cholangiocarcinoma,EU/3/20/2329,Withdrawn,25/11/2020,08/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2329
,,,26/08/2005,Treatment of progressive myoclonic epilepsies,EU/3/05/315,Withdrawn,18/08/2008,08/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-315
,,Sodium phenylbutyrate,11/11/2015,Treatment of pyruvate dehydrogenase complex deficiency,EU/3/15/1581,Positive,06/01/2016,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1581
,,Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded,15/10/2021,Treatment of osteopetrosis,EU/3/21/2507,Positive,21/01/2022,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2507
,,Tamoxifen citrate,,Treatment of neuronal ceroid lipofuscinosis,EU/3/22/2635,Positive,22/09/2022,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2635
,,Combination of two adeno-associated viral vectors of serotype 8 containing the 5'- and the 3'- half coding sequences of human ABCA4 fused to inteins,17/10/2019,Treatment of Stargardt's disease,EU/3/19/2208,Positive,22/01/2020,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2208
,,"Combination of three adeno-associated viral vectors of serotype 8 containing the 5'-, the body- and the 3'-  coding sequences of human CEP290 fused to inteins",28/02/2020,Treatment of inherited retinal dystrophies,EU/3/20/2254,Positive,06/05/2020,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2254
,,Autologous CD34+ cell enriched population containing haematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding the human ADA2 gene,20/08/2021,Treatment of adenosine deaminase 2 deficiency (DADA2),EU/3/21/2496,Positive,04/03/2022,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2496
,,Mixture of two adeno-associated viral vectors serotype 8 containing the 5'-half sequence of human MYO7A gene and the 3'-half sequence of human MYO7A gene,04/07/2014,Treatment of Usher syndrome,EU/3/14/1282,Positive,16/07/2014,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1282
,,Mixture of two adeno-associated viral vectors of serotye 8 containing the 5'-half sequence of human ABCA4 gene and the 3'-half sequence of human ABCA4 gene,04/07/2014,Treatment of Stargardt's disease,EU/3/14/1283,Positive,16/07/2014,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1283
,,Adeno-associated viral vector containing the human ARSB gene,13/05/2011,Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome),EU/3/11/864,Positive,27/05/2011,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-864
,,Adeno-associated viral vector serotype 8 containing the human GUCY2D gene,26/03/2014,Treatment of Leber's congenital amaurosis,EU/3/14/1256,Positive,07/05/2014,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1256
,,Adeno-associated viral vector serotype 8 encoding engineered rhodopsin DNA-binding repressor and human rhodopsin expression cassettes,12/12/2016,Treatment of retinitis pigmentosa,EU/3/16/1796,Positive,09/01/2017,07/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1796
,,acamprosate calcium,15/10/2014,Treatment of fragile X syndrome,EU/3/14/1337,Positive,12/11/2014,03/11/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1337
,,N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-carbamoyl}-methyl)-2-[2-(2-fluoro-phenyl)-ethylamino]-N-isobutyl-acetamide,31/03/2014,Treatment of optic neuritis,EU/3/14/1248,Positive,03/04/2014,31/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1248
,,Diflunisal,21/06/2022,Treatment of ATTR amyloidosis,EU/3/22/2640,Positive,22/09/2022,31/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2640
,,Ovine specific immunoglobulin (Fab) fragments raised against Vipera berus veno,09/10/2015,Treatment of snakebite envenomation,EU/3/15/1548,Positive,16/11/2015,21/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1548
,,Variant of recombinant human fibroblast growth factor 19,22/08/2014,Treatment of primary biliary cirrhosis,EU/3/14/1329,Positive,02/10/2014,21/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1329
,,"1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt",24/08/2018,Treatment of beta thalassaemia intermedia and major,EU/3/18/2058,Withdrawn,20/12/2018,21/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2058
,,Teclistamab,19/07/2022,Treatment of multiple myeloma,EU/3/20/2331,Withdrawn,11/02/2021,13/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2331
,,N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide,06/06/2012,Treatment of meningioma,EU/3/12/996,Positive,04/07/2012,12/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-996
,,N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide,06/06/2012,Treatment of schwannoma,EU/3/12/997,Positive,04/07/2012,12/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-997
Amvuttra,EMEA/H/C/005852,"synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues (Vutrisiran)",25/05/2018,Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis),EU/3/18/2026,Positive,23/07/2018,12/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2026
,,[Gly2]-recombinant human glucagon-like peptide,12/12/2001,Treatment of short bowel syndrome,EU/3/01/077,Positive,15/05/2009,12/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-077
,,"4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",12/12/2017,Treatment of familial cerebral cavernous malformations,EU/3/17/1948,Positive,23/01/2018,11/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1948
,,Adeno-associated viral vector serotype rh10 containing the human factor IX gene for the treatment of haemophilia B-,14/12/2015,Treatment of haemophilia B,EU/3/15/1599,Withdrawn,03/02/2016,11/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1599
,,Recombinant adeno-associated viral vector containing the human retinoschisin gene,12/03/2013,Treatment of X-linked juvenile retinoschisis,EU/3/13/1107,Positive,05/04/2013,06/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1107
,,Recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene,20/03/2007,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/07/440,Positive,19/07/2007,06/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-440
Omjjara,EMEA/H/C/005768,"N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt (momelotinib)",05/08/2011,Treatment of primary myelofibrosis,EU/3/11/888,Positive,16/08/2011,04/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-888
Omjjara,EMEA/H/C/005768,"N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt (momelotinib)",05/08/2011,Treatment of post-polycythaemia vera myelofibrosis,EU/3/11/886,Positive,16/08/2011,04/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-886
Omjjara,EMEA/H/C/005768,"N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt (momelotinib)",05/08/2011,Treatment of post-essential thrombocythaemia myelofibrosis,EU/3/11/887,Positive,16/08/2011,04/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-887
Takhzyro,EMEA/H/C/004806,Recombinant human IgG1 kappa light chain monoclonal antibody targeting plasma kallikrein (lanadelumab),09/10/2015,Treatment of hereditary angioedema,EU/3/15/1551,Positive,16/11/2015,04/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1551
Natpar,EMEA/H/C/003861,Recombinant human parathyroid hormone,16/01/2014,Treatment of hypoparathyroidism,EU/3/13/1210,Positive,23/01/2014,04/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1210
,,Recombinant human arylsulfatase A,26/11/2010,treatment of metachromatic leukodystrophy,EU/3/10/813,Positive,17/12/2010,04/10/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-813
,,"(S)-3-((3-(1-((6-(3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium (seralutinib)",29/05/2019,Treatment of  pulmonary arterial hypertension,EU/3/19/2158,Positive,09/08/2019,30/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2158
Imcivree,EMEA/H/C/005089,Setmelanotide,21/08/2019,Treatment of Bardet-Biedl syndrome,EU/3/19/2192,Positive,14/01/2020,30/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2192
,,Variant of recombinant human fibroblast growth factor 19,14/12/2015,Treatment of primary sclerosing cholangitis,EU/3/15/1584,Positive,02/02/2016,28/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1584
Roctavian; Roctavian,EMEA/H/C/004749; EMEA/H/C/005830,Adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene,21/03/2016,Treatment of haemophilia A,EU/3/16/1622,Positive,04/05/2016,28/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1622
,,Combretastatin A1 diphosphate,14/12/2015,Treatment of acute myeloid leukaemia,EU/3/15/1587,Positive,02/02/2016,28/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1587
,,Ilixadencel,26/03/2021,Treatment of gastrointestinal stromal tumours,EU/3/21/2418,Positive,19/01/2022,28/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2418
,,Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene,30/05/2016,Treatment of beta thalassaemia intermedia and major,EU/3/16/1660,Positive,23/06/2016,26/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1660
,,Ofranergene obadenovec,16/10/2017,Treatment of ovarian cancer,EU/3/17/1926,Withdrawn,08/01/2018,26/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1926
,,Adenovirus-associated vector containing human Fas-c gene (ofranergene obadenovec),06/06/2012,Treatment of glioma,EU/3/12/1002,Withdrawn,04/07/2012,26/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1002
,,Eltanexor,21/06/2022,Treatment of myelodysplastic syndromes,EU/3/22/2641,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2641
,,Modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671,21/06/2022,Treatment of methylmalonic acidaemia,EU/3/22/2638,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2638
,,2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl -(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl,21/06/2022,Treatment of cystic fibrosis,EU/3/22/2639,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2639
,,Human allogeneic keratinocytes,21/06/2022,Treatment of partial deep dermal and full thickness burns,EU/3/22/2637,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2637
,,2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting UBE3A antisense transcript RNA,21/06/2022,Treatment of Angelman syndrome,EU/3/22/2636,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2636
,,epcoritamab,21/06/2022,Treatment of follicular lymphoma,EU/3/22/2634,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2634
,,Sirolimus,21/06/2022,Treatment of lymphatic malformations,EU/3/22/2633,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2633
,,Lithium carbonate,21/06/2022,treatment of TBR1-related disorder,EU/3/22/2632,Positive,22/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2632
,,allogenic cytomegalovirus-specific cytotoxic T lymphocytes (adimlecleucel),18/11/2016,Treatment of cytomegalovirus infection in patients with impaired cell-mediated immunity,EU/3/16/1773,Withdrawn,13/12/2016,16/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1773
,,Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist (spanlecortemlocel),16/12/2014,Treatment of acute lymphoblastic leukaemia,EU/3/14/1382,Withdrawn,26/02/2015,16/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1382
,,Autologous CD34+ cells transduced ex vivo with a lentiviral vector containing a modified gamma-globin gene,13/11/2020,Treatment of sickle cell disease,EU/3/20/2356,Withdrawn,15/02/2021,16/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2356
,,Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene,20/09/2016,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",EU/3/16/1761,Positive,15/11/2016,16/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1761
,,"Sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z)10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate",21/06/2022,Prevention of retinopathy of prematurity,EU/3/22/2631,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2631
,,Pirfenidone,24/06/2022,Treatment of idiopathic pulmonary fibrosis,EU/3/22/2630,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2630
,,"4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide",21/06/2022,Treatment of SCN8A developmental and epileptic encephalopathy,EU/3/22/2629,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2629
,,"3-(1-(2',3'-dimethoxy-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-4-yl)benzoic acid",21/06/2022,Treatment of gain-of-function mutations of STIM1 and ORAI1 related diseases,EU/3/22/2628,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2628
,,ropeginterferon alfa-2b,21/06/2022,Treatment of chronic myeloid leukaemia,EU/3/22/2627,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2627
,,Allogeneic human dendritic cells derived from a CD34+ progenitor cell line,22/05/2012,Treatment of acute myeloid leukaemia,EU/3/12/969,Positive,06/07/2012,15/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-969
,,"Allogeneic faecal microbiota, pooled",19/11/2018,Treatment of graft-versus-host disease,EU/3/18/2083,Positive,25/02/2019,15/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2083
,,Sebetralstat,21/06/2022,Treatment of hereditary angioedema,EU/3/22/2625,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2625
,,Doxorubicin,21/06/2022,Treatment of soft tissue sarcoma,EU/3/22/2624,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2624
,,losartan,21/06/2022,Treatment of osteogenesis imperfecta,EU/3/22/2622,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2622
,,"Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase",21/06/2022,Treatment of hyperphenylalaninaemia,EU/3/22/2621,Positive,15/09/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2621
Kinpeygo,EMEA/H/C/005653,Budesonide,18/11/2016,Treatment of primary IgA nephropathy,EU/3/16/1778,Positive,13/12/2016,14/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1778
Agamree,EMEA/H/C/005679,"17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione (vamorolone)",22/08/2014,Treatment of Duchenne muscular dystrophy,EU/3/14/1309,Positive,01/10/2014,14/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1309
,,Modified mRNA encoding the UGT1A1 protein,27/06/2016,Treatment of Crigler-Najjar syndrome,EU/3/16/1684,Positive,26/07/2016,14/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1684
,,Radio-iodinated (131I) anti-CD45 murine monoclonal antibody,14/10/2016,Treatment in haematopoietic stem cell transplantation,EU/3/16/1760,Positive,17/11/2016,14/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1760
Vyvgart,EMEA/H/C/005849,Efgartigimod alfa,10/08/2022,Treatment of myasthenia gravis,EU/3/18/1992,Positive,17/05/2018,12/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1992
,,velaglucerase alfa,06/06/2010,Treatment of Gaucher disease,EU/3/10/752,Expired,23/06/2010,09/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-752
,,18‐mer antisense oligonucleotide complementary to SCN1A mRNA;sodium salt,24/02/2022,Treatment of Dravet syndrome,EU/3/22/2579,Positive,13/05/2022,08/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2579
Iqirvo,EMEA/H/C/006231,Elafibranor,25/07/2019,Treatment of primary biliary cholangitis,EU/3/19/2182,Positive,25/09/2019,08/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2182
Scemblix,EMEA/H/C/005605,Asciminib,24/03/2020,Treatment of chronic myeloid leukaemia,EU/3/20/2261,Positive,12/08/2020,07/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2261
,,1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one,19/07/2021,Treatment of propionic acidaemia,EU/3/21/2462,Positive,12/11/2021,05/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2462
,,1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one,19/07/2021,Treatment of pantothenate kinase-associated neurodegeneration,EU/3/21/2461,Positive,12/11/2021,05/09/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2461
,,setanaxib,06/01/2021,Treatment of primary biliary cholangitis,EU/3/20/2387,Positive,18/05/2021,30/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2387
,,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",09/10/2015,Treatment of systemic sclerosis,EU/3/15/1559,Positive,18/11/2015,30/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1559
,,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",26/11/2010,Treatment of idiopathic pulmonary fibrosis,EU/3/10/802,Positive,15/12/2010,30/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-802
Xegafri,EMEA/H/C/004053,Sirolimus,30/08/2011,Treatment of chronic non-infectious uveitis,EU/3/11/898,Withdrawn,21/09/2011,30/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-898
,,Human monoclonal antibody against human interleukin 13,13/11/2013,Treatment of eosinophilic oesophagitis,EU/3/13/1205,Withdrawn,02/12/2013,30/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1205
,,Melphalan flufenamide,19/03/2015,Treatment of plasma cell myeloma,EU/3/15/1463,Withdrawn,11/05/2015,22/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1463
,,autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo,16/04/2018,Treatment of ovarian cancer,EU/3/18/2009,Withdrawn,17/05/2018,17/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2009
,,Recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor,23/08/2017,Treatment of retinitis pigmentosa,EU/3/17/1908,Withdrawn,17/10/2017,12/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1908
,,"allogeneic peripheral blood mononuclear cells incubated ex-vivo with 16, 16-dimethyl prostaglandin E2;dexamethasone",18/11/2016,Treatment in haematopoietic stem cell transplantation,EU/3/16/1774,Withdrawn,13/12/2016,10/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1774
,,"N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor)",08/07/2008,Treatment of cystic fibrosis,EU/3/08/556,Expired,02/04/2009,10/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-556
Upstaza,EMEA/H/C/005352,recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein;Eladocagene exuparvovec,18/11/2016,Treatment of aromatic L-amino acid decarboxylase deficiency,EU/3/16/1786,Positive,14/12/2016,10/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1786
,,2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson),09/10/2015,Treatment of hepatocellular carcinoma,EU/3/15/1565,Positive,18/11/2015,10/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1565
,,Adenovirus associated viral vector serotype 4 containing the human RPE65 gene,14/11/2007,Treatment of retinitis pigmentosa,EU/3/07/486,Positive,02/07/2008,09/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-486
,,Adenovirus associated viral vector serotype 4 containing the human RPE65 gene,22/10/2007,Treatment of Leber's congenital amaurosis,EU/3/07/484,Positive,22/01/2008,09/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-484
,,Adeno-associated viral vector serotype 5 containing the human RLBP1 gene,14/10/2016,Treatment of retinitis pigmentosa,EU/3/16/1741,Positive,15/11/2016,09/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1741
,,Mazindol,09/10/2015,Treatment of narcolepsy,EU/3/15/1547,Positive,16/11/2015,03/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1547
,,Bilayer engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts,14/12/2015,Treatment of partial deep dermal and full-thickness burns,EU/3/15/1596,Positive,03/02/2016,03/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1596
,,Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan (avalglucosidase alfa),26/03/2014,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/14/1251,Withdrawn,06/05/2014,02/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1251
,,Pegylated recombinant arginine deiminase (pegargiminase),15/01/2015,Treatment of malignant mesothelioma,EU/3/14/1409,Positive,05/03/2015,02/08/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1409
Xermelo,EMEA/H/C/003937,"(S)-ethyl 2-amino-3-(4-(2-amino-6((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate",30/05/2016,Treatment of carcinoid syndrome,EU/3/09/661,Positive,20/10/2009,28/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-661
,,Moxetumomab pasudotox,19/07/2022,Treatment of B-lymphoblastic leukaemia/lymphoma,EU/3/13/1150,Withdrawn,22/08/2013,25/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1150
Zolgensma,EMEA/H/C/004750,Adeno-associated viral vector serotype 9 containing the human SMN gene (onasemnogene abeparvovec),19/06/2015,Treatment of spinal muscular atrophy,EU/3/15/1509,Positive,27/07/2015,25/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1509
,,,13/04/2022,Treatment of primary sclerosing cholangitis,EU/3/22/2604,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2604
,,tiratricol,13/04/2022,Treatment of resistance to thyroid hormone type beta,EU/3/22/2603,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2603
,,Adeno-associated virus serotype C102 containing the human GLA gene,13/04/2022,Treatment of Fabry disease,EU/3/22/2607,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2607
,,Obecabtagene autoleucel,13/04/2022,Treatment of acute lymphoblastic leukaemia,EU/3/22/2605,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2605
,,Devimistat,13/04/2022,Treatment of biliary tract cancer,EU/3/22/2602,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2602
,,"N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine",13/04/2022,Treatment in solid organ transplantation,EU/3/22/2601,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2601
,,arimoclomol citrate,18/07/2022,Treatment of inclusion body myositis,EU/3/16/1659,Withdrawn,28/06/2016,19/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1659
,,Arimoclomol,18/07/2022,Treatment of amyotrophic lateral sclerosis,EU/3/06/406,Withdrawn,02/04/2009,19/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-406
,,Adeno-associated virus vector serotype 9 encoding human gigaxonin gene,13/04/2022,Treatment of giant axonal neuropathy,EU/3/22/2598,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2598
,,Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1 (naratuximab emtansine),18/07/2022,Treatment of diffuse large B-cell lymphoma,EU/3/15/1494,Withdrawn,30/06/2015,19/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1494
,,Norucholic acid,13/04/2022,Treatment of primary biliary cholangitis,EU/3/22/2597,Positive,19/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2597
,,Sirolimus,20/06/2017,Treatment of tuberous sclerosis,EU/3/17/1886,Positive,17/07/2017,19/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1886
,,Adeno-associated virus serotype 9 containing human MYBPC3 gene,13/04/2022,Treatment of Hypertrophic cardiomyopathy due to mutations in the MYBPC3 gene encoding cardiac myosin-binding protein C,EU/3/22/2596,Positive,18/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2596
,,Glofitamab,13/04/2022,Treatment of mantle cell lymphoma,EU/3/22/2595,Positive,18/07/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2595
,,"autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA",26/10/2018,Treatment of mucopolysaccharidosis type I,EU/3/18/2073,Positive,10/01/2019,14/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2073
,,Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene,10/06/2014,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",EU/3/14/1280,Positive,09/07/2014,14/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1280
Libmeldy,EMEA/H/C/005321,Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA,13/04/2007,treatment of metachromatic leukodystrophy,EU/3/07/446,Positive,29/07/2008,14/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-446
,,Darinaparsin,15/04/2011,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/11/850,Positive,26/04/2011,14/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-850
Yescarta,EMEA/H/C/004480,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel),11/11/2015,Treatment of follicular lymphoma,EU/3/15/1579,Positive,06/01/2016,12/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1579
,,adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene,09/01/2020,Treatment of mucopolysaccharidosis type IVA (Morquio A Syndrome),EU/3/19/2238,Positive,19/05/2020,08/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2238
,,Adeno-associated viral vector serotype 9 containing the human sulfamidase gene,21/06/2011,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",EU/3/11/877,Positive,12/07/2011,08/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-877
,,Recombinant human monoclonal antibody binding to vascular adhesion protein-1,19/03/2015,Treatment of primary sclerosing cholangitis,EU/3/15/1461,Positive,11/05/2015,08/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1461
,,N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide,26/04/2012,Treatment of neurofibromatosis type 2,EU/3/12/993,Positive,18/06/2012,05/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-993
Vynpenta (previously AvacopanChemoCentryx); Tavneos,EMEA/H/C/004487; EMEA/H/C/005523,"(2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide",19/11/2014,Treatment of microscopic polyangiitis (avacopan),EU/3/14/1372,Positive,15/01/2015,04/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1372
Vynpenta (previously AvacopanChemoCentryx); Tavneos,EMEA/H/C/004487; EMEA/H/C/005523,,19/11/2014,Treatment of granulomatosis with polyangiitis,EU/3/14/1373,Positive,15/01/2015,04/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1373
,,Human autologous mesenchymal adult stem cells extracted from adipose tissue,26/08/2005,Treatment of anal fistula,EU/3/05/303,Withdrawn,22/10/2009,01/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-303
,,Setmelanotide,09/01/2020,Treatment of Alström syndrome,EU/3/19/2245,Positive,20/05/2020,01/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2245
Imcivree,EMEA/H/C/005089,Setmelanotide,19/11/2018,Treatment of leptin receptor deficiency,EU/3/18/2101,Positive,25/02/2019,01/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2101
Imcivree,EMEA/H/C/005089,Setmelanotide,14/07/2016,Treatment of pro-opiomelanocortin deficiency,EU/3/16/1703,Positive,06/09/2016,01/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1703
,,Setmelanotide,27/06/2016,Treatment of Prader-Willi syndrome,EU/3/16/1688,Positive,26/07/2016,01/07/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1688
Rezzayo,EMEA/H/C/005900,Rezafungin acetate,06/01/2021,Treatment of invasive candidiasis,EU/3/20/2385,Positive,18/05/2021,30/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2385
,,Recombinant human monoclonal antibody to insulin receptor,14/07/2016,Treatment of congenital hyperinsulinism,EU/3/16/1702,Positive,06/09/2016,30/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1702
,,"2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate (enasidenib)",28/04/2016,Treatment of acute myeloid leukaemia,EU/3/16/1640,Positive,31/05/2016,29/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1640
Lunsumio,EMEA/H/C/005680,Mosunetuzumab,12/11/2021,Treatment of follicular lymphoma,EU/3/21/2517,Positive,08/06/2022,23/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2517
,,Chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p,22/05/2017,Treatment of cutaneous T-cell lymphoma,EU/3/17/1872,Withdrawn,29/06/2017,22/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1872
,,Protein-based delivery vector carrying a DNA payload encoding an RNA-guided nuclease that targets stx genes of Shiga toxin-producing Escherichia coli,21/08/2020,Prevention of haemolytic uraemic syndrome,EU/3/20/2316,Positive,25/11/2020,22/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2316
,,Modified messenger ribonucleic acid encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticle,24/04/2019,Treatment of propionic acidaemia,EU/3/19/2156,Positive,14/06/2019,22/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2156
,,Synthetic signal peptide of human mucin-1 (amino acids 1-21),15/01/2015,Treatment of plasma cell myeloma,EU/3/14/1423,Positive,06/03/2015,22/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1423
,,Heterologous human adult liver-derived stem cells,16/03/2022,Treatment of argininosuccinic aciduria,EU/3/22/2594,Positive,20/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2594
,,Emactuzumab,16/03/2022,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",EU/3/22/2591,Positive,20/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2591
,,,14/01/2022,Treatment of Leber’s hereditary optic neuropathy,EU/3/21/2571,Positive,16/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2571
,,"(S)-12-fluoro-4-(2-methylpyridin-3-yl)-7a,8,13,14-tetrahydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine",16/03/2022,Treatment of sickle cell disease,EU/3/22/2589,Positive,16/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2589
,,Tropatepine hydrochloride,16/03/2022,Treatment of narcolepsy,EU/3/22/2587,Positive,16/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2587
,,Codergocrine mesilate;oxitriptan,16/03/2022,Treatment of fragile X syndrome,EU/3/22/2586,Positive,16/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2586
,,Hymecromone,16/03/2022,Treatment of spinal cord injury,EU/3/22/2584,Positive,16/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2584
,,"Chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment",14/01/2022,Treatment of primary biliary cholangitis,EU/3/21/2561,Positive,15/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2561
,,Sirolimus,14/01/2022,Treatment of bronchiolitis obliterans syndrome (BOS),EU/3/21/2570,Positive,15/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2570
,,"Trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide sesquifumarate",14/01/2022,Treatment of acute myeloid leukaemia,EU/3/21/2569,Positive,15/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2569
,,melatonin,14/01/2022,Treatment of pre-eclampsia,EU/3/21/2567,Positive,15/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2567
,,Adeno-associated viral vector serotype 9 containing the human SURF1 gene,12/11/2021,Treatment of Leigh syndrome,EU/3/21/2531,Positive,15/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2531
,,Olverembatinib,12/11/2021,Treatment of chronic myeloid leukaemia,EU/3/21/2530,Positive,15/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2530
,,"Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate (riociguat)  ",20/12/2007,Treatment of pulmonary arterial hypertension,EU/3/07/518,Withdrawn,23/09/2009,14/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-518
,,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",16/01/2014,Treatment of primary sclerosing cholangitis,EU/3/13/1217,Withdrawn,22/01/2014,14/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1217
,,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",16/01/2014,Treatment of primary biliary cirrhosis,EU/3/13/1215,Withdrawn,22/01/2014,14/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1215
,,Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene,16/04/2018,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/18/2007,Positive,17/05/2017,14/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2007
,,pasireotide,08/10/2009,Treatment of Cushing's disease,EU/3/09/671,Expired,20/10/2009,14/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-671
Carvykti,EMEA/H/C/005095,Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor for B-cell maturation antigen,28/02/2020,Treatment of multiple myeloma,EU/3/20/2252,Positive,06/05/2020,13/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2252
,,Adeno-associated virus serotype 9 expressing the human fukutin related protein and target sequence of the miR-208a,14/01/2022,Treatment of limb girdle muscular dystrophy,EU/3/21/2566,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2566
,,5' moemC-(sp)-moemC-(p)-moeA-(p)-moemC-(p)-moeG-(p)-moeA-(p)-dmC-(sp)-dA-(sp)-dT-(sp)-dA-(sp)-dT-(sp)-dT-(sp)-dT-(sp)-dT-(sp)-dT-(sp)-dmC-(sp)-moeT-(p)-moeA-(sp)-moemC-(sp)-moeA 3',14/01/2022,Treatment of SCN2A developmental and epileptic encephalopathy,EU/3/21/2565,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2565
,,"5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid",14/01/2022,Treatment of primary hyperoxaluria,EU/3/21/2564,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2564
,,Gadolinium-chelated polysiloxane nanoparticles,14/01/2022,Treatment of glioma,EU/3/21/2562,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2562
,,N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting the human transferrin receptor,14/01/2022,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),EU/3/21/2560,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2560
,,Fasudil hydrochloride,14/01/2022,Treatment of amyotrophic lateral sclerosis,EU/3/21/2559,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2559
,,mRNA encoding human glucose-6-phosphatase variant S298C,14/01/2022,treatment of glycogen storage disease type Ia,EU/3/21/2558,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2558
,,Insulin human,14/01/2022,Prevention of retinopathy of prematurity,EU/3/21/2557,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2557
,,Navtemadlin,14/01/2022,Treatment of Merkel cell carcinoma,EU/3/21/2556,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2556
,,Efgartigimod alfa,14/01/2022,Treatment of chronic inflammatory demyelinating polyneuropathy,EU/3/21/2555,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2555
,,"Enterovirus B, echovirus 7, live",11/01/2022,Treatment of uveal melanoma,-,Negative,09/06/2022,09/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-uveal-melanoma
,,5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl] pyridin-2-yl}pyridin-2-amine,12/11/2021,Treatment of diffuse large B-cell lymphoma,EU/3/21/2523,Positive,09/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2523
,,Cannabidiol;Dronabinol,12/11/2021,Treatment of complex regional pain syndrome,EU/3/21/2522,Positive,08/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2522
,,Udonitrectag lysine,12/11/2021,Treatment in solid organ transplantation,EU/3/21/2521,Positive,08/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2521
,,Sirolimus,14/12/2015,Treatment of beta thalassaemia intermedia and major,EU/3/15/1585,Positive,02/02/2016,08/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1585
,,paclitaxel;polyoligo(ethylene glycol)methacrylate-co-poly(vinylbenzyldithiodibutyric acid-gemcitabine),12/11/2021,Treatment of pancreatic cancer,EU/3/21/2518,Positive,08/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2518
,,Nadunolimab,12/11/2021,Treatment of pancreatic cancer,EU/3/21/2516,Positive,08/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2516
,,Autologous CD34+ cells transfected with a lentiviral vector containing codon optimised RPS19 gene,20/08/2021,Treatment of Diamond-Blackfan anaemia,EU/3/21/2488,Positive,25/02/2022,08/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2488
Polivy,EMEA/H/C/004870,polatuzumab vedotin,16/04/2018,Treatment of diffuse large B-cell lymphoma,EU/3/18/2013,Positive,17/05/2018,08/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2013
,,"D-lactic acid, glycolic acid",12/11/2021,Treatment of amyotrophic lateral sclerosis,EU/3/21/2528,Positive,07/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2528
,,"(14S)-8-[3-(2-{dispiro[2.0.24.13]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2lamba6-thia-3,9,11,18,23-penta-azatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione calcium salt hydrate, deutivacaftor, tezacaftor",12/11/2021,Treatment of cystic fibrosis,EU/3/21/2527,Positive,07/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2527
,,"2-[1-(3-{6-[(1E)-(hydroxyimino)methyl]-5-methyl-4-oxo-7-propyl-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-2-yl}-4-propoxybenzenesulfonyl)piperidin-4-yl]ethyl nitrate",12/11/2021,Treatment of systemic sclerosis,EU/3/21/2526,Positive,07/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2526
,,Anti-CD38 IgG4 human monoclonal antibody,12/11/2021,Treatment of amyotrophic lateral sclerosis,EU/3/21/2514,Positive,07/06/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2514
,,Trifarotene,24/03/2020,Treatment of autosomal recessive congenital ichthyosis,EU/3/20/2264,Withdrawn,12/08/2020,07/06/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2264
,,Tipifarnib,19/10/2020,Treatment of peripheral T-cell lymphoma,EU/3/20/2333,Positive,12/02/2021,24/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2333
,,"6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",26/10/2018,Treatment of cystic fibrosis,EU/3/18/2072,Positive,11/01/2019,24/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2072
,,N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride (defactinib),15/01/2015,Treatment of ovarian cancer,EU/3/14/1429,Positive,06/03/2015,24/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1429
,,Tipifarnib,10/03/2005,Treatment of acute myeloid leukaemia,EU/3/05/269,Positive,01/06/2005,24/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-269
,,tisagenlecleucel,19/07/2021,Treatment of follicular lymphoma,EU/3/21/2464,Positive,12/11/2021,19/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2464
,,Inebilizumab,20/03/2017,Treatment of neuromyelitis optica spectrum disorders,EU/3/17/1856,Withdrawn,05/05/2017,19/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1856
,,Lefitolimod,26/03/2021,Treatment of small cell lung cancer,EU/3/21/2415,Positive,19/01/2022,19/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2415
,,Avapritinib,26/10/2018,Treatment of mastocytosis,EU/3/18/2074,Positive,04/01/2019,18/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2074
,,synthetic human hepcidin,18/11/2016,Treatment of sickle cell disease,EU/3/16/1789,Withdrawn,13/12/2016,18/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1789
,,Synthetic hepcidin,09/10/2015,Treatment of beta thalassaemia intermedia and major,EU/3/15/1555,Withdrawn,16/11/2015,18/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1555
,,"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate (also known as mivavotinib)",22/02/2018,Treatment of acute myeloid leukaemia,EU/3/18/1974,Positive,10/04/2018,16/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1974
,,pentosan polysulfate sodium,30/05/2016,Treatment of interstitial cystitis,EU/3/16/1663,Positive,22/06/2016,16/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1663
,,Epcoritamab,24/02/2022,Treatment of diffuse large B-cell lymphoma,EU/3/22/2581,Positive,13/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2581
,,Adeno-associated viral vector LK03 encoding human methylmalonyl-CoA mutase,21/06/2021,Treatment of methylmalonic acidaemia,EU/3/21/2457,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2457
,,H-D-valyl1-D-alanyl-D-glutamyl-D-alanyl-D-arginyl5-D-glutamyl-D-glutamyl-D-leucyl-D-glutamyl-D-arginyl10-D-leucyl-D-glutamyl-D-alanyl-D-arginyl-D-leucyl15-glycyl-D-glutaminyl-D-alanyl-D-arginyl-glycyl20-D-glutamyl-D-leucyl-D-lysyl-D-lysyl-D-tryptophyl25-D-lysyl-D-methionyl-D-arginyl-D-arginyl-D-asparaginyl30-D-glutaminyl-D-phenylalanyl-D-tryptophyl-D-leucyl-D-lysyl35-D-leucyl-D-glutaminyl-D-arginine,21/06/2021,Treatment of glioma,EU/3/21/2455,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2455
,,melatonin,21/06/2021,Prevention of retinopathy of prematurity,EU/3/21/2453,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2453
,,Hydrocortisone hydrogen succinate,21/06/2021,Prevention of bronchopulmonary dysplasia,EU/3/21/2452,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2452
,,Adeno-associated virus serotype 9 containing the human FXN gene isoform 1,21/06/2021,Treatment of Friedreich's ataxia,EU/3/21/2456,Withdrawn,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2456
,,"(S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide",21/06/2021,Treatment of mantle cell lymphoma,EU/3/21/2450,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2450
,,Allogenic placenta-derived mesenchymal stromal cells secretome,21/06/2021,Treatment of pre-eclampsia,EU/3/21/2448,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2448
,,Adeno-associated virus serotype 9 expressing human CLN5,21/06/2021,Treatment of neuronal ceroid lipofuscinosis,EU/3/21/2447,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2447
,,Tislelizumab,21/06/2021,Treatment of nasopharyngeal cancer,EU/3/21/2446,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2446
,,Humanised IgG2 monoclonal antibody against TNFSF13,21/06/2021,Treatment of primary IgA nephropathy,EU/3/21/2444,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2444
,,L-ergothioneine,21/06/2021,Treatment of cystinuria,EU/3/21/2445,Positive,11/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2445
,,Obeticholic acid,16/03/2014,Treatment of primary sclerosing cholangitis,EU/3/13/1228,Withdrawn,24/03/2014,10/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1228
,,N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide (mocetinostat),14/09/2007,Treatment of Hodgkin's lymphoma,EU/3/07/478,Withdrawn,23/09/2009,10/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-478
,,Mannitolum,07/11/2005,Treatment of cystic fibrosis,EU/3/05/325,Expired,29/07/2008,05/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-325
,,Mercaptopurine,30/04/2009,Treatment of acute lymphoblastic leukaemia,EU/3/09/628,Expired,12/05/2009,05/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-628
,,Allogenic fetal mesenchymal stem cells,10/12/2021,Treatment of osteogenesis imperfecta,EU/3/21/2534,Positive,05/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2534
,,Octreotide acetate,10/12/2021,Treatment of idiopathic intracranial hypertension,EU/3/21/2554,Positive,05/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2554
,,2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanoylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl ...,10/12/2021,Treatment of cystic fibrosis,EU/3/21/2552,Positive,05/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2552
,,N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide (mocetinostat),31/01/2008,Treatment of acute myeloid leukaemia,EU/3/07/526,Withdrawn,23/09/2009,04/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-526
,,Lisocabtagene maraleucel,19/11/2018,Treatment of primary mediastinal large B-cell lymphoma,EU/3/18/2099,Withdrawn,25/02/2019,04/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2099
,,Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel),25/05/2018,Treatment of follicular lymphoma,EU/3/18/2018,Withdrawn,24/07/2018,04/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2018
,,Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel),17/07/2017,Treatment of diffuse large B-cell lymphoma,EU/3/17/1890,Withdrawn,14/08/2017,04/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1890
,,Human culture expanded autologous mesenchymal stromal cells,24/04/2019,Treatment of amyotrophic lateral sclerosis,EU/3/19/2155,Positive,14/06/2019,03/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2155
,,Adeno-associated virus vector serotype 9 encoding the human GRN gene,10/12/2021,Treatment of frontotemporal dementia,EU/3/21/2551,Positive,03/05/2022,03/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2551
,,Unesbulin,10/12/2021,Treatment of soft tissue sarcoma,EU/3/21/2550,Positive,03/05/2022,03/05/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2550
,,"Norrin (25-133), Lys86Pro",10/12/2021,Treatment of familial exudative vitreoretinopathy,EU/3/21/2549,Positive,03/05/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2549
,,Gadolinium-chelated polysiloxane nanoparticles,24/02/2022,Treatment of pancreatic cancer,EU/3/22/2576,Positive,29/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2576
,,aldesleukin,24/02/2022,Treatment of amyotrophic lateral sclerosis,EU/3/22/2578,Positive,29/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2578
,,"[Ala1,3,12,Gln10,Arg11,Trp14]PTH(1-14)/[Ala18,22, Lys26]PTHrP(15-36)COOH",24/02/2022,Treatment of hypoparathyroidism,EU/3/22/2577,Positive,29/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2577
,,Bovactant,24/02/2022,Treatment of respiratory distress syndrome,EU/3/22/2575,Positive,29/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2575
,,Pyridoxal 5'-phosphate,24/02/2022,Treatment of pyridoxamine 5'-phosphate oxidase deficiency,EU/3/22/2574,Positive,28/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2574
,,Vatiquinone,24/02/2022,"Treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes",EU/3/22/2573,Positive,28/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2573
,,Valemetostat tosilate,24/02/2022,Treatment of peripheral T-cell lymphoma,EU/3/22/2572,Positive,28/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2572
,,"Chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment",10/12/2021,Treatment of primary sclerosing cholangitis,EU/3/21/2547,Positive,28/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2547
,,recombinant human interleukin-3 truncated diphtheria toxin fusion protein,09/10/2015,Treatment of acute myeloid leukaemia,EU/3/15/1563,Positive,18/11/2015,25/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1563
,,Autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease mRNAs SB-mRENH1 and SB-mRENH2,19/02/2021,Treatment of sickle cell disease,EU/3/21/2406,Positive,23/02/2022,25/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2406
Kimmtrak,EMEA/H/C/004929,Tebentafusp,19/02/2021,Treatment of uveal melanoma,EU/3/21/2397,Positive,22/02/2022,22/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2397
,,N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol- 3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)  phenyl]acetamide,10/12/2021,Treatment of epileptic encephalopathy with continuous spike-and-wave during sleep,EU/3/21/2545,Positive,21/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2545
,,Ribonucleoprotein complex composed of two sgRNA and a Cas9 nuclease targeting the human COL7A1 gene,10/12/2021,Treatment of epidermolysis bullosa,EU/3/21/2544,Positive,20/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2544
,,copper (64Cu) chloride,10/12/2021,Treatment of glioma,EU/3/21/2543,Positive,20/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2543
,,Crofelemer,10/12/2021,Treatment of short bowel syndrome,EU/3/21/2541,Positive,19/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2541
,,"3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine",10/12/2021,Treatment of SCN8A developmental and epileptic encephalopathy,EU/3/21/2540,Positive,19/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2540
,,"3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine",10/12/2021,Treatment of SCN2A developmental and epileptic encephalopathy,EU/3/21/2539,Positive,13/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2539
,,Anti-(endothelin-1 receptor subtype A) IgG4 humanised monoclonal antibody,10/12/2021,Treatment of  pulmonary arterial hypertension,EU/3/21/2538,Positive,13/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2538
,,Retinol palmitate,10/12/2021,Prevention of bronchopulmonary dysplasia,EU/3/21/2537,Positive,13/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2537
,,Vatiquinone,10/12/2021,Treatment of Alpers-Huttenlocher syndrome,EU/3/21/2536,Positive,13/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2536
,,Mocravimod,15/10/2021,Treatment in haematopoietic stem cell transplantation,EU/3/21/2504,Positive,20/01/2022,13/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2504
,,Autologous T cells ex vivo modified with a lentiviral vector encoding a chimeric antigen receptor specific for CD1a,10/12/2021,Treatment of acute lymphoblastic leukaemia,EU/3/21/2535,Positive,13/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2535
,,Macitentan,10/12/2021,Treatment of chronic thromboembolic pulmonary hypertension,EU/3/21/2533,Positive,13/04/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2533
,,Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor,24/01/2013,Treatment of retinitis pigmentosa,EU/3/12/1098,Positive,01/03/2013,12/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1098
,,Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotropic factor,08/11/2012,Treatment of macular telangiectasia type 2,EU/3/12/1072,Positive,12/12/2012,12/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1072
,,Leniolisib,19/10/2020,Treatment of activated phosphoinositide 3-kinase delta syndrome,EU/3/20/2339,Positive,25/05/2021,11/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2339
,,"(5R,5aR,8aR,9S)-9-[[4,6-O-[(R)-Ethylidene]-β-D-glucopyranosyl]-oxy]-5-(4-({[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]carbonyl}oxy)-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydroisobenzofuro[5,6-f][1,3]benzodioxol-6(5aH)-one (etoposide toniribate)",04/06/2014,Treatment of biliary tract cancer,EU/3/14/1270,Positive,10/07/2014,08/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1270
,,Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19,27/06/2016,Treatment in haematopoietic stem cell transplantation,EU/3/16/1674,Withdrawn,26/07/2016,07/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1674
,,Rimiducid,30/05/2016,Treatment of graft-versus-host disease,EU/3/16/1666,Withdrawn,23/06/2016,07/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1666
,,Molgramostim,27/06/2016,Treatment of acute respiratory distress syndrome (ARDS),EU/3/16/1685,Positive,26/07/2016,06/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1685
,,Granulocyte-macrophage colony-stimulating factor,17/07/2013,Treatment of pulmonary alveolar proteinosis,EU/3/13/1147,Positive,21/08/2013,06/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1147
,,Ciprofloxacin,24/07/2009,Treatment of cystic fibrosis,EU/3/09/652,Positive,11/09/2009,06/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-652
,,"Multilamellar microvesicle comprising phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and cholesterol",30/08/2011,Treatment of cystic fibrosis,EU/3/11/896,Withdrawn,21/09/2011,06/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-896
,,Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA (elivaldogene autotemcel),06/06/2012,Treatment of adrenoleukodystrophy,EU/3/12/1003,Withdrawn,04/07/2012,04/04/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1003
,,Adeno-associated virus serotype 9 expressing the cDNA for human MECP2,20/05/2021,Treatment of Rett syndrome,EU/3/21/2442,Withdrawn,18/03/2022,30/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2442
,,"dantrolene sodium, hemiheptahydrate",20/05/2021,Treatment of malignant hyperthermia,EU/3/21/2443,Withdrawn,24/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2443
,,Veledimex,21/08/2019,Treatment of glioma,EU/3/19/2199,Withdrawn,16/01/2020,21/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2199
,,Adenoviral vector serotype 5 encoding the human interleukin-12 p70 transgene under the control of activator ligand veledimex,21/08/2019,Treatment of glioma,EU/3/19/2198,Withdrawn,16/01/2020,21/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2198
,,Adeno-associated viral vector serotype 5 expressing the human Cone-Rod Homeobox gene,20/05/2021,Treatment of Leber's congenital amaurosis,EU/3/21/2441,Positive,18/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2441
,,melatonin,20/05/2021,Treatment of retinitis pigmentosa,EU/3/21/2439,Positive,18/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2439
,,"Synthetic 2′-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a triantennary cluster of N-acetyl galactosamine sugars targeting transmembrane protease, serine 6 mRNA",20/05/2021,Treatment of beta thalassaemia intermedia and major,EU/3/21/2437,Positive,18/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2437
,,Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide,08/05/2008,Treatment of acute myeloid leukaemia,EU/3/08/542,Positive,29/07/2008,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-542
,,Recombinant human surfactant protein D,11/04/2014,Prevention of bronchopulmonary dysplasia,EU/3/14/1262,Positive,05/06/2014,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1262
,,N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase,27/02/2009,"Treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome)",EU/3/09/615,Positive,30/10/2009,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-615
,,Bovine bile extract,20/06/2005,Treatment of pancreatic cancer,EU/3/05/287,Positive,07/03/2007,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-287
Corluxin,EMEA/H/C/002830,mifepristone,27/10/2011,Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin,EU/3/11/925,Positive,23/11/2011,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-925
,,Trabedersen,24/07/2009,Treatment of pancreatic cancer,EU/3/09/660,Positive,11/09/2009,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-660
,,TGF-ß2-specific phosphorothioate antisense oligodeoxynucleotide,22/03/2002,Treatment of high-grade glioma,EU/3/02/091,Positive,08/01/2003,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-091
,,Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Gly-Gly-Asp-Leu-Leu-Pro-Arg-Gly-Ser,18/11/2016,Treatment of Huntington’s disease,EU/3/16/1790,Positive,14/12/2016,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1790
,,2-(2-phenylvinyl)-4-[4- methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,10/08/2015,Treatment of hepatocellular carcinoma,EU/3/15/1544,Positive,02/10/2015,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1544
,,carboplatin;Sodium valproate,31/07/2018,Treatment of glioma,EU/3/18/2043,Positive,11/10/2018,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2043
,,Trehalose,20/05/2021,Treatment of amyotrophic lateral sclerosis,EU/3/21/2436,Positive,18/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2436
,,"(S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one",20/05/2021,Treatment of hyperphenylalaninemia,EU/3/21/2435,Positive,18/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2435
,,Adeno-associated viral vector serotype 2.5T encoding the human cystic fibrosis transmembrane conductance regulator with a partial deletion in the R domain,20/05/2021,Treatment of cystic fibrosis,EU/3/21/2433,Positive,18/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2433
,,Ponatinib hydrochloride,15/01/2015,Treatment of gastrointestinal stromal tumours,EU/3/14/1421,Withdrawn,06/03/2015,18/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1421
,,C1 esterase inhibitor (human),14/12/2018,Treatment in solid organ transplantation,EU/3/18/2114,Positive,12/03/2019,17/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2114
,,2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol hydrochloride,20/05/2021,Treatment of fragile X syndrome,EU/3/21/2432,Positive,17/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2432
,,Human IgG1 monoclonal antibody against alpha-synuclein,20/05/2021,Treatment of multiple system atrophy,EU/3/21/2431,Positive,17/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2431
,,Eflornithine,20/05/2021,Treatment of neuroblastoma,EU/3/21/2429,Positive,17/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2429
,,Macitentan,20/05/2021,Treatment of functional single ventricle congenital heart disease,EU/3/21/2428,Positive,16/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2428
,,begelomab,20/05/2021,Treatment of dermatomyositis,EU/3/21/2427,Positive,16/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2427
,,Heat-killed Mycobacterium obuense (whole cell),16/12/2014,Treatment of pancreatic cancer,EU/3/14/1385,Positive,26/02/2015,08/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1385
,,Heat-killed Mycobacterium vaccae (whole cell),20/09/2010,Treatment of tuberculosis,EU/3/10/786,Positive,18/10/2010,08/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-786
,,losartan,26/02/2019,Treatment of epidermolysis bullosa,EU/3/19/2142,Positive,09/04/2019,07/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2142
,,Alvocidib,12/02/2015,Treatment of acute myeloid leukaemia,EU/3/15/1437,Positive,09/04/2015,07/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1437
,,Alvocidib,23/10/2007,Treatment of chronic lymphocytic leukaemia,EU/3/07/485,Positive,18/08/2008,07/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-485
,,Lurbinectedin,20/08/2021,Treatment of  malignant mesothelioma,EU/3/21/2495,Positive,04/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2495
,,Adeno-associated virus serotype 9 encoding human NGLY1 gene,20/08/2021,Treatment of NGLY1 deficiency,EU/3/21/2492,Positive,03/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2492
,,Recombinant human apolipoprotein A-I,20/08/2021,Treatment of lecithin-cholesterol acyltransferase deficiency,EU/3/21/2490,Positive,03/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2490
Ngenla,EMEA/H/C/005633,Recombinant modified human growth hormone,24/01/2013,Treatment of growth hormone deficiency,EU/3/12/1087,Positive,01/03/2013,03/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1087
,,Adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene,19/02/2021,Treatment of Gaucher disease,EU/3/21/2413,Positive,02/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2413
,,sabatolimab,20/08/2021,Treatment of myelodysplastic syndromes,EU/3/21/2494,Positive,02/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2494
,,Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene,20/08/2021,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/21/2493,Positive,02/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2493
,,fluticasone propionate,12/01/2017,Treatment of eosinophilic oesophagitis,EU/3/16/1815,Positive,14/07/2017,01/03/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1815
,,Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant,20/08/2021,Treatment of Gaucher disease,EU/3/21/2491,Positive,01/03/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2491
,,3-pentylbenzeneacetic acid sodium salt,09/10/2015,Treatment of idiopathic pulmonary fibrosis,EU/3/15/1550,Withdrawn,16/11/2015,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1550
,,3-pentylbenzeneacetic acid sodium salt,12/01/2017,Treatment of Alström syndrome,EU/3/16/1810,Withdrawn,14/07/2017,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1810
,,N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride (defactinib),07/06/2013,Treatment of malignant mesothelioma,EU/3/13/1132,Withdrawn,25/06/2013,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1132
,,Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (teprasiran),06/06/2010,Prevention of delayed graft function after renal transplantation,EU/3/10/751,Withdrawn,23/06/2010,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-751
Luxceptar,EMEA/H/C/002397,Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment-,27/06/2016,Treatment in haematopoietic stem cell transplantation,EU/3/16/1678,Withdrawn,26/07/2016,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1678
Luxceptar,EMEA/H/C/002397,Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment,19/11/2014,Treatment of acute myeloid leukaemia,EU/3/14/1356,Withdrawn,15/01/2015,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1356
Luxceptar,EMEA/H/C/002397,Donor lymphocyte preparation depleted of functional alloreactive T-cells,05/09/2008,Prevention of graft-versus-host disease,EU/3/08/561,Withdrawn,24/04/2009,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-561
,,Allogeneic peripheral blood mononuclear cells induced to an early apoptotic state,15/01/2015,Prevention of graft-versus-host disease,EU/3/14/1426,Withdrawn,06/03/2015,28/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1426
,,Adeno-associated virus serotype PTC3 expressing the human UBE3A gene,20/08/2021,Treatment of Angelman syndrome,EU/3/21/2487,Positive,25/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2487
,,Adeno-associated viral vector serotype 9 containing the human MECP2 gene,20/08/2021,Treatment of Rett syndrome,EU/3/21/2484,Positive,25/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2484
,,Human keratinocytes,20/08/2021,Treatment of partial deep dermal and full thickness burns,EU/3/21/2483,Positive,25/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2483
,,Adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes,20/08/2021,Treatment of GM2 gangliosidosis,EU/3/21/2482,Positive,25/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2482
,,Pro-Pro-Thr-Val-Pro-Thr-Arg,19/11/2014,Treatment of xeroderma pigmentosum,EU/3/14/1375,Withdrawn,16/01/2015,25/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1375
,,Dinaciclib,27/09/2011,Treatment of chronic lymphocytic leukaemia,EU/3/11/901,Withdrawn,17/10/2011,25/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-901
,,Adeno-associated virus serotype 5 containing the human NR2E3 gene,19/02/2021,Treatment of Leber's congenital amaurosis,EU/3/21/2412,Positive,24/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2412
,,Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Cys-Asp-Met-Ala-Glu-His-Thr-Glu-Arg-Leu-Lys-Ala-Asn-Asp-Ser-Leu-Lys-Leu-Ser-Gln-Glu-Tyr-Glu-Ser-Ile-NH2,19/02/2021,Treatment of spinal cord injury,EU/3/21/2411,Positive,23/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2411
,,Adeno-associated virus serotype 5 containing the human NR2E3 gene,19/02/2021,Treatment of retinitis pigmentosa,EU/3/21/2408,Positive,23/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2408
,,Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human claudin 18.2 antigen with CD28 and CD3-zeta intracellular signalling domains,19/02/2021,Treatment of gastric cancer,EU/3/21/2405,Positive,23/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2405
,,,19/02/2021,Treatment of leishmaniasis,EU/3/21/2404,Positive,22/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2404
,,Rintatolimod,19/02/2022,Treatment of pancreatic cancer,EU/3/21/2403,Positive,22/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2403
,,"2-(2-{[2-(1h-benzimidazol-2-yl)ethyl]amino}ethyl)-n-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride",19/02/2021,Treatment of sickle cell disease,EU/3/21/2402,Positive,22/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2402
,,,19/02/2021,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/21/2401,Positive,22/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2401
,,Anti-SIGLEC8 IgG1 humanised monoclonal antibody,19/02/2021,Treatment of eosinophilic gastroenteritis,EU/3/21/2400,Positive,22/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2400
,,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,19/02/2021,Treatment of lymphoplasmacytic lymphoma,EU/3/21/2399,Positive,22/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2399
,,"2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'",19/02/2021,Treatment of spinocerebellar ataxia,EU/3/21/2398,Positive,22/02/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2398
Mycapssa,EMEA/H/C/005826,Octreotide acetate,05/08/2013,Treatment of acromegaly,EU/3/13/1170,Positive,12/09/2013,21/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1170
,,Sirolimus,14/07/2016,Treatment of sporadic lymphangioleiomyomatosis,EU/3/16/1704,Positive,06/09/2016,18/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1704
,,Recombinant human insulin receptor monoclonal antibody-fused-α-L-iduronidase,15/10/2014,Treatment of mucopolysaccharidosis type I,EU/3/14/1349,Withdrawn,12/11/2014,18/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1349
,,Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase,13/11/2013,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/13/1198,Withdrawn,02/12/2013,18/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1198
,,Pracinostat,16/10/2017,Treatment of acute myeloid leukaemia,EU/3/17/1927,Withdrawn,09/01/2018,18/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1927
,,Pevonedistat,25/07/2019,Treatment of acute myeloid leukaemia,EU/3/19/2186,Withdrawn,24/09/2019,18/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2186
,,Pevonedistat,14/12/2018,Treatment of myelodysplastic syndromes,EU/3/18/2120,Withdrawn,12/03/2019,18/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2120
Skytrofa (previously Lonapegsomatropin Ascendis Pharma),EMEA/H/C/005367,lonapegsomatropin,17/10/2019,Treatment of growth hormone deficiency,EU/3/19/2213,Positive,22/01/2020,17/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2213
,,Pridopidine hydrochloride,19/07/2021,Treatment of amyotrophic lateral sclerosis,EU/3/21/2470,Positive,12/11/2021,17/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2470
,,"68Ga-2,2'-(7-(4-((S)-1-((4S,7S,10S,13R,16S,19R)-4-((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-ylcarbamoyl)-10-(4-aminobutyl)-16-(4-((S)-2,6-dioxohexahydropyrimidine-4-carboxamido)benzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-ylamino)-3-(4-chlorophenyl)-1-oxopropan-2-ylamino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (satoreotide trixozetan) ",19/02/2014,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,EU/3/14/1246,Positive,02/04/2014,09/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1246
,,"Lutetium-177(3+), S2,S7-cyclo[N-{4,7,10-tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl}-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4S)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide]-",20/09/2016,Treatment of gastro-entero-pancreatic neuroendocrine tumours,EU/3/16/1754,Positive,14/11/2016,09/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1754
,,Bifunctional fusion protein composed of two extracellular domains of transforming growth factor beta receptor II fused with a human immunoglobulin G1 monoclonal antibody against programmed death ligand 1,14/12/2018,Treatment of biliary tract cancer,EU/3/18/2112,Withdrawn,11/03/2019,07/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2112
,,Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein,09/08/2012,Treatment of cutaneous T-cell lymphoma,EU/3/12/1039,Positive,27/09/2012,04/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1039
,,Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein,09/08/2012,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/12/1038,Positive,27/09/2012,04/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1038
,,"6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (selisistat)",08/10/2009,Treatment of Huntington’s disease,EU/3/09/681,Positive,18/11/2009,04/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-681
,,Dimethyl sulfoxide,03/03/2005,Treatment of severe closed traumatic brain injury,EU/3/05/263,Positive,01/07/2005,04/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-263
,,Duramycin,13/11/2002,Treatment of cystic fibrosis,EU/3/02/120,Positive,12/12/2005,04/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-120
Turalio,EMEA/H/C/004832,"[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride",19/03/2015,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",EU/3/15/1457,Withdrawn,11/05/2015,02/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1457
,,synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker (zilucoplan),14/10/2016,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/16/1762,Withdrawn,15/11/2016,01/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1762
,,Anetumab ravtansine,19/11/2018,Treatment of ovarian cancer,EU/3/18/2084,Withdrawn,25/02/2019,01/02/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2084
,,"L-threo-3,4-dihydroxyphenylserine",02/08/2007,Treatment of orthostatic hypotension in patients with multiple system atrophy,EU/3/07/466,Withdrawn,21/09/2009,28/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-466
,,"L-threo-3,4-dihydroxyphenylserine",02/08/2007,Treatment of orthostatic hypotension in patients with pure autonomic failure,EU/3/07/465,Withdrawn,21/09/2009,28/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-465
,,Chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4,13/11/2019,Treatment of AL amyloidosis,EU/3/19/2222,Positive,13/02/2020,28/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2222
,,Nomacopan,26/06/2020,Treatment of bullous pemphigoid,EU/3/20/2289,Positive,22/09/2020,26/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2289
,,Recombinant protein derived from the saliva of the Ornithodoros moubata tick (nomacopan),29/08/2016,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/16/1725,Positive,03/10/2016,26/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1725
,,Recombinant protein derived from the saliva of the Ornithodoros moubata tick (nomacopan),27/06/2016,Treatment of Guillain-Barré syndrome,EU/3/16/1687,Positive,26/07/2016,26/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1687
,,Recombinant derivative of C3 transferase,05/09/2008,Treatment of traumatic spinal cord injury,EU/3/08/563,Positive,24/04/2009,25/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-563
,,"1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamide (tezacaftor)",04/07/2014,Treatment of cystic fibrosis,EU/3/14/1281,Positive,15/07/2014,25/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1281
Symkevi,EMEA/H/C/004682,ivacaftor;tezacaftor,27/02/2017,Treatment of cystic fibrosis,EU/3/17/1828,Positive,31/03/2017,25/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1828
Kaftrio,EMEA/H/C/005269,"Ivacaftor, N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, tezacaftor (ivacaftor / tezacaftor / elexacaftor)",14/12/2018,Treatment of cystic fibrosis,EU/3/18/2116,Positive,07/03/2019,25/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2116
,,"Ivacaftor, potassium(benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl) cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide, tezacaftor",14/12/2018,Treatment of cystic fibrosis,EU/3/18/2117,Positive,07/03/2019,25/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2117
Casgevy,EMEA/H/C/005763,Autologous CD34+ haematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene,17/10/2019,Treatment of beta thalassaemia intermedia and major,EU/3/19/2210,Positive,22/01/2020,25/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2210
Casgevy,EMEA/H/C/005763,autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene,09/01/2020,Treatment of sickle cell disease,EU/3/19/2242,Positive,19/05/2020,25/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2242
,,amivantamab,28/06/2021,Treatment of partial deep dermal and full-thickness burns,-,Negative,24/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-partial-deep-dermal-and-full-thickness-burns-0
,,Cevostamab,13/04/2021,Treatment of multiple myeloma,EU/3/21/2424,Positive,24/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2424
,,"S-[5-(omega-methoxypoly(oxyethylene)-2-oxopentyl)]-L-cysteinylglycyl-L-serinylglycylgylcyl-L-isoleucyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-histyl-L-isoleucyl-L-valyl-L-glutaminyl-L-serinyl-L-isoleucyl-L-isoleucyl-L-asparaginyl-L-threonyl-L-serinamide, acetate salt",13/04/2021,Treatment of cutaneous T-cell lymphoma,EU/3/21/2425,Positive,21/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2425
,,Psilocybine,15/10/2021,Treatment of fragile X syndrome,EU/3/21/2513,Positive,21/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2513
,,Idursulfase beta,15/10/2021,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/21/2512,Positive,21/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2512
,,encaleret,15/10/2021,Treatment of hypoparathyroidism,EU/3/21/2510,Positive,21/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2510
,,Selinexor,15/10/2021,Treatment of glioma,EU/3/21/2509,Positive,21/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2509
,,Allogeneic umbilical cord mesenchymal cells-derived extracellular vesicles,15/10/2021,Prevention of bronchopulmonary dysplasia,EU/3/21/2508,Positive,21/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2508
,,Adeno-associated viral vector serotype 5 expressing the human Cone-Rod Homeobox gene,15/10/2021,Treatment of cone-rod dystrophy,EU/3/21/2506,Positive,21/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2506
,,Ganaxolone,15/10/2021,Treatment of tuberous sclerosis,EU/3/21/2503,Positive,20/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2503
,,Batiraxcept,15/10/2021,Treatment of ovarian cancer,EU/3/21/2501,Positive,20/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2501
,,Devimistat,15/10/2021,Treatment of Burkitt's lymphoma,EU/3/21/2499,Positive,20/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2499
,,Human IgG1 monoclonal antibody against sortilin,15/10/2021,Treatment of frontotemporal dementia,EU/3/21/2498,Positive,20/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2498
Voraxaze; Voraxaze,EMEA/H/C/000681; EMEA/H/C/005467,Carboxypeptidase G2 (glucarpidase),03/02/2003,Adjunctive treatment in patients at risk of methotrexate toxicity,EU/3/02/128,Positive,17/02/2003,20/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-128
,,Denileukin diftitox,11/12/2001,Treatment of cutaneous T-cell lymphoma,EU/3/01/075,Positive,21/09/2009,19/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-075
,,Vatiquinone,26/03/2021,Treatment of Friedreich's ataxia,EU/3/21/2423,Positive,19/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2423
,,Lorcaserin hydrochloride,26/03/2021,Treatment of Dravet syndrome,EU/3/21/2422,Positive,19/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2422
Vijoice,EMEA/H/C/005468,Alpelisib,26/03/2021,Treatment of PIK3CA related overgrowth spectrum,EU/3/21/2420,Positive,19/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2420
,,"Messenger RNA encoding Cas9, single guide RNA targeting the human TTR gene",26/03/2021,Treatment of ATTR amyloidosis,EU/3/21/2419,Positive,19/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2419
,,Adeno-associated virus serotype hu68 containing the human GALC gene,26/03/2021,Treatment of Krabbe disease,EU/3/21/2417,Positive,19/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2417
,,Alpha-L-iduronidase fused to Fab fragment of a humanised monoclonal antibody targeting human transferrin receptor,26/03/2021,Treatment of mucopolysaccharidosis type I,EU/3/21/2414,Positive,19/01/2022,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2414
,,Fenretinide,14/10/2016,Treatment of peripheral T-cell lymphoma,EU/3/16/1751,Withdrawn,15/11/2016,19/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1751
,,Fenretinide,21/03/2016,Treatment of cutaneous T-cell lymphoma,EU/3/16/1630,Withdrawn,03/05/2016,19/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1630
,,chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2 (tralesinidase alfa),15/01/2015,Treatment of mucopolysaccharidosis type IIIB,EU/3/14/1422,Positive,06/03/2015,14/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1422
,,Resiquimod,28/04/2016,Treatment of cutaneous T-cell lymphoma,EU/3/16/1653,Positive,31/05/2016,13/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1653
Orepaxam,EMEA/H/C/005990,Treprostinil diethanolamine,26/08/2005,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/05/310,Positive,23/09/2009,13/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-310
Artesunate Amivas,EMEA/H/C/005550,artesunate,28/02/2020,Treatment of malaria,EU/3/20/2251,Positive,06/05/2020,13/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2251
,,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel),09/10/2015,Treatment of mantle cell lymphoma,EU/3/15/1552,Withdrawn,16/11/2015,12/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1552
,,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel),11/11/2015,Treatment of acute lymphoblastic leukaemia,EU/3/15/1571,Withdrawn,06/01/2016,12/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1571
,,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel),11/11/2015,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/15/1572,Withdrawn,06/01/2016,12/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1572
Filspari,EMEA/H/C/005783,Sparsentan,19/10/2020,Treatment of primary IgA nephropathy,EU/3/20/2345,Positive,16/02/2021,12/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2345
,,"4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide",11/11/2015,Treatment of focal segmental glomerulosclerosis,EU/3/15/1574,Positive,06/01/2016,12/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1574
,,Human plasminogen,28/07/2015,Treatment of plasminogen deficiency,EU/3/15/1511,Positive,18/08/2015,06/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1511
Albrioza,EMEA/H/C/005901,Sodium phenylbutyrate;Tauroursodeoxycholic acid,04/06/2020,Treatment of amyotrophic lateral sclerosis,EU/3/20/2284,Positive,19/08/2020,05/01/2022,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2284
,,Sirolimus,19/07/2021,Treatment of perivascular epithelioid cell tumours,EU/3/21/2467,Positive,12/11/2021,21/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2467
Aspaveli,EMEA/H/C/005553,"Poly(oxy-1,2-ethanediyl),.alpha.-hydro-.omega.-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-.alpha.-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain",22/05/2017,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/17/1873,Positive,29/06/2017,16/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1873
,,Zanubrutinib,29/05/2019,Treatment of lymphoplasmacytic lymphoma,EU/3/19/2167,Withdrawn,12/08/2019,15/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2167
,,Tislelizumab,13/11/2020,Treatment of oesophageal cancer,EU/3/20/2357,Positive,15/02/2021,14/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2357
Folcepri,EMEA/H/C/002570,"N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine (etarfolatide)",10/09/2012,Diagnosis of positive folate-receptor status in ovarian cancer,EU/3/12/1043,Withdrawn,27/09/2012,07/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1043
,,Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene,29/04/2014,The treatment of sickle cell disease,EU/3/14/1263,Withdrawn,04/06/2014,07/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1263
Abecma,EMEA/H/C/004662,Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains (idecabtagene vicleucel),20/04/2017,Treatment of multiple myeloma,EU/3/17/1863,Positive,15/05/2017,03/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1863
Livmarli,EMEA/H/C/005551,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",16/01/2014,Treatment of progressive familial intrahepatic cholestasis,EU/3/13/1216,Positive,22/01/2014,03/12/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1216
,,Glycosylation independent lysosomal targeting (GILT)-tagged recombinant human acid alpha glucosidase,27/10/2011,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/11/921,Positive,23/11/2011,30/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-921
,,CD34+ haematopoietic stem and progenitor cells with CD3+ T-cells,24/08/2018,Treatment in solid organ transplantation,EU/3/18/2063,Positive,20/12/2018,30/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2063
,,"N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate (tafamidis)",28/08/2006,Treatment of familial amyloid polyneuropathy,EU/3/06/401,Expired,02/04/2009,25/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-401
,,hydrocortisone,22/05/2006,Treatment of adrenal insufficiency,EU/3/06/372,Expired,21/09/2009,25/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-372
Qinlock,EMEA/H/C/005614,"1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea",08/11/2017,Treatment of gastrointestinal stromal tumours,EU/3/17/1936,Positive,15/01/2018,23/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1936
,,Ibrutinib,16/01/2014,Treatment of follicular lymphoma,EU/3/13/1212,Withdrawn,23/01/2014,23/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1212
,,Ibrutinib,13/11/2013,Treatment of diffuse large B-cell lymphoma,EU/3/13/1203,Withdrawn,02/12/2013,23/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1203
,,Ibrutinib,18/11/2016,Treatment of graft-versus-host disease,EU/3/16/1780,Withdrawn,14/12/2016,23/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1780
,,Ibrutinib,10/08/2015,Treatment of marginal zone lymphoma,EU/3/15/1541,Withdrawn,02/10/2015,23/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1541
,,Humanised Fc engineered monoclonal antibody against CD19 (tafasitamab),04/07/2014,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/14/1286,Positive,16/07/2014,18/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1286
,,recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1,19/07/2021,Treatment of adenosine triphosphate binding cassette transporter protein subfamily C member 6 deficiency,EU/3/21/2479,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2479
,,humanised IgG2k Fc-modified bispecific monoclonal antibody against CD3 and BCMA,19/07/2021,Treatment of multiple myeloma,EU/3/21/2471,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2471
,,mRNA encoding the human glycogen debranching enzyme,19/07/2021,Treatment of glycogen storage disease type III,EU/3/21/2472,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2472
,,adeno-associated viral vector serotype 9 containing the human SLC13A5 gene,19/07/2021,Treatment of SLC13A5-epileptic encephalopathy deficiencies,EU/3/21/2473,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2473
,,autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human palmitoyl-protein thioesterase 1 gene,19/07/2021,Treatment of neuronal ceroid lipofuscinosis,EU/3/21/2474,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2474
,,Infigratinib,19/07/2021,Treatment of achondroplasia,EU/3/21/2475,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2475
,,"3,5-diiodothyropropionic acid",19/07/2021,Treatment of Allan-Herndon-Dudley syndrome,EU/3/21/2476,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2476
,,Adeno-associated virus vector serotype 1 containing the human GRN gene,19/07/2021,Treatment of frontotemporal dementia,EU/3/21/2478,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2478
,,"Adeno-associated viral vector serotype Anc80 containing the 3' portion of human OTOF gene, adeno-associated viral vector serotype Anc80 containing the 5' portion of human OTOF gene",19/07/2021,Treatment of otoferlin gene-mediated hearing loss,EU/3/21/2477,Positive,16/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2477
,,Polyphenyl(disodium 3-O-sulfo-beta-D-glucopyranuronate)-(1->3)-beta-D-galactopyranoside,17/07/2017,Treatment of anti-MAG neuropathy,EU/3/17/1893,Withdrawn,16/08/2017,15/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1893
,,Agammaglobulinaemia tyrosine kinase,12/12/2017,Treatment of pemphigus,EU/3/17/1951,Withdrawn,24/01/2018,15/11/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1951
,,,19/07/2021,Treatment of chronic myeloid leukaemia,EU/3/21/2469,Positive,12/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2469
,,melatonin,19/07/2021,Treatment of non-traumatic spontaneous intracerebral haemorrhage,EU/3/21/2468,Positive,12/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2468
,,Lutetium (177Lu) omburtamab barzuxetan,19/07/2021,Treatment of medulloblastoma,EU/3/21/2466,Positive,12/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2466
,,Eftansomatropin alfa,19/07/2021,Treatment of growth hormone deficiency,EU/3/21/2465,Positive,12/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2465
,,Itolizumab,19/07/2021,Treatment of graft-versus-host disease,EU/3/21/2463,Positive,12/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2463
,,Saroglitazar magnesium,19/07/2021,Treatment of primary biliary cholangitis,EU/3/21/2460,Positive,12/11/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2460
,,"(E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt (rigosertib sodium)",26/04/2012,Treatment of myelodysplastic syndromes,EU/3/12/987,Withdrawn,18/06/2012,27/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-987
,,Ibrutinib,29/04/2014,Treatment of lymphoplasmacytic lymphoma,EU/3/14/1264,Withdrawn,04/06/2014,22/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1264
,,"1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one (ibrutinib)",12/03/2013,Treatment of mantle cell lymphoma,EU/3/13/1115,Withdrawn,05/04/2013,22/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1115
,,"1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one (ibrutinib)",26/04/2012,Treatment of chronic lymphocytic leukaemia,EU/3/12/984,Withdrawn,18/06/2012,21/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-984
,,Palovarotene,27/06/2018,Treatment of multiple osteochondromas,EU/3/18/2038,Withdrawn,21/08/2018,19/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2038
,,Seletalisib,22/02/2018,Treatment of activated phosphoinositide 3-kinase delta syndrome,EU/3/18/1986,Withdrawn,11/04/2018,19/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1986
,,Recombinant human alpha 1 chain homotrimer of type VII collagen,04/06/2014,Treatment of epidermolysis bullosa,EU/3/14/1272,Positive,10/07/2014,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1272
,,Ex-vivo cultured adult human mesenchymal stem cells,20/02/2007,Treatment of graft-versus-host disease,EU/3/07/432,Positive,19/07/2007,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-432
,,Recombinant human hepatocarcinoma-intestine-pancreas;pancreatic associated protein,11/02/2009,Treatment of acute liver failure,EU/3/08/611,Positive,29/06/2009,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-611
,,Pegylated carboxyhaemoglobin,26/11/2009,Treatment of sickle cell disease,EU/3/09/698,Positive,10/12/2009,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-698
,,Carbetocin,21/03/2012,Treatment of Prader-Willi syndrome,EU/3/12/975,Positive,19/04/2012,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-975
,,Allogeneic fetal human retinal progenitor cells expanded ex vivo,17/02/2016,Treatment of retinitis pigmentosa,EU/3/16/1620,Positive,07/04/2016,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1620
,,Myriocin,12/02/2015,Treatment of retinitis pigmentosa,EU/3/15/1449,Positive,09/04/2015,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1449
,,"(E)-(6-((N-methyl-((3-methylbenzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl phosphate, bis ethanolamine salt (afabicin)",14/10/2016,Treatment of osteomyelitis,EU/3/16/1737,Positive,15/11/2016,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1737
,,"Adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells",21/05/2015,Treatment of thromboangiitis obliterans (Buerger's disease),EU/3/15/1499,Positive,30/06/2015,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1499
,,225Ac-lintuzumab,22/05/2017,Treatment of acute myeloid leukaemia,EU/3/17/1871,Positive,30/06/2017,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1871
,,Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells,20/03/2017,Treatment in haematopoietic stem cell transplantation,EU/3/17/1852,Positive,05/05/2017,13/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1852
,,Venglustat,14/12/2018,Treatment of autosomal dominant polycystic kidney disease,EU/3/18/2122,Withdrawn,08/03/2019,12/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2122
,,Sulindac,09/12/2020,Treatment of fragile X syndrome,EU/3/20/2384,Positive,26/05/2021,12/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2384
,,Three human monoclonal antibodies against the EBOV glycoprotein,25/05/2018,Treatment of Ebola virus disease,EU/3/18/2027,Positive,23/07/2018,07/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2027
,,human monoclonal antibody against activin A,18/11/2016,Treatment of fibrodysplasia ossificans progressiva,EU/3/16/1779,Positive,14/12/2016,07/10/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1779
,,Single-chain urokinase plasminogen activator,16/12/2014,Treatment of pleural empyema,EU/3/14/1383,Positive,26/02/2015,27/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1383
,,Maralixibat chloride,27/07/2020,Treatment of biliary atresia,EU/3/20/2304,Positive,19/11/2020,24/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2304
,,humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain,11/11/2015,Prevention of graft-versus-host disease,EU/3/15/1575,Positive,06/01/2016,24/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1575
,,eptacog alfa (activated),14/12/2005,Treatment of diffuse alveolar haemorrhage,EU/3/05/333,Withdrawn,21/09/2009,21/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-333
,,drotrecogin alfa (activated),22/09/2008,Treatment of acute respiratory distress syndrome (ARDS),EU/3/08/565,Withdrawn,24/02/2009,21/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-565
,,"1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one (verdiperstat)",16/12/2014,Treatment of multiple system atrophy,EU/3/14/1404,Positive,27/02/2015,21/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1404
,,Allogeneic CD4+ and CD25+ T lymphocytes ex vivo incubated with GP120,22/02/2018,Treatment in haematopoietic stem cell transplantation,EU/3/18/1976,Positive,11/04/2018,17/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1976
Inrebic,EMEA/H/C/005026,N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib),26/11/2010,Treatment of post-polycythaemia vera myelofibrosis,EU/3/10/811,Positive,17/12/2010,17/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-811
Inrebic,EMEA/H/C/005026,N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib),26/11/2010,Treatment of post-essential thrombocythaemia myelofibrosis,EU/3/10/810,Positive,17/12/2010,17/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-810
Inrebic,EMEA/H/C/005026,N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib),01/10/2010,Treatment of primary myelofibrosis,EU/3/10/794,Positive,14/10/2010,17/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-794
,,perflubron,09/12/2020,Treatment of respiratory distress syndrome,EU/3/20/2383,Positive,26/05/2021,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2383
,,Perflubron,13/11/2020,Treatment of congenital pulmonary hypoplasia,EU/3/20/2361,Positive,15/02/2021,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2361
,,paclitaxel,17/10/2019,Treatment of soft tissue sarcoma,EU/3/19/2215,Positive,23/01/2020,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2215
,,"4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide (encequidar)",17/10/2019,Treatment of soft tissue sarcoma,EU/3/19/2207,Positive,21/01/2020,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2207
,,Dantrolene sodium,12/12/2016,Treatment of Wolfram syndrome,EU/3/16/1800,Positive,09/01/2017,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1800
,,teriparatide,27/06/2016,Treatment of hypoparathyroidism,EU/3/16/1689,Positive,26/07/2016,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1689
,,exenatide,21/03/2016,Treatment of idiopathic intracranial hypertension,EU/3/16/1629,Positive,02/05/2016,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1629
,,Sodium valproate fNor,15/01/2015,Treatment of Wolfram syndrome,EU/3/14/1428,Positive,06/03/2015,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1428
,,adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain (tasadenoturev),16/12/2014,Treatment of glioma,EU/3/14/1396,Positive,26/02/2015,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1396
,,hydroxy-propyl-beta-cyclodextrin (hydroxypropylbetadex),30/08/2011,"Treatment of Niemann-Pick's disease, type C",EU/3/11/895,Positive,21/09/2011,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-895
Cerepro; Cerepro; Cerepro,EMEA/H/C/000694; EMEA/H/C/001103; EMEA/H/C/001103,Adenovirus-mediated herpes-simplex-virus thymidine-kinase (HKSV-tk) gene,06/02/2002,Treatment of high-grade glioma with subsequent use of ganciclovir sodium,EU/3/01/083,Positive,06/01/2003,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-083
,,Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin,22/08/2014,Treatment of haemophilia B,EU/3/14/1319,Positive,01/10/2014,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1319
,,Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin,22/08/2014,Treatment of congenital factor VII deficiency,EU/3/14/1312,Positive,30/09/2014,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1312
,,Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin,22/08/2014,Treatment of haemophilia A,EU/3/14/1316,Positive,01/10/2014,16/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1316
,,Axicabtagene ciloleucel,26/06/2020,Treatment of marginal zone lymphoma,EU/3/20/2296,Positive,24/09/2020,15/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2296
Tecartus,EMEA/H/C/005102,autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel),13/11/2019,Treatment of mantle cell lymphoma,EU/3/19/2220,Positive,13/02/2020,15/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2220
Yescarta,EMEA/H/C/004480,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel),09/10/2015,Treatment of primary mediastinal large B-cell lymphoma,EU/3/15/1553,Positive,16/11/2015,15/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1553
Koselugo,EMEA/H/C/005244,Selumetinib,31/07/2018,Treatment of neurofibromatosis type 1,EU/3/18/2050,Positive,11/10/2018,15/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2050
Voxzogo,EMEA/H/C/005475,Modified recombinant human C-type natriuretic peptide (Vosoritide),24/01/2013,Treatment of achondroplasia,EU/3/12/1094,Positive,01/03/2013,09/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1094
Minjuvi,EMEA/H/C/005436,Humanised Fc engineered monoclonal antibody against CD19 (tafasitamab),15/01/2015,Treatment of diffuse large B-cell lymphoma,EU/3/14/1424,Positive,06/03/2015,08/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1424
,,Recombinant human heparan-N-sulfatase,07/11/2008,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",EU/3/08/582,Withdrawn,29/06/2009,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-582
,,Chimeric IgG monoclonal antibody cG250 (girentuximab),19/03/2002,Treatment of renal-cell carcinoma,EU/3/02/094,Withdrawn,08/01/2003,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-094
,,Fosbretabulin tromethamine,17/07/2013,Treatment of ovarian cancer,EU/3/13/1154,Withdrawn,21/08/2013,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1154
,,Reduced oxidised N-acetyl heparin (roneparstat),21/05/2015,Treatment of plasma cell myeloma,EU/3/15/1487,Withdrawn,30/06/2015,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1487
,,"N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide (edasalonexent)",09/10/2015,Treatment of Duchenne muscular dystrophy,EU/3/15/1560,Withdrawn,18/11/2015,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1560
,,Fosbretabulin tromethamine,21/03/2016,Treatment of gastro-entero-pancreatic neuroendocrine tumours,EU/3/16/1633,Withdrawn,04/05/2016,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1633
,,Efgartigimod alfa,16/12/2019,Treatment of immune thrombocytopenia,EU/3/19/2230,Positive,25/02/2020,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2230
,,Enoxacin,19/03/2015,Treatment of amyotrophic lateral sclerosis,EU/3/15/1459,Positive,11/05/2015,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1459
,,4-hydroxyandrostenedione;Serenoa serrulata;alpha lipoic acid,28/04/2016,Treatment of multiple symmetric lipomatosis,EU/3/16/1646,Positive,31/05/2016,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1646
,,Ibutamoren mesilate,20/06/2017,Treatment of growth hormone deficiency,EU/3/17/1882,Positive,17/07/2017,02/09/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1882
,,Heterologous human adult liver-derived stem cells,05/03/2012,Treatment of carbamoyl-phosphate synthase-1 deficiency,EU/3/12/971,Positive,19/04/2012,26/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-971
,,Heterologous human adult liver-derived stem cells,27/09/2011,Treatment of ornithine transcarbamylase deficiency,EU/3/11/904,Positive,17/10/2011,26/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-904
,,Heterologous human adult liver-derived stem cells,26/04/2012,Treatment of acute liver failure,EU/3/12/983,Positive,18/06/2012,26/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-983
Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron),EMEA/H/C/003918,Chimeric monoclonal antibody against GD2,08/11/2012,Treatment of neuroblastoma,EU/3/12/1062,Positive,13/12/2012,26/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1062
,,2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one,16/12/2019,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",EU/3/19/2227,Positive,24/02/2020,25/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2227
,,Murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38 ( Moxetumomab pasudotox),05/12/2008,Treatment of hairy cell leukaemia,EU/3/08/592,Withdrawn,17/09/2009,19/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-592
,,Adenovirus-associated viral vector serotype 5 containing the human RPGR gene,29/08/2016,Treatment of retinitis pigmentosa,EU/3/16/1715,Positive,03/10/2016,10/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1715
,,"1, 1'-[1,4-Phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (plerixafor)",20/10/2004,Treatment to mobilize progenitor cells prior to stem cell transplantation,EU/3/04/227,Expired,18/08/2008,10/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-227
,,imatinib,19/11/2014,Treatment of acute respiratory distress syndrome (ARDS),EU/3/14/1357,Positive,15/01/2015,06/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1357
,,Adeno-associated viral vector containing the human factor IX gene,11/01/2012,Treatment of haemophilia B,EU/3/11/938,Positive,01/02/2012,06/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-938
,,adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA,09/01/2020,Treatment of Fabry disease,EU/3/19/2241,Positive,19/05/2020,04/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2241
,,Daratumumab,25/05/2018,Treatment of AL amyloidosis,EU/3/18/2020,Positive,23/07/2018,03/08/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2020
,,"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide",29/05/2019,Treatment of cystic fibrosis,EU/3/19/2163,Withdrawn,09/08/2019,30/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2163
,,"Immunoglobulin G1, anti-(human tumour-associated calcium signal transducer 2)(human-Mus musculus monoclonal hRS7 heavy chain), disulfide with human-Mus musculus monoclonal hRS7 κ-chain, dimer, hexakis(thioether) with (4S)-4-[[[[4-[[(2S)-2-(4-aminobutyl)-2-[[2-[2-[[26-[4-[[[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-3,6,9,12,15,18,21,24-octaoxahexacos-1-yl]amino]-2-oxoethoxy]acetyl]amino]-1-oxoethyl]amino]phenyl]methoxy]carbonyl]oxy]-4,11-diethyl-9-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (sacituzumab govitecan)",15/10/2014,Treatment of pancreatic cancer,EU/3/14/1343,Positive,12/11/2014,28/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1343
,,Allogeneic anti-Epstein Barr virus cytotoxic T lymphocytes expanded ex vivo,21/07/2021,Treatment of post-transplant lymphoproliferative disorder,EU/3/19/2138,Withdrawn,02/10/2019,21/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2138
,,"2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol (fosbretabulin tromethamine)",21/07/2021,Treatment of anaplastic thyroid cancer,EU/3/04/195,Withdrawn,05/11/2004,21/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-195
,,(R-S) baclofen;naltrexone hydrochloride;D-sorbitol,26/03/2014,Treatment of Charcot-Marie-Tooth disease type 1A,EU/3/14/1260,Positive,07/05/2014,16/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1260
,,Human monoclonal antibody targeting Staphylococcus aureus alpha-toxin (tosatoxumab),05/03/2012,Treatment of pneumonia caused by Staphylococcus aureus,EU/3/12/968,Positive,06/07/2012,13/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-968
,,gallium citrate,21/08/2019,Treatment of cystic fibrosis,EU/3/19/2189,Positive,14/01/2020,13/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2189
,,Human monoclonal antibody against Pseudomonas aeruginosa serotype O11 (Panobacumab),29/06/2006,Treatment of pneumonia caused by serotype O11 Pseudomonas aeruginosa,EU/3/06/381,Positive,15/05/2009,13/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-381
,,dimethyl fumarate,21/03/2018,Treatment of Friedreich’s ataxia,EU/3/18/1990,Positive,15/05/2018,08/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1990
Hemgenix,EMEA/H/C/004827,Recombinant adeno-associated viral vector containing a codon-optimized Padua derivative of human coagulation factor IX cDNA (etranacogene dezaparvovec),21/03/2018,Treatment of haemophilia B,EU/3/18/1999,Positive,17/05/2018,01/07/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1999
Hepcludex,EMEA/H/C/004854,,19/06/2015,Treatment of hepatitis delta virus infection,EU/3/15/1500,Positive,27/07/2015,30/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1500
Enspryng,EMEA/H/C/004788,Humanised anti-IL-6 receptor monoclonal antibody (satralizumab),27/06/2016,Treatment of neuromyelitis optica spectrum disorders,EU/3/16/1680,Positive,26/07/2016,30/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1680
,,Recombinant human acid ceramidase,10/08/2015,Treatment of cystic fibrosis,EU/3/15/1536,Positive,02/10/2015,25/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1536
,,Recombinant human acid ceramidase,19/02/2014,Treatment of Farber disease,EU/3/14/1243,Positive,02/04/2014,25/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1243
,,Recombinant human aspartylglucosaminidase,15/01/2015,Treatment of aspartylglucosaminuria,EU/3/14/1410,Withdrawn,05/03/2015,25/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1410
,,Chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions (enadenotucirev),12/02/2015,Treatment of ovarian cancer,EU/3/15/1434,Withdrawn,08/04/2015,25/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1434
,,"Allogeneic hepatoblastoma cells encapsulated in alginate, ex vivo expanded",21/08/2020,Treatment of acute liver failure,EU/3/20/2312,Positive,25/11/2020,24/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2312
,,Bacterial lipase (burlulipase),07/11/2005,Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency,EU/3/05/323,Positive,09/02/2006,21/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-323
,,hydrocortisone,27/07/2005,Treatment of congenital adrenal hyperplasia,EU/3/05/296,Positive,21/09/2009,14/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-296
,,Adeno-associated viral vector serotype 2/2 containing a gene encoding the channelrhodopsin-2 protein,14/10/2016,Treatment of retinitis pigmentosa,EU/3/16/1740,Withdrawn,15/11/2016,11/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1740
,,"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (bimiralisib)",27/02/2017,Treatment of diffuse large B-cell lymphoma,EU/3/17/1830,Positive,31/03/2017,10/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1830
,,carglumic acid,07/11/2008,Treatment of propionic acidaemia,EU/3/08/577,Expired,02/04/2009,09/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-577
,,carglumic acid,07/11/2008,Treatment of isovaleric acidaemia,EU/3/08/575,Expired,02/04/2009,09/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-575
,,carglumic acid,07/11/2008,Treatment of methylmalonic acidaemia,EU/3/08/576,Expired,02/04/2009,09/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-576
,,Selinexor,19/11/2014,Treatment of plasma cell myeloma,EU/3/14/1355,Positive,15/01/2015,07/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1355
,,R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride (berotralstat),27/06/2018,Treatment of hereditary angioedema,EU/3/18/2028,Positive,21/08/2018,01/06/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2028
,,(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one,17/07/2013,Treatment of follicular lymphoma,EU/3/13/1157,Positive,16/08/2013,31/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1157
,,(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (duvelisib),26/04/2013,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/13/1125,Positive,14/05/2013,31/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1125
,,Adeno-associated viral vector expressing lipoprotein lipase (alipogene tiparvovec),09/03/2004,Treatment of lipoprotein-lipase deficiency,EU/3/04/194,Withdrawn,07/03/2007,31/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-194
,,"4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide",09/12/2020,Treatment of congenital hyperinsulinism,EU/3/20/2376,Positive,27/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2376
,,Synthetic oligonucleotide selectively targeting UBE3A antisense RNA transcripts,09/12/2020,Treatment of Angelman syndrome,EU/3/20/2379,Positive,27/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2379
,,Adeno-associated viral vector serotype 9 encoding human ATP7B,09/12/2020,Treatment of Wilson's disease,EU/3/20/2378,Positive,27/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2378
,,2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glycogen synthase 1 pre‑mRNA,09/12/2020,Treatment of progressive myoclonic epilepsy type 2 (Lafora disease),EU/3/20/2377,Positive,27/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2377
,,4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1 (pridopidine hydrochloride),20/06/2005,Treatment of Huntington’s disease,EU/3/05/288,Positive,04/07/2007,26/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-288
,,Autologous CD4+ and CD8+ T cells genetically modified with a lentiviral vector encoding a B-cell maturation antigen-specific chimeric antigen receptor,09/12/2020,Treatment of multiple myeloma,EU/3/20/2366,Withdrawn,26/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2366
,,Humanised IgG1 monoclonal antibody against the extracellular domain of receptor tyrosine kinase-like orphan receptor 1 coupled via a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker to monomethyl auristatin E,09/12/2020,Treatment of mantle cell lymphoma,EU/3/20/2373,Positive,25/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2373
Spexotras,EMEA/H/C/005886,Trametinib dimethyl sulfoxide,09/12/2020,Treatment of glioma,EU/3/20/2374,Positive,25/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2374
,,2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA,09/12/2020,Treatment of Duchenne muscular dystrophy,EU/3/20/2375,Positive,25/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2375
,,Aspacytarabine,09/12/2020,Treatment of acute myeloid leukaemia,EU/3/20/2371,Positive,21/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2371
,,Adeno-associated virus serotype rh74 containing the human sarcoglycan beta gene,09/12/2020,Treatment of limb-girdle muscular dystrophy,EU/3/20/2365,Positive,19/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2365
,,"(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea fumarate",09/12/2020,Treatment of Prader-Willi syndrome,EU/3/20/2367,Positive,19/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2367
,,Human interleukin 12 fused with immunoglobulin G4 C-terminal Fc fragment,09/12/2020,Treatment of glioma,EU/3/20/2368,Positive,19/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2368
,,Alpha galactosidase A,06/01/2021,Treatment of Fabry disease,EU/3/20/2396,Positive,18/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2396
,,Humanised IgG1K monoclonal antibody against interferon beta,06/01/2021,Treatment of dermatomyositis,EU/3/20/2392,Positive,18/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2392
,,"Human laminin-111, recombinant",06/01/2021,Treatment of congenital muscular dystrophy,EU/3/20/2388,Positive,18/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2388
,,sodium oxybate;calcium oxybate;magnesium oxybate;potassium oxybate,06/01/2021,Treatment of idiopathic hypersomnia,EU/3/20/2386,Positive,18/05/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2386
,,18-(p-(131I)-iodophenyl)octadecyl phosphocholine,17/10/2019,Treatment of multiple myeloma,EU/3/19/2204,Positive,21/01/2020,11/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2204
,,Recombinant human alpha-1-microglobulin,04/07/2014,Treatment of pre-eclampsia,EU/3/14/1289,Withdrawn,16/07/2014,11/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1289
,,Teicoplanin,23/08/2017,Treatment of cystic fibrosis,EU/3/17/1913,Positive,17/10/2017,06/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1913
,,Anti-neonatal Fc receptor human monoclonal antibody,17/10/2019,Prevention of haemolytic disease of the foetus and newborn,EU/3/19/2209,Positive,22/01/2020,05/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2209
Pemazyre,EMEA/H/C/005266,pemigatinib,24/08/2018,Treatment of biliary tract cancer,EU/3/18/2066,Positive,19/12/2018,04/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2066
,,tripotassium citrate monohydrate;Potassium hydrogen carbonate,20/06/2017,Treatment of distal renal tubular acidosis,EU/3/17/1888,Withdrawn,17/07/2017,03/05/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1888
,,L-cystine bis(N-methylpiperazide),27/06/2018,Treatment of cystinuria,EU/3/18/2036,Positive,21/08/2018,30/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2036
,,Mexiletine hydrochloride,07/06/2013,Treatment of non-dystrophic myotonia,EU/3/13/1126,Positive,25/06/2013,30/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1126
,,"1,2:5,6-Dianhydrogalactitol",24/01/2013,Treatment of glioma,EU/3/12/1093,Positive,01/03/2013,28/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1093
,,Codon-optimised human ornithine transcarbamylase mRNA complexed with lipid-based nanoparticles,27/06/2018,Treatment of ornithine transcarbamylase deficiency,EU/3/18/2033,Withdrawn,21/08/2018,28/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2033
,,Diclofenamide,17/02/2016,Treatment of periodic paralysis,EU/3/16/1616,Positive,07/04/2016,26/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1616
,,Eicosapentaenoic acid,08/10/2009,Treatment of familial adenomatous polyposis (FAP),EU/3/09/666,Positive,20/10/2009,22/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-666
Sogroya,EMEA/H/C/005030,Somapacitan,24/08/2018,Treatment of growth hormone deficiency,EU/3/18/2068,Positive,19/12/2018,15/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2068
,,Ribavirin,21/02/2018,Treatment of Lassa fever,EU/3/18/2003,Positive,15/05/2018,12/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2003
,,Ribavirin,21/03/2018,Treatment of Crimean-Congo haemorrhagic fever,EU/3/18/2002,Positive,15/05/2018,12/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2002
,,Ixazomib,08/11/2012,Treatment of systemic light chain amyloidosis,EU/3/12/1060,Withdrawn,12/12/2012,09/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1060
,,Adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene,29/07/2014,Treatment of catecholaminergic polymorphic ventricular tachycardia,EU/3/14/1296,Positive,01/09/2014,09/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1296
,,"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile (ziritaxestat)",29/08/2016,Treatment of idiopathic pulmonary fibrosis,EU/3/16/1712,Withdrawn,04/10/2016,09/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1712
,,Chimeric monoclonal antibody against claudin 6,24/01/2013,Treatment of ovarian cancer,EU/3/12/1092,Withdrawn,01/03/2013,08/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1092
,,Recombinant human glutamate oxaloacetate transaminase 1,12/02/2015,Treatment of glioma,EU/3/15/1443,Withdrawn,09/04/2015,07/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1443
,,Synthetic 12 amino acid peptide designed after subcommissural organ-spondin,13/11/2013,Treatment of spinal cord injury,EU/3/13/1206,Positive,02/12/2013,07/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1206
,,romilkimab,09/01/2020,Treatment of systemic sclerosis,EU/3/19/2246,Withdrawn,20/05/2020,06/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2246
,,ziritaxestat,09/01/2020,Treatment of systemic sclerosis,EU/3/19/2244,Withdrawn,20/05/2020,06/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2244
,,Adeno-associated virus serotype 9 containing the human ASPA gene,04/06/2020,Treatment of Canavan disease,EU/3/20/2287,Positive,19/08/2020,06/04/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2287
,,Terguride,24/01/2013,Treatment of systemic sclerosis,EU/3/12/1096,Withdrawn,01/03/2013,22/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1096
,,Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2,23/08/2017,Treatment of glioma,EU/3/17/1909,Positive,17/10/2017,22/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1909
,,Pirfenidone,16/11/2004,Treatment of idiopathic pulmonary fibrosis,EU/3/04/241,Expired,23/09/2009,22/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-241
,,milciclib maleate,08/11/2012,Treatment of malignant thymoma,EU/3/12/1059,Withdrawn,09/07/2013,22/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1059
,,Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (dilanubicel),17/01/2018,Treatment in haematopoietic stem cell transplantation,EU/3/17/1958,Withdrawn,14/03/2018,22/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1958
,,Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor,16/12/2014,Treatment of malignant mesothelioma,EU/3/14/1398,Positive,26/02/2015,19/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1398
,,genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor,19/06/2013,Treatment of soft tissue sarcoma,EU/3/13/1145,Positive,11/07/2013,19/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1145
,,Levosimendan,22/02/2018,Treatment of amyotrophic lateral sclerosis,EU/3/18/1980,Withdrawn,11/04/2018,19/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1980
,,Humanised single-chain monoclonal antibody against CD37 (otlertuzumab),06/12/2012,Treatment chronic lymphocytic leukaemia,EU/3/12/1083,Withdrawn,25/01/2013,19/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1083
,,Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec),22/08/2014,Treatment of Crigler-Najjar syndrome,EU/3/14/1321,Withdrawn,01/10/2014,19/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1321
,,Nimorazole maleate,09/02/2012,Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy,EU/3/12/952,Withdrawn,01/03/2012,19/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-952
,,Three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein (porgaviximab),09/10/2015,Treatment for Ebola virus disease,EU/3/15/1558,Withdrawn,18/11/2015,19/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1558
,,"R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (netazepide)",14/06/2007,Treatment of gastric carcinoid,EU/3/07/452,Positive,19/07/2007,02/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-452
,,N-(4-(1-cyanocyclopentyl)phenyl)-2-(4-pyridinylmethyl)amino-3-pyridinecarboxamide methanesulfonate,27/02/2017,Treatment of gastric cancer,EU/3/17/1840,Positive,31/03/2017,02/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1840
,,N-acetylgalactosamine-conjugated synthetic double-stranded oligomer specific to serpin family A member 1 gene,31/07/2018,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/18/2048,Positive,11/10/2018,02/03/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2048
,,Tadekinig alfa,14/10/2016,Treatment of haemophagocytic lymphohistiocytosis,EU/3/16/1763,Positive,15/11/2016,19/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1763
,,miglustat,19/10/2020,Treatment of neuronal ceroid lipofuscinosis,EU/3/20/2349,Positive,18/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2349
,,"Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with cystathionine γ-lyase [Pyridoxal 5’-phosphate cofactor] (synthetic engineered human), tetramer",19/10/2020,Treatment of homocystinuria,EU/3/20/2348,Positive,18/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2348
Reblozyl,EMEA/H/C/004444,Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept),22/08/2014,Treatment of myelodysplastic syndromes,EU/3/14/1331,Positive,29/09/2014,18/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1331
,,Luspatercept,28/02/2020,Treatment of myelofibrosis,EU/3/20/2255,Positive,06/05/2020,18/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2255
,,Adeno-associated virus serotype hu68 containing the human GLB1 gene,19/10/2020,Treatment of GM1 gangliosidosis,EU/3/20/2346,Positive,16/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2346
,,retifanlimab,19/10/2020,Treatment of anal cancer,EU/3/20/2343,Positive,16/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2343
,,Highly branched poly (beta-amino ester) complexed with a nanoplasmid containing the human COL7A1 gene,19/10/2020,Treatment of epidermolysis bullosa,EU/3/20/2342,Positive,16/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2342
,,"2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine",19/10/2020,Diagnosis of corticobasal degeneration,EU/3/20/2340,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2340
,,DNA plasmid encoding human transferrin gene,13/11/2020,Treatment of retinitis pigmentosa,EU/3/20/2364,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2364
,,decitabine;tetrahydrouridine,19/10/2020,Treatment of sickle cell disease,EU/3/20/2338,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2338
,,"(4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1))",19/10/2020,Treatment of primary IgA nephropathy,EU/3/20/2336,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2336
,,Triheptanoin,13/11/2020,Treatment of carnitine palmitoyltransferase I deficiency,EU/3/20/2360,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2360
,,Adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene,13/11/2020,Treatment of frontotemporal dementia,EU/3/20/2359,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2359
,,L-pyroglutamyl-L-asparaginyl-L-prolyl-D-tyrosyl-D-tryptophan amide,13/11/2020,Treatment of amyotrophic lateral sclerosis,EU/3/20/2358,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2358
,,Anti-(pancreatic adenocarcinoma upregulated factor) IgG1 humanised monoclonal antibody,13/11/2020,Treatment of pancreatic cancer,EU/3/20/2355,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2355
,,"(R)‑tetrahydrofuran‑3‑yl 4‑(6‑(5‑(4‑ethoxy‑1‑isopropylpiperidin‑4‑yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate",13/11/2020,Treatment of fibrodysplasia ossificans progressiva,EU/3/20/2352,Positive,15/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2352
,,retigabine,19/10/2020,Treatment of KCNQ2 developmental and epileptic encephalopathy,EU/3/20/2332,Positive,12/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2332
,,5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (ezutromid),04/12/2008,Treatment of Duchenne muscular dystrophy,EU/3/08/591,Withdrawn,29/06/2009,10/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-591
,,"1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt",19/10/2020,Treatment of polycythaemia vera,EU/3/20/2330,Positive,10/02/2021,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2330
,,Human monoclonal antibody against Pseudomonas aeruginosa IATS-O1,28/01/2010,Treatment of pneumonia caused by serotype O1 Pseudomonas aeruginosa,EU/3/09/705,Withdrawn,25/02/2010,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-705
,,"RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5') (C-m5U-m5U-A-C-A-G-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5' [P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N-dimethylaminophosphonamidate], 3'-[2'a-[N2-acetyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-6-aminohexanoyl-β-alanyl], octahydrochloride",02/02/2010,Treatment of Duchenne muscular dystrophy,EU/3/09/725,Withdrawn,04/03/2010,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-725
,,Sodium thiosulfate,23/02/2011,Treatment of calciphylaxis,EU/3/10/848,Withdrawn,07/03/2011,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-848
,,Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec),18/11/2016,Treatment of Crigler-Najjar syndrome,EU/3/16/1772,Withdrawn,13/12/2016,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1772
,,Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulfate hemihydrate),27/07/2010,Treatment of traumatic spinal cord injury,EU/3/10/754,Withdrawn,05/08/2010,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-754
,,"Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain (pegcetacoplan)",21/08/2019,Treatment of C3 glomerulopathy,EU/3/19/2201,Positive,16/01/2020,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2201
,,"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",12/12/2017,"Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes",EU/3/17/1947,Positive,23/01/2018,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1947
,,ciclosporin,01/10/2010,Treatment of moderate and severe closed traumatic brain injury,EU/3/10/791,Positive,14/10/2010,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-791
,,2-Hydroxyoleic acid,27/10/2011,Treatment of glioma,EU/3/11/916,Positive,23/11/2011,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-916
,,,09/02/2012,Treatment of West syndrome,EU/3/12/953,Withdrawn,01/03/2012,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-953
,,Rovalpituzumab tesirine,30/05/2016,Treatment of small cell lung cancer,EU/3/16/1667,Withdrawn,23/06/2016,03/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1667
,,Oxalobacter formigenes strain HC-1,17/02/2006,Treatment of primary hyperoxaluria,EU/3/06/354,Positive,15/05/2009,02/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-354
,,Oxalobacter formigenes strain HC-1,15/10/2014,Treatment of short bowel syndrome,EU/3/14/1346,Positive,12/11/2014,02/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1346
Pemazyre,EMEA/H/C/005266,pemigatinib,17/10/2019,"Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK",EU/3/19/2216,Positive,23/01/2020,01/02/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2216
Elzonris,EMEA/H/C/005031,recombinant human interleukin-3 truncated diphtheria toxin fusion protein,11/11/2015,Treatment of blastic plasmacytoid dendritic cell neoplasm,EU/3/15/1567,Positive,05/01/2016,25/01/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1567
,,Oxytocin,29/07/2014,Treatment of Prader-Willi syndrome,EU/3/14/1302,Positive,01/09/2014,25/01/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1302
,,rasagiline,28/06/2019,Treatment of Duchenne muscular dystrophy,EU/3/19/2174,Withdrawn,10/10/2019,12/01/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2174
,,Tetrahydrobiopterin,08/06/2004,Treatment of hyperphenylalaninaemia,EU/3/04/199,Withdrawn,18/08/2008,11/01/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-199
,,adeno-associated viral vector serotype 2 containing the human REP1 gene (timrepigene emparvovec),24/08/2018,Treatment of spinal muscular atrophy,EU/3/18/2060,Withdrawn,19/12/2018,07/01/2021,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2060
,,Miransertib,21/03/2018,Treatment of Proteus syndrome,EU/3/18/1997,Positive,15/05/2018,22/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1997
,,Antisense oligonucleotide targeting the F508delta mutation of CFTR (eluforsen),07/10/2013,Treatment of cystic fibrosis,EU/3/13/1195,Withdrawn,31/10/2013,18/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1195
,,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid (lanifibranor),19/11/2014,Treatment of systemic sclerosis,EU/3/14/1361,Withdrawn,15/01/2015,14/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1361
,,5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate],16/10/2017,Treatment of biliary tract cancer,EU/3/17/1916,Withdrawn,10/01/2018,11/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1916
,,Recombinant antibody derivative against human CD19 and CD3 (blinatumomab),01/12/2003,Treatment of chronic lymphocytic leukaemia,EU/3/03/176,Withdrawn,04/01/2006,11/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-176
,,Recombinant antibody derivative against human CD19 and CD3 (blinatumomab),01/12/2003,Treatment of mantle cell lymphoma,EU/3/03/175,Withdrawn,05/11/2004,11/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-175
,,Treosulfan,22/02/2004,Conditioning treatment prior to haematopoietic-progenitor-cell transplantation,EU/3/04/186,Positive,22/11/2004,11/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-186
,,pentetrazol,11/11/2015,Treatment of idiopathic hypersomnia,EU/3/15/1569,Withdrawn,06/01/2016,10/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1569
,,"copper meso-5,15-bis[3-[(1,2-dicarba-closo-dodecaboranyl)methoxy]phenyl]-meso-10,20-dinitroporphyrin",27/06/2013,Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy,EU/3/13/1138,Withdrawn,11/07/2013,10/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1138
,,Ecothiopate iodide,24/04/2015,Treatment of Stargardt's disease,EU/3/15/1474,Withdrawn,21/05/2015,10/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1474
,,Allantoin,16/01/2014,Treatment of epidermolysis bullosa,EU/3/13/1232,Withdrawn,24/03/2014,10/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1232
Dovprela (previously Pretomanid FGK),EMEA/H/C/005167,"(S)-2-nitro-6-(4-trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine (pretomanid)",29/11/2007,Treatment of tuberculosis,EU/3/07/513,Positive,02/07/2008,09/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-513
,,Alpha-1 proteinase inhibitor,14/09/2007,Treatment of cystic fibrosis,EU/3/07/474,Withdrawn,17/01/2008,08/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-474
,,Sodium cromoglicate,26/06/2020,Treatment of idiopathic pulmonary fibrosis,EU/3/20/2294,Withdrawn,23/09/2020,08/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2294
,,Adeno-associated viral vector expressing acid alpha-glucosidase gene,27/07/2020,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/20/2303,Positive,19/11/2020,08/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2303
,,"L-cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-complex with keyhole limpet haemocyanin",27/10/2011,Treatment of glioma,EU/3/11/923,Withdrawn,23/11/2011,04/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-923
,,Adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter,23/08/2017,Treatment of Wilson's disease,EU/3/17/1898,Withdrawn,17/10/2017,03/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1898
,,"Sodium (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl ((2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl phosphate (guadecitabine)",14/12/2015,Treatment of acute myeloid leukaemia,EU/3/15/1597,Withdrawn,03/02/2016,01/12/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1597
,,Recombinant adeno-associated viral vector serotype 5 encoding Staphylococcus aureus Cas9 endonuclease and two guide RNAs complementary to two regions of intron 26 of the CEP290 gene,16/10/2017,Treatment of Leber's congenital amaurosis,EU/3/17/1928,Positive,08/01/2018,30/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1928
,,Recombinant human bone morphogenetic protein 4,15/10/2014,Treatment of glioma,EU/3/14/1348,Positive,12/11/2014,30/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1348
,,Obiltoxaximab,24/08/2018,Treatment of anthrax,EU/3/18/2065,Withdrawn,19/12/2018,27/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2065
,,Picropodophyllin,23/08/2017,Treatment of glioma,EU/3/17/1904,Positive,17/10/2017,27/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1904
Oxlumo,EMEA/H/C/005040,Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (lumasiran),21/03/2016,Treatment of primary hyperoxaluria,EU/3/16/1637,Positive,02/05/2016,25/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1637
,,Dextran sulfate low molecular weight,21/08/2020,Treatment of amyotrophic lateral sclerosis,EU/3/20/2318,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2318
,,Copper histidinate,21/08/2020,Treatment of Menkes disease,EU/3/20/2320,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2320
,,Adeno-associated viral vector serotype 3B encoding shortened human ATP7B,21/08/2020,Treatment of Wilson's disease,EU/3/20/2321,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2321
,,Trehalose,21/08/2020,Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome),EU/3/20/2323,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2323
,,Autologous T cells transduced with lentiviral vector containing a tandem chimeric antigen receptor directed against CD20 and CD19,21/08/2020,Treatment of diffuse large B-cell lymphoma,EU/3/20/2327,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2327
,,Human frataxin fused to TAT cell-penetrating peptide,21/08/2020,Treatment of Friedreich’s ataxia,EU/3/20/2328,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2328
,,"Allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured",21/08/2020,Treatment in haematopoietic stem cell transplantation,EU/3/20/2317,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2317
,,Humanised IgG1 monoclonal antibody against human eotaxin-2,21/08/2020,Treatment of primary sclerosing cholangitis,EU/3/20/2314,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2314
,,"2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine",21/08/2020,Diagnosis of progressive supranuclear palsy,EU/3/20/2313,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2313
,,Adeno-associated virus serotype 2/8 vector containing the human PDE6A gene,21/08/2020,Treatment of retinitis pigmentosa,EU/3/20/2310,Positive,25/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2310
,,Hydroxychloroquine,12/01/2017,Treatment of antiphospholipid syndrome,EU/3/16/1820,Positive,13/07/2017,24/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1820
,,Allogeneic umbilical cord tissue-derived mesenchymal stromal cells ex vivo expanded,21/08/2020,Prevention of bronchopulmonary dysplasia,EU/3/20/2308,Positive,24/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2308
,,Humanised monoclonal antibody against P-selectin (crizanlizumab),09/08/2012,Treatment of sickle cell disease,EU/3/12/1034,Positive,26/09/2012,24/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1034
,,Retinol palmitate,27/07/2020,Prevention of bronchopulmonary dysplasia,EU/3/20/2306,Positive,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2306
,,Tinostamustine,27/07/2020,Treatment of T-cell prolymphocytic leukaemia,EU/3/20/2307,Positive,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2307
,,Benzyl benzoate;beta-caryophyllene;cineole;cinnamaldehyde;cinnamyl acetate;linalool;trans-2-methoxycinnamaldehyde,18/06/2020,Treatment of eumycetoma,-,Negative,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-eumycetoma
,,melatonin,06/07/2020,Treatment of intracerebral haemorrhage,-,Negative,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-intracerebral-haemorrhage
,,Triheptanoin,27/07/2020,Treatment of carnitine-acylcarnitine translocase deficiency,EU/3/20/2302,Positive,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2302
,,Fasudil hydrochloride,27/07/2020,Treatment of non-traumatic subarachnoid haemorrhage,EU/3/20/2300,Positive,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2300
,,C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker,27/07/2020,Treatment of achondroplasia,EU/3/20/2299,Positive,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2299
,,Hemopexin,27/07/2020,Treatment of sickle cell disease,EU/3/20/2298,Positive,19/11/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2298
Mepsevii,EMEA/H/C/004438,Recombinant human beta-glucuronidase (vestronidase alfa),21/03/2012,Treatment of mucopolysaccharidosis type VII (Sly syndrome),EU/3/12/973,Positive,19/04/2012,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-973
,,acalabrutinib,21/03/2016,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/16/1624,Withdrawn,02/05/2016,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1624
,,Triheptanoin,28/07/2015,Treatment of carnitine palmitoyltransferase II deficiency,EU/3/15/1526,Positive,18/08/2015,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1526
,,Triheptanoin,28/07/2015,Treatment of mitochondrial trifunctional protein deficiency,EU/3/15/1525,Positive,18/12/2015,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1525
,,Triheptanoin,28/07/2015,Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency,EU/3/15/1524,Positive,18/08/2015,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1524
,,Triheptanoin,19/06/2015,Treatment of very long-chain acyl-CoA dehydrogenase deficiency,EU/3/15/1508,Positive,27/07/2015,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1508
,,adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene (pariglasgene brecaparvovec),18/11/2016,treatment of glycogen storage disease type Ia,EU/3/16/1771,Positive,14/12/2016,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1771
,,Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase (avalotcagene ontaparvovec),21/03/2016,Treatment of ornithine transcarbamylase deficiency,EU/3/16/1623,Positive,04/05/2016,11/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1623
Zejula,EMEA/H/C/004249,(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosilate monohydrate salt (niraparib),04/08/2010,Treatment of ovarian cancer,EU/3/10/760,Positive,11/08/2010,06/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-760
Arikayce liposomal,EMEA/H/C/005264,Amikacin sulfate,08/04/2014,Treatment of nontuberculous mycobacterial lung disease,EU/3/14/1259,Positive,07/05/2014,03/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1259
,,Amikacin sulfate,25/07/2006,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,EU/3/06/387,Positive,02/04/2009,03/11/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-387
,,"5,7-dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)-one mesilate",16/12/2019,Treatment of multiple system atrophy,EU/3/19/2228,Positive,25/02/2020,27/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2228
,,Humanised monoclonal antibody against myostatin (domagrozumab),08/02/2013,Treatment of Duchenne muscular dystrophy,EU/3/13/1105,Withdrawn,04/03/2013,23/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1105
,,Mepolizumab,12/03/2013,Treatment of Churg-Strauss syndrome,EU/3/13/1116,Withdrawn,05/04/2013,23/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1116
Bosatria; Bosatria,EMEA/H/C/001069; EMEA/H/C/001069,Mepolizumab,29/07/2004,Treatment of hypereosinophilic syndrome,EU/3/04/213,Withdrawn,23/09/2009,23/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-213
,,Adeno-associated virus serotype rh74 containing the human micro-dystrophin gene,28/02/2020,Treatment of Duchenne muscular dystrophy,EU/3/20/2250,Positive,05/05/2020,22/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2250
,,hydrocortisone,20/03/2007,Treatment of adrenal insufficiency,EU/3/07/441,Positive,21/09/2009,20/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-441
,,somatropin,08/08/2000,AIDS wasting,EU/3/00/001,Withdrawn,03/03/2009,15/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-001
,,"2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one",16/12/2014,Treatment of ovarian cancer,EU/3/14/1386,Positive,26/02/2015,13/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1386
,,2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one,25/07/2019,Treatment of myelodysplastic syndromes,EU/3/19/2180,Positive,24/09/2019,13/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2180
,,"2-Methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one",10/06/2010,Treatment of acute myeloid leukaemia,EU/3/10/742,Positive,25/06/2010,13/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-742
,,2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA,31/07/2018,treatment of behavioural variant frontotemporal dementia,EU/3/18/2041,Positive,11/10/2018,13/10/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2041
,,DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain,17/02/2016,Treatment of non-infectious uveitis,EU/3/16/1619,Positive,07/04/2016,29/09/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1619
,,Synthetic glucagon analogue modified to contain 7 amino acid substitutions,20/06/2017,Treatment of congenital hyperinsulinism,EU/3/17/1887,Positive,17/07/2017,25/09/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1887
,,Lys40(NODAGA-68Ga)NH2-exendin-4,26/06/2020,Diagnosis of insulinoma,EU/3/20/2295,Positive,24/09/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2295
,,stiripentol,26/06/2020,Treatment of primary hyperoxaluria,EU/3/20/2290,Positive,22/09/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2290
,,Onfekafusp alfa,26/06/2020,Treatment of glioma,EU/3/20/2291,Positive,22/09/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2291
,,Adeno-associated viral vector serotype 8 containing the human MTM1 gene (resamirigene bilparvovec),10/08/2015,Treatment of X-linked myotubular myopathy,EU/3/15/1539,Positive,02/10/2015,18/09/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1539
,,2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid,12/03/2013,Treatment of systemic sclerosis,EU/3/13/1108,Positive,05/04/2013,18/09/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1108
Idefirix,EMEA/H/C/004849,Recombinant IgG degrading enzyme of Streptococcus pyogenes (imlifidase),12/01/2017,Prevention of graft rejection following solid organ transplantation,EU/3/16/1826,Positive,14/07/2017,28/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1826
,,"(16E)-14-methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid",17/10/2019,Treatment of glioma,EU/3/19/2202,Positive,21/01/2020,27/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2202
,,Autologous stromal vascular cell fraction from adipose tissue,28/04/2016,Treatment of systemic sclerosis,EU/3/16/1643,Withdrawn,31/05/2016,27/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1643
,,Autologous adult live cultured osteoblasts,26/02/2019,Treatment of non-traumatic osteonecrosis,EU/3/19/2139,Positive,09/04/2019,27/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2139
,,P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide,14/10/2016,Treatment of acute myeloid leukaemia,EU/3/16/1758,Positive,15/11/2016,27/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1758
Alofisel,EMEA/H/C/004258,Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue (darvadstrocel),08/10/2009,Treatment of anal fistula,EU/3/09/667,Positive,20/10/2009,26/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-667
,,Balipodect,14/04/2019,Treatment of fragile X syndrome,EU/3/19/2154,Positive,14/06/2019,26/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2154
Ninlaro,EMEA/H/C/003844,"2,2'-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid",27/09/2011,Treatment of multiple myeloma,EU/3/11/899,Positive,07/12/2016,26/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-899
,,Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(discrete-polyethylene glycol)24,04/06/2020,Treatment of neonatal encephalopathy,EU/3/20/2283,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2283
,,"1-((2S,4S)-2-((((S)-(4-bromophenoxy)(((S)-1-oxo-1-(((S)-pentan-2-yl)oxy)propan-2-yl)amino)phosphoryl)oxy)methyl)-1,3-dioxolan-4-yl)-2-oxo-1,2-dihydropyrimidin-4-aminium chloride",04/06/2020,Treatment of hepatocellular carcinoma,EU/3/20/2285,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2285
,,Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4,04/06/2020,Treatment of soft tissue sarcoma,EU/3/20/2286,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2286
Fabhalta,EMEA/H/C/005764,"(4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1))",04/06/2020,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/20/2281,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2281
,,Lutetium (177Lu) lilotomab satetraxetan,04/06/2020,Treatment of marginal zone lymphoma,EU/3/20/2280,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2280
,,Lumacaftor,04/06/2020,Treatment of non-traumatic subarachnoid haemorrhage,EU/3/20/2279,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2279
,,Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains,04/06/2020,Treatment of multiple myeloma,EU/3/20/2277,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2277
,,methotrexate,04/06/2020,Treatment of retinal detachment,EU/3/20/2276,Positive,19/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2276
,,Glucagon analogue linked to a human immunoglobulin Fc fragment,22/04/2020,Treatment of insulin autoimmune syndrome,EU/3/20/2275,Positive,13/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2275
,,adeno-associated virus vector serotype hu37 encoding human factor VIII,22/04/2020,Treatment of  haemophilia A,EU/3/20/2274,Positive,13/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2274
,,anti-(integrin beta-3) human monoclonal antibody,22/04/2020,Prevention of fetal and neonatal alloimmune thrombocytopenia due to human platelet antigen-1a incompatibility,EU/3/20/2273,Positive,13/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2273
Rystiggo,EMEA/H/C/005824,Rozanolixizumab,22/04/2020,Treatment of myasthenia gravis,EU/3/20/2272,Positive,13/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2272
,,"Methyl 3-((2R)-2-hydroxy-4-(((((S)-1-methoxy-1-oxopropan-2-yl) amino)(phenoxy)phosphoryl)oxy)-3,3-dimethylbutanamido)propanoate",17/02/2016,Treatment of pantothenate-kinase-associated neurodegeneration,EU/3/16/1612,Withdrawn,06/04/2016,13/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1612
,,florbetaben (18F),22/04/2020,Diagnosis of AL amyloidosis,EU/3/20/2268,Positive,12/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2268
,,icatibant acetate,18/02/2003,Treatment of angioedema,EU/3/03/133,Expired,09/04/2003,12/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-133
,,Recombinant human galactocerebrosidase,27/09/2011,Treatment of globoid cell leukodystrophy (Krabbe disease),EU/3/11/911,Withdrawn,17/10/2011,12/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-911
,,Recombinant human porphobilinogen deaminase,12/06/2002,Treatment of acute intermittent porphyria,EU/3/02/103,Withdrawn,08/01/2003,12/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-103
,,Fosgemcitabine palabenamide,24/03/2020,Treatment of biliary tract cancer,EU/3/20/2262,Positive,12/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2262
,,Cabiralizumab,12/12/2016,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",EU/3/16/1799,Withdrawn,09/01/2017,12/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1799
,,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride",08/10/2009,Treatment of pancreatic cancer,EU/3/09/685,Withdrawn,19/11/2009,12/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-685
,,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride",17/12/2010,Treatment of acute myeloid leukaemia,EU/3/10/824,Withdrawn,20/01/2011,12/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-824
,,Adeno-associated viral vector serotype 3B encoding human multidrug resistance protein 3A,22/04/2020,Treatment of progressive familial intrahepatic cholestasis,EU/3/20/2267,Positive,11/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2267
,,DNA plasmid encoding IL-12 p35 and p40 genes,22/04/2020,Treatment of ovarian cancer,EU/3/20/2266,Positive,11/08/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2266
,,Humanised monoclonal antibody to the folate receptor alpha,01/04/2008,Treatment of ovarian cancer,EU/3/08/535,Positive,10/07/2008,11/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-535
,,Amatuximab,16/01/2014,Treatment of malignant mesothelioma,EU/3/13/1222,Positive,21/03/2014,11/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1222
,,"N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide",23/08/2017,Treatment of hepatocellular carcinoma,EU/3/17/1902,Positive,17/10/2017,11/08/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1902
,,cholic acid,29/10/2009,Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid,EU/3/09/683,Withdrawn,18/11/2009,29/07/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-683
,,Oleylphosphocholine,23/04/2012,Treatment of leishmaniasis,EU/3/12/964,Positive,03/05/2012,10/07/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-964
Isturisa,EMEA/H/C/004821,Osilodrostat,15/10/2014,Treatment of Cushing's syndrome,EU/3/14/1345,Positive,12/11/2014,07/07/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1345
,,"2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'",12/02/2015,Treatment of Huntington’s disease,EU/3/15/1432,Positive,08/04/2015,23/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1432
,,Humanised monoclonal antibody against CD38 for the treatment of plasma cell myeloma (isatuximab),29/04/2014,Treatment of plasma cell myeloma,EU/3/14/1268,Withdrawn,04/06/2014,12/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1268
,,Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL,28/07/2015,Treatment of pancreatic cancer,EU/3/15/1516,Positive,18/08/2015,11/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1516
,,Human monoclonal antibody against Fas ligand,09/02/2012,Treatment of pemphigus,EU/3/12/956,Positive,01/03/2012,11/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-956
,,nintedanib,26/04/2013,Treatment of idiopathic pulmonary fibrosis,EU/3/13/1123,Withdrawn,14/05/2013,09/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1123
,,Sirolimus,17/01/2018,Treatment of sickle cell disease,EU/3/17/1970,Positive,14/03/2018,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1970
,,Trehalose,19/06/2015,Treatment of spinocerebellar ataxia,EU/3/15/1502,Positive,27/07/2015,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1502
,,Etamsylate,19/11/2018,Treatment of hereditary haemorrhagic telangiectasia,EU/3/18/2087,Positive,25/02/2019,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2087
,,"4,6,4'-trimethylangelicin",19/06/2013,Treatment of cystic fibrosis,EU/3/13/1137,Positive,11/07/2013,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1137
Garsun,EMEA/H/C/005718,artesunate,28/07/2015,Treatment of malaria,EU/3/15/1521,Positive,18/08/2015,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1521
,,"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide",21/03/2018,Treatment of C3 glomerulopathy,EU/3/18/1989,Positive,08/05/2018,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1989
Voydeya,EMEA/H/C/005517,"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide",12/12/2017,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/17/1946,Positive,24/01/2018,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1946
,,Recombinant modified ricin toxin A-chain subunit,21/03/2018,Prevention of ricin poisoning,EU/3/18/2001,Positive,17/05/2018,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2001
orBec,EMEA/H/C/000803,"Beclomethasone 17, 21-dipropionate",13/03/2002,Treatment of intestinal graft-versus-host disease,EU/3/02/093,Positive,18/08/2008,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-093
,,Trehalose,21/05/2015,Treatment of oculopharyngeal muscular dystrophy,EU/3/15/1496,Positive,30/06/2015,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1496
,,vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions,18/11/2016,Treatment of ovarian cancer,EU/3/16/1791,Positive,14/12/2016,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1791
,,Recombinant human pentraxin-2,19/11/2014,Treatment of post-essential thrombocythaemia myelofibrosis,EU/3/14/1358,Positive,15/01/2015,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1358
,,Recombinant human pentraxin-2,19/11/2014,Treatment of primary myelofibrosis,EU/3/14/1366,Positive,15/01/2015,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1366
,,Recombinant human pentraxin-2,19/11/2014,Treatment of post-polycythaemia vera myelofibrosis,EU/3/14/1365,Positive,15/01/2015,08/06/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1365
,,"Autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo",14/07/2016,Treatment of post-transplantation lymphoproliferative disorders,EU/3/16/1696,Withdrawn,06/09/2016,25/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1696
,,"Autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo",14/07/2016,"Treatment of extranodal NK/T-cell lymphoma, nasal type",EU/3/16/1695,Withdrawn,06/09/2016,25/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1695
,,Mertansine functionalised gold nanoconjugate,22/02/2018,Treatment of hepatocellular carcinoma,EU/3/18/1981,Withdrawn,11/04/2018,20/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1981
,,motixafortide,09/01/2020,Treatment of pancreatic cancer,EU/3/19/2243,Positive,19/05/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2243
,,nicardipine,09/01/2020,Treatment of non-traumatic subarachnoid haemorrhage,EU/3/19/2240,Positive,19/05/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2240
,,Itraconazole,25/05/2018,Prevention of invasive aspergillosis,EU/3/18/2024,Positive,24/07/2018,15/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2024
,,"2-(3,7-Dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone",09/01/2020,Treatment of Huntington's disease,EU/3/19/2237,Positive,15/05/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2237
,,liposomal mannose-1-phosphate,31/07/2018,treatment of phosphomannomutase 2-congenital disorder of glycosylation,EU/3/18/2047,Positive,11/10/2018,07/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2047
,,Sirolimus,17/07/2017,Treatment of pachyonychia congenita,EU/3/17/1896,Positive,14/08/2017,07/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1896
,,Rusalatide acetate,22/02/2018,Treatment of acute radiation syndrome,EU/3/18/1985,Positive,11/04/2018,07/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1985
,,Entolimod,11/01/2016,Treatment of acute radiation syndrome,EU/3/15/1607,Withdrawn,05/02/2016,07/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1607
,,melatonin;sorafenib,23/09/2019,Treatment of hepatocellular carcinoma,-,Negative,06/05/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-hepatocellular-carcinoma
,,Sintilimab,28/02/2020,Treatment of peripheral T-cell lymphoma,EU/3/20/2257,Positive,06/05/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2257
,,Adeno-associated virus serotype 8 containing the human RdCVF sequence and the human RdCVFL sequence,28/02/2020,Treatment of inherited retinal dystrophies,EU/3/20/2249,Positive,05/05/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2249
,,Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA,28/02/2020,Treatment of Fabry disease,EU/3/20/2248,Positive,05/05/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2248
,,Imidazolyl ethanamide pentandioic acid,28/06/2019,Treatment of acute radiation syndrome,EU/3/19/2173,Positive,07/10/2019,04/05/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2173
,,Recombinant human pentraxin-2,17/07/2012,Treatment of idiopathic pulmonary fibrosis,EU/3/12/1020,Positive,30/08/2012,24/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1020
,,,05/08/2013,Treatment of sickle cell disease,EU/3/13/1184,Positive,16/09/2013,23/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1184
,,thiotepa,29/01/2007,Conditioning treatment prior to haematopoietic-progenitor-cell transplantation,EU/3/06/424,Withdrawn,19/07/2007,20/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-424
,,2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide,21/05/2015,Treatment of cystic fibrosis,EU/3/15/1498,Withdrawn,30/06/2015,16/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1498
Trepulmix,EMEA/H/C/005207,Treprostinil sodium,08/02/2013,Treatment of chronic thromboembolic pulmonary hypertension,EU/3/13/1103,Positive,04/03/2013,08/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1103
,,"N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide",22/02/2018,Treatment of pulmonary arterial hypertension,EU/3/18/1982,Positive,11/04/2018,08/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1982
,,nitisinone,13/03/2002,Treatment of alkaptonuria,EU/3/02/096,Withdrawn,06/01/2003,01/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-096
,,Humanised recombinant IgG4 anti-human tau antibody (tilavonemab),28/04/2016,Treatment of progressive supranuclear palsy,EU/3/16/1649,Withdrawn,30/05/2016,01/04/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1649
,,Autologous adult bone marrow-derived non-expanded CD133+ haematopoietic stem cells,20/04/2017,Treatment of Asherman's syndrome,EU/3/17/1862,Positive,15/05/2017,31/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1862
,,Human monoclonal IgG2 antibody against tissue factor pathway inhibitor,22/02/2018,Treatment of haemophilia A,EU/3/18/1979,Withdrawn,11/04/2018,26/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1979
Givlaari,EMEA/H/C/004775,"Synthetic double-stranded siRNA oligonucleotide directed against delta-aminolevulinic acid synthase 1 mRNA, covalently linked to a ligand containing three N-acetylgalactosamine residues (givosiran)",29/08/2016,Treatment of acute hepatic porphyria,EU/3/16/1731,Positive,11/10/2016,09/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1731
,,Yttrium (90Y)-DOTA-radiolabelled humanized monoclonal antibody against mucin 1,06/02/2009,Treatment of pancreatic cancer,EU/3/08/608,Withdrawn,29/06/2009,06/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-608
,,Veltuzumab,29/01/2010,Treatment of chronic lymphocytic leukaemia,EU/3/09/713,Withdrawn,25/02/2010,06/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-713
,,Adeno-associated viral vector serotype 8 containing the human factor-VII gene,15/01/2015,Treatment of congenital factor VII deficiency,EU/3/14/1430,Positive,06/03/2015,05/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1430
,,"3,4-diaminopyridine phosphate (amifampridine)",19/12/2002,Treatment of Lambert-Eaton myasthenic syndrome,EU/3/02/124,Withdrawn,18/08/2008,04/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-124
,,dimethyl fumarate,14/07/2016,Treatment of bullous pemphigoid,EU/3/16/1698,Positive,06/09/2016,02/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1698
,,Human platelet antigen-1a immunoglobulin,27/10/2011,Prevention of fetal and neonatal alloimmune thrombocytopenia,EU/3/11/922,Positive,23/11/2011,02/03/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-922
Vyndaqel,EMEA/H/C/002294,tafamidis,08/11/2012,Treatment of senile systemic amyloidosis,EU/3/12/1066,Positive,13/12/2012,25/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1066
,,navitoclax,16/12/2019,Treatment of myelofibrosis,EU/3/19/2233,Positive,25/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2233
,,H-Leu-Pro-Pro-Leu-Pro-Tyr-Pro-OH,16/12/2019,Treatment of amyotrophic lateral sclerosis,EU/3/19/2231,Positive,25/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2231
,,Adeno-associated virus vector encoding human phenylalanine hydroxylase,16/12/2019,Treatment of phenylalanine hydroxylase deficiency,EU/3/19/2229,Positive,25/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2229
,,"(E)-2-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-10-(carboxymethyl)-1-hydroxy-13-(2-(2-(2-((E)-3-(3-((3-hydroxy-3,3 diphosphonopropyl)(methyl)amino)propoxy)benzylidene)hydrazine-1-carbonothioyl)hydrazineyl)-2-oxoethyl)-8-oxo-5-thioxo-3,4,6,7,10,13-hexaazapentadec-2-en-15-oic acid",16/12/2019,Treatment of osteosarcoma,EU/3/19/2226,Positive,24/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2226
,,Naltrexone,07/11/2020,Treatment of fibromyalgia,-,Negative,24/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-fibromyalgia-0
,,"Autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha)",19/02/2014,Treatment of glioma,EU/3/14/1247,Positive,02/04/2014,19/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1247
,,Milatuzumab,19/01/2009,Treatment of chronic lymphocytic leukaemia,EU/3/08/602,Withdrawn,29/06/2009,18/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-602
,,Milatuzumab,19/01/2009,Treatment of multiple myeloma,EU/3/08/601,Withdrawn,29/06/2009,18/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-601
,,Exendin (9-39),13/11/2019,Treatment of congenital hyperinsulinism,EU/3/19/2223,Positive,13/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2223
,,Camsirubicin,13/11/2019,Treatment of soft tissue sarcoma,EU/3/19/2221,Positive,13/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2221
,,,13/11/2019,Treatment of GM2 gangliosidosis,EU/3/19/2218,Positive,12/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2218
,,4-((E)-(5-(2-(2-((S)-2-((S)-1-(L-threonyl-L-lysyl)pyrrolidine-2-carboxamido)-5-guanidinopentanamido)acetamido)-2-carboxyethyl)-2-hydroxyphenyl)diazenyl)phenyl (2-(trimethylammonio)ethyl) phosphate,13/11/2019,Treatment of non-infectious uveitis,EU/3/19/2219,Positive,12/02/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2219
,,"505 amino acid protein, corresponding to amino acids 2-506 of the wild-type human histidyl-tRNA synthetase",27/02/2017,Treatment of limb-girdle muscular dystrophy,EU/3/17/1831,Withdrawn,13/03/2017,12/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1831
,,"505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase",12/02/2015,treatment of facioscapulohumeral muscular dystrophy,EU/3/15/1448,Withdrawn,09/04/2015,12/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1448
,,"Adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo",16/01/2014,Treatment of adenovirus infection in allogeneic haematopoietic stem cell transplant recipients,EU/3/13/1227,Withdrawn,21/03/2014,12/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1227
,,lenalidomide,24/01/2013,Treatment of follicular lymphoma,EU/3/12/1097,Withdrawn,01/03/2013,11/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1097
,,Beraprost sodium,10/07/2008,Treatment of pulmonary arterial hypertension,EU/3/08/554,Withdrawn,24/04/2009,11/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-554
,,Bromelain,14/12/2018,Treatment of pseudomyxoma peritonei,EU/3/18/2113,Positive,08/03/2019,05/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2113
,,acetylcysteine,14/12/2018,Treatment of pseudomyxoma peritonei,EU/3/18/2107,Positive,08/03/2019,05/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2107
Upkanz,EMEA/H/C/005004,Deferiprone,27/06/2018,Treatment of neurodegeneration with brain iron accumulation,EU/3/18/2034,Positive,21/08/2018,04/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2034
,,Deferiprone,23/02/2011,Treatment of sickle cell disease,EU/3/10/832,Positive,04/03/2011,04/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-832
,,Recombinant human monoclonal antibody against hepatitis-B virus (active ingredient lenvervimab),15/08/2013,Prevention of hepatitis-B re-infection following liver transplantation,EU/3/13/1156,Positive,22/08/2013,04/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1156
,,glycine;L-alanine;L-arginine;L-aspartic acid;L-cysteine;L-glutamic acid;L-histidine;L-lysine monohydrate;L-methionine;L-phenylalanine;L-proline;L-serine;L-threonine;L-tryptophan;L-tyrosine;taurine,26/10/2018,Treatment of maple syrup urine disease,EU/3/18/2076,Positive,10/01/2019,03/02/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2076
,,propranolol hydrochloride,17/10/2019,Treatment of retinopathy of prematurity,EU/3/19/2217,Positive,23/01/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2217
,,leriglitazone,17/10/2019,Treatment of Friedreich’s ataxia,EU/3/19/2212,Positive,22/01/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2212
,,2'-O-(2-methoxyethyl)-D-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid,17/10/2019,Treatment of Alexander disease,EU/3/19/2206,Positive,21/01/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2206
,,nilotinib,22/05/2006,Treatment of chronic myeloid leukaemia,EU/3/06/375,Expired,04/12/2007,20/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-375
,,"1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine hydrochloride",21/08/2019,Treatment of Rett syndrome,EU/3/19/2195,Positive,16/01/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2195
,,Herpes simplex 1 virus-thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes,20/10/2003,Adjunctive treatment in haematopoietic cell transplantation,EU/3/03/168,Withdrawn,04/01/2006,16/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-168
,,Triheptanoin,21/05/2015,Treatment of glucose transporter type-1 deficiency syndrome,EU/3/15/1495,Withdrawn,30/06/2015,16/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1495
,,"6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile",26/10/2018,Treatment of medullary thyroid carcinoma,EU/3/18/2071,Withdrawn,11/01/2019,16/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2071
,,Olaratumab,12/02/2015,Treatment of soft tissue sarcoma,EU/3/15/1447,Withdrawn,09/04/2015,15/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1447
,,"4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine",21/08/2019,Treatment of congenital adrenal hyperplasia,EU/3/19/2194,Positive,14/01/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2194
,,acetazolamide,21/08/2019,Treatment of periodic paralysis,EU/3/19/2193,Positive,14/01/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2193
,,Peginterferon lambda-1a,21/08/2019,Treatment of hepatitis D virus infection,EU/3/19/2190,Positive,14/01/2020,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2190
,,lenalidomide,24/04/2015,Treatment of marginal zone lymphoma,EU/3/15/1473,Withdrawn,21/05/2015,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1473
,,lenalidomide,13/05/2011,Treatment of diffuse large B-cell lymphoma,EU/3/11/868,Withdrawn,30/05/2011,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-868
,,lenalidomide,19/11/2007,Treatment of chronic lymphocytic leukaemia,EU/3/07/494,Withdrawn,21/09/2009,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-494
,,lenalidomide,27/10/2011,Treatment of mantle cell lymphoma,EU/3/11/924,Withdrawn,23/11/2011,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-924
,,,08/03/2004,Treatment of myelodysplastic syndromes,EU/3/04/192,Withdrawn,29/07/2008,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-192
,,Two allogeneic irradiated pancreatic tumour cell lines,11/01/2016,Treatment of pancreatic cancer,EU/3/15/1604,Withdrawn,05/02/2016,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1604
,,Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin,11/01/2016,Treatment of pancreatic cancer,EU/3/15/1603,Withdrawn,05/02/2016,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1603
,,Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin,14/12/2015,Treatment of malignant mesothelioma,EU/3/15/1594,Withdrawn,03/02/2016,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1594
,,Ulocuplumab,12/02/2015,Treatment of acute myeloid leukaemia,EU/3/15/1445,Withdrawn,09/04/2015,13/01/2020,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1445
,,Vatiquinone,17/01/2018,Treatment of RARS2 syndrome,EU/3/17/1971,Positive,12/03/2018,03/12/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1971
,,(R)-troloxamide quinone,12/10/2017,Treatment of amyotrophic lateral sclerosis,EU/3/17/1934,Positive,15/01/2018,03/12/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1934
,,Alpha-tocotrienol quinone,09/12/2011,Treatment of Leigh syndrome,EU/3/11/937,Positive,20/12/2011,03/12/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-937
,,"S-acetyl-(S)-4'-phosphopantetheine, calcium salt",28/04/2016,Treatment of pantothenate-kinase-associated neurodegeneration,EU/3/16/1654,Positive,31/05/2016,02/12/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1654
,,trabectedin,17/10/2003,Treatment of ovarian cancer,EU/3/03/171,Expired,01/10/2004,27/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-171
,,N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 monoclonal antibody,03/12/2008,Treatment of multiple myeloma,EU/3/08/593,Withdrawn,29/06/2009,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-593
,,4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one,01/04/2019,Treatment of Friedreich’s ataxia,EU/3/19/2148,Withdrawn,07/05/2019,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2148
,,Human autologous bone-forming cells derived from bone marrow stem cells,29/10/2007,Treatment of non-traumatic osteonecrosis,EU/3/07/490,Withdrawn,17/01/2008,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-490
,,"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride",21/05/2015,Treatment of Huntington’s disease,EU/3/15/1497,Withdrawn,30/06/2015,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1497
,,Halofuginone hydrobromide,11/12/2001,Treatment of systemic sclerosis,EU/3/01/074,Withdrawn,15/06/2009,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-074
Strensiq,EMEA/H/C/003794,Recombinant human tissue non-specific alkaline phosphatase - Fc - deca-aspartate fusion protein,04/12/2008,Treatment of hypophosphatasia,EU/3/08/594,Positive,24/04/2009,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-594
,,Choline tetrathiomolybdate,24/01/2013,Treatment of Wilson's disease,EU/3/12/1089,Positive,01/03/2013,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1089
Kanuma,EMEA/H/C/004004,Recombinant human lysosomal acid lipase,17/12/2010,Treatment of lysosomal acid lipase deficiency,EU/3/10/827,Positive,20/01/2011,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-827
Soliris,EMEA/H/C/000791,Eculizumab,29/07/2014,Treatment myasthenia gravis,EU/3/14/1304,Positive,01/09/2014,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1304
Soliris,EMEA/H/C/000791,Eculizumab,05/08/2013,Treatment of neuromyelitis optica spectrum disorders,EU/3/13/1185,Positive,16/09/2013,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1185
,,Eculizumab,17/10/2003,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/03/166,Expired,21/09/2009,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-166
,,Eculizumab,24/07/2009,Treatment of atypical haemolytic uraemic syndrome (aHUS),EU/3/09/653,Positive,11/09/2009,20/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-653
,,Autologous collagen type II-specific regulatory T cells,16/12/2014,Treatment of non-infectious uveitis,EU/3/14/1405,Withdrawn,27/02/2015,19/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1405
Xospata,EMEA/H/C/004752,Gilteritinib,17/01/2018,Treatment of acute myeloid leukaemia,EU/3/17/1961,Positive,13/03/2018,08/11/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1961
,,Larotrectinib,21/03/2018,Treatment of salivary gland cancer,EU/3/18/1995,Withdrawn,08/05/2018,24/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1995
,,"(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (larotrectinib)",11/01/2016,Treatment of soft tissue sarcoma,EU/3/15/1606,Withdrawn,05/02/2016,24/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1606
,,Larotrectinib,19/11/2018,Treatment of glioma,EU/3/18/2097,Withdrawn,19/02/2019,24/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2097
,,Larotrectinib,19/11/2018,Treatment of papillary thyroid cancer,EU/3/18/2098,Withdrawn,22/02/2019,24/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2098
,,Recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/kappa class (atinumab),19/01/2009,Treatment of spinal cord injury,EU/3/08/605,Withdrawn,15/05/2009,16/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-605
,,Aztreonam lysinate,21/06/2004,Treatment of Gram-negative bacterial lung infection in cystic fibrosis,EU/3/04/204,Expired,30/05/2007,16/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-204
,,Recombinant human soluble Fc-gamma receptor II b,02/08/2007,Treatment of idiopathic thrombocytopenic purpura,EU/3/07/462,Withdrawn,29/07/2008,16/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-462
,,Ibudilast,12/12/2016,Treatment of amyotrophic lateral sclerosis,EU/3/16/1801,Positive,09/01/2017,16/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1801
,,Recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (avelumab),14/12/2015,Treatment of Merkel cell carcinoma,EU/3/15/1590,Withdrawn,03/02/2016,15/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1590
,,avelumab,12/12/2016,Treatment of gastric cancer,EU/3/16/1798,Withdrawn,09/01/2017,15/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1798
,,Humanised recombinant monoclonal antibody against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F(depatuxizumab mafodotin,29/07/2014,Treatment of glioma,EU/3/14/1305,Withdrawn,01/09/2014,15/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1305
,,Glucopyranosyl lipid A,16/10/2017,Treatment of follicular lymphoma,EU/3/17/1924,Withdrawn,09/01/2018,15/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1924
,,Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein,21/03/2016,Treatment of soft tissue sarcoma,EU/3/16/1634,Withdrawn,02/05/2016,15/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1634
,,Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein,21/03/2016,Treatment of soft tissue sarcoma,EU/3/16/1636,Withdrawn,04/05/2016,15/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1636
,,Sodium benzoate;Sodium phenylacetate,28/06/2019,Treatment of hyperargininaemia,EU/3/19/2179,Positive,14/10/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2179
,,Sodium benzoate;Sodium phenylacetate,28/06/2019,Treatment of argininosuccinic aciduria,EU/3/19/2178,Positive,14/10/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2178
Altuvoct,EMEA/H/C/005968,Recombinant human coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein,28/06/2019,Treatment of  haemophilia A,EU/3/19/2176,Positive,14/10/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2176
,,Recombinant adeno-associated viral vector containing a bioengineered capsid serotype AAV-rh74 and a codon-optimised expression cassette to drive the expression of a secretable form of human acid alpha-glucosidase,28/06/2019,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/19/2175,Positive,10/10/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2175
,,Gaboxadol monohydrate,28/06/2019,Treatment of Angelman syndrome,EU/3/19/2172,Positive,07/10/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2172
,,S[+] apomorphine,09/02/2012,Treatment of amyotrophic lateral sclerosis,EU/3/12/954,Positive,01/03/2012,03/10/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-954
,,5'-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-sp-dA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3' (also known as DYN101),28/06/2019,Treatment of centronuclear myopathies,EU/3/19/2171,Positive,03/10/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2171
,,"2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridine-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride",28/06/2019,Treatment of beta thalassaemia intermedia and major,EU/3/19/2170,Positive,02/10/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2170
,,Diaspirin cross-linked haemoglobin,19/11/2014,Treatment of hepatocellular carcinoma,EU/3/14/1378,Positive,16/01/2015,30/09/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1378
,,Diaspirin cross-linked haemoglobin,21/03/2016,Treatment of oesophageal cancer,EU/3/16/1628,Positive,02/05/2016,30/09/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1628
,,Recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1,25/07/2019,Treatment of myasthenia gravis,EU/3/19/2187,Positive,24/09/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2187
,,"Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2",13/05/2011,Treatment of acute myeloid leukaemia,EU/3/11/867,Withdrawn,30/05/2011,30/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-867
,,2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate,05/12/2008,Treatment of acute myeloid leukaemia,EU/3/08/590,Withdrawn,24/04/2009,30/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-590
,,5'-CTG CCA CGT TCT CCT GC-(2' methoxy)A-(2' methoxy)C-(2' methoxy)C-3',21/06/2004,Treatment of myasthenia gravis,EU/3/04/203,Withdrawn,06/09/2005,30/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-203
,,Exendin (9-39),14/10/2016,Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome,EU/3/16/1750,Positive,14/11/2016,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1750
,,Ubenimex,21/03/2016,Treatment of pulmonary arterial hypertension,EU/3/16/1638,Positive,02/05/2016,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1638
,,Lonafarnib,16/01/2014,Treatment of hepatitis delta virus infection,EU/3/13/1225,Positive,21/03/2014,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1225
,,Sodium benzoate,11/01/2016,Treatment of hyperargininaemia,EU/3/15/1600,Positive,05/02/2016,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1600
,,Sodium benzoate,11/01/2016,Treatment of argininosuccinic aciduria,EU/3/15/1601,Positive,05/02/2016,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1601
,,Sodium thiosulfate,15/01/2015,Treatment for calciphylaxis,EU/3/14/1414,Positive,05/03/2015,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1414
,,Sodium nitrite,16/01/2014,Treatment of aneurysmal subarachnoid haemorrhage,EU/3/13/1224,Positive,21/03/2014,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1224
,,Diacerein,29/05/2019,Treatment of epidermolysis bullosa,EU/3/19/2161,Positive,09/08/2019,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2161
,,Recombinant fragment of human surfactant protein-D,23/08/2017,Prevention of bronchopulmonary dysplasia,EU/3/17/1907,Positive,17/10/2017,19/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1907
,,Sodium benzoate,29/05/2019,Treatment of carbamoyl-phosphate synthase-1 deficiency,EU/3/19/2166,Positive,12/08/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2166
,,Sodium phenylacetate;Sodium benzoate,29/05/2019,Treatment of citrullinaemia type 1,EU/3/19/2165,Positive,12/08/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2165
,,Emixustat hydrochloride,29/05/2019,Treatment of Stargardt's disease,EU/3/19/2162,Positive,09/08/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2162
,,Allogeneic skin-derived ABCB5-positive mesenchymal stem cells,29/05/2019,Treatment of epidermolysis bullosa,EU/3/19/2160,Positive,09/08/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2160
Zokinvy,EMEA/H/C/005271,Lonafarnib,14/12/2018,Treatment of Hutchinson-Gilford progeria,EU/3/18/2118,Positive,11/03/2019,01/08/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2118
,,Tamoxifen citrate,12/10/2017,Treatment of Duchenne muscular dystrophy,EU/3/17/1944,Positive,15/01/2018,30/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1944
,,metformin;l-citrulline,17/01/2018,Treatment of Duchenne muscular dystrophy,EU/3/17/1965,Positive,12/03/2018,30/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1965
,,Recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII,22/05/2017,Treatment of haemophilia A,EU/3/17/1874,Positive,29/06/2017,30/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1874
,,trientine dihydrochloride,24/10/2003,Treatment of Wilson's disease,EU/3/03/172,Withdrawn,26/04/2004,29/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-172
Sohonos,EMEA/H/C/004867,Palovarotene,19/11/2014,Treatment of fibrodysplasia ossificans progressiva,EU/3/14/1368,Positive,15/01/2015,18/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1368
,,diazoxide choline,12/10/2017,Treatment of Prader-Willi syndrome,EU/3/17/1941,Positive,12/01/2018,17/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1941
Xyndari,EMEA/H/C/004734,Levoglutamide,04/07/2012,Treatment of sickle cell disease,EU/3/12/1011,Positive,24/07/2012,12/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1011
,,Muramyl tripeptide phosphatidyl ethanolamine,21/06/2004,Treatment of osteosarcoma,EU/3/04/206,Expired,23/09/2009,11/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-206
,,Caffeine citrate,18/02/2003,Treatment of primary apnoea of premature newborns,EU/3/03/132,Expired,07/03/2007,11/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-132
,,Fc- and CDR-modified humanised monoclonal antibody against C5 (ravulizumab),30/05/2016,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/16/1661,Withdrawn,28/06/2016,11/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1661
,,ciclosporin,29/07/2004,Prevention of graft rejection after lung transplantation,EU/3/04/209,Positive,13/12/2007,10/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-209
,,N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulfate salt,12/02/2015,Treatment of progressive supranuclear palsy,EU/3/15/1446,Positive,09/04/2015,10/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1446
,,ciclosporin,24/05/2017,Treatment of bronchiolitis obliterans syndrome,EU/3/04/210,Positive,13/12/2007,10/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-210
,,Recombinant monoclonal antibody to human serum amyloid P component (dezamizumab),29/07/2014,Treatment of AL amyloidosis,EU/3/14/1293,Withdrawn,01/09/2014,09/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1293
,,Carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (miridesap),29/07/2014,Treatment of AL amyloidosis,EU/3/14/1292,Withdrawn,01/09/2014,09/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1292
,,Cyclocreatine,27/06/2016,Treatment of creatine deficiency syndromes,EU/3/16/1676,Withdrawn,26/07/2016,09/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1676
,,CD33-directed antibody-drug conjugate consisting of an antibody conjugated to a DNA cross-linking pyrrolobenzodiazepine dimer drug (vadastuximab talirine),10/08/2015,Treatment of acute myeloid leukaemia,EU/3/15/1545,Withdrawn,02/10/2015,09/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1545
,,Doxorubicine polyisohexylcyanoacrylate nanoparticles,21/10/2004,Treatment of hepatocellular carcinoma,EU/3/04/229,Withdrawn,21/09/2009,09/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-229
,,Recombinant human type I pancreatic elastase for the prevention of arteriovenous access dysfunction in haemodialysis patients (vonapanitase),16/01/2014,Prevention of arteriovenous access dysfunction in haemodialysis patients,EU/3/13/1218,Withdrawn,23/01/2014,09/07/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1218
,,PEGylated recombinant factor VIII (turoctocog alfa pegol),26/04/2012,Treatment of haemophilia A,EU/3/12/995,Withdrawn,18/06/2012,28/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-995
,,melatonin,11/01/2019,Treatment of perinatal asphyxia,EU/3/18/2127,Positive,27/03/2019,28/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2127
Gamifant,EMEA/H/C/004386,Recombinant human anti-interferon gamma monoclonal antibody (emapalumab),09/06/2010,Treatment of haemophagocytic lymphohistiocytosis,EU/3/10/749,Positive,23/06/2010,19/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-749
,,Autologous mesenchymal stromal cells on a decellularised tracheal scaffold from a cadaveric donor,29/08/2016,Treatment of tracheal stenosis,EU/3/16/1717,Positive,03/10/2016,19/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1717
,,Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene,04/07/2012,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/12/1018,Positive,24/07/2012,18/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1018
,,"4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate",26/04/2013,Treatment of glioma,EU/3/13/1120,Withdrawn,14/05/2013,17/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1120
,,"4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate",12/03/2013,Treatment of hepatocellular carcinoma,EU/3/13/1109,Withdrawn,05/04/2013,17/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1109
,,Human/murine chimeric monoclonal antibody against endoglin (carotuximab),28/04/2016,Treatment of soft tissue sarcoma,EU/3/16/1648,Withdrawn,30/05/2016,17/06/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1648
,,Diacerein,08/11/2018,Treatment of epidermolysis bullosa,-,Negative,14/06/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-epidermolysis-bullosa
,,Sodium benzoate;Sodium phenylacetate,24/04/2019,Treatment of ornithine transcarbamylase deficiency,EU/3/19/2157,Positive,14/06/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2157
,,"Autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes",24/04/2019,Treatment of spinal cord injury,EU/3/19/2153,Positive,14/06/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2153
Palynziq,EMEA/H/C/004744,Pegylated recombinant phenylalanine ammonia lyase (pegvaliase),28/01/2010,Treatment of hyperphenylalaninaemia,EU/3/09/708,Positive,25/02/2010,29/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-708
,,Human plasma-derived alpha-1 proteinase inhibitor,19/03/2015,Treatment of graft-versus-host disease,EU/3/15/1455,Positive,11/05/2015,27/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1455
,,Recombinant protein consisting of modified human growth hormone releasing hormone and the translocation and endopeptidase domains of botulinum toxin serotype D,11/01/2012,Treatment of acromegaly,EU/3/11/947,Withdrawn,01/02/2012,23/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-947
,,Glucagon analogue linked to a human immunoglobulin Fc fragment,25/05/2018,Treatment of congenital hyperinsulinism,EU/3/18/2022,Positive,24/07/2018,23/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2022
,,Efpegsomatropin,27/06/2018,Treatment of growth hormone deficiency,EU/3/18/2035,Positive,21/08/2018,23/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2035
,,Siplizumab,16/10/2017,Treatment in solid organ transplantation,EU/3/17/1931,Positive,09/01/2018,23/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1931
,,Brincidofovir,18/11/2016,Treatment of smallpox,EU/3/16/1777,Positive,14/12/2016,23/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1777
,,Fibrinogen-coated albumin spheres,10/08/2015,Treatment of acute radiation syndrome,EU/3/15/1535,Positive,02/10/2015,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1535
,,Fibrinogen-coated albumin spheres,12/02/2015,Treatment of Ebola virus disease,EU/3/15/1442,Positive,09/04/2015,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1442
,,Gemfibrozil,21/03/2018,Treatment of neuronal ceroid lipofuscinosis,EU/3/18/1993,Positive,14/05/2018,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1993
,,sinapultide;Dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol sodium salt;palmitic acid,27/10/2011,Treatment of cystic fibrosis,EU/3/11/927,Positive,23/11/2011,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-927
,,sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid,29/07/2004,Respiratory distress syndrome in premature neonates of less then 37 weeks of gestational age,EU/3/04/217,Positive,02/09/2009,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-217
Ayvakyt,EMEA/H/C/005208,"(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine",17/07/2017,Treatment of gastrointestinal stromal tumours,EU/3/17/1889,Positive,14/07/2017,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1889
Surfaxin; Surfaxin,EMEA/H/C/000625; EMEA/H/C/000625,sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid,29/07/2004,Respiratory distress syndrome in  premature neonates of less than 32 weeks of gestational age,EU/3/04/216,Positive,23/09/2009,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-216
,,sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid,04/02/2002,Treatment of acute lung Injury,EU/3/01/079,Positive,30/05/2007,22/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-079
,,Adeno-associated viral vector serotype 9 containing the human HGSNAT gene,21/05/2015,Treatment of mucopolysaccharidosis IIIC (Sanfilippo C syndrome),EU/3/15/1491,Positive,30/06/2015,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1491
,,Tamibarotene,31/07/2018,Treatment of acute myeloid leukaemia,EU/3/18/2053,Positive,10/10/2018,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2053
Cresemba,EMEA/H/C/002734,Isavuconazonium sulfate,04/07/2014,Treatment of invasive aspergillosis,EU/3/14/1284,Positive,16/07/2014,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1284
Cresemba,EMEA/H/C/002734,Isavuconazonium sulfate,04/06/2014,Treatment of mucormycosis,EU/3/14/1276,Positive,10/07/2014,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1276
,,Forodesine,20/09/2010,Treatment of chronic lymphocytic leukaemia,EU/3/10/780,Positive,18/10/2010,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-780
,,Cysteamine,09/12/2011,Treatment of cystic fibrosis,EU/3/11/928,Positive,20/12/2011,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-928
,,Forodesine hydrochloride,29/01/2007,Treatment of cutaneous T-cell lymphoma,EU/3/06/428,Positive,13/12/2007,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-428
,,Forodesine hydrochloride,18/12/2006,Treatment of acute lymphoblastic leukaemia,EU/3/06/421,Positive,13/12/2007,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-421
Galafold,EMEA/H/C/004059,1-Deoxygalactonojirimycin hydrochloride,22/05/2006,Treatment of Fabry disease,EU/3/06/368,Positive,15/05/2009,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-368
,,Methoxsalen,22/05/2006,Treatment of graft-versus-host disease,EU/3/06/374,Positive,24/04/2009,21/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-374
,,"(Manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21a-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,4,7,10] tetraazacycloheptadecine-κN5, κN13, κN18, κN21, κN22]-) (misopasem manganese)",31/01/2008,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,EU/3/07/522,Positive,10/07/2008,17/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-522
,,Heparin (sodium),22/05/2006,Treatment of cystic fibrosis,EU/3/06/371,Positive,15/05/2009,17/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-371
Tegsedi,EMEA/H/C/004782,Phosphorothioate oligonucleotide targeted to transthyretin (inotersen),26/03/2014,Treatment of ATTR amyloidosis,EU/3/14/1250,Positive,06/05/2014,17/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1250
,,Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene,20/03/2017,Treatment of Fabry disease,EU/3/17/1849,Positive,05/05/2017,13/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1849
,,9-cis-Retinyl acetate,13/05/2011,Treatment of Leber's congenital amaurosis,EU/3/11/861,Positive,27/05/2011,13/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-861
,,9-cis-Retinyl acetate,13/05/2011,Treatment of retinitis pigmentosa,EU/3/11/865,Positive,27/05/2011,13/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-865
,,"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride (derazantinib)",30/05/2016,Treatment of biliary tract cancer,EU/3/16/1657,Positive,28/06/2016,13/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1657
,,S-Nitrosoglutathione,13/05/2011,Treatment of pre-eclampsia,EU/3/11/870,Positive,31/05/2011,13/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-870
,,Pegylated proline-interferon alpha-2b (ropeginterferon alfa-2b),09/12/2011,Treatment of polycythaemia vera,EU/3/11/932,Withdrawn,20/12/2011,08/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-932
,,"2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)",01/04/2019,Treatment of primary sclerosing cholangitis,EU/3/19/2147,Positive,07/05/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2147
Infinia,EMEA/H/C/003934,Alpha-1 antitrypsin,16/11/2004,Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency,EU/3/04/244,Positive,17/09/2009,07/05/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-244
,,Eflornithine,20/09/2010,Treatment of familial adenomatous polyposis (FAP),EU/3/10/779,Positive,18/10/2010,29/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-779
Flynpovi,EMEA/H/C/005043,Eflornithine,24/01/2013,Treatment of familial adenomatous polyposis (FAP),EU/3/12/1086,Positive,01/03/2013,29/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1086
,,Humanised IgG4 monoclonal antibody against extracellular tau,28/07/2015,Treatment of progressive supranuclear palsy,EU/3/15/1522,Positive,18/08/2015,29/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1522
,,"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt",17/01/2018,Treatment of congenital adrenal hyperplasia,EU/3/17/1967,Positive,13/03/2018,26/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1967
,,Alpha-1 antitrypsin,16/11/2004,Treatment of cystic fibrosis,EU/3/04/243,Positive,17/09/2009,25/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-243
,,acetylleucine,22/11/2018,Treatment of spinocerebellar ataxia,EU/3/18/2059,Positive,20/12/2018,25/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2059
,,acetylleucine,11/01/2019,Treatment of ataxia telangiectasia,EU/3/18/2124,Positive,27/03/2019,25/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2124
,,acetylleucine,20/03/2017,Treatment of Niemann-Pick disease,EU/3/17/1848,Positive,05/05/2017,25/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1848
,,Ursodeoxycholic acid,22/05/2017,Treatment of Niemann-Pick disease,EU/3/17/1878,Positive,29/06/2017,25/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1878
,,acetylleucine,12/12/2017,Treatment of GM2 gangliosidosis,EU/3/17/1949,Positive,24/01/2018,25/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1949
,,Adeno-associated viral vector serotype 2 containing the human CHM gene encoding human Rab escort protein 1,04/06/2014,Treatment of choroideraemia,EU/3/14/1278,Positive,10/07/2014,24/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1278
,,Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII,26/10/2018,Treatment of haemophilia A,EU/3/18/2079,Positive,10/01/2019,24/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2079
,,Chimeric monoclonal antibody to shiga toxin 1 and 2,26/08/2005,Treatment of shiga-toxin-producing bacterial infection,EU/3/05/301,Positive,09/02/2006,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-301
,,Adeno-associated viral vector serotype 2 containing the human REP1 gene,04/07/2014,Treatment of choroideraemia,EU/3/14/1290,Positive,15/07/2014,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1290
,,"Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met-His-Gln-Arg-Asn-Met-Thr-Lys-Leu and Pro-Gly-Cys-Asn-Lys-Arg-Tyr-Phe-Lys-Leu-Ser-His-Leu-Gln-Met-His-Ser-Arg-Lys-His-Thr-Gly",28/04/2016,Treatment of  malignant mesothelioma,EU/3/16/1656,Positive,30/05/2016,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1656
,,"Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met-His-Gln-Arg-Asn-Met-Thr-Lys-Leu and Pro-Gly-Cys-Asn-Lys-Arg-Tyr-Phe-Lys-Leu-Ser-His-Leu-Gln-Met-His-Ser-Arg-Lys-His-Thr-Gly",28/04/2016,Treatment of acute myeloid leukaemia,EU/3/16/1655,Positive,30/05/2016,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1655
,,Recombinant human minibody against complement component C5 fused with RGD-motif,20/01/2009,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,EU/3/08/604,Withdrawn,29/06/2009,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-604
,,Recombinant human minibody against complement component C5,27/10/2011,Treatment of primary membranoproliferative glomerulonephritis,EU/3/11/926,Withdrawn,23/11/2011,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-926
,,Recombinant human minibody against complement component C5,22/09/2008,Treatment of atypical haemolytic uraemic syndrome (aHUS),EU/3/08/571,Withdrawn,02/04/2009,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-571
,,"cholest-4-en-3-one, oxime",10/03/2005,Treatment of 5q spinal muscular atrophy,EU/3/05/264,Withdrawn,11/10/2005,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-264
,,"Fusion proteins composed by a genetically modified cholera toxin subunit A1, peptides from the acetylcholine receptor alpha chain and a dimer of the D fragment from Staphylococcus aureus protein A",21/05/2015,Treatment of myasthenia gravis,EU/3/15/1489,Withdrawn,30/06/2015,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1489
,,Venetoclax,17/02/2016,Treatment of acute myeloid leukaemia,EU/3/16/1617,Withdrawn,07/04/2016,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1617
,,Nitric oxide,24/04/2015,Treatment of cystic fibrosis,EU/3/15/1484,Withdrawn,22/05/2015,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1484
,,tosedostat,24/07/2009,Treatment of acute myeloid leukaemia,EU/3/09/659,Withdrawn,11/09/2009,12/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-659
,,Allogeneic cultured postnatal thymus-derived tissue,26/02/2019,Treatment of severe combined immunodeficiency due to FOXN1 deficiency,EU/3/19/2137,Positive,09/04/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2137
,,"Poly(N-acetyl, N-arginyl)glucosamine",26/02/2019,Treatment of cystic fibrosis,EU/3/19/2144,Positive,09/04/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2144
,,"9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester",26/02/2019,Treatment of infantile neuroaxonal dystrophy,EU/3/19/2134,Positive,09/04/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2134
,,Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase,26/02/2019,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/19/2140,Positive,09/04/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2140
,,Lurbinectedin,26/02/2019,Treatment of small cell lung cancer,EU/3/19/2143,Positive,09/04/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2143
,,Recombinant human club cell 10 KDa protein,27/02/2017,Treatment of bronchiolitis obliterans syndrome,EU/3/17/1842,Positive,31/03/2017,08/04/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1842
,,Methylthioninium,26/11/2010,treatment of frontotemporal dementia with parkinsonism-17,EU/3/10/807,Positive,15/12/2010,28/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-807
,,Methylthioninium,26/11/2010,treatment of progressive non-fluent aphasia,EU/3/10/806,Positive,15/12/2010,28/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-806
,,Methylthioninium,26/11/2010,treatment of behavioural variant frontotemporal dementia,EU/3/10/805,Positive,15/12/2010,28/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-805
,,Methylthioninium,26/11/2010,Treatment of progressive supranuclear palsy,EU/3/10/804,Positive,15/12/2010,28/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-804
,,Mercaptamine-pantetheine disulfide,11/01/2019,Treatment of Rett syndrome,EU/3/18/2128,Positive,27/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2128
,,Vinorelbine tartrate,11/01/2019,Treatment of soft tissue sarcoma,EU/3/18/2133,Positive,27/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2133
,,Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues,11/01/2019,Treatment of beta thalassaemia intermedia and major,EU/3/18/2132,Positive,27/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2132
,,Benserazide hydrochloride,11/01/2019,The treatment of sickle cell disease,EU/3/18/2125,Positive,27/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2125
,,Human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment,11/01/2019,Treatment of short bowel syndrome,EU/3/18/2126,Positive,27/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2126
Coagadex,EMEA/H/C/003855,Human coagulation factor X,14/09/2007,Treatment of hereditary factor X deficiency,EU/3/07/471,Positive,29/07/2008,26/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-471
,,acebutolol hydrochloride,14/10/2016,Treatment of Smith-Magenis syndrome,EU/3/16/1742,Positive,15/11/2016,18/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1742
,,Human haptoglobin,09/12/2011,Treatment of sickle cell disease,EU/3/11/936,Positive,20/12/2011,18/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-936
,,"6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole",14/12/2018,Treatment of sudden sensorineural hearing loss,EU/3/18/2106,Positive,12/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2106
,,"6,8-bis(benzylthio)octanoic acid",14/12/2018,Treatment of acute myeloid leukaemia,EU/3/18/2123,Positive,12/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2123
,,"6,8-bis(benzylthio)octanoic acid",14/12/2018,Treatment of pancreatic cancer,EU/3/18/2105,Positive,12/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2105
,,,14/12/2018,Treatment of biliary atresia,EU/3/18/2103,Positive,12/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2103
,,Marizomib,14/12/2018,Treatment of glioma,EU/3/18/2119,Positive,12/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2119
,,"(4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1))",14/12/2018,Treatment of C3 glomerulopathy,EU/3/18/2104,Positive,11/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2104
,,Allogeneic ABCB5-positive limbal stem cells,14/12/2018,Treatment of limbal stem cell deficiency,EU/3/18/2111,Positive,11/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2111
,,Sodium 2-hydroxylinoleate,14/12/2018,Treatment of biliary tract cancer,EU/3/18/2121,Positive,08/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2121
,,Adeno-associated viral vector expressing human 21- hydroxylase,14/12/2018,Treatment of congenital adrenal hyperplasia,EU/3/18/2108,Positive,07/03/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2108
,,Avacopan,20/06/2017,Treatment of C3 glomerulopathy,EU/3/17/1880,Positive,17/07/2017,06/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1880
Luxturna,EMEA/H/C/004451,Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec),28/07/2015,Treatment of retinitis pigmentosa,EU/3/15/1518,Positive,18/08/2015,04/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1518
Luxturna,EMEA/H/C/004451,Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec),02/04/2012,Treatment of Leber's congenital amaurosis,EU/3/12/981,Positive,30/04/2012,04/03/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-981
,,H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-213-bismuth,19/11/2018,Treatment of glioma,EU/3/18/2092,Positive,25/02/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2092
,,Anti-GD2 monoclonal antibody 3F8 humanised,19/11/2018,Treatment of neuroblastoma,EU/3/18/2094,Positive,25/02/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2094
,,Smilagenin,27/09/2011,Treatment of amyotrophic lateral sclerosis,EU/3/11/914,Positive,17/10/2011,22/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-914
,,Pegylated recombinant human hyaluronidase PH20(pegvorhyaluronidase alfa),16/12/2014,Treatment of pancreatic cancer,EU/3/14/1394,Positive,26/02/2015,22/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1394
,,Ciprofloxacin,03/08/2007,Treatment of cystic fibrosis,EU/3/07/469,Withdrawn,15/06/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-469
,,Chimeric monoclonal antibody against GD2 (dinutuximab),21/06/2011,Treatment of neuroblastoma,EU/3/11/879,Withdrawn,12/07/2011,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-879
,,Celecoxib,21/11/2001,Treatment of familial adenomatous polyposis (FAP),EU/3/01/070,Withdrawn,15/06/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-070
,,Rilonacept,10/07/2007,Treatment of cryopirin-associated periodic syndromes,EU/3/07/456,Withdrawn,29/07/2008,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-456
,,"2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one",26/04/2012,Treatment of ovarian cancer,EU/3/12/989,Withdrawn,18/03/2012,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-989
,,Amphotericin B,28/08/2006,Prevention of pulmonary fungal infection in patients deemed at risk,EU/3/06/391,Withdrawn,02/04/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-391
,,Halofuginone hydrobromide,26/04/2012,Treatment of Duchenne muscular dystrophy,EU/3/12/988,Withdrawn,18/06/2012,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-988
,,riociguat,29/07/2014,Treatment of systemic sclerosis,EU/3/14/1299,Withdrawn,01/09/2014,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1299
,,Alpha-1 proteinase inhibitor,16/02/2006,Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency,EU/3/06/350,Withdrawn,17/09/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-350
,,Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan),05/08/2013,Treatment of growth hormone deficiency,EU/3/13/1179,Withdrawn,13/09/2013,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1179
,,Adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin;adeno-associated viral vector containing a rhodopsin gene,17/12/2010,Treatment of rhodopsin-linked retinitis pigmentosa,EU/3/10/817,Withdrawn,19/01/2011,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-817
,,Becatecarin,25/07/2006,Treatment of cancers of the biliary tree,EU/3/06/388,Withdrawn,24/04/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-388
,,"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4 methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide (entrectinib)",11/11/2015,Treatment of neuroblastoma,EU/3/15/1580,Withdrawn,06/01/2016,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1580
,,Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes,09/08/2012,Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity,EU/3/12/1042,Withdrawn,26/09/2012,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1042
,,(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosilate monohydrate salt,01/10/2010,Treatment of mantle cell lymphoma,EU/3/10/787,Withdrawn,14/10/2010,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-787
,,Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt,14/09/2012,Treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia),EU/3/12/1036,Withdrawn,05/12/2012,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1036
,,Tideglusib,19/03/2015,Treatment of fragile X syndrome,EU/3/15/1452,Withdrawn,11/05/2015,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1452
,,Iodine (131I) chlorotoxin,22/10/2007,Treatment of glioma,EU/3/07/492,Withdrawn,21/09/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-492
,,Isofagomine tartrate,23/10/2007,Treatment of Gaucher disease,EU/3/07/493,Withdrawn,21/09/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-493
,,1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,26/11/2009,Treatment of acute myeloid leukaemia,EU/3/09/693,Withdrawn,10/12/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-693
,,Obinutuzumab,22/08/2014,Treatment of diffuse large B-cell lymphoma,EU/3/14/1325,Withdrawn,02/10/2014,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1325
,,"8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one mono-hydrochloride",30/11/2009,Treatment of ovarian cancer,EU/3/09/695,Withdrawn,10/12/2009,21/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-695
,,Histamine dihydrochloride,11/04/2005,Treatment of acute myeloid leukaemia,EU/3/05/272,Expired,07/03/2007,20/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-272
,,miglustat,16/02/2006,"Treatment of Niemann-Pick's disease, type C",EU/3/06/351,Expired,24/08/2006,20/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-351
,,azacitidine,06/02/2002,Treatment of myelodysplastic syndromes,EU/3/01/084,Expired,17/09/2009,20/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-084
,,azacitidine,29/11/2007,Treatment of acute myeloid leukaemia,EU/3/07/509,Expired,17/09/2009,20/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-509
,,Rufinamide,20/10/2004,Treatment of Lennox-Gastaut syndrome,EU/3/04/240,Expired,28/02/2007,20/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-240
,,Recombinant megakaryopoiesis-stimulating protein,27/05/2005,Treatment of idiopathic thrombocytopenic purpura,EU/3/05/283,Expired,29/06/2005,20/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-283
,,autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand,19/11/2018,Treatment of pancreatic cancer,EU/3/18/2085,Positive,20/02/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2085
,,apraglutide,19/11/2018,Treatment of short bowel syndrome,EU/3/18/2102,Positive,19/02/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2102
,,"4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid (acebilustat)",19/11/2014,Treatment of cystic fibrosis,EU/3/14/1363,Positive,15/01/2015,19/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1363
,,human apotransferrin,19/11/2018,Treatment of beta thalassaemia intermedia and major,EU/3/18/2093,Positive,19/02/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2093
,,cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate,19/11/2018,Treatment of cystic fibrosis,EU/3/18/2086,Positive,19/02/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2086
,,Rucaparib,10/10/2012,Treatment of ovarian cancer,EU/3/12/1049,Withdrawn,16/11/2012,19/02/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1049
,,Imlifidase,19/11/2018,Treatment of anti-glomerular basement membrane disease,EU/3/18/2096,Positive,13/02/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2096
,,Pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol),23/02/2011,Treatment of haemophilia A,EU/3/10/847,Withdrawn,07/03/2011,28/01/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-847
Poteligeo,EMEA/H/C/004232,Mogamulizumab,14/10/2016,Treatment of cutaneous T-cell lymphoma,EU/3/16/1756,Positive,14/11/2016,28/01/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1756
,,"3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",27/06/2016,Treatment of diffuse large B-cell lymphoma,EU/3/16/1672,Positive,26/07/2016,23/01/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1672
Exondys,EMEA/H/C/004355,"RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5') (C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N dimethylaminophosphonamidate (Eteplirsen)",03/12/2008,Treatment of Duchenne muscular dystrophy,EU/3/08/586,Positive,29/06/2009,22/01/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-586
,,doxorubicin hydrochloride,23/02/2011,Treatment of hepatocellular carcinoma,EU/3/10/833,Positive,04/03/2011,22/01/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-833
,,Autologous skeletal myoblasts expanded ex vivo,13/04/2018,Treatment of oculopharyngeal muscular dystrophy,-,Negative,11/01/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-oculopharyngeal-muscular-dystrophy
,,"Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG",26/10/2018,Treatment of multiple myeloma,EU/3/18/2078,Positive,10/01/2019,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2078
Amglidia,EMEA/H/C/004379,glibenclamide,15/01/2016,Treatment of neonatal diabetes,EU/3/15/1589,Positive,02/02/2016,04/01/2019,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1589
,,bertilimumab,24/11/2018,Treatment of bullous pemphigoid,EU/3/18/2062,Positive,20/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2062
,,(S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid,24/08/2018,Treatment of idiopathic pulmonary fibrosis,EU/3/18/2056,Positive,19/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2056
Aliqopa,EMEA/H/C/004334,Copanlisib,24/08/2018,Treatment of marginal zone lymphoma,EU/3/18/2064,Positive,19/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2064
,,,24/08/2018,Treatment of glioma,EU/3/18/2055,Positive,19/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2055
,,autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor,24/08/2018,Treatment of glioma,EU/3/18/2061,Positive,19/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2061
,,Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2,24/08/2018,Treatment in haematopoietic stem cell transplantation,EU/3/18/2067,Positive,19/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2067
,,tilorone,24/08/2018,Treatment of idiopathic pulmonary fibrosis,EU/3/18/2069,Positive,19/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2069
,,melatonin,26/10/2018,Treatment of acute radiation syndrome,EU/3/18/2077,Positive,19/12/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2077
,,Recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase,28/04/2016,Treatment of Angelman syndrome,EU/3/16/1651,Positive,30/05/2016,18/12/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1651
,,Recombinant adeno-associated viral vector serotype 5 carrying the gene for the human frataxin protein,23/08/2017,Treatment of Friedreich's ataxia,EU/3/17/1906,Positive,17/10/2017,18/12/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1906
,,H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide),30/05/2016,Treatment of amyotrophic lateral sclerosis,EU/3/16/1662,Positive,22/06/2016,18/12/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1662
Onivyde pegylated liposomal (previously Onivyde),EMEA/H/C/004125,Nanoliposomal irinotecan,09/12/2011,Treatment of pancreatic cancer,EU/3/11/933,Positive,20/12/2011,17/12/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-933
,,,12/10/2017,Treatment of systemic sclerosis,EU/3/17/1933,Positive,15/01/2018,07/12/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1933
,,paclitaxel,17/12/2006,Treatment of ovarian cancer,EU/3/06/422,Withdrawn,02/04/2009,05/12/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-422
,,"4-(4-{[2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (venetoclax)",06/12/2012,Treatment of chronic lymphocytic leukaemia,EU/3/12/1080,Withdrawn,25/01/2013,22/11/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1080
,,Recombinant human monoclonal antibody against activin receptor type IIB,09/08/2012,Treatment of inclusion body myositis,EU/3/12/1035,Withdrawn,27/09/2012,24/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1035
,,Maytansinoid-conjugated human monoclonal antibody against mesothelin (anetumab ravtansine),06/12/2012,Treatment of malignant mesothelioma,EU/3/12/1073,Withdrawn,24/01/2013,24/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1073
,,Adenovirus-associated viral vector serotype 8 containing the human RPGR gene,22/02/2018,Treatment of retinitis pigmentosa,EU/3/18/1975,Positive,11/04/2018,24/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1975
Vimizim,EMEA/H/C/002779,Recombinant human N-acetylgalactosamine-6-sulfatase (elosulfase alfa),24/07/2009,"Treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome)",EU/3/09/657,Positive,11/09/2009,24/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-657
,,Bitopertin,16/10/2017,Treatment of beta thalassaemia intermedia and major,EU/3/17/1919,Withdrawn,10/01/2018,24/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1919
,,melatonin,14/10/2016,Treatment of Smith-Magenis syndrome,EU/3/16/1755,Positive,15/11/2016,23/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1755
,,melatonin,01/08/2016,Treatment of necrotising enterocolitis,EU/3/16/1682,Positive,02/08/2016,23/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1682
,,melatonin,27/06/2016,Treatment of neonatal sepsis,EU/3/16/1683,Positive,26/07/2016,23/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1683
,,sildenafil citrate,26/11/2010,treatment of postcardiotomy right ventricular failure,EU/3/10/815,Positive,17/12/2010,23/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-815
,,Pegylated recombinant human interleukin-10,12/12/2016,Treatment of pancreatic cancer,EU/3/16/1804,Positive,09/01/2017,23/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1804
,,Lenvatinib,19/03/2015,Treatment of hepatocellular carcinoma,EU/3/15/1460,Withdrawn,11/05/2015,22/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1460
,,Lenvatinib,26/04/2013,Treatment of papillary thyroid cancer,EU/3/13/1121,Withdrawn,14/05/2013,22/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1121
,,Lenvatinib,26/04/2013,Treatment of follicular thyroid cancer,EU/3/13/1119,Withdrawn,14/05/2013,22/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1119
Crysvita,EMEA/H/C/004275,Recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23 (burosumab),15/10/2014,Treatment of X-linked hypophosphataemia,EU/3/14/1351,Positive,12/11/2014,22/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1351
,,Mogamulizumab,11/01/2012,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/11/943,Positive,01/02/2012,18/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-943
,,3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone,19/02/2014,Treatment of Rett syndrome,EU/3/14/1242,Positive,02/04/2014,18/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1242
,,Ofatumumab,07/11/2008,Treatment of chronic lymphocytic leukaemia,EU/3/08/581,Withdrawn,02/04/2009,18/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-581
Spinraza,EMEA/H/C/004312,Antisense oligonucleotide targeted to the SMN2 gene (nusinersen),02/04/2012,Treatment of 5q spinal muscular atrophy,EU/3/12/976,Positive,30/04/2012,16/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-976
,,Macitentan,27/09/2011,Treatment of pulmonary arterial hypertension,EU/3/11/909,Positive,17/10/2011,12/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-909
,,Macitentan,28/01/2010,Treatment of idiopathic pulmonary fibrosis,EU/3/09/707,Positive,25/02/2010,12/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-707
Theraloc; Theraloc,EMEA/H/C/000931; EMEA/H/C/000931,Anti epidermal growth factor receptor antibody h-R3,02/09/2004,Treatment of glioma,EU/3/04/220,Positive,01/10/2004,12/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-220
,,nimotuzumab,03/06/2008,Treatment of pancreatic cancer,EU/3/08/550,Positive,18/08/2008,12/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-550
Istodax,EMEA/H/C/002122,"(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone",28/10/2005,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/05/328,Positive,17/09/2009,12/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-328
,,"(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone",27/05/2005,Treatment of cutaneous T-cell lymphoma,EU/3/05/279,Positive,17/09/2009,12/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-279
,,melatonin,15/03/2018,Treatment of non-traumatic subarachnoid haemorrhage,-,Negative,11/10/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-non-traumatic-subarachnoid-haemorrhage
,,Givinostat,31/07/2018,Treatment of Becker muscular dystrophy,EU/3/18/2046,Positive,11/10/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2046
,,,31/07/2018,Treatment of primary hyperoxaluria,EU/3/18/2052,Positive,11/10/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2052
,,recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1,31/07/2018,treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency,EU/3/18/2049,Positive,11/10/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2049
,,Tetracosactide,31/07/2018,Treatment of Duchenne muscular dystrophy,EU/3/18/2054,Positive,11/10/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2054
,,Synthetic antisense oligonucleotide directed against human dystrophin pre-mRNA,31/07/2018,Treatment of Duchenne muscular dystrophy,EU/3/18/2051,Positive,10/10/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2051
,,"Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded",31/07/2018,Treatment of graft-versus-host disease,EU/3/18/2044,Positive,10/10/2018,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2044
,,Imexon,23/12/2005,Treatment of ovarian cancer,EU/3/05/341,Positive,08/08/2006,04/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-341
Darzalex,EMEA/H/C/004077,Daratumumab,17/07/2013,Treatment of plasma-cell myeloma,EU/3/13/1153,Positive,16/08/2013,02/10/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1153
,,Recombinant human von Willebrand factor,26/11/2010,Treatment of von Willebrand disease,EU/3/10/814,Withdrawn,17/12/2010,21/09/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-814
Cablivi,EMEA/H/C/004426,Nanobody directed towards the human A1 domain of von Willebrand factor (caplacizumab) ,30/04/2009,Treatment of thrombotic thrombocytopenic purpura,EU/3/09/629,Positive,12/05/2009,10/09/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-629
,,Recombinant human placental growth factor,27/06/2018,Treatment of pre-eclampsia,EU/3/18/2040,Positive,22/08/2018,22/08/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2040
,,Argon,27/06/2018,Treatment of perinatal asphyxia,EU/3/18/2031,Positive,22/08/2018,22/08/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2031
,,Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene,27/06/2018,Treatment of mucopolysaccharidosis type I,EU/3/18/2039,Positive,22/08/2018,22/08/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2039
,,20-hydroxyecdysone,27/06/2018,Treatment of Duchenne muscular dystrophy,EU/3/18/2030,Positive,21/08/2018,21/08/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2030
,,carmustine,27/06/2018,Treatment in haematopoietic stem cell transplantation,EU/3/18/2032,Positive,21/08/2018,21/08/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2032
,,"2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one",27/06/2018,Treatment of tuberculosis,EU/3/18/2029,Positive,21/08/2018,21/08/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2029
,,Peretinoin,05/08/2011,Treatment of hepatocellular carcinoma,EU/3/11/890,Positive,16/08/2011,26/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-890
,,H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-Actinium,25/05/2018,Treatment of glioma,EU/3/18/2023,Positive,24/07/2018,24/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2023
,,Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin,25/05/2018,Prevention of haemolytic uraemic syndrome,EU/3/18/2021,Positive,24/07/2018,24/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2021
,,Ambroxol hydrochloride,25/05/2018,Treatment of amyotrophic lateral sclerosis,EU/3/18/2017,Positive,24/07/2018,24/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2017
,,Adeno-associated viral vector serotype 9 containing the human CLN1 gene,25/05/2018,Treatment of neuronal ceroid lipofuscinosis,EU/3/18/2016,Positive,23/07/2018,23/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2016
,,"N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide",18/11/2016,Treatment of acute pancreatitis,EU/3/16/1783,Positive,13/12/2016,20/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1783
,,Gevokizumab,22/08/2014,Treatment of Schnitzler syndrome,EU/3/14/1311,Withdrawn,30/09/2014,18/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1311
,,Gevokizumab,12/03/2013,Treatment of chronic non-infectious uveitis,EU/3/13/1111,Withdrawn,05/04/2013,18/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1111
,,Recombinant humanised anti-human interleukin-1 beta monoclonal antibody,01/10/2010,Treatment of Behçet's Disease,EU/3/10/796,Withdrawn,14/10/2010,18/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-796
,,ambrisentan,11/04/2005,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/05/273,Withdrawn,29/07/2008,18/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-273
,,Thalidomide,20/11/2001,Treatment of multiple myeloma,EU/3/01/067,Withdrawn,29/07/2008,18/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-067
,,Arsenic trioxide,12/12/2016,Treatment of graft-versus-host disease,EU/3/16/1797,Positive,10/01/2017,16/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1797
Verkazia; Vekacia; Vekacia,EMEA/H/C/004411; EMEA/H/C/000904; EMEA/H/C/000904,ciclosporin,06/04/2006,Treatment of vernal keratoconjunctivitis,EU/3/06/360,Positive,24/02/2009,12/07/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-360
,,Letermovir,06/06/2012,Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity,EU/3/12/999,Positive,04/07/2012,28/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-999
Prevymis,EMEA/H/C/004536,"(S)-{8-Fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3, 4-dihydro-4-quinazolinyl} acetic acid (letermovir)",15/04/2011,Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity,EU/3/11/849,Positive,26/04/2011,28/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-849
,,Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt,20/03/2013,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/13/1114,Positive,08/04/2013,14/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1114
,,Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt,27/02/2017,Treatment of primary ciliary dyskinesia,EU/3/17/1834,Positive,31/03/2017,14/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1834
,,"2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate (remdesivir)",17/02/2016,Treatment of Ebola virus disease,EU/3/16/1615,Positive,17/04/2018,13/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1615
,,Sialic acid (also known as aceneuramic acid),16/10/2015,Treatment of GNE myopathy,EU/3/12/972,Withdrawn,19/04/2012,13/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-972
,,Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene,28/07/2015,Treatment of primary hyperoxaluria type 1,EU/3/15/1528,Withdrawn,18/08/2015,13/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1528
Kymriah,EMEA/H/C/004090,Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel),29/04/2014,Treatment of B-lymphoblastic leukaemia/lymphoma,EU/3/14/1266,Positive,04/06/2014,13/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1266
,,Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel),14/10/2016,Treatment of diffuse large B-cell lymphoma,EU/3/16/1745,Positive,14/11/2016,13/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1745
Namuscla,EMEA/H/C/004584,Mexiletine hydrochloride,19/11/2014,Treatment of myotonic disorders,EU/3/14/1353,Positive,15/01/2015,13/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1353
,,Staphylococcus aureus protein A,09/10/2015,Treatment of immune thrombocytopenia,EU/3/15/1562,Positive,18/11/2015,12/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1562
,,"Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}ethyl]sulfanyl}-3-{[(2S)-1-ethoxy-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}propanamido)-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)propanoyl ethyl ester))-methoxy]acetyl}oxy)butyl)sulfanyl]-3-(hexadecylcarbamoyl)propanoic acid]-PEG1500-ester]",16/01/2014,Treatment of dengue,EU/3/13/1220,Positive,23/01/2014,12/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1220
,,Human donor haematopoietic stem and progenitor cells that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor,12/01/2017,Treatment in haematopoietic stem cell transplantation,EU/3/16/1817,Positive,11/07/2017,12/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1817
,,Para-aminosalicylic acid,17/12/2010,Treatment of tuberculosis,EU/3/10/826,Positive,20/01/2011,08/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-826
,,"(1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine",16/12/2014,Treatment of neurotrophic keratitis,EU/3/14/1400,Positive,26/02/2015,08/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1400
,,Mavoglurant ,10/10/2012,Treatment of fragile X syndrome,EU/3/12/1046,Positive,16/11/2012,04/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1046
,,Recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor (lacnotuzumab),15/10/2014,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",EU/3/14/1350,Positive,12/11/2014,04/06/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1350
Onpattro,EMEA/H/C/004699,Synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA (also known as patisiran),06/04/2017,Treatment of transthyretin-mediated amyloidosis,EU/3/11/857,Positive,26/04/2011,30/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-857
,,Chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA,19/03/2015,Treatment of Huntington’s disease,EU/3/15/1453,Positive,11/05/2015,30/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1453
Rydapt,EMEA/H/C/004095,Midostaurin,04/08/2010,Treatment of mastocytosis,EU/3/10/765,Positive,11/08/2010,29/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-765
Rydapt,EMEA/H/C/004095,Midostaurin,29/07/2004,Treatment of acute myeloid leukaemia,EU/3/04/214,Positive,11/10/2005,29/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-214
,,Venetoclax,14/10/2016,Treatment of multiple myeloma,EU/3/16/1767,Positive,15/11/2016,29/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1767
,,Mazindol,12/02/2015,Treatment of narcolepsy,EU/3/15/1444,Withdrawn,09/04/2015,29/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1444
,,2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid,14/07/2016,Treatment of Huntington’s disease,EU/3/16/1691,Withdrawn,06/09/2016,29/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1691
,,Yttrium (90Y) edotreotide,04/08/2008,Treatment of gastro-entero-pancreatic neuroendocrine tumours,EU/3/08/589,Withdrawn,20/04/2009,29/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-589
,,Olaparib,06/12/2007,Treatment of ovarian cancer,EU/3/07/501,Withdrawn,02/07/2008,28/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-501
,,adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1,16/04/2018,Treatment of amyotrophic lateral sclerosis,EU/3/18/2008,Positive,17/05/2018,17/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2008
,,Docosahexaenoic acid ethyl ester,21/03/2018,Treatment of sickle cell disease,EU/3/18/1991,Positive,17/05/2018,17/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1991
,,melatonin,21/03/2018,Treatment of neonatal encephalopathy,EU/3/18/1996,Positive,15/05/2018,23/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1996
,,Bosutinib,04/08/2010,Treatment of chronic myeloid leukaemia,EU/3/10/762,Withdrawn,11/08/2010,07/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-762
,,Recombinant human interleukin-12,29/08/2016,Treatment of acute radiation syndrome,EU/3/16/1727,Positive,03/10/2016,03/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1727
,,"4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one",12/10/2017,Treatment of pancreatic cancer,EU/3/17/1937,Positive,15/01/2018,03/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1937
,,2'-O-(2-Methoxyethyl) phosphorothioate antisense oligonucleotide targeting the growth hormone receptor,27/06/2016,Treatment of acromegaly,EU/3/16/1671,Positive,26/07/2016,03/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1671
,,"(1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione",28/04/2016,Treatment of X-linked spinal and bulbar muscular atrophy (Kennedy's disease),EU/3/16/1639,Positive,31/05/2016,03/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1639
,,live attenuated Listeria monocytogenes bioengineered with a chimeric human epidermal growth factor receptor 2 fused to a truncated form of the Lm protein listeriolysin O,14/12/2015,Treatment of osteosarcoma,EU/3/15/1595,Positive,03/02/2016,03/05/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1595
,,Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2,22/02/2018,Treatment of primary IgA nephropathy,EU/3/18/1984,Positive,11/04/2018,11/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1984
,,"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate",22/02/2018,Treatment of cystic fibrosis,EU/3/18/1988,Positive,11/04/2018,11/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1988
,,Pyridoxal 5'-phosphate,22/02/2018,Treatment of pyridoxamine 5'-phosphate oxidase deficiency,EU/3/18/1983,Positive,11/04/2018,11/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1983
,,melatonin,13/03/2018,Treatment of partial deep dermal and full-thickness burns,-,Negative,11/04/2018,11/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-partial-deep-dermal-full-thickness-burns
,,1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride,22/02/2018,Treatment of soft tissue sarcoma,EU/3/18/1972,Positive,11/04/2018,11/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1972
Lamzede,EMEA/H/C/003922,Recombinant human alpha-Mannosidase (velmanase alfa),26/01/2005,Treatment of alpha-mannosidosis,EU/3/04/260,Positive,01/07/2005,10/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-260
Vyloy,EMEA/H/C/005868,Chimeric monoclonal antibody against claudin-18 splice variant 2,26/11/2010,Treatment of gastric cancer,EU/3/10/803,Positive,15/12/2010,03/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-803
,,"Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide",22/05/2017,Treatment of acute myeloid leukaemia,EU/3/17/1876,Positive,29/06/2017,03/04/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1876
,,Recombinant fusion protein linking coagulation factor VIIa with albumin,07/10/2013,Treatment of congenital factor VII deficiency,EU/3/13/1188,Positive,31/10/2013,28/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1188
,,Human alpha1-proteinase inhibitor,09/07/2001,Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency,EU/3/01/044,Positive,24/02/2009,28/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-044
,,C1-esterase-inhibitor human,12/10/2017,Treatment in solid organ transplantation,EU/3/17/1939,Positive,12/01/2018,28/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1939
Idelvion,EMEA/H/C/003955,Recombinant fusion protein linking human coagulation factor IX with human albumin,04/02/2010,Treatment of haemophilia B,EU/3/09/723,Positive,04/03/2010,28/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-723
,,Recombinant fusion protein linking human coagulation factor VIIa with human albumin,15/04/2011,Treatment of haemophilia A,EU/3/11/855,Positive,26/04/2011,28/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-855
,,Recombinant fusion protein linking human coagulation factor VIIa with human albumin,13/05/2011,Treatment of haemophilia B,EU/3/11/863,Positive,31/05/2011,28/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-863
,,"(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (deferitazole)",24/07/2009,Treatment of chronic iron overload requiring chelation therapy,EU/3/09/647,Withdrawn,11/09/2009,26/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-647
,,Ciclopirox,17/01/2018,Treatment of congenital erythropoietic porphyria,EU/3/17/1960,Positive,14/03/2018,14/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1960
,,Itacitinib,17/01/2018,Treatment of graft-versus-host disease,EU/3/17/1964,Positive,13/03/2018,13/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1964
,,Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits,17/01/2018,Treatment of GM2 gangliosidosis,EU/3/17/1969,Positive,13/03/2018,13/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1969
,,"N-(bromoacetyl)-3,3-dinitroazetidine",17/01/2018,Treatment of small cell lung cancer,EU/3/17/1966,Positive,12/03/2018,12/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1966
,,Adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene,17/01/2018,Treatment of Huntington’s disease,EU/3/17/1957,Positive,12/03/2018,12/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1957
,,"Pyrazolo[1,5-a]pyrimidine, 3-[4-chloro-2-(4-morpholinyl)-5-thiazolyl]-7-(1-ethylpropyl)-2,5-dimethyl-pyrazolo[1,3-a]pyrimidine",17/01/2018,Treatment of congenital adrenal hyperplasia,EU/3/17/1968,Positive,12/03/2018,12/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1968
,,Humanised Fc-engineered monoclonal antibody against CD19,17/01/2018,Treatment of IgG4-related disease,EU/3/17/1962,Positive,12/03/2018,12/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1962
,,Siponimod,19/11/2014,Treatment of dermatomyositis,EU/3/14/1369,Withdrawn,16/01/2015,12/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1369
,,Siponimod,19/11/2014,Treatment of polymyositis,EU/3/14/1370,Withdrawn,16/01/2015,12/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1370
,,Human plasmin,23/02/2011,Treatment of acute peripheral arterial occlusion,EU/3/10/834,Withdrawn,04/03/2011,12/03/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-834
,,Ataluren,19/11/2014,Treatment of mucopolysaccharidosis type I,EU/3/14/1380,Withdrawn,16/01/2015,22/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1380
,,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile (tanziertib)",15/10/2014,Treatment of pemphigus,EU/3/14/1335,Withdrawn,12/11/2014,22/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1335
,,"4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol (tanzisertib)",09/12/2011,Treatment of idiopathic pulmonary fibrosis,EU/3/11/934,Withdrawn,20/12/2011,22/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-934
,,Obinutuzumab,10/10/2012,Treatment of chronic lymphocytic leukaemia,EU/3/12/1054,Positive,16/11/2012,21/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1054
Gazyvaro,EMEA/H/C/002799,Obinutuzumab,19/06/2015,Treatment of follicular lymphoma,EU/3/15/1504,Positive,27/07/2015,21/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1504
,,Marizomib,29/07/2014,Treatment of plasma cell myeloma,EU/3/14/1295,Positive,01/09/2014,13/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1295
,,"2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide",26/08/2005,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/05/316,Withdrawn,17/09/2009,12/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-316
,,dexamethasone,09/06/2010,Treatment of multiple myeloma,EU/3/10/745,Withdrawn,23/06/2010,12/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-745
,,L-Asparaginase,26/01/2005,Treatment of acute lymphoblastic leukaemia,EU/3/04/258,Withdrawn,26/07/2005,12/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-258
,,Lumacaftor;ivacaftor,22/08/2014,Treatment of cystic fibrosis,EU/3/14/1333,Withdrawn,29/09/2014,12/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1333
,,Recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 (efmoroctocog alfa),20/09/2010,Treatment of haemophilia A,EU/3/10/783,Withdrawn,18/10/2010,12/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-783
,,Tolvaptan,05/08/2013,Treatment of autosomal dominant polycystic kidney disease,EU/3/13/1175,Withdrawn,13/09/2013,12/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1175
,,Tobramycin,28/02/2009,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,EU/3/09/613,Withdrawn,29/06/2009,09/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-613
,,Levofloxacin hemihydrate,23/09/2008,Treatment of cystic fibrosis,EU/3/08/566,Withdrawn,24/04/2009,09/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-566
,,"Trans-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride",05/08/2013,Treatment of acute myeloid leukaemia,EU/3/13/1174,Positive,13/09/2013,05/02/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1174
,,Sorafenib tosilate,11/04/2006,Treatment of hepatocellular carcinoma,EU/3/06/364,Expired,23/09/2009,31/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-364
,,Modified messenger ribonucleic acid encoding human argininosuccinate lyase enzyme encapsulated into lipid nanoparticles,12/12/2017,Treatment of argininosuccinic aciduria,EU/3/17/1952,Positive,23/01/2018,23/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1952
,,Tivantinib,13/11/2013,Treatment of hepatocellular carcinoma,EU/3/13/1202,Withdrawn,02/12/2013,23/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1202
,,naproxcinod,07/10/2013,Treatment of Duchenne muscular dystrophy,EU/3/13/1194,Withdrawn,31/10/2013,23/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1194
,,"Mixture of two allogeneic human pancreatic cancer cell lines stably transduced with a retroviral vector encoding the murine alpha-(1,3)-galactosyltransferase gene",10/10/2012,Treatment of pancreatic cancer,EU/3/12/1048,Withdrawn,16/11/2012,23/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1048
,,"Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells;allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells",15/01/2015,Treatment of acute myeloid leukaemia,EU/3/14/1413,Withdrawn,05/03/2015,23/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1413
,,"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy)phenyl]thio]phenyl]ethyl]-1,3-propanediol hydrochloride",14/12/2015,Prevention of graft-versus-host disease,EU/3/15/1583,Withdrawn,02/02/2016,22/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1583
,,Temsirolimus,06/04/2006,Treatment of renal-cell carcinoma,EU/3/06/365,Expired,02/04/2009,22/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-365
Jorveza,EMEA/H/C/004655,Budesonide,05/08/2013,Treatment of eosinophilic oesophagitis,EU/3/13/1181,Positive,13/09/2013,18/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1181
,,Hydroxychloroquine sulfate,08/10/2009,Treatment of LIPIN1 disease,EU/3/17/1963,Positive,17/01/2018,17/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1963
,,Recombinant adeno-associated viral vector serotype 9 containing human iduronate-2-sulfatase gene,12/10/2017,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/17/1943,Positive,15/01/2018,15/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1943
,,"N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide",12/10/2017,Treatment of peripheral T-cell lymphoma,EU/3/17/1942,Positive,15/01/2018,15/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1942
,,"1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene",12/10/2017,Treatment of non-traumatic subarachnoid haemorrhage,EU/3/17/1935,Positive,15/01/2018,15/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1935
,,Autologous ex-vivo-expanded peripheral polyclonal lymphocytes enriched in activated natural killer cells,16/10/2017,Treatment of multiple myeloma,EU/3/17/1918,Positive,10/01/2018,10/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1918
,,"Adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters",16/10/2017,Treatment of pancreatic cancer,EU/3/17/1917,Positive,09/01/2018,09/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1917
Daurismo,EMEA/H/C/004878,Glasdegib maleate,16/10/2017,Treatment of acute myeloid leukaemia,EU/3/17/1923,Positive,09/01/2018,09/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1923
,,Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8,16/10/2017,Treatment of mastocytosis,EU/3/17/1929,Positive,08/01/2018,08/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1929
,,"S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid",16/10/2017,Treatment of primary sclerosing cholangitis,EU/3/17/1914,Positive,08/01/2018,08/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1914
,,Synthetic cyclic 8 amino acid analogue of human unacylated ghrelin,16/10/2017,Treatment of Prader-Willi syndrome,EU/3/17/1932,Positive,08/01/2018,08/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1932
,,2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine,16/10/2017,Treatment of Charcot-Marie-Tooth disease,EU/3/17/1915,Positive,08/01/2018,08/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1915
,,Sodium chlorite,19/06/2013,Treatment of amyotrophic lateral sclerosis,EU/3/13/1139,Positive,11/07/2013,03/01/2018,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1139
,,Alicaforsen,15/05/2009,Treatment of pouchitis,EU/3/09/641,Positive,09/06/2009,18/12/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-641
,,"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino) phenyl]cyclopentyl]methyl]urea, hydrochloride salt",07/06/2013,Treatment of adrenocortical carcinoma,EU/3/13/1128,Positive,25/06/2013,13/11/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1128
,,Inolimomab,05/03/2001,Treatment of graft-versus-host disease,EU/3/01/028,Positive,18/08/2008,26/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-028
,,Recombinant humanised monoclonal antibody against human complement component C5a,29/08/2016,Treatment of graft-versus-host disease,EU/3/16/1728,Withdrawn,03/10/2016,19/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1728
,,recombinant human alpha-N-acetylglucosaminidase,19/06/2013,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),EU/3/13/1144,Withdrawn,11/07/2013,19/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1144
,,"(1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate",17/07/2013,Treatment of pancreatic cancer,EU/3/13/1152,Withdrawn,16/08/2013,19/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1152
,,"Phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis(1,1-dimethylethyl) monohydrochloride",24/04/2015,Treatment of Huntington’s disease,EU/3/15/1481,Withdrawn,22/05/2015,19/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1481
,,Adeno-associated viral vector containing the human factor IX gene,19/06/2015,Treatment of haemophilia B,EU/3/15/1501,Withdrawn,27/07/2015,19/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1501
,,Salirasib,21/06/2011,Treatment of pancreatic cancer,EU/3/11/871,Withdrawn,12/07/2011,19/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-871
,,tacrolimus,23/08/2017,Treatment of pulmonary arterial hypertension,EU/3/17/1912,Positive,17/10/2017,17/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1912
,,Purified pasteurised and freeze-dried cell-wall fragments from Mycobacterium tuberculosis strain RUTI,23/08/2017,Treatment of tuberculosis,EU/3/17/1905,Positive,17/10/2017,17/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1905
,,Antisense oligonucleotide targeting exon 13 in the USH2A gene,23/08/2017,Treatment of retinitis pigmentosa,EU/3/17/1899,Positive,17/10/2017,17/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1899
,,Sodium 2-hydroxylinoleate,23/08/2017,Treatment of pancreatic cancer,EU/3/17/1911,Positive,17/10/2017,17/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1911
,,Odiparcil,23/08/2017,Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome),EU/3/17/1903,Positive,17/10/2017,17/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1903
,,Trientine tetrahydrochloride,19/03/2015,Treatment of Wilson's disease,EU/3/15/1471,Withdrawn,19/05/2015,03/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1471
,,Ecteinascidin 743 (trabectedin),30/05/2001,Treatment of soft tissue sarcoma,EU/3/01/039,Expired,04/12/2007,03/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-039
,,5-aminolevulinic acid hydrochloride,14/11/2002,Intra-operative photodynamic diagnosis of residual glioma,EU/3/02/121,Expired,04/12/2007,03/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-121
,,nelarabine,16/06/2005,Treatment of acute lymphoblastic leukaemia,EU/3/05/293,Expired,29/07/2008,03/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-293
,,Mecasermin,22/05/2006,Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects,EU/3/06/373,Expired,24/04/2009,03/10/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-373
,,Lutetium (177Lu) edotreotide,04/06/2014,Treatment of gastro-entero-pancreatic neuroendocrine tumours,EU/3/14/1269,Positive,10/07/2014,05/09/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1269
,,Adeno-associated viral vector serotype 5 containing the human CHM gene,24/04/2015,Treatment of choroideraemia,EU/3/15/1482,Positive,22/05/2015,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1482
,,Recombinant humanised monoclonal IgG2 lambda antibody against human sclerostin,27/06/2016,Treatment of osteogenesis imperfecta,EU/3/16/1686,Positive,26/07/2016,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1686
,,"N,N'-bis(2-mercaptoethyl)isophthalamide (emeramide)",11/01/2012,Treatment of mercury toxicity,EU/3/11/944,Positive,01/02/2012,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-944
,,Emeramide,20/04/2017,Prevention of mercury toxicity,EU/3/17/1864,Positive,15/05/2017,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1864
,,Fluocinolone acetonide,28/04/2016,Treatment of non-infectious uveitis,EU/3/16/1647,Withdrawn,30/05/2016,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1647
,,"4-[(2E)-1-oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide",30/05/2016,Treatment of retinitis pigmentosa,EU/3/16/1658,Withdrawn,28/06/2016,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1658
,,"Pyr-His-Trp-Ser-Tyr-D-Lys(doxorubicinylglutarate)-Leu-Arg-Pro-Gly-NH2, acetate salt",04/08/2010,Treatment of ovarian cancer,EU/3/10/766,Withdrawn,11/08/2010,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-766
,,Desipramine chlorhydrate,12/06/2009,Treatment of Rett syndrome,EU/3/09/643,Withdrawn,01/07/2009,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-643
,,"(2-aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxy benzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosu (pasireotide)",08/06/2004,Treatment of functional gastro-entero-pancreatic endocrine tumours,EU/3/04/200,Withdrawn,03/09/2006,16/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-200
,,Oxymetazoline hydrochloride,17/07/2017,Treatment of spinal cord injury,EU/3/17/1892,Positive,15/08/2017,15/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1892
,,Bacillus subtilis oxalate decarboxylase,17/07/2017,Treatment of primary hyperoxaluria,EU/3/17/1891,Positive,15/08/2017,15/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1891
,,Retinol,17/07/2017,Prevention of retinopathy of prematurity,EU/3/17/1895,Positive,15/08/2017,15/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1895
,,5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin,08/06/2007,Treatment of osteosarcoma,EU/3/07/450,Withdrawn,29/07/2008,14/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-450
,,Tirapazamine,17/07/2017,Treatment of hepatocellular carcinoma,EU/3/17/1897,Positive,14/08/2017,14/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1897
,,Recombinant human heat-shock protein 70,12/03/2013,"Treatment of Niemann-Pick's disease, type C",EU/3/13/1110,Withdrawn,05/04/2013,14/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1110
,,Recombinant human antibody directed against misfolded human superoxide dismutase 1,17/07/2017,Treatment of amyotrophic lateral sclerosis,EU/3/17/1894,Positive,14/08/2017,14/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1894
,,"N-carboxymethyl-glycyl-L-threonyl-L-histidyl-L-3,3-diphenylalanyl-L-piperidincarboxy-3-yl-L-arginyl-L-S-methylthio-cystyl-L-arginyl-L-tryptophyl-aminohexanyl-N-carboxamidomethyl-glycine N-hexadecylamide",28/04/2016,Treatment of beta thalassaemia intermedia and major,EU/3/16/1650,Withdrawn,30/05/2016,10/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1650
,,"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]-(3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide",21/05/2015,Treatment of ovarian cancer,EU/3/15/1488,Withdrawn,30/06/2015,10/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1488
,,Hydroxyurea,09/07/2003,Treatment of sickle cell syndrome,EU/3/03/154,Expired,29/07/2008,06/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-154
,,Pegylated recombinant human factor IX (nonacog beta pegol),15/05/2009,Treatment of haemophilia B,EU/3/09/640,Expired,09/06/2009,03/08/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-640
,,decitabine;tetrahydrouridine,20/06/2017,Treatment of sickle cell disease,EU/3/17/1881,Positive,17/07/2017,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1881
,,Pentamer formyl thiophene acetic acid,20/06/2017,Treatment of Creutzfeldt-Jakob disease,EU/3/17/1883,Positive,17/07/2017,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1883
,,sildenafil,20/06/2017,Treatment of congenital diaphragmatic hernia,EU/3/17/1885,Positive,17/07/2017,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1885
,,Murine IgM monoclonal antibody binding to alpha beta T-cell receptor,12/03/2013,Prevention of graft rejection following solid organ transplantation,EU/3/13/1113,Withdrawn,05/04/2013,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1113
,,Adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene,19/03/2015,Treatment of Gaucher disease,EU/3/15/1468,Withdrawn,11/05/2015,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1468
,,"Humanised monoclonal modified IgG4 antibody with bispecific structure targeting factors IX, IXa, X and Xa (emicizumab)",16/01/2014,Treatment of haemophilia A,EU/3/13/1221,Withdrawn,23/01/2014,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1221
,,Poloxamer 188,12/03/2013,Treatment of sickle cell disease,EU/3/13/1112,Withdrawn,05/04/2013,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1112
,,Sodium phenylbutyrate,11/01/2012,Treatment of 5q spinal muscular atrophy,EU/3/11/948,Withdrawn,01/02/2012,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-948
,,"3-(4'Aminoisoindoline-1'-one)-1-piperidine-2,6-dione (lenalidomide)",12/12/2003,Treatment of multiple myeloma,EU/3/03/177,Withdrawn,29/07/2008,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-177
,,"3-(6-(1-(2,2-Difluorobenzo [d] [1,3] dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (lumacaftor)",04/08/2010,Treatment of cystic fibrosis,EU/3/10/761,Withdrawn,11/08/2010,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-761
,,Betaine anhydrous,09/07/2001,Treatment of homocystinuria,EU/3/01/045,Withdrawn,15/05/2009,17/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-045
,,Doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin,12/01/2017,Treatment of malignant mesothelioma,EU/3/16/1814,Positive,14/07/2017,14/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1814
,,Antroquinonol,12/01/2017,Treatment of pancreatic cancer,EU/3/16/1812,Positive,14/07/2017,14/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1812
,,Humanised IgG1 monoclonal antibody against the receptor-binding site of human placental growth factor,12/01/2017,Treatment of medulloblastoma,EU/3/16/1819,Positive,14/07/2017,14/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1819
,,Autologous dendritic cells incubated ex vivo with zebularine and factor VIII,12/01/2017,Treatment of haemophilia A,EU/3/16/1813,Positive,14/07/2017,14/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1813
,,Human hepatoma cell line HepaRG in bioartificial liver,12/01/2017,Treatment of acute liver failure,EU/3/16/1818,Positive,14/07/2017,14/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1818
,,Pr-D-Cys-Met-Pip-Arg-Leu-Arg-Sar-Cys-Lys-Arg-Pro-Tyr-Tle-Leu-OH,12/01/2017,Treatment of perinatal asphyxia,EU/3/16/1824,Positive,13/07/2017,13/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1824
,,Trans-resveratrol,12/01/2017,Treatment of spinocerebellar ataxia,EU/3/16/1827,Positive,13/07/2017,13/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1827
,,"[5,10,15,20-tetrakis(4-carboxyphenyl)-21H,23H-porphine]manganese(III) chloride",12/01/2017,Treatment of Cockayne syndrome,EU/3/16/1809,Positive,13/07/2017,13/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1809
,,Genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimised shRNA-insensitive wildtype PABPN1,12/01/2017,Treatment of oculopharyngeal muscular dystrophy,EU/3/16/1816,Positive,11/07/2017,11/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1816
,,pioglitazone hydrochloride,12/01/2017,Treatment of sudden sensorineural hearing loss,EU/3/16/1823,Positive,11/07/2017,11/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1823
,,pentosan polysulfate sodium,12/01/2017,Treatment of interstitial cystitis,EU/3/16/1822,Positive,11/07/2017,11/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1822
,,Leuprorelin acetate,12/01/2017,Treatment of congenital hypogonadotropic hypogonadism,EU/3/16/1821,Positive,11/07/2017,11/07/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1821
,,Tamoxifen citrate,22/05/2017,Treatment of cystic fibrosis,EU/3/17/1877,Positive,29/06/2017,29/06/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1877
,,Recombinant human interleukin-7 fused to a hybrid crystallisable fragment region of a human antibody-,22/05/2017,Treatment of idiopathic CD4 lymphocytopenia,EU/3/17/1875,Positive,29/06/2017,29/06/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1875
Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau),EMEA/H/C/004061,Chenodeoxycholic acid,16/12/2014,Treatment of inborn errors in primary bile acid synthesis,EU/3/14/1406,Positive,27/02/2015,29/06/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1406
,,Chimaeric monoclonal antibody against claudin-18 splice variant 2,05/08/2013,Treatment of pancreatic cancer,EU/3/13/1177,Positive,13/09/2013,08/06/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1177
,,Chimeric locked nucleic acid-deoxynucleoside phosphorothioate-linked oligonucleotide directed against microRNA-451,11/01/2012,Treatment of polycythaemia vera,EU/3/11/940,Withdrawn,01/02/2012,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-940
,,"3-[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid",27/05/2005,Treatment of cystic fibrosis,EU/3/05/277,Withdrawn,04/07/2007,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-277
,,Eculizumab,19/02/2014,Prevention of delayed graft function after solid organ transplantation,EU/3/14/1238,Withdrawn,01/04/2014,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1238
,,"N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate",09/06/2010,Treatment of renal-cell carcinoma,EU/3/10/747,Withdrawn,23/06/2010,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-747
,,apremilast,05/08/2013,Treatment of Behçet's Disease,EU/3/13/1180,Withdrawn,13/09/2013,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1180
,,"Synthetic double-stranded oligomer specific to the SERPINA1 gene and containing a cholesterol-conjugated, acyclic nucleobase analogue",11/01/2016,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/15/1605,Withdrawn,05/02/2016,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1605
,,Beloranib,04/07/2014,Treatment of Prader-Willi syndrome,EU/3/14/1287,Withdrawn,15/07/2014,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1287
,,Synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues for the treatment of ATTR amyloidosis,29/04/2014,Treatment of ATTR amyloidosis,EU/3/14/1267,Withdrawn,04/06/2014,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1267
,,Beloranib,08/10/2009,Treatment of craniopharyngioma,EU/3/15/1530,Withdrawn,18/08/2015,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1530
,,Doxorubicin,28/11/2012,Treatment of glioma,EU/3/12/1006,Withdrawn,17/12/2012,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1006
,,Synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine,08/11/2012,Treatment of glioma,EU/3/12/1065,Withdrawn,12/12/2012,17/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1065
,,"20% Intravenous fat emulsion consisting of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection",03/04/2017,Treatment of poisoning by local anaesthetics,-,Negative,15/05/2017,15/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-poisoning-local-anaesthetics
,,rituximab,20/04/2017,Treatment in solid organ transplantation,EU/3/17/1869,Positive,15/05/2017,15/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1869
,,Human normal immunoglobulin,20/04/2017,Treatment in solid organ transplantation,EU/3/17/1866,Positive,15/05/2017,15/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1866
,,Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles,20/04/2017,Treatment of ornithine transcarbamylase deficiency,EU/3/17/1867,Positive,15/05/2017,15/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1867
,,Estetrol,20/04/2017,Treatment of neonatal encephalopathy,EU/3/17/1865,Positive,15/05/2017,15/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1865
,,Poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate,20/03/2017,Treatment of ovarian cancer,EU/3/17/1860,Positive,05/05/2017,05/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1860
,,Phosphoinositide 3-kinase gamma peptide,20/03/2017,Treatment of cystic fibrosis,EU/3/17/1859,Positive,05/05/2017,05/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1859
,,Ketoconazole,20/03/2017,Treatment of granulosa cell tumours,EU/3/17/1857,Positive,05/05/2017,05/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1857
,,Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase,20/03/2017,Treatment of GM1 gangliosidosis,EU/3/17/1851,Positive,05/05/2017,05/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1851
,,Megestrol acetate,20/03/2017,Treatment of granulosa cell tumours,EU/3/17/1858,Positive,05/05/2017,05/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1858
,,Antisense oligonucleotide targeting the USH2A gene,20/03/2017,Treatment of retinitis pigmentosa,EU/3/17/1853,Positive,05/05/2017,05/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1853
,,Autologous adipose tissue-derived mesenchymal stem cells,20/03/2017,Treatment of thromboangiitis obliterans (Buerger's disease),EU/3/17/1854,Positive,05/05/2017,05/05/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1854
,,3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid (avoralstat),12/02/2015,Treatment of hereditary angioedema,EU/3/15/1431,Withdrawn,08/04/2015,25/04/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1431
,,Irinotecan hydrochloride,30/11/2007,Treatment of glioma,EU/3/07/504,Withdrawn,02/07/2008,25/04/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-504
,,doxorubicin hydrochloride,30/11/2007,Treatment of glioma,EU/3/07/507,Withdrawn,02/07/2008,25/04/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-507
,,Cysteamine,19/02/2014,Treatment of cystic fibrosis,EU/3/14/1240,Positive,01/04/2014,20/04/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1240
,,Resminostat,27/09/2011,Treatment of hepatocellular carcinoma,EU/3/11/913,Positive,17/10/2011,05/04/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-913
,,vemurafenib,27/02/2017,Treatment of Erdheim-Chester disease,EU/3/17/1846,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1846
,,Autologous T-cells transduced with lentiviral vector encoding an anti-SLAMF7 CD28/CD3-zeta chimeric antigen receptor,27/02/2017,Treatment of plasma cell myeloma,EU/3/17/1833,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1833
,,Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2,27/02/2017,Treatment of myelodysplastic syndromes,EU/3/17/1837,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1837
Omblastys,EMEA/H/C/005499,Iodine (131I) murine IgG1 monoclonal antibody against CD276,27/02/2017,Treatment of neuroblastoma,EU/3/17/1839,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1839
,,Thalidomide,27/02/2017,Treatment of hereditary haemorrhagic telangiectasia,EU/3/17/1845,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1845
,,propranolol hydrochloride,27/02/2017,Treatment of von Hippel-Lindau disease,EU/3/17/1841,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1841
,,Tauroursodeoxycholic acid,27/02/2017,Treatment of amyotrophic lateral sclerosis,EU/3/17/1844,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1844
,,alpha-tocopherol;ascorbic acid,27/02/2017,Treatment of fragile X syndrome,EU/3/17/1832,Positive,31/03/2017,31/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1832
,,Sevuparin sodium,12/02/2015,Treatment of sickle cell disease,EU/3/15/1433,Positive,08/04/2015,17/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1433
Ledaga,EMEA/H/C/002826,Chlormethine,22/05/2012,Treatment of cutaneous T-cell lymphoma,EU/3/12/963,Positive,06/07/2012,16/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-963
,,Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2,27/02/2017,Treatment of pancreatic cancer,EU/3/17/1838,Positive,13/03/2017,13/03/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1838
Cystadrops,EMEA/H/C/003769,Cysteamine hydrochloride,07/11/2008,Treatment of cystinosis,EU/3/08/578,Positive,29/06/2009,22/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-578
Winfuran,EMEA/H/C/002683,,11/09/2002,Treatment of uraemic pruritus,EU/3/02/115,Positive,10/02/2009,14/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-115
,,mifepristone,27/07/2005,Treatment of Cushing's syndrome secondary to ectopic ACTH secretion,EU/3/05/298,Withdrawn,11/10/2005,10/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-298
,,Pomalidomide,27/07/2010,Treatment of post-essential thrombocythaemia myelofibrosis,EU/3/10/759,Withdrawn,06/08/2010,10/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-759
,,Pomalidomide,27/07/2010,Treatment of post-polycythaemia vera myelofibrosis,EU/3/10/758,Withdrawn,06/08/2010,10/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-758
,,Recombinant human factor XIII (composed of two A subunits),12/12/2003,Treatment of hereditary factor-XIII deficiency,EU/3/03/179,Withdrawn,12/12/2005,10/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-179
,,Pomalidomide,27/07/2010,Treatment of primary myelofibrosis,EU/3/10/757,Withdrawn,06/08/2010,10/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-757
,,axitinib,23/02/2011,Treatment of renal-cell carcinoma,EU/3/10/844,Withdrawn,04/03/2011,10/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-844
,,heparin sodium,02/09/2004,Treatment of idiopathic pulmonary fibrosis,EU/3/04/223,Withdrawn,01/07/2005,10/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-223
,,azacitidine,11/11/2015,Treatment of nasopharyngeal carcinoma,EU/3/15/1570,Withdrawn,06/01/2016,08/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1570
,,Anagrelide hydrochloride,30/12/2000,Treatment of essential thrombocythaemia,EU/3/00/010,Expired,15/06/2009,08/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-010
,,stiripentol,06/12/2001,Treatment of severe myoclonic epilepsy in infancy,EU/3/01/071,Expired,31/07/2007,08/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-071
,,Iduronate-2-sulfatase,11/12/2001,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),EU/3/01/078,Expired,18/10/2010,08/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-078
,,dasatinib,23/12/2005,Treatment of acute lymphoblastic leukaemia,EU/3/05/338,Expired,28/02/2007,08/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-338
,,dasatinib,23/12/2005,Treatment of chronic myeloid leukaemia,EU/3/05/339,Expired,28/02/2007,08/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-339
,,Alisertib,06/12/2012,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/12/1074,Withdrawn,24/01/2013,07/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1074
,,Alisertib,08/11/2012,Treatment of ovarian cancer,EU/3/12/1064,Withdrawn,13/12/2012,07/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1064
,,folic acid,10/09/2012,Diagnosis of positive folate-receptor status in ovarian cancer,EU/3/12/1044,Withdrawn,26/09/2012,07/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1044
,,"Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2",13/05/2011,Treatment of acute myeloid leukaemia,EU/3/11/866,Withdrawn,30/05/2011,07/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-866
,,"Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2",10/08/2015,Treatment of acute lymphoblastic leukaemia,EU/3/15/1546,Withdrawn,02/10/2015,07/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1546
,,Fingolimod,02/02/2010,Treatment of chronic inflammatory demyelinating polyneuropathy,EU/3/09/718,Withdrawn,04/03/2010,07/02/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-718
,,Udenafil,12/12/2016,Treatment of functional single ventricle congenital heart disease,EU/3/16/1807,Positive,10/01/2017,10/01/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1807
,,Propranolol,12/12/2016,Treatment of soft tissue sarcoma,EU/3/16/1805,Positive,09/01/2017,09/01/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1805
,,3-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine hydrochloride,13/07/2016,Treatment of narcolepsy,-,Negative,09/01/2017,09/01/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-narcolepsy
,,Recombinant human dyskerin,08/11/2012,Treatment of dyskeratosis congenita,EU/3/12/1070,Positive,12/12/2012,05/01/2017,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1070
Prohippur,EMEA/H/C/004150,Sodium benzoate,18/11/2016,Treatment of N-acetylglutamate synthetase (NAGS) deficiency,EU/3/16/1788,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1788
Prohippur,EMEA/H/C/004150,Sodium benzoate,18/11/2016,Treatment of argininosuccinic aciduria,EU/3/16/1787,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1787
,,zinc gluconate,18/11/2016,treatment of facioscapulohumeral muscular dystrophy,EU/3/16/1793,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1793
,,alpha-tocopherol,18/11/2016,treatment of facioscapulohumeral muscular dystrophy,EU/3/16/1775,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1775
,,ascorbic acid,18/11/2016,treatment of facioscapulohumeral muscular dystrophy,EU/3/16/1776,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1776
,,L-selenomethionine,18/11/2016,treatment of facioscapulohumeral muscular dystrophy,EU/3/16/1782,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1782
,,Valproic acid,18/11/2016,Treatment of diffuse large B-cell lymphoma,EU/3/16/1792,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1792
,,live-attenuated non-replicative Pseudomonas aeruginosa strain expressing large T antigen of Merkel cell polyomavirus,18/11/2016,Treatment of Merkel cell carcinoma,EU/3/16/1781,Positive,14/12/2016,14/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1781
,,R-azasetron besilate,18/11/2016,Treatment of sudden sensorineural hearing loss,EU/3/16/1785,Positive,13/12/2016,13/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1785
,,"particles comprised of methacrylic acid based co-polymer, cross-linked with a bi-functional cross-linker, purified to bind L-phenylalanine and L-phenylalanine containing peptides",18/11/2016,Treatment of hyperphenylalaninaemia,EU/3/16/1784,Positive,13/12/2016,13/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1784
,,Naltrexone,06/10/2016,Treatment of fibromyalgia,-,Negative,13/12/2016,13/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-fibromyalgia
,,Exon 52 specific phosphorothioate oligonucleotide,06/12/2012,Treatment of Duchenne muscular dystrophy,EU/3/12/1077,Positive,25/01/2013,05/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1077
,,Exon 53 specific phosphorothioate oligonucleotide,26/04/2012,Treatment of Duchenne muscular dystrophy,EU/3/12/992,Positive,18/06/2012,05/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-992
,,Exon 55 specific phosphorothioate oligonucleotide,06/12/2012,Treatment of Duchenne muscular dystrophy,EU/3/12/1078,Positive,25/01/2013,05/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1078
,,Exon 45 specific phosphorothioate oligonucleotide,26/04/2012,Treatment of Duchenne muscular dystrophy,EU/3/12/991,Positive,18/06/2012,05/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-991
,,Exon 44 specific phosphorothioate oligonucleotide,27/02/2009,Treatment of Duchenne muscular dystrophy,EU/3/08/598,Positive,29/06/2009,02/12/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-598
,,Recombinant human monoclonal IgM antibody targeting glucose regulated protein 78,07/10/2013,Treatment of plasma cell myeloma,EU/3/13/1190,Positive,31/10/2013,18/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1190
,,Carbamazepine,14/10/2016,"Treatment of metaphyseal chondrodysplasia, Schmid type",EU/3/16/1746,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1746
,,Crenolanib besilate,14/10/2016,Treatment of acute myeloid leukaemia,EU/3/16/1748,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1748
,,Tetrofosmin,20/09/2016,Diagnosis of glioma,EU/3/16/1764,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1764
,,Chemically modified human recombinant sulfamidase,14/10/2016,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",EU/3/16/1747,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1747
,,Autologous mononuclear cells derived from human cord blood,14/10/2016,Treatment of neonatal encephalopathy,EU/3/16/1743,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1743
,,Crenolanib besilate,20/09/2016,Treatment of soft tissue sarcoma,EU/3/16/1749,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1749
,,Xenon,14/10/2016,Treatment of ischaemia/reperfusion injury associated with cardiac arrest,EU/3/16/1768,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1768
,,A non-covalent trimer of tumour necrosis factor fused to an antibody specific to the extra-domain B of fibronectin in single-chain variable fragment format,20/09/2016,Treatment of soft tissue sarcoma,EU/3/16/1739,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1739
,,"2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide (also known as F901318)(olorofim)",14/10/2016,Treatment of invasive aspergillosis,EU/3/16/1738,Positive,15/11/2016,15/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1738
,,Autologous mononuclear cells derived from human cord blood,14/10/2016,Treatment of periventricular leukomalacia,EU/3/16/1744,Positive,14/11/2016,14/11/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1744
,,Dexamethasone phosphate,15/05/2009,Treatment of corneal graft rejection,EU/3/09/636,Withdrawn,09/06/2009,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-636
,,Adeno-associated viral vector encoding an inducible short hairpin RNA targeting claudin-5,08/11/2012,Treatment of retinitis pigmentosa,EU/3/12/1069,Withdrawn,13/12/2012,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1069
,,Tralokinumab,08/11/2012,Treatment of idiopathic pulmonary fibrosis,EU/3/12/1061,Withdrawn,13/12/2012,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1061
,,"Vincaleukoblastin-23-oic acid, O4-deacetyl-, 2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine",09/02/2012,Treatment of ovarian cancer,EU/3/12/959,Withdrawn,24/02/2012,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-959
,,"(1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate",05/03/2012,Treatment of soft tissue sarcoma,EU/3/12/966,Withdrawn,19/04/2012,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-966
,,ciclosporin,10/03/2005,Prevention of graft rejection after lung transplantation,EU/3/05/266,Withdrawn,04/12/2007,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-266
,,"2'-deoxyguanosylyl-(3',5'-phosphoryl)-2'-deoxythymidylyl-(3',5'-phosphoryl)- 2'-deoxyguanosylyl-(3',5'-phosphoryl)-2'-deoxycytidylyl-(3',5'-phosphoryl)-2'-deoxycytidylyl -(3',5'-phosphoryl)-2'-deoxycytidylyl-(3',5'-phosphoryl)-2'-deoxyguanosylyl...",10/08/2015,Treatment of diffuse large B-cell lymphoma,EU/3/15/1542,Withdrawn,02/10/2015,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1542
,,Denufosol tetrasodium,23/12/2005,Treatment of cystic fibrosis,EU/3/05/342,Withdrawn,04/07/2007,21/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-342
,,Pseudomonas exotoxin (domains II/III)-interleukin 13 chimeric protein,30/04/2002,Treatment of glioma,EU/3/02/101,Withdrawn,04/12/2007,20/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-101
,,HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS),15/02/2007,Treatment of renal-cell carcinoma,EU/3/07/433,Withdrawn,10/07/2008,20/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-433
,,Obinutuzumab,19/06/2015,Treatment of marginal zone lymphoma,EU/3/15/1505,Withdrawn,27/07/2015,20/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1505
,,Iodine (131I) anti-nucleohistone H1 chimeric biotinylated monoclonal antibody,13/11/2002,Treatment of glioma,EU/3/02/119,Withdrawn,26/05/2003,20/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-119
,,Fimaporfin,29/08/2016,Treatment of cholangiocarcinoma,EU/3/16/1720,Positive,10/10/2016,10/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1720
,,Cannabidiol,29/08/2016,Treatment of graft-versus-host disease,EU/3/16/1718,Positive,10/10/2016,10/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1718
,,methotrexate,29/08/2016,Treatment of alkaptonuria,EU/3/16/1723,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1723
,,temozolomide,29/08/2016,Treatment of glioma,EU/3/16/1733,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1733
,,Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene,29/08/2016,Treatment of Duchenne muscular dystrophy,EU/3/16/1716,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1716
,,L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (cibinetide),29/08/2016,Prevention of graft loss in pancreatic islet transplantation,EU/3/16/1721,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721
,,nintedanib,29/08/2016,Treatment of systemic sclerosis,EU/3/16/1724,Withdrawn,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1724
,,Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues,29/08/2016,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/16/1726,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1726
,,Cisplatin,29/08/2016,Treatment of malignant mesothelioma,EU/3/16/1719,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1719
Prohippur,EMEA/H/C/004150,Sodium benzoate,29/08/2016,Treatment of lysinuric protein intolerance,EU/3/16/1729,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1729
,,Valproic acid,29/08/2016,Treatment of McArdle's disease,EU/3/16/1734,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1734
,,zoledronic acid,29/08/2016,Treatment of glioma,EU/3/16/1735,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1735
Prohippur,EMEA/H/C/004150,Sodium benzoate,29/08/2016,Treatment of ornithine translocase deficiency,EU/3/16/1730,Positive,03/10/2016,03/10/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1730
,,"4-(3,5-Bis(hydroxy-phenyl)-1,2,4) triazol-1-yl) benzoic acid",13/03/2002,Treatment of chronic iron overload requiring chelation therapy,EU/3/02/092,Expired,28/02/2007,30/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-092
,,sitaxentan sodium,21/10/2004,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/04/234,Withdrawn,28/02/2007,30/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-234
,,Dexrazoxane,19/09/2001,Treatment of anthracycline extravasations,EU/3/01/059,Expired,15/06/2009,30/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-059
,,Sodium hypochlorite,14/07/2016,Treatment of partial deep dermal and full-thickness burns,EU/3/16/1709,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1709
,,Adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene,14/07/2016,Treatment of retinitis pigmentosa,EU/3/16/1693,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1693
,,Triheptanoin,14/07/2016,Treatment of McArdle's disease,EU/3/16/1710,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1710
Prohippur,EMEA/H/C/004150,Sodium benzoate,14/07/2016,Treatment of carbamoyl-phosphate synthase-1 deficiency,EU/3/16/1706,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1706
Prohippur,EMEA/H/C/004150,Sodium benzoate,14/07/2016,Treatment of hyperargininaemia,EU/3/16/1708,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1708
,,mifamurtide,14/07/2016,Treatment of echinococcosis,EU/3/16/1699,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1699
,,16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7 amino acid peptide,14/07/2016,Treatment of soft tissue sarcoma,EU/3/16/1690,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1690
,,mifamurtide,14/07/2016,Treatment of hepatocellular carcinoma,EU/3/16/1700,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1700
Prohippur,EMEA/H/C/004150,Sodium benzoate,14/07/2016,Treatment of citrullinaemia type 1,EU/3/16/1707,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1707
Prohippur,EMEA/H/C/004150,Sodium benzoate,14/07/2016,Treatment of ornithine transcarbamylase deficiency,EU/3/16/1705,Positive,06/09/2016,06/09/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1705
,,N-[4-(3-amino-1H-indazol-4 yl)phenyl]-N'-(2-fluoro-5-methylphenyl) urea,20/12/2007,Treatment of hepatocellular carcinoma,EU/3/07/517,Withdrawn,02/07/2008,19/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-517
,,Recombinant antibody construct against human CD30 and CD16A,09/10/2009,Treatment of Hodgkin's lymphoma,EU/3/09/673,Positive,20/10/2009,17/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-673
,,defibrotide,29/07/2004,Treatment of hepatic veno-occlusive disease,EU/3/04/212,Positive,12/12/2005,17/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-212
,,defibrotide,29/07/2004,Prevention of hepatic veno-occlusive disease,EU/3/04/211,Positive,12/12/2005,17/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-211
,,defibrotide,13/11/2013,Prevention of graft-versus-host disease,EU/3/13/1201,Positive,02/12/2013,17/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1201
Heparesc,EMEA/H/C/003750,Human heterologous liver cells,17/12/2010,Treatment of argininosuccinic aciduria,EU/3/10/820,Positive,20/01/2011,16/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-820
Heparesc,EMEA/H/C/003750,Human heterologous liver cells,17/12/2010,Treatment of carbamoyl-phosphate synthase-1 deficiency,EU/3/10/821,Positive,20/01/2011,16/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-821
,,sodium ascorbate;menadione sodium bisulfite,22/08/2014,Treatment of autosomal dominant polycystic liver disease,EU/3/14/1308,Positive,29/09/2014,16/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1308
Heparesc,EMEA/H/C/003750,Human heterologous liver cells,14/09/2007,Treatment of ornithine-transcarbamylase deficiency,EU/3/07/470,Positive,22/01/2008,16/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-470
,,paclitaxel,31/10/2006,Treatment of pancreatic cancer,EU/3/06/419,Positive,02/04/2009,16/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-419
Heparesc,EMEA/H/C/003750,Human heterologous liver cells,08/10/2009,Treatment of citrullinaemia type 1,EU/3/10/818,Positive,19/01/2011,16/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-818
Heparesc,EMEA/H/C/003750,Human heterologous liver cells,17/12/2010,Treatment of hyperargininaemia,EU/3/10/819,Positive,19/01/2011,16/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-819
,,Human heterologous liver cells,11/04/2006,Treatment of acute liver failure,EU/3/06/362,Positive,24/04/2009,15/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-362
,,human apotransferrin,17/07/2012,Treatment of congenital hypotransferrinaemia,EU/3/12/1027,Positive,31/08/2012,15/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1027
,,Chimeric monoclonal antibody to O-acetyl-GD2 antigen,15/01/2015,Treatment of neuroblastoma,EU/3/14/1416,Positive,05/03/2015,15/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1416
,,Metronidazole,21/06/2011,Treatment of pouchitis,EU/3/11/875,Positive,12/07/2011,15/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-875
,,Humanised IgG1 monoclonal antibody against human eotaxin-2,19/11/2014,Treatment of systemic sclerosis,EU/3/14/1371,Positive,16/01/2015,15/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1371
,,Recombinant human lecithin cholesterol acyltransferase,10/10/2012,Treatment of lecithin-cholesterol-acyltransferase deficiency,EU/3/12/1051,Positive,16/11/2012,15/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1051
,,Triheptanoin,06/12/2012,Treatment of very-long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency,EU/3/12/1081,Withdrawn,25/01/2013,12/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1081
,,unoprostone isopropyl,19/06/2013,Treatment of retinitis pigmentosa,EU/3/13/1146,Withdrawn,11/07/2013,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1146
,,Amrubicin hydrochloride,02/04/2008,Treatment of small cell lung cancer,EU/3/08/538,Withdrawn,17/09/2009,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-538
,,Human anthrax immunoglobulin,09/11/2009,Post-exposure prophylaxis of inhalation anthrax disease,EU/3/09/690,Withdrawn,18/11/2009,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-690
,,17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin,28/11/2012,Treatment of retinitis pigmentosa,EU/3/12/1007,Withdrawn,17/12/2012,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1007
,,Chimeric antibody to mesothelin,17/03/2008,Treatment of pancreatic cancer,EU/3/08/536,Withdrawn,10/07/2008,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-536
,,Human anthrax monoclonal antibody,15/04/2011,Treatment of inhalation anthrax disease,EU/3/11/852,Withdrawn,26/04/2011,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-852
,,Human anthrax immunoglobulin,18/11/2009,Treatment of inhalation anthrax disease,EU/3/09/691,Withdrawn,18/11/2009,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-691
,,Triheptanoin,06/12/2012,Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency,EU/3/12/1082,Withdrawn,25/01/2013,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1082
,,Ramucirumab,04/07/2012,Treatment of hepatocellular carcinoma,EU/3/12/1019,Withdrawn,24/07/2012,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1019
,,Human anthrax monoclonal antibody,05/08/2011,For post-exposure prophylaxis of inhalation anthrax disease,EU/3/11/891,Withdrawn,16/08/2011,11/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-891
,,Homoharringtonine,20/10/2004,Treatment of acute myeloid leukaemia,EU/3/04/228,Withdrawn,21/09/2009,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-228
,,Homoharringtonine,02/09/2004,Treatment of chronic myeloid leukaemia,EU/3/04/224,Withdrawn,21/09/2009,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-224
,,2-Chloro-9-[2-deoxy-2-fluoro-ß-D-arabinofuranosyl]adenine,05/02/2002,Treatment of acute lymphoblastic leukaemia,EU/3/01/082,Expired,18/08/2008,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-082
,,Recombinant human bile-salt-stimulated lipase,26/01/2005,Treatment of cystic fibrosis,EU/3/04/257,Withdrawn,11/10/2005,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-257
,,Sorafenib tosilate,29/07/2004,Treatment of renal-cell carcinoma,EU/3/04/207,Expired,23/09/2009,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-207
,,Iodine (123I) Serum Amyloid P,14/02/2003,Diagnosis of the extent of histologically proven amyloidosis,EU/3/03/134,Withdrawn,29/07/2008,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-134
,,Liarozole,10/06/2003,Treatment of congenital ichthyoses,EU/3/03/144,Withdrawn,26/09/2003,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-144
,,Fumagillin,05/02/2002,Treatment of diarrhoea associated with intestinal microsporidial infection,EU/3/01/081,Withdrawn,30/05/2007,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-081
,,Recombinant human acid alpha-glucosidase,15/02/2001,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/01/018,Expired,15/06/2009,10/08/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-018
,,pyridoxine;l-pyroglutamic acid,27/06/2016,Treatment of fragile X syndrome,EU/3/16/1673,Positive,26/07/2016,26/07/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1673
,,Eflornithine,27/06/2016,Treatment of glioma,EU/3/16/1679,Positive,26/07/2016,26/07/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1679
,,Diclofenamide,27/06/2016,Treatment of periodic paralysis,EU/3/16/1677,Positive,26/07/2016,26/07/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1677
,,vemurafenib,30/05/2016,Treatment of Langerhans' cell histiocytosis,EU/3/16/1670,Positive,24/06/2016,24/06/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1670
,,Sodium nitrite;ethylenediaminetetraacetic acid,30/05/2016,Treatment of cystic fibrosis,EU/3/16/1668,Positive,22/06/2016,22/06/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1668
,,Cannabidiol,28/04/2016,Prevention of graft-versus-host disease,EU/3/16/1645,Positive,30/05/2016,30/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1645
,,Recombinant human cerebral dopamine neurotrophic factor,28/04/2016,Treatment of amyotrophic lateral sclerosis,EU/3/16/1652,Positive,30/05/2016,30/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1652
,,Autologous dermal fibroblasts genetically modified ex vivo with a lentiviral vector containing the human COL7A1 gene,28/04/2016,Treatment of epidermolysis bullosa,EU/3/16/1642,Positive,30/05/2016,30/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1642
Alprolix,EMEA/H/C/004142,Recombinant fusion protein consisting of human coagulation factor IX attached to the Fc domain of human IgG1,08/06/2007,Treatment of haemophilia B (congenital factor IX deficiency),EU/3/07/453,Positive,29/07/2008,30/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-453
,,Elotuzumab,09/08/2012,Treatment of multiple myeloma,EU/3/12/1037,Withdrawn,26/09/2012,23/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1037
,,Allopurinol sodium,06/12/2012,Treatment of perinatal asphyxia,EU/3/12/1076,Positive,25/01/2013,23/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1076
,,acalabrutinib,21/03/2016,Treatment of mantle cell lymphoma,EU/3/16/1625,Positive,04/05/2016,04/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1625
,,acalabrutinib,21/03/2016,Treatment of lymphoplasmacytic lymphoma,EU/3/16/1626,Positive,04/05/2016,04/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1626
,,N-acetyl-D-mannosamine monohydrate,21/03/2016,Treatment of GNE myopathy,EU/3/16/1635,Positive,04/05/2016,04/05/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1635
Wakix,EMEA/H/C/002616,"1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride",10/07/2007,Treatment of narcolepsy,EU/3/07/459,Positive,04/12/2007,20/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-459
,,vosaroxin,26/04/2012,Treatment of acute myeloid leukaemia,EU/3/12/990,Positive,18/06/2012,12/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-990
Lumevoq,EMEA/H/C/005047,Adeno-associated viral vector containing the human NADH-dehydrogenase-4 gene,13/05/2011,Treatment of Leber's hereditary optic neuropathy,EU/3/11/860,Positive,27/05/2011,11/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-860
,,afamelanotide,24/07/2009,Treatment of solar urticaria,EU/3/09/648,Positive,11/09/2009,11/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-648
,,,08/05/2008,Treatment of congenital erythropoietic porphyria,EU/3/08/545,Positive,17/09/2009,11/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-545
,,"Human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and non-glycosylated)",27/10/2006,Treatment of renal-cell carcinoma,EU/3/06/417,Positive,29/07/2008,11/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-417
,,afamelanotide,04/07/2014,Treatment of familial benign chronic pemphigus (Hailey-Hailey disease),EU/3/14/1285,Positive,15/07/2014,11/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1285
,,H-D-Asp-D-Gln-D-Ser-D-Arg-D-Pro-D-Val-D-Gln-D-Pro-D-Phe-D-Leu-D-Asn-D-Leu-D-Thr-D-Thr-D-Pro-D-Arg-D-Lys-D-Pro-D-Arg-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-NH2,16/06/2005,"Hearing loss (acute acoustic trauma, sudden deafness and surgery induced acoustic trauma)",EU/3/05/292,Positive,21/09/2009,11/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-292
,,"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine",16/02/2016,Treatment of glioma,EU/3/16/1618,Positive,07/04/2016,07/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1618
,,Tolfenamic acid,17/02/2016,treatment of behavioural variant frontotemporal dementia,EU/3/16/1614,Positive,07/04/2016,07/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1614
,,Tolfenamic acid,17/02/2016,Treatment of progressive supranuclear palsy,EU/3/16/1613,Positive,07/04/2016,07/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1613
,,Ex-vivo-expanded autologous fibroblasts transduced with lentiviral vector containing the COL7A1 gene,17/02/2016,Treatment of epidermolysis bullosa,EU/3/16/1611,Positive,06/04/2016,06/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1611
,,Arsenic trioxide,17/02/2016,Treatment of acute myeloid leukaemia,EU/3/16/1610,Positive,06/04/2016,06/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1610
,,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",17/02/2016,Treatment of C3 glomerulopathy,EU/3/16/1608,Positive,06/04/2016,06/04/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1608
,,Macromolecular conjugate of heparin sodium on a polymer backbone,22/08/2014,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,EU/3/14/1332,Positive,02/10/2014,29/03/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1332
,,Genetically modified Lactococcus lactis bacteria containing the human trefoil factor 1 gene,27/09/2011,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,EU/3/11/903,Positive,17/10/2011,29/03/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-903
,,5-hydroxymethyl-2-furfural,12/02/2015,Treatment of sickle cell disease,EU/3/15/1441,Withdrawn,09/04/2015,10/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1441
,,Verucerfont,10/08/2015,Treatment of congenital adrenal hyperplasia,EU/3/15/1537,Withdrawn,02/10/2015,10/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1537
,,Iodine (131I) anti-tenascin monoclonal antibody 81C6,30/10/2006,Treatment of glioma,EU/3/06/418,Withdrawn,15/06/2009,10/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-418
,,5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine,16/12/2014,Treatment of malignant mesothelioma,EU/3/14/1391,Withdrawn,26/02/2015,10/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1391
,,N-acetylgalactosamine 4-sulfatase,15/02/2001,Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome),EU/3/01/025,Expired,20/02/2009,10/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-025
,,Miltefosine,27/05/2005,Treatment of acanthamoeba keratitis,EU/3/05/282,Positive,23/09/2009,09/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-282
Brineura,EMEA/H/C/004065,Recombinant human tripeptidyl-peptidase 1,12/03/2013,Treatment of neuronal ceroid lipofuscinosis type 2,EU/3/13/1118,Positive,05/04/2013,09/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1118
,,pentosan polysulfate sodium,15/01/2015,Treatment of interstitial cystitis,EU/3/14/1411,Withdrawn,05/03/2015,09/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1411
,,Selinexor,19/11/2014,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/14/1354,Positive,15/01/2015,09/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1354
,,"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide",22/08/2014,Treatment of diffuse large B-cell lymphoma,EU/3/14/1317,Positive,01/10/2014,09/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1317
,,"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide",22/08/2014,Treatment of acute myeloid leukaemia,EU/3/14/1313,Positive,30/09/2014,09/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1313
,,Belinostat,17/07/2013,Treatment of malignant thymoma,EU/3/13/1151,Positive,21/08/2013,08/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1151
,,Belinostat,10/10/2012,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/12/1055,Positive,16/11/2012,08/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1055
,,Ataluren,04/07/2012,Treatment of Becker muscular dystrophy,EU/3/12/1010,Positive,24/07/2012,08/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1010
,,2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate,14/12/2015,Treatment of Charcot-Marie-Tooth disease,EU/3/15/1598,Positive,03/02/2016,03/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1598
,,"Synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-, cyclic (1.fwdarw.17)-disulfide-",14/12/2015,Treatment of pseudohypoaldosteronism 1B,EU/3/15/1591,Positive,03/02/2016,03/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1591
,,-[4-Aminobutanoic acid-glycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-L-aspartyl](cyclo 1-Dgamma17),14/12/2015,Treatment of pseudohypoaldosteronism 1B,EU/3/15/1592,Positive,03/02/2016,03/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1592
Oxervate,EMEA/H/C/004209,Recombinant human nerve growth factor (cenegermin),14/12/2015,Treatment of neurotrophic keratitis,EU/3/15/1586,Positive,02/02/2016,02/02/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1586
,,Ramucirumab,04/07/2012,Treatment of gastric cancer,EU/3/12/1004,Withdrawn,24/07/2012,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1004
,,recombinant modified vaccinia virus Ankara expressing tuberculosis antigen 85A,28/10/2005,Prevention of tuberculosis disease in Bacille-Calmette-Guerin-vaccinated individuals,EU/3/05/318,Withdrawn,23/09/2009,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-318
,,Liposomal daunorubicin,10/10/2012,Treatment of acute myeloid leukaemia,EU/3/12/1056,Withdrawn,16/11/2012,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1056
,,Asp-Arg-Val-Tyr-Ile-His-Pro,10/10/2012,Treatment of acute lung Injury,EU/3/12/1047,Withdrawn,16/11/2012,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1047
,,Sequence-modified recombinant human factor VIIa,08/10/2009,Treatment of haemophilia B,EU/3/09/676,Withdrawn,20/10/2009,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-676
,,Sequence-modified recombinant human factor VIIa,09/10/2009,Treatment of haemophilia A,EU/3/09/675,Withdrawn,20/10/2009,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-675
,,Eculizumab,04/07/2012,Treatment of infection-associated haemolytic uraemic syndrome,EU/3/12/1015,Withdrawn,24/07/2012,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1015
,,levodopa;carbidopa,10/05/2001,Treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations,EU/3/01/035,Withdrawn,03/03/2009,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-035
,,Talarozole,04/07/2012,Treatment of recessive X-linked ichthyosis,EU/3/12/1017,Withdrawn,24/07/2012,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1017
,,sildenafil citrate,12/12/2003,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/03/178,Expired,28/02/2007,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-178
,,Talarozole,04/07/2012,Treatment of autosomal recessive congenital ichthyosis,EU/3/12/1005,Withdrawn,24/07/2012,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1005
,,Fampridine,10/07/2007,Treatment of Guillain-Barré syndrome,EU/3/07/458,Withdrawn,17/01/2008,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-458
,,Recombinant humanised monoclonal antibody to human Nogo-A protein of the IgG1/kappa class,01/10/2010,Treatment of amyotrophic lateral sclerosis,EU/3/10/797,Withdrawn,14/10/2010,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-797
,,"Recombinant human monoclonal antibody against transforming growth factor beta-1, 2 and 3",01/04/2008,Treatment of idiopathic pulmonary fibrosis,EU/3/08/533,Withdrawn,10/07/2008,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-533
,,Fresolimumab,05/08/2011,Treatment of focal segmental glomerulosclerosis,EU/3/11/882,Withdrawn,16/08/2011,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-882
,,Recombinant porcine factor VIII (B-domain-deleted),20/09/2010,Treatment of haemophilia A,EU/3/10/784,Withdrawn,18/10/2010,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-784
,,Talarozole,04/07/2012,Treatment of keratinopathic ichthyosis,EU/3/12/1014,Withdrawn,24/07/2012,19/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1014
,,Ethanol,09/03/2004,Treatment of congenital venous malformations,EU/3/04/191,Withdrawn,28/04/2005,18/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-191
,,Ethanol,09/03/2004,Treatment of congenital lymphatic malformations,EU/3/04/190,Withdrawn,28/04/2005,14/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-190
,,Canakinumab,08/11/2012,Treatment of tumour-necrosis-factor-receptor-associated periodic syndrome,EU/3/12/1071,Withdrawn,17/12/2012,14/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1071
,,Palifosfamide,03/12/2008,Treatment of soft tissue sarcoma,EU/3/08/584,Withdrawn,30/10/2009,14/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-584
,,Adeno-associated viral vector serotype 8 containing the human CNGA3 gene under the control of a cone arrestin promoter,12/12/2016,Treatment of achromatopsia caused by mutations in the CNGA3 gene,EU/3/16/1795,Positive,09/01/2016,09/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1795
,,adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter,11/11/2015,Treatment of Wilson's disease,EU/3/15/1573,Positive,06/01/2016,06/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1573
,,interferon alfa-n3,11/11/2015,Treatment of Middle East respiratory syndrome,EU/3/15/1568,Positive,05/01/2016,05/01/2016,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1568
Blincyto,EMEA/H/C/003731,blinatumomab,24/07/2009,Treatment of acute lymphoblastic leukaemia,EU/3/09/650,Positive,11/09/2009,08/12/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-650
Kyprolis,EMEA/H/C/003790,carfilzomib,03/06/2008,Treatment of multiple myeloma,EU/3/08/548,Positive,17/09/2009,02/12/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-548
,,Cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulfate,30/06/2003,Treatment of pancreatic cancer in combination with ifosfamide,EU/3/03/149,Positive,21/09/2009,26/11/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-149
,,Sirolimus,09/10/2015,Treatment of tuberous sclerosis,EU/3/15/1557,Positive,18/11/2015,18/11/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1557
,,Ataluren,09/10/2015,Treatment of aniridia,EU/3/15/1561,Positive,18/11/2015,18/11/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1561
,,Dronabinol;Cannabidiol,09/10/2015,Treatment of glioma,EU/3/15/1564,Withdrawn,18/11/2015,18/11/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1564
,,Nimodipine,09/10/2015,Treatment of aneurysmal subarachnoid haemorrhage,EU/3/15/1554,Positive,16/11/2015,16/11/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1554
,,Autologous human peripheral blood Vdelta1+ T lymphocytes activated in vitro by cytokine and monoclonal antibody treatment,09/10/2015,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/15/1566,Positive,16/11/2015,16/11/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1566
,,"Synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-, cyclic (1.fwdarw.17)-disulfide",09/10/2015,Treatment of primary graft dysfunction following lung transplantation,EU/3/15/1549,Positive,16/11/2015,16/11/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1549
,,Nalbuphine hydrochloride,27/02/2015,Treatment of uraemic pruritus,-,Negative,02/10/2015,02/10/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-uraemic-pruritus
,,Insulin human,10/08/2015,Treatment of short bowel syndrome,EU/3/15/1532,Positive,02/10/2015,02/10/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1532
,,fosfomycin disodium;Tobramycin,10/08/2015,Treatment of cystic fibrosis,EU/3/15/1538,Positive,02/10/2015,02/10/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1538
,,Sarizotan hydrochloride,28/07/2015,Treatment of Rett syndrome,EU/3/15/1531,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1531
,,Hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]acetate,28/07/2015,Treatment of amyotrophic lateral sclerosis,EU/3/15/1527,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1527
,,Inecalcitol,28/07/2015,Treatment of acute myeloid leukaemia,EU/3/15/1523,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1523
,,"Allogeneic human adult stem cells, isolated from skeletal muscle and expanded ex vivo",28/07/2015,Treatment of Duchenne muscular dystrophy,EU/3/15/1519,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1519
,,"2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride",28/07/2015,Treatment of acute myeloid leukaemia,EU/3/15/1517,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1517
,,Doxorubicin,28/07/2015,Treatment of hepatoblastoma,EU/3/15/1513,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1513
,,Lanreotide acetate,10/08/2015,Treatment of autosomal dominant polycystic kidney disease,EU/3/15/1514,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1514
,,Anti-H5N1 equine immunoglobulin F(ab')2 fragments,28/07/2015,Treatment of avian influenza,EU/3/15/1512,Positive,18/08/2015,18/08/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1512
,,Antisense oligonucleotide directed against TGF-β2 mRNA,19/06/2015,Prevention of scarring post glaucoma filtration surgery,EU/3/15/1506,Positive,27/07/2015,27/07/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1506
,,Allogeneic ex-vivo-expanded human umbilical cord blood-derived mesenchymal stem cells,19/06/2015,Prevention of bronchopulmonary dysplasia,EU/3/15/1503,Positive,27/07/2015,27/07/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1503
,,Allopurinol sodium,21/05/2015,Treatment of perinatal asphyxia,EU/3/15/1493,Positive,30/06/2015,30/06/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1493
,,AASSGVSTPGSAGHDIITEQPRS,12/05/2015,Treatment of Huntington’s disease,EU/3/15/1492,Positive,30/06/2015,30/06/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1492
,,"1-(4-{4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea",06/06/2012,Treatment of ovarian cancer,EU/3/12/1001,Withdrawn,04/07/2012,08/06/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1001
,,Pomalidomide,26/04/2012,Treatment of systemic sclerosis,EU/3/12/986,Withdrawn,18/06/2012,08/06/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-986
,,Chimeric monoclonal antibody against kappa myeloma antigen,22/05/2012,Treatment of multiple myeloma,EU/3/12/962,Withdrawn,06/07/2012,08/06/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-962
,,"1-(4-{4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea",27/10/2011,Treatment of acute myeloid leukaemia,EU/3/11/915,Withdrawn,23/11/2011,08/06/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-915
,,Paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe,04/06/2014,Treatment of glioma,EU/3/14/1274,Positive,10/07/2014,27/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1274
,,Exon 51 specific phosphorothioate oligonucleotide,27/02/2009,Treatment of Duchenne muscular dystrophy,EU/3/08/599,Positive,29/06/2009,27/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-599
,,Sodium 2-hydroxylinoleate,24/04/2015,Treatment of neuroblastoma,EU/3/15/1485,Positive,22/05/2015,22/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1485
,,Xenon,24/04/2015,Treatment of perinatal asphyxia,EU/3/15/1483,Positive,22/05/2015,22/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1483
,,Recombinant monoclonal IgG1 antibody against T-cell immune response cDNA 7,24/04/2015,Prevention of graft rejection following solid organ transplantation,EU/3/15/1479,Positive,22/05/2015,22/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1479
,,Rintatolimod,24/04/2015,Treatment of Ebola virus disease,EU/3/15/1480,Positive,22/05/2015,22/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1480
,,Human reovirus type 3 Dearing strain,24/04/2015,Treatment of pancreatic cancer,EU/3/15/1477,Positive,21/05/2015,21/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1477
,,1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride,24/04/2015,Treatment of tularaemia,EU/3/15/1476,Positive,21/05/2015,21/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1476
,,1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride,24/04/2015,Treatment of cryptococcosis,EU/3/15/1475,Positive,21/05/2015,21/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1475
,,Fluciclovine (18F),24/04/2015,Diagnosis of glioma,EU/3/15/1472,Positive,21/05/2015,21/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1472
,,"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",19/03/2015,Treatment of adenovirus infection following haematopoietic stem cell transplantation,EU/3/15/1438,Positive,19/05/2015,19/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1438
,,"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",19/03/2015,Treatment of Epstein-Barr virus infection following haematopoietic stem cell transplantation,EU/3/15/1440,Positive,19/05/2015,19/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1440
,,Repertaxin L-lysine salt,19/09/2001,Prevention of delayed graft function in organ transplant,EU/3/01/058,Positive,15/05/2009,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-058
,,Recombinant human nerve growth factor,07/06/2013,Treatment of retinitis pigmentosa,EU/3/13/1135,Positive,25/06/2013,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1135
,,Reparixin,27/09/2011,Prevention of graft loss in pancreatic islet transplantation,EU/3/11/912,Positive,17/10/2011,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-912
,,Sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH,29/07/2014,Treatment of necrotising soft tissue infections,EU/3/14/1294,Positive,01/09/2014,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1294
,,ciclosporin,29/10/2007,Treatment of herpes simplex virus stromal keratitis,EU/3/07/489,Positive,02/07/2008,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-489
,,Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs,20/09/2010,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",EU/3/10/772,Positive,18/10/2010,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-772
,,ciclosporin,22/10/2007,Prevention of corneal graft rejection,EU/3/07/455,Positive,02/07/2008,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-455
,,Adeno-associated viral vector serotype rh.rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA,16/12/2014,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",EU/3/14/1389,Positive,26/02/2015,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1389
,,2-iminobiotin,28/01/2010,Treatment of perinatal asphyxia,EU/3/09/701,Positive,25/02/2010,13/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-701
,,"Sodium 3-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo [3,2-d][1,3,2] dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H-imidazo[1,2-a]purin-9-one",19/03/2015,Treatment of retinitis pigmentosa,EU/3/15/1462,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1462
,,Recombinant human club cell 10 KDa protein,19/03/2015,Prevention of bronchopulmonary dysplasia,EU/3/15/1456,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1456
,,Human reovirus type 3 Dearing strain,19/03/2015,Treatment of ovarian cancer,EU/3/15/1469,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1469
,,Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a LAMB3-encoding retroviral vector,19/03/2015,Treatment of epidermolysis bullosa,EU/3/15/1465,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1465
,,Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL7A1-encoding retroviral vector,19/03/2015,Treatment of epidermolysis bullosa,EU/3/15/1466,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1466
,,Autologous adipose tissue-derived stromal vascular fraction cells,19/03/2015,Treatment of systemic sclerosis,EU/3/15/1464,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1464
,,Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL17A1-encoding retroviral vector,19/03/2015,Treatment of epidermolysis bullosa,EU/3/15/1467,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1467
,,"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one",19/03/2015,Treatment of Netherton syndrome,EU/3/15/1454,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1454
,,"5,10,15,20-tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl)bacteriochlorin (redaporfin)",19/03/2015,Treatment of biliary tract cancer,EU/3/15/1470,Positive,11/05/2015,11/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1470
,,Tositumomab,14/02/2003,Treatment of follicular lymphoma,EU/3/03/137,Withdrawn,12/12/2005,09/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-137
,,nitisinone,30/12/2000,Treatment of tyrosinaemia type 1,EU/3/00/012,Expired,03/03/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-012
,,Ruxolitinib,19/02/2014,Treatment of polycythaemia vera,EU/3/14/1244,Withdrawn,02/04/2014,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1244
,,ziconotide,09/07/2001,Treatment of chronic pain requiring intraspinal analgesia,EU/3/01/048,Expired,19/07/2007,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-048
,,Lestaurtinib,25/07/2006,Treatment of acute myeloid leukaemia,EU/3/06/389,Withdrawn,24/02/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-389
,,Iodine (131I) tositumomab,14/02/2003,Treatment of follicular lymphoma,EU/3/03/136,Withdrawn,12/12/2005,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-136
,,Mixture of recombinant human IgG1 monoclonal antibodies against human cytomegalovirus envelope glycoproteins,20/02/2014,Prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection,EU/3/14/1235,Withdrawn,01/04/2014,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1235
,,Glutathione-pegylated liposomal doxorubicin hydrochloride,20/09/2010,Treatment of glioma,EU/3/10/781,Withdrawn,18/10/2010,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-781
,,Allogeneic ex-vivo-expanded umbilical-cord blood cells,27/02/2009,Treatment of acute myeloid leukaemia,EU/3/09/619,Withdrawn,30/10/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-619
,,Allogeneic ex-vivo-expanded umbilical-cord blood cells,27/02/2009,Treatment of acute lymphoblastic leukaemia,EU/3/09/618,Withdrawn,30/10/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-618
,,Allogeneic ex-vivo-expanded umbilical-cord blood cells,08/10/2009,Treatment of myelodysplastic syndromes,EU/3/09/664,Withdrawn,20/10/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-664
,,Allogeneic ex-vivo-expanded umbilical-cord blood cells,08/10/2009,Treatment of chronic myeloid leukaemia,EU/3/09/665,Withdrawn,20/10/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-665
,,Allogeneic ex-vivo-expanded umbilical-cord blood cells,24/07/2009,Treatment of Hodgkin's lymphoma,EU/3/09/649,Withdrawn,11/09/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-649
,,"(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate",03/04/2009,Treatment of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia,EU/3/09/620,Withdrawn,28/04/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-620
,,"(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate",07/11/2008,Treatment of chronic idiopathic myelofibrosis,EU/3/08/572,Withdrawn,29/06/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-572
,,"5-(2,6-Difluoro-phenoxy)-3(R,S)-{2(S)-[2(S)-(3-methoxycarbonyl-2(S)-{3-methyl-2(S)-[(quinoline-2-carbonyl)-amino]-butyrylamino}-propionylamino)-3-methyl-butyrylamino]-propionylamino}-4-oxo-pentanoic acid methyl ester",23/10/2006,Treatment of neonatal brain injury,EU/3/06/403,Withdrawn,30/10/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-403
,,"2,3,4,5 Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride",21/01/2009,Treatment of Huntington’s disease,EU/3/08/597,Withdrawn,15/06/2009,08/05/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-597
,,Lactobacillus reuteri,12/02/2015,Prevention of necrotising enterocolitis,EU/3/15/1436,Positive,09/04/2015,09/04/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1436
,,"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",12/02/2015,Treatment of cytomegalovirus infection following haematopoietic stem cell transplantation,EU/3/15/1439,Positive,09/04/2015,09/04/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1439
,,Nitroglycerin,12/02/2015,Treatment of systemic sclerosis,EU/3/15/1435,Positive,08/04/2015,08/04/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1435
,,filgrastim,07/11/2008,Treatment of spinal cord injury,EU/3/08/580,Positive,24/04/2009,26/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-580
,,Eculizumab,26/03/2014,Prevention of graft rejection following solid organ transplantation,EU/3/14/1254,Withdrawn,06/05/2014,26/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1254
,,"Pancreatic enzymes (cross linked enzyme crystal lipase, protease, amylase)",02/09/2004,Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency,EU/3/04/222,Positive,18/08/2008,26/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-222
,,filgrastim,01/04/2008,Treatment of amyotrophic lateral sclerosis,EU/3/08/532,Positive,10/07/2008,26/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-532
,,N-butyldeoxygalactonojirimycin,09/08/2012,Treatment of Fabry disease,EU/3/12/1033,Positive,27/09/2012,24/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1033
,,"R,S-O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride",26/04/2013,Treatment of Duchenne muscular dystrophy,EU/3/13/1122,Positive,14/05/2013,24/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1122
,,Glufosfamide,15/04/2011,Treatment of pancreatic cancer,EU/3/11/851,Positive,26/04/2011,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-851
,,ciclosporin,10/03/2005,Treatment of graft rejection after lung transplantation,EU/3/05/265,Withdrawn,04/12/2007,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-265
,,Herpes simplex virus lacking infected cell protein 34.5,09/07/2003,Treatment of glioma,EU/3/03/153,Positive,23/10/2003,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-153
,,Autologous dendritic cells pulsed with allogeneic tumour cell lysate,16/01/2014,Treatment of malignant mesothelioma,EU/3/13/1229,Positive,24/03/2014,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1229
,,Cenersen,03/12/2008,Treatment of chronic lymphocytic leukaemia,EU/3/08/587,Positive,29/06/2009,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-587
,,5-Methyl-pyridine-2-sulfonic acid{6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt,12/12/2003,Treatment of aneurysmal subarachnoid haemorrhage,EU/3/03/182,Positive,12/12/2005,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-182
,,Antisense NF-kBp65 oligonucleotide,30/07/2002,Treatment of active ulcerative colitis,EU/3/02/106,Positive,23/01/2003,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-106
,,Antisense oligonucleotide 5'-d[P-Thio] (CCCTG CTCCC CCCTG GCTCC)-3',03/11/2006,Treatment of acute myeloid leukaemia,EU/3/06/416,Positive,02/04/2009,23/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-416
,,"2,2-Dimethylbutyric acid, sodium salt",27/02/2009,Treatment of beta thalassaemia intermedia and major,EU/3/09/617,Positive,29/06/2009,20/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-617
,,"2,2-Dimethylbutyric acid, sodium salt",18/03/2009,Treatment of sickle cell disease,EU/3/09/621,Positive,08/04/2009,20/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-621
,,"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",30/08/2011,Treatment of tuberculosis,EU/3/11/897,Positive,21/09/2011,12/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-897
,,Clonidine hydrochloride,27/10/2011,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,EU/3/11/919,Positive,23/11/2011,12/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-919
,,Bilayer engineered skin composed of keratinocytes from the patient (autologous) and fibroblasts from a donor (allogeneic) embedded in a plasma matrix,22/05/2006,Treatment of epidermolysis bullosa,EU/3/06/369,Positive,15/05/2009,11/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-369
,,"3-[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid (ataluren)",27/05/2005,Treatment of Duchenne muscular dystrophy,EU/3/05/278,Positive,04/07/2007,10/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-278
,,"5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine",28/03/2014,Treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive,-,Negative,10/03/2015,10/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-non-small-cell-lung-cancer-nsclc-anaplastic-lymphoma-kinase-alk-positive
,,sodium ascorbate;menadione sodium bisulfite,11/12/2014,Treatment of autosomal dominant polycystic kidney disease,-,Negative,10/03/2015,10/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-autosomal-dominant-polycystic-kidney-disease
,,Vatreptacog alfa (activated),09/08/2012,Treatment of haemophilia B,EU/3/12/1032,Withdrawn,27/09/2012,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1032
,,Maytansinoid-conjugated humanised monoclonal antibody against CD56,09/06/2010,Treatment of Merkel cell carcinoma,EU/3/10/746,Withdrawn,23/06/2010,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-746
,,Pegylated recombinant factor VIIa,04/06/2008,Treatment of  haemophilia A,EU/3/08/551,Withdrawn,18/08/2008,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-551
,,N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide benzenesulfonic acid salt,16/03/2014,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/13/1234,Withdrawn,24/03/2014,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1234
,,Recombinant fusion protein consisting of the extracellular portion of human activin receptor IIB linked to the human IgG1 Fc domain,26/11/2010,Treatment of Duchenne muscular dystrophy,EU/3/10/812,Withdrawn,17/12/2010,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-812
,,Pegylated recombinant factor VIIa,03/06/2008,Treatment of haemophilia B,EU/3/08/552,Withdrawn,18/08/2008,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-552
,,Adeno-associated viral vector serotype 8 containing the human AIPL1 gene,09/12/2011,Treatment of Leber's congenital amaurosis type 4,EU/3/11/929,Withdrawn,20/12/2011,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-929
,,Zinc acetate dihydrate,31/07/2001,Treatment of Wilson's disease,EU/3/01/050,Expired,03/03/2009,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-050
,,Chimeric anti-interleukin-6 monoclonal antibody,12/06/2009,Treatment of multiple myeloma,EU/3/09/642,Withdrawn,01/07/2009,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-642
,,Recombinant human monoclonal antibody to human interleukin (IL)-17A of the IgG1/k class,02/02/2010,Treatment of chronic non-infectious uveitis,EU/3/09/724,Withdrawn,04/03/2010,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-724
,,Maytansinoid-conjugated humanised monoclonal antibody against CD56,01/10/2010,Treatment of small cell lung cancer,EU/3/10/792,Withdrawn,14/10/2010,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-792
,,Recombinant human rod-derived cone viability factor,29/11/2007,Treatment of retinitis pigmentosa,EU/3/07/500,Withdrawn,23/09/2009,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-500
,,Ibuprofen,15/02/2001,Treatment of patent ductus arteriosus,EU/3/01/020,Expired,15/05/2009,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-020
,,Maytansinoid-conjugated humanised monoclonal antibody against CD56,23/02/2011,Treatment of multiple myeloma,EU/3/10/835,Withdrawn,04/03/2011,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-835
,,Plerixafor,09/12/2011,Adjunctive treatment to cytotoxic therapy in acute myeloid leukaemia,EU/3/11/931,Withdrawn,20/12/2011,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-931
,,Pegylated recombinant anti-Pseudomonas aeruginosa antibody,05/08/2013,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,EU/3/13/1178,Withdrawn,13/09/2013,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1178
,,"1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea",20/09/2010,Treatment of acute myeloid leukaemia,EU/3/10/770,Withdrawn,18/10/2010,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-770
,,Vatreptacog alfa (activated),09/08/2012,Treatment of haemophilia A,EU/3/12/1030,Withdrawn,27/09/2012,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1030
,,emtricitabine,15/01/2015,Treatment of Aicardi-Goutières syndrome,EU/3/14/1420,Positive,06/03/2015,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1420
,,Ceftriaxone,15/01/2015,Treatment of spinocerebellar ataxia,EU/3/14/1425,Positive,06/03/2015,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1425
,,Recombinant human alkaline phosphatase,15/01/2015,Treatment of hypophosphatasia,EU/3/14/1427,Positive,06/03/2015,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1427
,,Tazarotene,18/12/2006,Treatment of congenital ichthyoses,EU/3/06/423,Withdrawn,02/04/2009,06/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-423
,,Herpes simplex type 1 virus containing cellular B-myb gene as tumour-specific promoter,15/01/2015,Treatment of pancreatic cancer,EU/3/14/1412,Positive,05/03/2015,05/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1412
,,Adenoviral vector serotype 5 containing the vascular endothelial growth factor D isoform (preprocessed short form) from a CMV promoter,15/01/2015,Treatment of placental insufficiency,EU/3/14/1415,Positive,05/03/2015,05/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1415
,,"A lentiviral vector pseudotyped by the Indiana serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins",15/01/2015,Treatment of adult T-cell leukaemia/lymphoma,EU/3/14/1417,Positive,05/03/2015,05/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1417
,,"A lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins",15/01/2015,Treatment of adult T-cell leukaemia/lymphoma,EU/3/14/1418,Positive,05/03/2015,05/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1418
,,tenofovir disoproxil fumarate,15/01/2015,Treatment of Aicardi-Goutières syndrome,EU/3/14/1419,Positive,05/03/2015,05/03/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1419
,,Allogeneic adipose-derived adult mesenchymal stem cells contained in a fibrin-based bioengineered dermis,16/12/2014,Treatment of epidermolysis bullosa,EU/3/14/1407,Positive,27/02/2015,27/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1407
,,"5,5'-(4-(trifluromethyl)benzylazanediyl)bis(methylene)diquinolin-8-ol",16/12/2014,Treatment of glioma,EU/3/14/1408,Positive,27/02/2015,27/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1408
,,Benserazide hydrochloride,16/12/2014,Treatment of beta thalassaemia intermedia and major,EU/3/14/1402,Positive,27/02/2015,27/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1402
,,Plerixafor,16/12/2014,Treatment of WHIM syndrome,EU/3/14/1403,Positive,27/02/2015,27/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1403
,,Riluzole,16/12/2014,Treatment of traumatic spinal cord injury,EU/3/14/1401,Positive,27/02/2015,27/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1401
,,Amikacin sulfate,16/12/2014,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,EU/3/14/1397,Positive,26/02/2015,26/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1397
,,Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells,16/12/2014,Treatment of acute myeloid leukaemia,EU/3/14/1395,Positive,26/02/2015,26/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1395
,,Allogeneic bone marrow derived mesenchymal cells expanded ex vivo in synthetic media,16/12/2014,Prevention of graft-versus-host disease,EU/3/14/1388,Positive,26/02/2015,26/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1388
,,Exisulind,16/12/2014,Treatment of familial cerebral cavernous malformations,EU/3/14/1387,Positive,26/02/2015,26/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1387
,,"5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidine-4,6-diamine",16/12/2014,Treatment of Huntington’s disease,EU/3/14/1392,Positive,26/02/2015,26/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1392
,,,16/12/2014,Treatment of WHIM syndrome,EU/3/14/1384,Positive,26/02/2015,26/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1384
,,Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class,05/02/2008,Treatment of systemic-onset juvenile idiopathic arthritis,EU/3/08/527,Withdrawn,29/07/2008,12/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-527
,,Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class,20/03/2007,"Treatment of cryopirin-associated periodic syndromes (FCUS, MWS, and NOMID)",EU/3/07/439,Withdrawn,08/04/2009,12/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-439
,,Recombinant human monoclonal antibody to hsp90,05/12/2001,Treatment of invasive fungal infections,EU/3/01/073,Withdrawn,12/03/2009,12/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-073
,,Patupilone,05/11/2009,Treatment of primary peritoneal cancer,EU/3/09/687,Withdrawn,18/11/2009,11/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-687
,,Panobinostat lactate,02/08/2007,Treatment of cutaneous T-cell lymphoma,EU/3/07/464,Withdrawn,22/01/2008,11/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-464
,,Panobinostat,02/02/2010,Treatment of Hodgkin's lymphoma,EU/3/09/721,Withdrawn,04/03/2010,11/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-721
,,Nilotinib hydrochloride monohydrate,13/04/2007,Treatment of gastrointestinal stromal tumours,EU/3/07/447,Withdrawn,29/07/2008,10/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-447
,,"N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide",25/11/2009,Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome),EU/3/09/697,Withdrawn,10/12/2009,10/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-697
,,imatinib mesilate,15/02/2001,Treatment of chronic myeloid leukaemia,EU/3/01/021,Expired,28/02/2007,10/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-021
,,imatinib mesilate,26/08/2005,Treatment of  mastocytosis,EU/3/05/306,Withdrawn,04/12/2007,10/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-306
,,imatinib mesilate,26/08/2005,Treatment of acute lymphoblastic leukaemia,EU/3/05/304,Expired,28/02/2007,10/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-304
,,imatinib mesilate,20/11/2001,Treatment of malignant gastrointestinal stromal tumours,EU/3/01/061,Expired,29/11/2005,09/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-061
,,imatinib mesilate,23/12/2005,Treatment of myelodysplastic / myeloproliferative diseases,EU/3/05/340,Expired,28/02/2007,09/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-340
,,imatinib mesilate,28/10/2005,Treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome,EU/3/05/320,Expired,28/02/2007,09/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-320
,,imatinib mesilate,26/08/2005,Treatment of  dermatofibrosarcoma protuberans,EU/3/05/305,Expired,28/02/2007,09/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-305
,,everolimus,14/11/2007,Treatment of gastro-entero-pancreatic neuroendocrine tumours,EU/3/07/488,Withdrawn,02/07/2008,09/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-488
,,everolimus,30/08/2011,Treatment of gastric cancer,EU/3/11/894,Withdrawn,21/09/2011,09/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-894
,,Epothilone B,22/03/2002,Treatment of ovarian cancer,EU/3/02/098,Withdrawn,11/06/2003,09/02/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-098
,,Chloroquine,19/11/2014,Treatment of glioma,EU/3/14/1377,Positive,16/01/2015,16/01/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1377
,,Adeno-associated viral vector serotype 8 containing the human MD1 gene,19/11/2014,Treatment of Duchenne muscular dystrophy,EU/3/14/1381,Positive,16/01/2015,16/01/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1381
,,Dantrolene sodium,19/11/2014,Treatment of malignant hyperthermia,EU/3/14/1379,Positive,16/01/2015,16/01/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1379
,,Olaptesed pegol,19/11/2014,Treatment of glioma,EU/3/14/1364,Positive,15/01/2015,15/01/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1364
,,Bazedoxifene acetate,19/11/2014,Treatment of hereditary haemorrhagic telangiectasia,EU/3/14/1367,Positive,15/01/2015,15/01/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1367
,,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid (lanifibranor),19/11/2014,Treatment of idiopathic pulmonary fibrosis,EU/3/14/1362,Positive,15/01/2015,15/01/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1362
,,Obinutuzumab,22/08/2014,Treatment of diffuse large B-cell lymphoma,EU/3/14/1325,Positive,02/10/2014,01/01/2015,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1325-0
Dropcys,EMEA/H/C/004038,Cysteamine hydrochloride,15/10/2014,Treatment of cystinosis,EU/3/14/1341,Positive,12/11/2014,12/11/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1341
,,,15/10/2014,Treatment of fragile X syndrome,EU/3/14/1334,Positive,12/11/2014,12/11/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1334
,,Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec),15/10/2014,Treatment of Crigler-Najjar syndrome,EU/3/14/1338,Positive,12/11/2014,12/11/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1338
,,Cultured allogeneic corneal limbal stem cells,15/10/2014,Treatment of limbal stem cell deficiency,EU/3/14/1340,Positive,12/11/2014,12/11/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1340
,,Raxibacumab,15/10/2014,Treatment of inhalation anthrax disease,EU/3/14/1352,Positive,12/11/2014,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1352
,,Nitric oxide,15/10/2014,Treatment of cystic fibrosis,EU/3/14/1344,Positive,12/11/2014,12/11/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1344
,,Pyridoxal 5'-phosphate,15/10/2014,Treatment of pyridoxamine 5'-phosphate oxidase deficiency,EU/3/14/1347,Positive,12/11/2014,12/11/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1347
,,Progesterone,08/02/2013,Treatment of moderate and severe traumatic brain injury,EU/3/13/1101,Withdrawn,04/03/2013,16/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1101
,,Recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem-cell antigen,24/01/2013,Treatment of pancreatic cancer,EU/3/12/1090,Positive,01/03/2013,16/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1090
,,Glutathione,11/04/2006,Treatment of cystic fibrosis,EU/3/06/361,Withdrawn,15/05/2009,16/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-361
,,Recombinant inhibitor of human plasma kallikrein,18/12/2002,Treatment of angioedema,EU/3/02/126,Withdrawn,23/09/2009,16/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-126
,,Adeno-associated viral vector serotype 5 containing the human ABCA4 gene,07/02/2009,Treatment of Stargardt's disease,EU/3/08/609,Withdrawn,30/10/2009,16/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-609
,,2-Chloro-9-[2-deoxy-2-fluoro-ß-D-arabinofuranosyl]adenine,08/05/2003,Treatment of acute myeloid leukaemia,EU/3/03/141,Withdrawn,18/08/2008,16/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-141
,,Recombinant human interleukin-21,02/09/2004,Treatment of renal-cell carcinoma,EU/3/04/226,Withdrawn,01/10/2004,16/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-226
Vyxeos liposomal (previously Vyxeos),EMEA/H/C/004282,cytarabine;daunorubicin,11/01/2012,Treatment of acute myeloid leukaemia,EU/3/11/942,Positive,01/02/2012,08/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-942
,,Lipopolysaccharide of Ochrobactrum intermedium,11/01/2012,Prevention of sepsis in at-risk premature infants of less than or equal to 32 weeks,EU/3/11/941,Positive,01/02/2012,08/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-941
,,Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector,30/04/2009,Treatment of dystrophic epidermolysis bullosa,EU/3/09/630,Positive,12/05/2009,07/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-630
,,Peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis,09/11/2009,Treatment of myasthenia gravis,EU/3/09/689,Positive,18/11/2009,07/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-689
,,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",22/10/2014,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/14/1327,Positive,02/10/2014,02/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1327
,,"Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gene under the control of the human thyroxine binding globulin promoter",22/08/2014,Treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE),EU/3/14/1326,Positive,02/10/2014,02/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1326
,,2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide,22/08/2014,Treatment of small cell lung cancer,EU/3/14/1324,Positive,02/10/2014,02/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1324
,,"[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone",22/08/2014,Treatment of pancreatic cancer,EU/3/14/1323,Positive,02/10/2014,02/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1323
,,Humanised IgG1 monoclonal antibody against human KIR3DL2,22/08/2014,Treatment of cutaneous T-cell lymphoma,EU/3/14/1322,Positive,01/10/2014,01/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1322
,,Recombinant human diamine oxidase,22/08/2014,Treatment of mastocytosis,EU/3/14/1320,Positive,01/10/2014,01/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1320
,,Ulinastatin,22/08/2014,Treatment of acute pancreatitis,EU/3/14/1318,Positive,01/10/2014,01/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1318
,,Recombinant human apolipoprotein A-I in a complex with phospholipids,22/08/2014,Treatment of apolipoprotein A-I deficiency,EU/3/14/1315,Positive,01/10/2014,01/10/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1315
,,Recombinant human apolipoprotein A-I in a complex with phospholipids,22/08/2014,Treatment of ATP-binding cassette transporter A1 deficiency,EU/3/14/1314,Positive,30/09/2014,30/09/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1314
,,Retinol,22/08/2014,Prevention of bronchopulmonary dysplasia,EU/3/14/1307,Positive,29/09/2014,29/09/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1307
,,Cysteamine bitartrate (gastroresistant) (mercaptamine),29/07/2014,Treatment of Huntington’s disease,EU/3/14/1306,Positive,01/09/2014,01/09/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1306
,,Rilotumumab,29/07/2014,Treatment of gastric cancer,EU/3/14/1291,Positive,01/09/2014,01/09/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1291
,,Cediranib,29/07/2014,Treatment of ovarian cancer,EU/3/14/1303,Positive,01/09/2014,01/09/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1303
,,N-carbamyl-L-glutamic acid,18/10/2000,Treatment of N-acetylglutamate synthetase (NAGS) deficiency,EU/3/00/007,Expired,03/03/2009,25/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-007
,,Norursodeoxycholic acid,04/07/2014,Treatment of primary sclerosing cholangitis,EU/3/14/1288,Positive,16/07/2014,16/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1288
,,Temocillin sodium,14/01/2004,Treatment of Burkholderia cepacia lung infection in cystic fibrosis,EU/3/03/183,Positive,23/09/2004,14/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-183
,,Recombinant human interleukin-7,04/07/2012,Treatment of progressive multifocal leukoencephalopathy,EU/3/12/1013,Positive,24/07/2012,14/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1013
,,methotrexate,24/10/2007,Treatment of acute lymphoblastic leukaemia,EU/3/07/495,Positive,02/07/2008,11/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-495
,,Aganirsen,10/06/2014,Treatment of central retinal vein occlusion,EU/3/14/1275,Positive,10/07/2014,10/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1275
,,Autologous dendritic cells pulsed with RNA from glioma stem cells,04/06/2014,Treatment of glioma,EU/3/14/1273,Positive,10/07/2014,10/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1273
,,177Lu-tetraxetan-tetulomab,04/06/2014,Treatment of follicular lymphoma,EU/3/14/1271,Positive,10/07/2014,10/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1271
,,"Plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a non-viral, cationic lipid based gene transfer agent",04/06/2014,Treatment of cystic fibrosis,EU/3/14/1277,Positive,10/07/2014,10/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1277
,,4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid,04/06/2014,Prevention of scarring post glaucoma filtration surgery,EU/3/14/1279,Positive,10/07/2014,10/07/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1279
,,Mitotane,12/06/2002,Treatment of adrenal cortical carcinoma,EU/3/02/102,Expired,29/11/2005,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-102
,,Ombrabulin,15/04/2011,Treatment of soft tissue sarcoma,EU/3/11/853,Withdrawn,26/04/2011,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-853
,,melatonin,11/04/2005,Treatment of non-24-hour sleep-wake disorders in blind people with no light perception,EU/3/05/274,Withdrawn,27/10/2005,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-274
,,Lentiviral vector containing the human Wiskott Aldrich Syndrome Protein gene,24/01/2006,Treatment of Wiskott-Aldrich syndrome,EU/3/05/345,Withdrawn,24/04/2009,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-345
,,Kifunensine,27/09/2011,Treatment of gamma sarcoglycanopathy,EU/3/11/908,Withdrawn,17/10/2011,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-908
,,Kifunensine,27/09/2011,Treatment of delta sarcoglycanopathy,EU/3/11/907,Withdrawn,17/10/2011,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-907
,,Kifunensine,27/09/2011,Treatment of beta sarcoglycanopathy,EU/3/11/906,Withdrawn,17/10/2011,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-906
,,Kifunensine,27/09/2011,Treatment of alpha-sarcoglycanopathy,EU/3/11/905,Withdrawn,17/10/2011,19/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-905
,,Iodine (131I) chimeric IgG monoclonal antibody cG250,19/03/2002,Treatment of renal-cell carcinoma,EU/3/02/095,Withdrawn,06/01/2003,18/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-095
,,Cladribine,18/09/2001,Treatment of indolent non-Hodgkin's lymphoma,EU/3/01/055,Expired,29/11/2005,18/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-055
,,Adeno-associated viral vector containing the human gamma-sarcoglycan gene,21/10/2004,Treatment of gamma sarcoglycanopathy,EU/3/04/233,Withdrawn,11/10/2005,18/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-233
Deltyba,EMEA/H/C/002552,"(R)-2-Methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole (delamanid)",02/02/2008,Treatment of tuberculosis,EU/3/07/524,Positive,10/07/2008,18/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-524
,,Adeno-associated viral vector containing the human alpha-sarcoglycan gene,07/11/2008,Treatment of alpha-sarcoglycanopathy,EU/3/08/573,Withdrawn,02/04/2009,18/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-573
,,Adeno-associated viral vector containing the human calpain 3 gene,06/04/2006,Treatment of calpainopathy,EU/3/06/359,Withdrawn,24/02/2009,18/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-359
Blectifor,EMEA/H/C/004100,Caffeine citrate,11/04/2014,Prevention of bronchopulmonary dysplasia,EU/3/14/1261,Positive,05/06/2014,05/06/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1261
,,Recombinant human vascular endothelial growth factor,29/01/2010,Treatment of amyotrophic lateral sclerosis,EU/3/09/711,Positive,25/02/2010,12/05/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-711
,,"5'-O-(trans-9""-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine",14/09/2007,Treatment of acute myeloid leukaemia,EU/3/07/476,Positive,29/07/2008,08/05/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-476
,,Bosentan,18/03/2003,Treatment of systemic sclerosis (scleroderma),EU/3/03/139,Withdrawn,30/05/2007,08/05/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-139
,,Bosentan,05/09/2008,Treatment of idiopathic pulmonary fibrosis,EU/3/08/559,Withdrawn,02/04/2009,08/05/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-559
,,Volasertib,26/03/2014,Treatment of acute myeloid leukaemia,EU/3/14/1255,Positive,06/05/2014,06/05/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1255
,,Ex-vivo cultured human mesenchymal stromal cells,26/03/2014,Prevention of graft rejection following solid organ transplantation,EU/3/14/1253,Positive,06/05/2014,06/05/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1253
,,Cysteamine bitartrate (gastroresistant) (mercaptamine),26/03/2014,Treatment of pancreatic cancer,EU/3/14/1252,Positive,06/05/2014,06/05/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1252
,,Vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar,08/06/2004,Prevention of stenosis in synthetic grafts used in haemodialysis,EU/3/04/201,Positive,06/12/2004,03/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-201
,,Sacrosidase,05/08/2013,Treatment of congenital sucrase-isomaltase deficiency,EU/3/13/1183,Positive,16/09/2013,03/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1183
,,Recombinant human serum amyloid P,09/10/2009,Prevention of scarring post glaucoma filtration surgery,EU/3/09/674,Withdrawn,20/10/2009,03/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-674
,,pioglitazone,19/02/2014,Treatment of adrenoleukodystrophy,EU/3/14/1245,Positive,02/04/2014,02/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1245
,,Recombinant homodimer of the human annexin V,11/01/2012,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,EU/3/11/946,Withdrawn,01/02/2012,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-946
,,Picoplatin,06/12/2007,Treatment of small cell lung cancer,EU/3/07/502,Withdrawn,02/07/2008,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-502
,,Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh,21/06/2011,Treatment of epidermolysis bullosa,EU/3/11/873,Withdrawn,12/07/2011,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-873
,,ascorbic acid,01/04/2008,Treatment of Charcot-Marie-Tooth disease type 1A,EU/3/08/531,Positive,10/07/2008,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-531
,,16-base single-stranded PNA oligonucleotide linked to a 7-aminoacid peptide,25/11/2009,Treatment of neuroblastoma,EU/3/09/692,Positive,10/12/2009,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-692
,,16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide,01/10/2010,Treatment of medulloblastoma,EU/3/10/789,Positive,14/10/2010,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-789
,,16-base single-stranded peptide nucleic acid oligonucleotide linked to 7-amino acid peptide,04/07/2012,Treatment of neuroblastoma,EU/3/12/1016,Positive,24/07/2012,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1016
,,"11-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-aza-cyclopentadecane-13,15-dione",19/02/2014,Treatment of cystic fibrosis,EU/3/14/1239,Positive,01/04/2014,01/04/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1239
,,Allogeneic bone-marrow-derived ex-vivo-expanded multipotent adult progenitor cells,16/01/2014,Prevention of graft-versus-host disease,EU/3/13/1233,Positive,24/03/2014,24/03/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1233
,,"(6aS)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol",16/01/2014,Treatment of dystrophic myotonia,EU/3/13/1226,Positive,21/03/2014,21/03/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1226
,,Inecalcitol,16/01/2014,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/13/1223,Positive,21/03/2014,21/03/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1223
,,Perifosine,10/06/2010,Treatment of multiple myeloma,EU/3/10/740,Withdrawn,24/06/2010,07/02/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-740
,,catumaxomab,03/11/2006,Treatment of gastric cancer,EU/3/06/414,Positive,24/02/2009,07/02/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-414
,,Anti-epithelial cell adhesion molecule/anti-CD3 monoclonal antibody,08/03/2004,Treatment of ovarian cancer,EU/3/04/193,Positive,27/10/2005,07/02/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-193
,,Nitric oxide,16/01/2014,Treatment of cystic fibrosis,EU/3/13/1209,Positive,23/01/2014,23/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1209
,,Lactobacillus acidophilus and Bifidobacterium bifidum,16/01/2014,Prevention of necrotising enterocolitis,EU/3/13/1213,Positive,23/01/2014,23/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1213
,,Allogeneic and autologous haptenised and irradiated cells and cell lysates derived from glioma,16/01/2014,Treatment of glioma,EU/3/13/1211,Positive,22/01/2014,22/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1211
Loulla,EMEA/H/C/002501,Mercaptopurine,22/10/2007,Treatment of acute lymphoblastic leukaemia,EU/3/07/496,Positive,02/07/2008,22/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-496
,,heparin sodium,23/12/2005,Treatment of cystic fibrosis,EU/3/05/337,Withdrawn,08/08/2006,22/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-337
,,,08/10/2009,Treatment of soft tissue sarcoma,EU/3/09/678,Withdrawn,20/10/2009,22/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-678
Begedina,EMEA/H/C/004144,Murine monoclonal antibody against CD26,26/11/2010,Treatment of graft-versus-host disease,EU/3/10/808,Positive,15/12/2010,22/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-808
,,"Heparin-binding epidermal growth factor-like growth factor, amino acids 74-148",31/10/2006,Prevention of necrotising enterocolitis,EU/3/06/407,Positive,02/04/2009,13/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-407
,,Human monoclonal antibody against inhibitory killer cell lg-like receptors (1-7 F9),28/08/2006,Treatment of acute myeloid leukaemia,EU/3/06/392,Withdrawn,24/04/2009,13/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-392
,,"Valproic acid, sodium",30/11/2004,Treatment of familial adenomatous polyposis (FAP),EU/3/04/246,Withdrawn,04/01/2006,13/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-246
,,Recombinant human alpha-1 antitrypsin,30/04/2002,Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency,EU/3/02/100,Withdrawn,04/06/2012,13/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-100
,,Sodium valproate,26/08/2005,Treatment of 5q spinal muscular atrophy,EU/3/05/309,Withdrawn,29/11/2005,13/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-309
,,Murine anti-idiotypic antibody against OC125 antibody against CA125 antigen,09/07/2003,Treatment of ovarian cancer,EU/3/03/155,Withdrawn,04/01/2006,13/01/2014,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-155
,,Autologous regulatory T cells with an immunophenotype of CD4+CD25hiFoxP3+,08/10/2013,Prevention of rejection following solid organ transplantation,EU/3/13/1171,Positive,03/12/2013,03/12/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1171
,,Soraprazan,13/11/2013,Treatment of Stargardt's disease,EU/3/13/1208,Positive,02/12/2013,02/12/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1208
,,Trebananib,13/11/2013,Treatment of ovarian cancer,EU/3/13/1207,Positive,02/12/2013,02/12/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1207
,,Autologous ex-vivo-expanded leucocytes treated with 5-aza-2'-deoxycytidine,13/11/2013,Treatment of glioma,EU/3/13/1197,Positive,28/11/2013,28/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1197
,,6-Thioguanine,26/11/2009,Treatment of acute lymphoblastic leukaemia,EU/3/09/694,Positive,10/12/2009,28/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-694
,,,05/09/2008,Treatment of moderate and severe closed traumatic brain injury,EU/3/08/560,Positive,24/04/2009,28/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-560
,,Terguride,08/02/2013,Treatment of systemic sclerosis,EU/3/13/1104,Withdrawn,04/03/2013,25/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1104
,,Idelalisib,05/08/2013,Treatment of splenic marginal-zone lymphoma,EU/3/13/1187,Withdrawn,16/09/2013,18/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1187
,,Idelalisib,05/08/2013,Treatment of extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma),EU/3/13/1186,Withdrawn,16/09/2013,18/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1186
,,Idelalisib,17/07/2013,Treatment of lymphoplasmacytic lymphoma,EU/3/13/1160,Withdrawn,22/08/2013,18/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1160
,,Idelalisib,05/08/2013,Treatment of nodal marginal-zone lymphoma,EU/3/13/1172,Withdrawn,12/09/2013,18/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1172
,,Idelalisib,05/08/2013,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,EU/3/13/1173,Withdrawn,13/09/2013,18/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1173
,,Idelalisib,17/07/2013,Treatment of follicular lymphoma,EU/3/13/1159,Withdrawn,22/08/2013,15/11/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1159
,,"3,5-diiodothyropropionic acid",07/10/2013,Treatment of Allan-Herndon-Dudley syndrome,EU/3/13/1193,Positive,31/10/2013,31/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1193
,,zoledronic acid,07/10/2013,Treatment of complex regional pain syndrome,EU/3/13/1192,Positive,31/10/2013,31/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1192
,,L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (cibinetide),07/10/2013,Treatment of sarcoidosis,EU/3/13/1191,Positive,31/10/2013,31/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1191
,,Mexiletine hydrochloride,07/10/2013,Treatment of myotonic disorders,EU/3/13/1189,Positive,31/10/2013,31/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1189
,,Autologous dendritic cells pulsed with recombinant human-fusion protein (mucin 1 - glutathione S transferase) coupled to oxidised polymannose,20/09/2010,Treatment of ovarian cancer,EU/3/10/776,Positive,18/10/2010,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-776
,,carmustine,05/03/2002,Treatment of glioma,EU/3/02/085,Withdrawn,23/01/2003,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-085
,,HLA-B27-derived peptide (amino acid 125-138),02/09/2004,Treatment of autoimmune uveitis,EU/3/04/219,Positive,09/06/2006,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-219
,,Complement factor H,27/01/2007,Atypical haemolytic uraemic syndrome,EU/3/06/425,Withdrawn,29/07/2008,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-425
,,"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}",14/09/2007,Treatment of chronic non-infectious uveitis,EU/3/07/472,Withdrawn,29/07/2008,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-472
,,,03/06/2008,Treatment of congenital alpha-1 antitrypsin deficiency,EU/3/08/546,Positive,18/08/2008,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-546
,,artesunate,07/12/2007,Treatment of malaria,EU/3/07/510,Positive,02/07/2008,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-510
,,Arsenic trioxide,18/10/2000,Treatment of acute promyelocytic leukaemia,EU/3/00/008,Expired,04/07/2007,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-008
,,abarelix,20/09/2010,Treatment of low-flow priapism,EU/3/10/771,Withdrawn,18/10/2010,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-771
,,"4,6,8-Trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one",15/05/2009,Treatment of glioma,EU/3/09/639,Withdrawn,09/06/2009,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-639
,,"cholest-4-en-3-one, oxime",28/08/2006,Treatment of amyotrophic lateral sclerosis,EU/3/06/397,Withdrawn,24/04/2009,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-397
,,"4-Benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione",28/10/2009,Treatment of progressive supranuclear palsy,EU/3/09/679,Withdrawn,18/11/2009,17/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-679
,,Cysteamine bitartrate (gastroresistant) (mercaptamine),20/09/2010,Treatment of cystinosis,EU/3/10/778,Positive,18/10/2010,10/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-778
,,Sodium phenylbutyrate,09/02/2012,Treatment of ornithine-transcarbamylase deficiency,EU/3/12/950,Withdrawn,01/03/2012,09/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-950
,,iloprost,30/12/2000,Treatment of primary and of the following forms of secondary pulmonary hypertension…,EU/3/00/014,Expired,12/03/2009,08/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-014
,,Human immunoglobulin,24/10/2003,Treatment of polymyositis,EU/3/03/170,Withdrawn,26/04/2004,08/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-170
,,Human immunoglobulin,20/10/2003,Treatment of dermatomyositis,EU/3/03/169,Withdrawn,26/04/2004,08/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-169
,,Deferoxamine mesilate,20/10/2004,Treatment of traumatic spinal cord injury,EU/3/04/231,Withdrawn,21/09/2009,08/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-231
,,Autologous bone-marrow-derived mononuclear-cell fraction,20/09/2010,Treatment of thromboangiitis obliterans (Buerger's disease),EU/3/10/775,Positive,18/10/2010,08/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-775
,,"5-[1-(2,6-Dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride",07/06/2013,Treatment of 5q spinal muscular atrophy,EU/3/13/1136,Positive,25/06/2013,07/10/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1136
,,Polyinosine-polycytidylic acid coupled with the polycationic polyethyleneimine,06/06/2012,Treatment of pancreatic cancer,EU/3/12/1000,Withdrawn,04/07/2012,23/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1000
,,Humanised monoclonal antibody against epidermal-growth-factor receptor,09/08/2012,Treatment of glioma,EU/3/12/1029,Withdrawn,26/09/2012,23/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1029
,,Diphenylcyclopropenone,29/06/2006,Treatment of alopecia universalis,EU/3/06/380,Withdrawn,24/04/2009,23/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-380
,,Diphenylcyclopropenone,29/06/2006,Treatment of alopecia totalis,EU/3/06/379,Withdrawn,24/04/2009,19/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-379
,,decitabine,08/06/2006,Treatment of acute myeloid leukaemia,EU/3/06/370,Positive,19/07/2007,19/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-370
Kiacta; Kiacta,EMEA/H/C/000779; EMEA/H/C/000779,"1,3-Propanedisulfonic acid, disodium salt",31/07/2001,Treatment of systemic secondary amyloidosis,EU/3/01/051,Positive,15/05/2009,19/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-051
,,Cladribine,05/08/2013,Treatment of mastocytosis,EU/3/13/1182,Positive,16/09/2013,16/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1182
,,Cisplatin,05/08/2013,Treatment of osteosarcoma,EU/3/13/1169,Positive,12/09/2013,12/09/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1169
,,Human haemin,17/07/2013,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,EU/3/13/1149,Positive,22/08/2013,22/08/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1149
,,Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes,17/07/2013,Treatment of ataxia telangiectasia,EU/3/13/1158,Positive,16/08/2013,16/08/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1158
,,Ex-vivo-expanded autologous human corneal epithelium containing stem cells,17/07/2013,Treatment of limbal stem cell deficiency,EU/3/13/1168,Positive,16/08/2013,16/08/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1168
,,Autologous bone-marrow-derived mesenchymal stromal cells secreting neurotrophic factors,17/07/2013,Treatment of amyotrophic lateral sclerosis,EU/3/13/1148,Positive,16/08/2013,16/08/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1148
,,Allogeneic motor neuron progenitor cells derived from human embryonic stem cells,17/07/2013,Treatment of amyotrophic lateral sclerosis,EU/3/13/1155,Positive,16/08/2013,16/08/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1155
,,Sodium phenylbutyrate,09/02/2012,Treatment of carbamoyl-phosphate synthase-1 deficiency,EU/3/12/951,Withdrawn,01/03/2012,08/08/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-951
,,Sodium phenylbutyrate,09/02/2012,Treatment of citrullinaemia type 1,EU/3/12/949,Withdrawn,01/03/2012,08/08/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-949
,,titanium dioxide;Bisoctrizole,03/03/2005,Treatment of ultraviolet-A- and visible-light-induced photosensitivity disorders,EU/3/05/262,Withdrawn,01/07/2005,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-262
,,Tamibarotene,24/07/2009,Treatment of acute promyelocytic leukaemia,EU/3/09/658,Withdrawn,11/09/2009,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-658
,,Bafetinib,10/06/2010,Treatment of chronic myeloid leukaemia,EU/3/10/731,Withdrawn,24/06/2010,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-731
,,busulfan,30/12/2000,Conditioning treatment prior to haematopoietic-progenitor-cell transplantation,EU/3/00/011,Expired,15/05/2009,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-011
,,acadesine,27/05/2005,Treatment of B-cell chronic lymphocytic leukaemia,EU/3/05/280,Positive,17/09/2009,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-280
,,"[N-((2S,3R,3aS,3'R,4a'R,6S,6a'R,6b'S,7aR,12a'S,12b'S,Z)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulene]-3'-yl)methanesulfonamide hydrochloride]",13/05/2011,Treatment of chondrosarcoma,EU/3/11/859,Withdrawn,27/05/2011,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-859
,,acadesine,05/08/2011,Treatment of multiple myeloma,EU/3/11/881,Positive,16/08/2011,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-881
,,Genetically modified human adenovirus encoding human PH20 hyaluronidase,21/06/2011,Treatment of pancreatic cancer,EU/3/11/880,Positive,12/07/2011,31/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-880
,,expanded human allogeneic neural retinal progenitor cells extracted from neural retina,19/06/2013,Treatment of retinitis pigmentosa,EU/3/13/1140,Positive,11/07/2013,11/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1140
,,synthetic double-stranded siRNA oligonucleotide directed against the keratin 6a N171K mutation,19/06/2013,Treatment of pachyonychia congenita,EU/3/13/1141,Positive,11/07/2013,11/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1141
,,immortalised human C3A hepatoblastoma cells,19/06/2013,Treatment of acute liver failure,EU/3/13/1143,Positive,11/07/2013,11/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1143
,,allogeneic bone-marrow-derived mesenchymal cells expanded ex vivo in synthetic media,07/06/2013,Treatment of graft-versus-host disease,EU/3/13/1129,Positive,25/06/2013,09/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1129
,,Octocog alfa,24/07/2009,Treatment of haemophilia A,EU/3/09/655,Withdrawn,11/09/2009,08/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-655
,,brostallicin,23/12/2005,Treatment of soft tissue sarcoma,EU/3/05/336,Withdrawn,17/09/2009,08/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-336
,,laronidase,15/02/2001,Treatment of mucopolysaccharidosis type I,EU/3/01/022,Expired,15/06/2009,08/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-022
,,tretazicar,04/02/2008,Treatment of visceral leishmaniasis,EU/3/08/529,Positive,10/07/2008,08/07/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-529
,,Human-papilloma-virus-type-16 E6;E7 synthetic long peptides,20/12/2007,Treatment of epithelial neoplasia of the vulva positive for human papilloma virus,EU/3/07/520,Positive,21/09/2009,26/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-520
,,Givinostat,28/01/2010,Treatment of systemic-onset juvenile idiopathic arthritis,EU/3/09/704,Withdrawn,25/02/2010,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-704
,,Recombinant human CXCL8 mutant,07/06/2013,Treatment of cystic fibrosis,EU/3/13/1131,Positive,25/06/2013,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1131
Besponsa,EMEA/H/C/004119,Inotuzumab ozogamicin,07/06/2013,Treatment of B-cell acute lymphoblastic leukaemia,EU/3/13/1127,Positive,25/06/2013,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1127
,,Recombinant human transglutaminase 1 encapsulated into liposomes,07/06/2013,Treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis,EU/3/13/1130,Positive,25/06/2013,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1130
,,Etilefrine,13/11/2002,Treatment of low-flow priapism,EU/3/02/122,Positive,13/12/2002,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-122
,,Davunetide,23/03/2010,Treatment of progressive supranuclear palsy,EU/3/10/728,Withdrawn,26/03/2010,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-728
,,Brivanib alaninate,27/10/2011,Treatment of hepatocellular carcinoma,EU/3/11/918,Withdrawn,23/11/2011,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-918
,,Ovine anti-colchicine polyclonal antibody fragments,17/12/2010,Treatment of colchicine poisoning,EU/3/10/825,Positive,20/01/2011,25/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-825
,,"5'-O-(trans-9''-octadecenoyl)-1-beta-D-2'-deoxy-2',2'-difluorocytidine",28/10/2009,Treatment of pancreatic cancer,EU/3/09/680,Withdrawn,18/11/2009,24/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-680
,,porfimer sodium,06/03/2002,Treatment of high-grade dysplasia in Barrett's oesophagus,EU/3/02/086,Withdrawn,28/02/2007,20/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-086
,,Yttrium (90Y) antiferritin polyclonal antibodies,02/10/2003,Treatment of Hodgkin's lymphoma,EU/3/03/162,Positive,30/05/2007,20/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-162
,,Human MHC non-restricted cytotoxic T-cell line,30/11/2009,Treatment of ovarian cancer,EU/3/09/696,Positive,10/12/2009,19/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-696
Mylotarg; Mylotarg,EMEA/H/C/004204; EMEA/H/C/000705,gemtuzumab ozogamicin,18/10/2000,Treatment of acute myeloid leukaemia,EU/3/00/005,Positive,08/11/2004,19/06/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-005
,,zoledronic acid,17/04/2013,Treatment of complex regional pain syndrome,-,Negative,23/04/2013,23/04/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-complex-regional-pain-syndrome
,,Deoxyribose phosphorothioate (5'-tct-ccc-agc-gtg-cgc-cat-3'),21/11/2001,Treatment of chronic lymphocytic leukaemia,EU/3/01/063,Withdrawn,06/01/2005,09/04/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-063
,,Deoxyribose phosphorothioate (5'-tct-ccc-agc-gtg-cgc-cat-3'),20/11/2001,Treatment of multiple myeloma,EU/3/01/065,Withdrawn,12/12/2005,09/04/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-065
,,Lisuride hydrogen maleate,13/05/2011,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/11/869,Positive,31/05/2011,09/04/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-869
,,Siplizumab,29/06/2006,Treatment of T-cell and NK-cell neoplasms,EU/3/06/383,Withdrawn,23/09/2009,09/04/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-383
,,porfimer sodium,29/07/2004,Treatment of cholangiocarcinoma,EU/3/04/215,Withdrawn,22/11/2004,09/04/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-215
,,cilengitide,15/01/2004,Treatment of glioma,EU/3/03/184,Withdrawn,08/07/2004,09/04/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-184
,,Hypothiocyanite;lactoferrin,24/07/2009,Treatment of cystic fibrosis,EU/3/09/654,Positive,11/09/2009,20/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-654
,,Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2,15/05/2009,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,EU/3/09/638,Positive,09/06/2009,20/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-638
,,Tobramycin,11/04/2006,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,EU/3/06/366,Withdrawn,15/05/2009,14/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-366
,,Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3,20/12/2007,Treatment of acute myeloid leukaemia,EU/3/07/516,Positive,10/07/2008,13/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-516
,,Pegylated L-asparaginase,22/09/2008,Treatment of acute lymphoblastic leukaemia,EU/3/08/569,Positive,29/06/2009,13/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-569
,,Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3,23/02/2011,Treatment of acute lymphoblastic leukaemia,EU/3/10/840,Positive,07/03/2011,13/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-840
,,Vorinostat,15/04/2011,Treatment of multiple myeloma,EU/3/11/854,Withdrawn,26/04/2011,12/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-854
,,Suberolylanilide hydroxamic acid,21/06/2004,Treatment of cutaneous T-cell lymphoma,EU/3/04/205,Withdrawn,11/10/2005,12/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-205
,,Vorinostat,20/09/2010,Treatment of malignant mesothelioma,EU/3/10/785,Withdrawn,18/10/2010,12/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-785
,,"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene",17/07/2012,Prevention of poliomyelitis in patients with immunodeficiencies deemed at risk,EU/3/12/1021,Positive,31/08/2012,12/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1021
,,Nanoparticle albumin-bound paclitaxel,26/11/2010,Treatment of pancreatic cancer,EU/3/10/809,Withdrawn,17/12/2010,11/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-809
,,Linsitinib,02/04/2012,Treatment of adrenal cortical carcinoma,EU/3/12/977,Withdrawn,30/04/2012,11/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-977
,,Allogeneic aortic endothelial cells cultured in a porcine gelatin matrix,23/02/2011,Prevention of arteriovenous access failure in haemodialysis patients,EU/3/10/843,Withdrawn,04/03/2011,11/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-843
,,"(1R, 2R, 4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R, 27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetra-cosahydro-3H-23,2",26/08/2005,Treatment of soft tissue sarcoma,EU/3/05/312,Withdrawn,17/09/2009,11/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-312
,,"(1R, 2R, 4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R, 27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetra-cosahydro-3H-23,2",28/10/2005,Treatment of primary malignant bone tumours,EU/3/05/321,Withdrawn,17/09/2009,11/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-321
,,L-asparaginase encapsulated in erythrocytes,08/02/2013,Treatment of acute myeloid leukaemia,EU/3/13/1106,Positive,04/03/2013,04/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1106
,,Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys,08/02/2013,Treatment of high-altitude pulmonary oedema,EU/3/13/1102,Positive,04/03/2013,04/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1102
,,Autologous dendritic cells pulsed with autologous tumour cell lysate,15/02/2007,Treatment of glioma,EU/3/07/431,Positive,10/07/2008,01/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-431
,,Recombinant microbial lipase,28/10/2005,Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency,EU/3/05/331,Withdrawn,13/03/2006,01/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-331
,,Allogeneic motor neuron progenitor cells derived from human embryonic stem cells,24/01/2013,Treatment of 5q spinal muscular atrophy,EU/3/12/1088,Positive,01/03/2013,01/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1088
,,Interferon gamma,29/10/2007,Treatment of idiopathic pulmonary fibrosis,EU/3/07/491,Positive,02/07/2008,01/03/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-491
,,Synthetic double-stranded short interfering RNA oligonucleotide directed against proopiomelanocortin,01/10/2010,Treatment of adrenocorticotropin-dependent Cushing's syndrome,EU/3/10/798,Positive,14/10/2010,28/02/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-798
,,"1,5-(Butylimino)-1,5-dideoxy, D-glucitol",18/10/2000,Treatment of Gaucher disease,EU/3/00/006,Expired,15/05/2009,27/02/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-006
,,Bosentan,15/02/2001,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/01/019,Expired,28/02/2007,27/02/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-019
,,Pegvisomant,15/02/2001,Treatment of acromegaly,EU/3/01/023,Expired,29/11/2005,27/02/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-023
,,Erdosteine,06/12/2012,Treatment of lead toxicity,EU/3/12/1084,Positive,25/01/2013,25/01/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1084
,,Voclosporin,06/12/2012,Treatment of non-infectious uveitis,EU/3/12/1085,Positive,25/01/2013,25/01/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1085
,,artesunate,06/12/2012,Treatment of malaria,EU/3/12/1079,Positive,25/01/2013,25/01/2013,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1079
,,Naloxone hydrochloride dihydrate,08/11/2012,Treatment of cutaneous T-cell lymphoma,EU/3/12/1057,Positive,13/12/2012,13/12/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1057
,,"IL-12-secreting dendritic cells, loaded with autologous tumour lysate",08/11/2012,Treatment of glioma,EU/3/12/1058,Positive,13/12/2012,13/12/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1058
,,Erdosteine,08/11/2012,Treatment of mercury toxicity,EU/3/12/1067,Positive,13/12/2012,13/12/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1067
,,Melarsoprol,08/11/2012,Treatment of African trypanosomiasis,EU/3/12/1068,Positive,13/12/2012,13/12/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1068
,,Lurbinectedin,10/10/2012,Treatment of ovarian cancer,EU/3/12/1053,Positive,16/11/2012,01/01/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1053
,,Alpha-1 proteinase inhibitor,10/10/2012,Treatment of cystic fibrosis,EU/3/12/1045,Positive,16/11/2012,16/11/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1045
,,[2-Cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-trifluoromethylphenyl)prop-2-enamide],10/10/2012,Treatment of traumatic spinal cord injury,EU/3/12/1050,Positive,16/11/2012,16/11/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1050
,,"N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine;folic acid",09/02/2012,Diagnosis of positive folate-receptor status in ovarian cancer,EU/3/12/958,Withdrawn,24/02/2012,12/11/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-958
,,Ketoconazole,09/08/2012,Treatment of Cushing's syndrome,EU/3/12/1031,Positive,26/09/2012,26/09/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1031
,,,09/08/2012,Treatment of primary biliary cirrhosis,EU/3/12/1041,Positive,26/09/2012,26/09/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1041
,,,09/08/2012,Treatment of Alagille syndrome,EU/3/12/1040,Positive,26/09/2012,26/09/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1040
,,Tariquidar,21/03/2012,treatment of P-gp positive breast cancer,-,Negative,06/09/2012,06/09/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-p-gp-positive-breast-cancer
,,Sarsasapogenin,08/05/2008,Treatment of amyotrophic lateral sclerosis,EU/3/08/543,Withdrawn,29/07/2008,06/09/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-543
,,Givinostat,04/07/2012,Treatment of Duchenne muscular dystrophy,EU/3/12/1009,Positive,24/07/2012,24/07/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1009
,,Human erythrocytes encapsulating inositol hexaphosphate,04/07/2012,Treatment of sickle cell disease,EU/3/12/1008,Positive,24/07/2012,24/07/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1008
,,Sodium nitrite,05/03/2012,Treatment of pulmonary arterial hypertension,EU/3/12/967,Positive,06/07/2012,06/07/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-967
,,Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10,25/05/2012,Treatment of soft tissue sarcoma,EU/3/12/994,Positive,18/06/2012,18/06/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-994
,,Recombinant human methionine proinsulin,26/04/2012,Treatment of retinitis pigmentosa,EU/3/12/985,Positive,18/06/2012,18/06/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-985
Lympreva,EMEA/H/C/002772,Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin,28/08/2006,Treatment of follicular lymphoma,EU/3/06/394,Positive,02/04/2009,14/06/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-394
,,Pegylated recombinant Erwinia chrysanthemi L-asparaginase,05/08/2011,Treatment of acute lymphoblastic leukaemia,EU/3/11/889,Positive,16/08/2011,24/05/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-889
,,Doxycycline hyclate,02/04/2012,Treatment of familial amyloid polyneuropathy,EU/3/12/955,Positive,24/05/2012,24/05/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-955
,,Autologous urothelial and smooth muscle cells,18/03/2008,Treatment of spina bifida,EU/3/08/537,Withdrawn,10/07/2008,24/05/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-537
,,Autologous urothelial and smooth muscle cells,08/11/2008,Treatment of spinal cord injury,EU/3/08/574,Withdrawn,24/04/2009,24/05/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-574
,,Sodium thiosulfate,02/04/2012,Treatment of calciphylaxis,EU/3/12/979,Positive,30/04/2012,30/04/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-979
,,Genistein sodium salt dihydrate,02/04/2012,Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome),EU/3/12/980,Positive,30/04/2012,30/04/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-980
,,"Dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, sodium salt, synthetic surfactant protein C analogue and synthetic surfactant protein B analogue",02/04/2012,Respiratory distress syndrome in premature neonates of less than 37 weeks  of gestational age,EU/3/12/982,Positive,30/04/2012,30/04/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-982
,,Glucagon,05/03/2012,Treatment of congenital hyperinsulinism,EU/3/12/960,Positive,19/04/2012,19/04/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-960
,,Doxycycline hyclate,05/03/2012,Treatment of systemic amyloidosis caused by beta-2 microglobulin,EU/3/12/961,Positive,19/04/2012,19/04/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-961
,,"Lentiviral vector expressing the truncated form of human tyrosine hydroxylase gene, human aromatic L amino-acid decarboxylase gene, human GTP-cyclohydrolase 1 gene",09/09/2010,Treatment of off-periods in adult patients with advanced Parkinson's disease,-,Negative,30/03/2012,30/03/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-periods-adult-patients-advanced-parkinson039s-disease
,,Tecovirimat,01/10/2010,Treatment of cowpox infection,EU/3/10/799,Withdrawn,14/10/2010,28/03/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-799
,,Allogeneic human dermal fibroblasts,20/09/2010,Treatment of epidermolysis bullosa,EU/3/10/774,Positive,18/10/2010,09/02/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-774
,,Recombinant kallikrein inhibitor,29/01/2010,Treatment of Netherton syndrome,EU/3/09/712,Positive,25/02/2010,09/02/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-712
,,Pagibaximab,09/06/2010,Prevention of sepsis caused by Gram-positive pathogens in premature infants less than or equal to 34,EU/3/10/743,Withdrawn,23/06/2010,02/02/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-743
,,eltrombopag olamine,03/08/2007,Treatment of idiopathic thrombocytopenic purpura,EU/3/07/467,Withdrawn,21/09/2009,12/01/2012,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-467
,,Resminostat,09/12/2011,Treatment of Hodgkin's lymphoma,EU/3/11/930,Positive,20/12/2011,20/12/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-930
,,Nabilone,16/01/2011,Treatment of amyotrophic lateral sclerosis,-,Negative,20/12/2011,20/12/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-amyotrophic-lateral-sclerosis
,,Interferon gamma,09/12/2011,Treatment of Friedreich's ataxia,EU/3/11/935,Positive,20/12/2011,20/12/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-935
,,Gallium (68Ga)-pasireotide tetraxetan,27/10/2011,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,EU/3/11/920,Positive,23/11/2011,23/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-920
,,Adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene,27/10/2011,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),EU/3/11/917,Positive,23/11/2011,23/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-917
Spanidin; Spanidin,EMEA/H/C/000809; EMEA/H/C/000809,Gusperimus trihydrochloride,29/03/2001,Treatment of Wegener's granulomatosis,EU/3/01/034,Positive,03/03/2009,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-034
,,dextran sulfate,05/08/2011,Treatment for mobilisation of progenitor cells prior to stem cell transplantation,EU/3/11/883,Positive,16/08/2011,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-883
,,dextran sulfate,09/10/2009,Prevention of graft rejection during pancreatic islet transplantation,EU/3/09/669,Positive,20/10/2009,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-669
,,estradiol hemihydrate;Progesterone,11/04/2005,Bronchopulmonary dysplasia in premature neonates of less than 30 weeks of gestational age,EU/3/05/275,Positive,04/01/2006,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-275
,,Colistimethate sodium,19/02/2002,Treatment of Pseudomonas aeruginosa lung infection (including colonisation) in cystic fibrosis,EU/3/02/088,Withdrawn,08/01/2003,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-088
,,Vaccinia GM-CSF/TK-deactivated virus,26/11/2009,Treatment of hepatocellular carcinoma (pexastimogene devacirepvec),EU/3/09/700,Positive,10/12/2009,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-700
,,Recombinant human arylsulfatase A,09/07/2003,treatment of metachromatic leukodystrophy,EU/3/03/158,Withdrawn,18/08/2008,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-158
,,Temsirolimus,07/11/2006,Treatment of mantle cell lymphoma,EU/3/06/420,Expired,02/04/2009,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-420
,,Alpha-galactosidase A,08/08/2000,Treatment of Fabry disease,EU/3/00/003,Expired,19/11/2009,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-003
,,Adrenomedullin,09/06/2010,Treatment of acute lung Injury,EU/3/10/744,Positive,23/06/2010,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-744
,,,23/03/2010,Treatment of acute myeloid leukaemia,EU/3/10/729,Withdrawn,26/03/2010,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-729
,,Alpha-galactosidase A,08/08/2000,Treatment of Fabry disease,EU/3/00/002,Expired,18/10/2010,18/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-002
,,Naptumomab estafenatox,14/09/2007,Treatment of renal-cell carcinoma,EU/3/07/480,Positive,22/01/2008,11/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-480
,,Lintuzumab,30/04/2009,Treatment of acute myeloid leukaemia,EU/3/09/627,Withdrawn,12/05/2009,11/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-627
,,Lintuzumab,29/04/2009,Treatment of myelodysplastic syndromes,EU/3/09/626,Withdrawn,12/05/2009,11/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-626
,,Chimeric anti-interleukin-6 monoclonal antibody,30/06/2003,Treatment of renal-cell carcinoma,EU/3/03/148,Withdrawn,08/07/2003,11/11/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-148
,,"20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate",27/09/2011,Treatment of ovarian cancer,EU/3/11/900,Positive,17/10/2011,17/10/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-900
,,NH2-Cys-Ser-Ser-Val-Thr-Ala-Trp-Thr-Thr-Gly-Cys-Gly-CONH2,27/09/2011,Treatment of traumatic spinal cord injury,EU/3/11/910,Positive,17/10/2011,17/10/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-910
,,"5-[1-(2,6-Dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride",30/08/2011,Treatment of 5q spinal muscular atrophy,EU/3/11/892,Positive,21/09/2011,21/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-892
,,Cardiotrophin-1,30/08/2011,Treatment of acute liver failure,EU/3/11/893,Positive,21/09/2011,21/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-893
,,Iodine (131I) Anti-CEA sheep-human chimeric monoclonal antibody,08/05/2003,Treatment of pancreatic cancer,EU/3/03/142,Withdrawn,21/05/2003,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-142
,,Plitidepsin,23/02/2011,Treatment of post-essential thrombocythaemia myelofibrosis,EU/3/10/838,Withdrawn,07/03/2011,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-838
,,Streptococcus pyogenes Su strain cells treated with benzylpenicillin,29/01/2010,Treatment of congenital lymphatic malformations,EU/3/09/714,Withdrawn,25/02/2010,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-714
,,Plitidepsin,23/02/2011,Treatment of post-polycythaemia vera myelofibrosis,EU/3/10/839,Withdrawn,07/03/2011,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-839
,,everolimus,05/06/2007,Treatment of renal-cell carcinoma,EU/3/07/449,Withdrawn,19/07/2007,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-449
,,Plitidepsin,23/02/2011,Treatment of primary myelofibrosis,EU/3/10/837,Withdrawn,07/03/2011,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-837
,,eptacog alfa (activated),20/03/2007,Treatment of post-neonatal intracerebral haemorrhage,EU/3/07/436,Withdrawn,04/12/2007,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-436
,,Aplidine,09/07/2003,Treatment of acute lymphoblastic leukaemia,EU/3/03/151,Withdrawn,12/12/2005,06/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-151
,,Dihydroartemisinin;piperaquine,03/08/2007,Treatment of malaria,EU/3/07/468,Withdrawn,29/07/2008,05/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-468
,,ambrisentan,01/10/2010,Treatment idiopathic pulmonary fibrosis,EU/3/10/790,Withdrawn,14/10/2010,05/09/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-790
,,"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-α-asparaginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-lysyl]amino]ethoxy]ethoxy]ethoxy]ethyl]-2,3-di-O-methyl-6-O-sulfo-α-D-glucopyranosyl....",05/08/2011,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,EU/3/11/884,Positive,16/08/2011,16/08/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-884
,,Viral vector containing DNA encoding the human SMN protein,21/06/2011,Treatment of 5q spinal muscular atrophy,EU/3/11/876,Positive,12/07/2011,12/07/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-876
,,Allogeneic T cells encoding an exogenous TK gene,21/06/2011,Treatment of acute lymphoblastic leukaemia,EU/3/11/878),Positive,12/07/2011,12/07/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-878
,,Vincristine sulfate liposomes,08/07/2008,Treatment of acute lymphoblastic leukaemia,EU/3/08/555,Positive,29/06/2009,21/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-555
,,Recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3,21/10/2004,Treatment of Rabson-Mendenhall syndrome,EU/3/04/237,Withdrawn,20/02/2009,21/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-237
,,Recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3,21/10/2004,Treatment of type A extreme insulin resistance syndrome,EU/3/04/236,Withdrawn,21/06/2011,21/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-236
,,Recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3,09/07/2003,Treatment of primary growth hormone insensitivity syndrome (laron syndrome),EU/3/03/159,Withdrawn,30/05/2007,21/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-159
,,Recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3,21/10/2004,Treatment of leprechaunism,EU/3/04/238,Withdrawn,20/02/2009,21/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-238
,,Budesonide,03/11/2006,Treatment of graft-versus-host disease,EU/3/06/413,Positive,20/02/2009,21/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-413
,,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,21/12/2004,Treatment of multiple myeloma,EU/3/04/248,Positive,06/01/2006,01/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-248
,,Recombinant P-selectin glycoprotein immunoglobulin,22/05/2006,Prevention of  post transplantation graft dysfunction,EU/3/06/376,Positive,24/02/2009,01/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-376
,,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,21/12/2004,Treatment of mantle cell lymphoma,EU/3/04/250,Positive,06/01/2006,01/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-250
,,Pazopanib hydrochloride,29/06/2006,Treatment of renal-cell carcinoma,EU/3/06/382,Withdrawn,20/02/2009,01/06/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-382
,,abetimus sodium,20/11/2001,Treatment of lupus nephritis,EU/3/01/064,Withdrawn,03/03/2009,31/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-064
,,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,24/07/2009,Treatment of diffuse large B-cell lymphoma,EU/3/09/656,Positive,11/09/2009,31/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-656
,,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,23/12/2004,Treatment of follicular lymphoma,EU/3/04/249,Positive,06/01/2006,31/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-249
,,apomorphine hydrochloride,13/05/2011,Treatment of moderate and severe traumatic brain injury,EU/3/11/862,Positive,27/05/2011,27/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-862
,,"(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate",27/02/2009,Treatment of amyotrophic lateral sclerosis,EU/3/09/616,Positive,30/10/2009,19/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-616
,,Human C1 inhibitor,08/10/2009,Treatment of angioedema caused by C1 inhibitor deficiency,EU/3/09/668,Withdrawn,20/10/2009,19/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-668
,,"4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid",22/10/2007,Treatment of hepatocellular carcinoma,EU/3/07/497,Withdrawn,29/07/2008,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-497
,,Talampanel,29/04/2009,Treatment of glioma,EU/3/09/631,Withdrawn,12/05/2009,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-631
,,Paromomycin sulfate,11/04/2005,Treatment of visceral leishmaniasis,EU/3/05/271,Withdrawn,01/07/2005,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-271
,,Recombinant human residue 41 glutamic acid to glutamine variant of interferon alfa-2b,19/01/2009,Treatment of Behçet's Disease,EU/3/08/606,Withdrawn,29/06/2009,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-606
,,Amonafide L-malate,22/10/2007,Treatment of acute myeloid leukaemia,EU/3/07/483,Withdrawn,17/09/2009,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-483
,,26 base single stranded phosphodiester DNA oligonucleotide,08/10/2009,Treatment of acute myeloid leukaemia,EU/3/09/662,Withdrawn,20/10/2009,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-662
,,pixantrone dimaleate,02/02/2010,Treatment of diffuse large B-cell lymphoma,EU/3/09/722,Withdrawn,04/03/2010,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-722
,,26 base single stranded phosphodiester DNA oligonucleotide,16/02/2006,Treatment of pancreatic cancer,EU/3/06/352,Withdrawn,17/09/2009,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-352
,,26 base single stranded phosphodiester DNA oligonucleotide,16/02/2006,Treatment of renal-cell carcinoma,EU/3/06/353,Withdrawn,17/09/2009,18/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-353
,,Ribavirin,08/03/2001,Treatment of adenovirus infection in immunocompromised patients,EU/3/01/029,Withdrawn,03/03/2009,07/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-029
,,Ribavirin,14/02/2001,Treatment of haemorrhagic fever with renal syndrome,EU/3/01/024,Withdrawn,03/03/2009,07/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-024
,,pemetrexed disodium,17/09/2001,Treatment of malignant mesothelioma,EU/3/01/060,Withdrawn,03/03/2009,06/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-060
,,Xaliproden hydrochloride,17/01/2001,Treatment of amyotrophic lateral sclerosis,EU/3/00/015,Withdrawn,11/03/2009,06/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-015
,,Fomepizole,30/05/2001,Treatment of methanol poisoning,EU/3/01/040,Withdrawn,24/02/2009,06/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-040
,,Human engineered monoclonal antibody specific for transforming growth factor β2,30/05/2001,Prevention of scarring in glaucoma filtration surgical procedures,EU/3/01/042,Withdrawn,17/09/2009,05/05/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-042
,,Recombinant thymidine phosphorylase encapsulated in autologous erythrocytes,15/04/2011,Treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE),EU/3/11/856,Positive,26/04/2011,26/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-856
,,R-baclofen,15/04/2011,Treatment of fragile X syndrome,EU/3/11/858,Positive,26/04/2011,26/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-858
,,Metastable technetium 99 [99mTc] demogastrin 2,28/08/2006,Diagnosis of medullary thyroid carcinoma,EU/3/06/400,Positive,24/04/2009,12/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-400
Folotyn; Folotyn,EMEA/H/C/002096; EMEA/H/C/002096,Pralatrexate,13/04/2007,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/07/444,Positive,02/07/2008,07/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-444
,,"Soluble yeast beta-1,3/1,6- glucan",16/06/2005,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,EU/3/05/294,Positive,26/06/2005,07/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-294
,,Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene,09/07/2007,Treatment of glycogen storage disease type II (Pompe's disease),EU/3/07/454,Withdrawn,04/12/2007,07/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-454
,,"N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide",22/09/2008,Treatment of partial deep dermal and full-thickness burns,EU/3/08/568,Positive,24/04/2009,06/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-568
,,Pralatrexate,19/01/2009,Treatment of non-papillary transitional cell carcinoma of the urinary bladder,EU/3/08/603,Positive,29/06/2009,06/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-603
,,4-Amino-5-oxo-4 (pyridinium-1-ylmethyl) proline,16/02/2006,Treatment of renal-cell carcinoma,EU/3/06/356,Positive,24/08/2006,04/04/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-356
,,Patupilone,05/11/2009,Treatment of fallopian tube cancer,EU/3/09/688,Withdrawn,18/11/2009,29/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-688
,,Sapropterin,26/08/2005,Treatment of hyperphenylalaninaemia,EU/3/05/308,Withdrawn,04/01/2006,29/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-308
,,Murine monoclonal antibody to GD2,12/06/2009,Treatment of neuroblastoma,EU/3/09/644,Withdrawn,01/07/2009,28/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-644
,,tegafur;gimeracil;oteracil potassium,20/12/2007,Treatment of gastric cancer,EU/3/07/515,Withdrawn,23/09/2009,28/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-515
,,Fenretinide,30/01/2007,Treatment of soft tissue sarcoma,EU/3/06/427,Withdrawn,29/07/2008,25/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-427
,,Fenretinide,26/01/2007,Treatment of primary malignant bone tumours,EU/3/06/426,Withdrawn,29/07/2008,25/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-426
,,"17-(Allylamino)-17-demethoxygeldanamycin, hydroquinone hydrochloride",29/11/2007,Treatment of malignant gastrointestinal stromal tumours,EU/3/07/512,Withdrawn,17/09/2009,25/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-512
,,human monoclonal antibody against CD4,14/04/2004,Treatment of cutaneous T-cell lymphoma,EU/3/04/198,Positive,18/08/2008,10/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-198
Elelyso,EMEA/H/C/002250,Taliglucerase alfa,23/03/2010,Treatment of Gaucher disease,EU/3/10/726,Positive,26/03/2010,10/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-726
,,Zanolimumab,20/03/2007,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",EU/3/07/438,Positive,18/08/2008,10/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-438
,,Pralatrexate,10/06/2010,Treatment of cutaneous T-cell lymphoma,EU/3/10/741,Positive,24/06/2010,10/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-741
,,Paquinimod,23/02/2011,Treatment of systemic sclerosis,EU/3/10/836,Positive,07/03/2011,07/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-836
,,Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin,23/02/2011,Treatment of mantle cell lymphoma,EU/3/10/831,Positive,04/03/2011,04/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-831
,,paclitaxel,23/02/2011,Treatment of oesophagus carcinoma,EU/3/10/846,Positive,04/03/2011,04/03/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-846
,,"Silibinin-C-2',3-dihydrogensuccinate, disodium salt",17/12/2010,Prevention of recurrent hepatitis C in liver transplant recipients,EU/3/10/828,Positive,20/01/2011,20/01/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-828
,,Tesetaxel,17/12/2010,Treatment of gastric cancer,EU/3/10/829,Positive,20/01/2011,20/01/2011,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-829
,,dexamethasone,04/08/2010,Treatment of non-infectious uveitis affecting the posterior segment of the eye,EU/3/10/763,Withdrawn,11/08/2010,19/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-763
,,Ranpirnase,29/03/2001,Treatment of  malignant mesothelioma,EU/3/01/033,Withdrawn,03/03/2009,19/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-033
,,Anti-EphA2 monoclonal antibody conjugated to maleimidocaproyl monomethylauristatin phenylalanine,28/10/2009,Treatment of ovarian cancer,EU/3/09/682,Withdrawn,18/11/2009,19/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-682
,,Talampanel,12/06/2009,Treatment of amyotrophic lateral sclerosis,EU/3/09/646,Withdrawn,01/07/2009,18/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-646
,,Anti-von Willebrand aptamer,03/06/2008,Treatment of thrombotic thrombocytopenic purpura,EU/3/08/547,Withdrawn,29/07/2008,18/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-547
,,Adenovirus-interferon gamma-coding DNA sequence,09/07/2003,Treatment of cutaneous T-cell lymphoma,EU/3/03/150,Withdrawn,23/10/2003,18/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-150
,,Recombinant human C1-inhibitor,11/05/2001,Treatment of angioedema caused by C1 inhibitor deficiency,EU/3/01/036,Withdrawn,15/05/2009,18/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-036
,,"(R, S)-3-(bromomethyl)-3-butanol-1-yl-disphosphate",29/07/2004,Treatment of renal-cell carcinoma,EU/3/04/218,Withdrawn,30/05/2007,18/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-218
,,human monoclonal hepatitis B immunoglobulins,23/02/2004,Prevention of hepatitis-B re-infection following liver transplantation,EU/3/04/187,Withdrawn,10/07/2004,18/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-187
,,Thalidomide,20/11/2001,Treatment of erythema nodosum leprosum (ENL) or type II lepra reactions,EU/3/01/066,Withdrawn,20/02/2009,18/11/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-066
,,Allogeneic T cells encoding an exogenous TK gene,20/09/2010,Treatment of acute myeloid leukaemia,EU/3/10/773,Positive,18/10/2010,18/10/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-773
,,Nafamostat mesilate,20/09/2010,Treatment of cystic fibrosis,EU/3/10/782,Positive,18/10/2010,18/10/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-782
,,N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide,01/10/2010,Treatment of Friedreich's ataxia,EU/3/10/793,Positive,14/02/2010,14/10/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-793
,,Pralatrexate,01/10/2010,Treatment of Hodgkin's lymphoma,EU/3/10/795,Positive,14/10/2010,14/10/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-795
,,"(S)-10-[(dimethylamino)methyl]-4-ethyl-9-hydroxy-4-O-[alpha-(2"", 4"", 5"", 7""-tetranitro-9""-fluorenylideneaminooxy)propionyl]-1H-pyrano[3', 4', 6', 7']indolizino[1,2-beta]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride",01/10/2010,Treatment of hepatocellular carcinoma,EU/3/10/788,Positive,14/10/2010,14/10/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-788
,,Tacrolimus Hydrate,14/01/2004,Treatment of vernal keratoconjunctivitis,EU/3/03/185,Withdrawn,26/04/2004,14/10/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-185
,,Molgramostim,16/07/2010,Treatment of cystic fibrosis,-,Negative,09/08/2010,09/08/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-cystic-fibrosis
,,octenidine dihydrochloride,27/07/2010,Prevention of late-onset sepsis in premature infants of ≤ to 32 weeks of gestational age,EU/3/10/755,Positive,05/08/2010,05/08/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-755
,,Gastrin 17C diphtheria toxoid conjugate,16/07/2010,Treatment of pancreatic cancer,-,Negative,05/08/2010,05/08/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-pancreatic-cancer-0
,,raloxifene hydrochloride,10/06/2010,Treatment of hereditary haemorrhagic telangiectasia,EU/3/10/730,Positive,24/06/2010,24/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-730
,,Cardiotrophin-1,28/08/2006,Prevention of the ischemia/reperfusion injury associated with solid organ transplantation,EU/3/06/396,Positive,24/04/2009,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-396
,,Allogeneic human umbilical cord tissue-derived cells,01/04/2008,Treatment of retinitis pigmentosa,EU/3/08/534,Withdrawn,10/07/2008,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-534
,,Pravastatin;zoledronic acid,09/06/2010,Treatment of Hutchinson-Gilford progeria,EU/3/10/748,Positive,23/06/2010,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-748
,,Peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN),28/10/2005,Treatment of localised scleroderma,EU/3/05/329,Positive,30/05/2007,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-329
,,Lumiliximab,03/02/2008,Treatment chronic lymphocytic leukaemia,EU/3/08/528,Withdrawn,10/07/2008,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-528
,,Vasoactive Intestinal Peptide,22/12/2003,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/03/173,Positive,23/09/2009,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-173
,,Peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN),28/10/2005,Treatment of systemic sclerosis,EU/3/05/326,Positive,30/05/2007,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-326
,,sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid,19/09/2001,Treatment of meconium aspiration syndrome,EU/3/01/054,Withdrawn,30/05/2007,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-054
,,Alpha-1-acid glycoprotein,20/03/2003,Treatment of tricyclic anti-depressants poisoning,EU/3/03/138,Withdrawn,09/04/2003,23/06/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-138
,,Recombinant human proinsulin,11/02/2009,Treatment of retinitis pigmentosa,EU/3/08/612,Positive,29/10/2009,15/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-612
,,ciclosporin,03/11/2006,Prevention of rejection for corneal transplant,EU/3/06/415,Withdrawn,02/04/2009,15/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-415
,,"H-Arg-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt& H-Tyr-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt",18/12/2007,Treatment of TERT positive non-small cell lung cancer in HLA-A2 positive patients,EU/3/07/521,Positive,21/10/2008,15/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-521
,,Arsenic trioxide,02/08/2007,Treatment of acute myeloid leukaemia,EU/3/07/460,Withdrawn,10/07/2008,15/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-460
,,Arsenic trioxide,29/03/2001,Treatment of multiple myeloma,EU/3/01/032,Withdrawn,04/07/2007,15/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-032
,,Arsenic trioxide,29/03/2001,Treatment of myelodysplastic syndromes,EU/3/01/031,Withdrawn,04/07/2007,15/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-031
,,Givinostat,03/02/2010,Treatment of polycythaemia vera,EU/3/09/719,Positive,04/03/2010,04/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-719
,,Ecopipam,03/02/2010,Treatment of Lesch-Nyhan disease,EU/3/09/717,Positive,04/03/2010,04/03/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-717
,,Lithium citrate tetrahydrate,28/01/2010,Treatment of Huntington’s disease,EU/3/09/706,Positive,25/02/2010,25/02/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-706
,,Brivudine,28/01/2010,Treatment of pancreatic cancer,EU/3/09/703,Positive,25/02/2010,25/02/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-703
,,Beta-artemether;lumefantrine,28/01/2010,Treatment of malaria,EU/3/09/702,Positive,25/02/2010,25/02/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-702
,,sodium oxybate,03/02/2003,Treatment of narcolepsy,EU/3/02/131,Withdrawn,28/02/2007,22/02/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-131
,,Dexamethasone sodium phosphate encapsulated in human erythrocytes,20/10/2004,Treatment of cystic fibrosis,EU/3/04/230,Positive,05/11/2009,22/02/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-230
,,Monoclonal antibody to human interleukin-6,18/12/2002,Treatment of post-transplantation lymphoproliferative disorders,EU/3/02/125,Withdrawn,18/08/2008,22/02/2010,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-125
,,"Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)",21/12/2004,Treatment of chronic myeloid leukaemia,EU/3/04/252,Withdrawn,06/01/2006,19/11/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-252
,,"Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)",21/12/2004,Treatment of acute myeloid leukaemia,EU/3/04/253,Withdrawn,06/01/2006,19/11/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-253
Masican; Masiviera,EMEA/H/C/002670; EMEA/H/C/002659,Masitinib mesilate,28/10/2009,Treatment of pancreatic cancer,EU/3/09/684,Positive,18/11/2009,18/11/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-684
,,NGR-human tumour necrosis factor,09/11/2009,Treatment of hepatocellular carcinoma,EU/3/09/686,Positive,18/11/2009,18/11/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-686
,,daunorubicin,03/12/2008,Treatment of acute myeloid leukaemia,EU/3/08/585,Positive,30/10/2009,30/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-585
,,4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide,10/09/2008,Prevention of graft rejection after liver transplantation,-,Negative,30/10/2009,30/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-prevention-graft-rejection-after-liver-transplantation
,,Human tumour necrosis factor alpha-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys,08/10/2009,Treatment of acute lung Injury,EU/3/09/677,Positive,20/10/2009,20/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-677
,,Doxorubicin carbon;iron magnetically targeted microparticles,11/09/2002,Treatment of hepatocellular carcinoma,EU/3/02/112,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-112
,,Sodium dichloroacetate,02/09/2004,Treatment of systemic monochloroacetate poisoning,EU/3/04/225,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-225
,,Thalidomide,09/07/2001,Treatment of graft-versus-host disease,EU/3/01/046,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-046
,,"(Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate",10/03/2005,Treatment of malignant gastrointestinal stromal tumours,EU/3/05/267,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-267
,,"(Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate",10/03/2005,Treatment of renal-cell carcinoma,EU/3/05/268,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-268
,,"4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid",12/12/2003,Treatment of chronic iron overload requiring chelation therapy,EU/3/03/180,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-180
,,Thalidomide,19/12/2001,Treatment of multiple myeloma,EU/3/01/068,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-068
,,2'-O-methyl-phosphorothioate oligonucleotide,16/02/2006,Treatment of Duchenne muscular dystrophy,EU/3/06/357,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-357
,,Sabarubicin,21/12/2004,Treatment of small cell lung cancer,EU/3/04/255,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-255
,,"5,10-Methylene-tetrahydrofolic acid",02/09/2004,Treatment of pancreatic cancer in combination with 5-fluorouracil,EU/3/04/221,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-221
,,Thalidomide,09/07/2001,Treatment of multiple myeloma,EU/3/01/047,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-047
,,N-acetylsarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide,12/12/2003,Treatment of soft tissue sarcoma,EU/3/03/181,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-181
,,Tilarginine acetate,03/11/2005,Treatment of cardiogenic shock,EU/3/05/330,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-330
,,Sulfonated monophosphorylated mannose oligosaccharide,14/09/2007,Treatment of hepatocellular carcinoma,EU/3/07/482,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-482
,,5-10-Methylene-tetrahydrofolate,11/06/2003,Treatment pancreatic cancer in combination with 5-fluorouracil,EU/3/03/143,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-143
,,"2-(4-(Diethylamino) phenyl)-6-methyl-2H-benzo[d][1,2,3] triazol-5-amine",25/07/2006,Treatment of Duchenne muscular dystrophy,EU/3/06/385,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-385
,,acetylcysteine,26/01/2005,Treatment of idiopathic pulmonary fibrosis,EU/3/04/259,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-259
,,Lusupultide,10/07/2007,Treatment of aspiration pneumonitis requiring intubation and mechanical ventilation,EU/3/07/457,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-457
,,Engineered protein inhibitor of human neutrophil elastase,09/07/2003,Treatment of cystic fibrosis,EU/3/03/152,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-152
,,H-Tyrosine-Glycine-Phenylalanine-Glycine-Glycine-OH,20/10/2003,Treatment of chronic idiopathic myelofibrosis,EU/3/03/167,Withdrawn,15/10/2009,15/10/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-167
,,Myristolated-peptidyl-recombinant SCR1-3 of human complement receptor type I,30/07/2002,Prevention of post transplantation graft dysfunction,EU/3/02/108,Withdrawn,23/09/2009,23/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-108
,,Myristolated-peptidyl-recombinant human CD59,11/09/2002,Treatment of paroxysmal nocturnal haemoglobinuria,EU/3/02/114,Withdrawn,23/09/2009,23/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-114
,,Recombinant human C1-inhibitor,20/02/2007,Prevention of delayed graft function after solid organ transplantation,EU/3/07/435,Positive,23/09/2009,23/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-435
,,Purified inactivated Japanese encephalitis SA14-4-2 virus vaccine,24/01/2006,Prevention of Japanese encephalitis,EU/3/05/348,Withdrawn,23/09/2009,23/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-348
,,G17(9) gastrin-Diphtheria Toxoid Conjugate,24/01/2003,Treatment of pancreatic cancer,EU/3/02/129,Positive,21/09/2009,21/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-129
,,Gimatecan,01/12/2003,Treatment of glioma,EU/3/03/174,Positive,21/09/2009,21/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-174
,,G17(9) gastrin-Diphtheria Toxoid Conjugate,28/01/2003,Treatment of gastric cancer,EU/3/02/130,Positive,21/09/2009,21/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-130
,,Amiloride hydrochloride dihydrate,30/06/2003,Treatment of cystic fibrosis,EU/3/03/147,Withdrawn,17/09/2009,17/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-147
,,Alginate oligosaccharide (G-block) fragment,14/09/2007,Treatment of cystic fibrosis,EU/3/07/475,Positive,17/09/2009,17/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-475
,,ibritumomab tiuxetan,01/02/2002,Treatment of B-cell non-Hodgkin`s lymphoma,-,Negative,17/09/2009,17/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-b-cell-non-hodgkins-lymphoma
,,17-Allylamino-17-demethoxygeldanamycin,26/01/2005,Treatment of chronic myeloid leukaemia,EU/3/04/256,Withdrawn,17/09/2009,17/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-256
,,17-Allylamino-17-demethoxygeldanamycin,21/12/2004,Treatment of multiple myeloma,EU/3/04/247,Withdrawn,17/09/2009,17/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-247
,,ciclosporin,24/07/2009,Treatment of atopic keratoconjunctivitis,EU/3/09/651,Positive,11/09/2009,11/09/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-651
,,Type I native bovine skin collagen,09/02/2009,Treatment of systemic sclerosis,EU/3/08/607,Positive,29/06/2009,29/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-607
,,gadodiamide,03/12/2008,Treatment of glioma,EU/3/08/583,Positive,29/06/2009,29/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-583
,,mifepristone,27/02/2009,Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin,EU/3/09/614,Positive,29/06/2009,29/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-614
,,Sapacitabine,08/07/2008,Treatment of myelodysplastic syndromes,EU/3/08/557,Positive,29/06/2009,29/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-557-0
,,Human anti-intercellular adhesion molecule-1 monoclonal antibody,20/01/2009,Treatment of multiple myeloma,EU/3/08/600,Positive,15/06/2009,15/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-600
,,HLA-A2 restricted CD8 T-cell line expressing MART-1 T-cell receptor,21/06/2004,Treatment of MART-1 YES malignant melanoma in HLA-A2 YES patients,EU/3/04/202,Positive,15/06/2009,15/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-202
,,L-asparaginase encapsulated in erythrocytes,15/05/2009,Treatment of pancreatic cancer,EU/3/09/633,Positive,09/06/2009,09/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-633
,,"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDESNISFKEK",15/05/2009,Treatment of pancreatic cancer,EU/3/09/634,Positive,09/06/2009,09/06/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-634
,,Human cytomegalovirus immunoglobulin,31/10/2006,Prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection,EU/3/06/408,Positive,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-408
,,phenylephrine hydrochloride,20/11/2001,Treatment of ileal pouch anal anastomosis (IPAA) related faecal incontinence,EU/3/01/069,Positive,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-069
,,L-Lysine-N-Acetyl-L-Cysteinate,14/02/2001,Treatment of cystic fibrosis,EU/3/01/026,Positive,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-026
,,Lusupultide,17/01/2001,Treatment of acute respiratory distress syndrome (ARDS),EU/3/00/016,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-016
,,Thalidomide,29/12/2000,Treatment of erythema nodosum leprosum (ENL) or type II lepra reactions,EU/3/00/009,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-009
,,Recombinant human alpha-1 antitrypsin,30/05/2001,Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency,EU/3/01/041,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-041
,,"8-Cyclopentyl-1, 3-dipropylxanthine",29/03/2001,Treatment of cystic fibrosis,EU/3/01/030,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-030
,,Fluorouracil,18/10/2000,Treatment of glioblastoma,EU/3/00/004,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-004
,,Sapacitabine,10/07/2008,Treatment of acute myeloid leukaemia,EU/3/08/558,Positive,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-558
,,H-Val-Ile-Val-Lys-Leu-Ile-Pro-Ser-Thr-Ser-Ser-Ala-Val-Asp-Thr-Pro-Tyr-Leu-Asp-Ile-Thr-Tyr-His-Phe-Val-Ala-Gln-Arg-Leu-Pro-Leu-OH,28/08/2006,Treatment of myasthenia gravis,EU/3/06/398,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-398
,,Arsenic trioxide,17/01/2001,Treatment of acute promyelocytic leukaemia,EU/3/00/017,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-017
,,Retroviral gamma c cDNA containing vector,30/05/2001,Treatment of severe combined immunodeficiency (SCID)-Xl Disease,EU/3/01/038,Positive,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-038
,,Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate,11/12/2001,Prevention of Pseudomonas aeruginosa infections in patients with cystic fibrosis,EU/3/01/076,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-076
,,Ibuprofen,06/03/2001,Patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age,EU/3/01/027,Withdrawn,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-027
,,Sapacitabine,08/07/2008,Treatment of myelodysplastic syndromes,EU/3/08/557,Positive,15/05/2009,15/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-557
,,Guanabenz,29/04/2009,Treatment of traumatic spinal cord injury,EU/3/09/625,Positive,12/05/2009,12/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-625
,,Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex,29/04/2009,Treatment of glioma,EU/3/09/624,Positive,12/05/2009,12/05/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-624
,,Parathyroid hormone (1-34) transglutaminase fusion protein fibrin matrix complex,11/04/2006,Treatment of solitary bone cysts,EU/3/06/367,Positive,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-367
,,Topotecan hydrochloride,05/09/2008,Treatment of glioma,EU/3/08/562,Positive,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-562
,,Mecasermin rinfabate,20/06/2006,Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects,EU/3/06/378,Withdrawn,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-378
,,Autologous CD34+ cells transduced with retroviral vector containing the human gp91 (phox) gene,13/07/2006,Treatment of chronic granulomatous disease,EU/3/06/393,Withdrawn,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-393
,,Zosuquidar trihydrochloride,17/02/2006,Treatment of acute myeloid leukaemia,EU/3/06/355,Positive,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-355
,,Avian polyclonal IgY antibody,23/09/2008,Treatment of cystic fibrosis,EU/3/08/564,Positive,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-564
,,Opebacan,28/08/2006,Treatment of meningococcal disease,EU/3/06/402,Withdrawn,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-402
,,"Genetically modified allogenic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)",23/10/2006,Treatment of renal-cell carcinoma,EU/3/06/405,Positive,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-405
,,4-[123I] Iodo-L-phenylalanine,25/07/2006,Diagnosis of glioma,EU/3/06/386,Positive,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-386
,,Miltefosine,22/09/2008,Treatment of cutaneous T-cell lymphoma,EU/3/08/567,Positive,24/04/2009,24/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-567
,,Aviptadil,28/08/2006,Treatment of acute lung Injury,EU/3/06/395,Positive,02/04/2009,02/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-395
,,Recombinant human CXCL8 mutant,22/09/2008,Prevention of delayed graft function after solid organ transplantation,EU/3/08/570,Positive,02/04/2009,02/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-570
,,doxorubicin hydrochloride,27/10/2006,Treatment of soft tissue sarcoma,EU/3/06/410,Positive,02/04/2009,02/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-410
,,Mecasermin rinfabate,20/06/2006,Treatment of growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH,EU/3/06/377,Withdrawn,02/04/2009,02/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-377
Advexin; Advexin,EMEA/H/C/000919; EMEA/H/C/000919,Adenoviral vector containing human p53 gene,23/10/2006,Treatment of  Li Fraumeni Syndrome,EU/3/06/404,Positive,02/04/2009,02/04/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-404
,,apomorphine,05/12/2001,Treatment of off-periods in Parkinson's disease not responding  to other oral treatment,EU/3/01/072,Withdrawn,03/03/2009,03/03/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-072
,,Recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3,20/10/2004,Treatment of type B extreme insulin resistance syndrome,EU/3/04/235,Withdrawn,20/02/2009,20/02/2009,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-235
,,Human Staphylococcus aureus immunoglobulin,03/11/2005,Treatment of Staphylococcus aureus bacteraemia,EU/3/05/319,Positive,18/08/2008,18/08/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-319
,,"Recombinant fusion protein of circulary-permuted IL-4 and pseudomonas exotoxin A, [IL-4(38-37)-PE38KDEL]",03/06/2008,Treatment of glioma,EU/3/08/553,Positive,18/08/2008,18/08/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-553
,,Hepatitis C immunoglobulin,08/07/2005,Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients,EU/3/05/295,Positive,18/08/2008,18/08/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-295
,,Recombinant human hepatitis C monoclonal antibody against C4 region of E1,06/12/2007,Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients,EU/3/07/503,Positive,18/08/2008,18/08/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-503
Graspa; Graspa,EMEA/H/C/004736; EMEA/H/C/004055,L-asparaginase encapsulated in erythrocytes,27/10/2006,Treatment of acute lymphoblastic leukaemia,EU/3/06/409,Positive,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-409
,,Alfimeprase,28/10/2005,Treatment of acute peripheral arterial occlusion,EU/3/05/322,Withdrawn,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-322
,,N-adamantanyl-N'-Geranyl-ethylenediamine,14/09/2007,Treatment of tuberculosis,EU/3/07/479,Positive,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-479
,,Human Staphylococcus aureus immunoglobulin;human Staphylococcus epidermidis polyclonal immunoglobulin,14/12/2005,Late onset sepsis in premature infants of less or equal than 32 weeks of gestational age,EU/3/05/335,Withdrawn,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-335
,,Pyridoxalated hemoglobin polyoxyethylene,02/08/2007,Treatment of cardiogenic shock,EU/3/07/463,Positive,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-463
,,Terguride,29/11/2007,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/07/499,Positive,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-499
,,"4-Ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indol",14/11/2007,Treatment of chronic lymphocytic leukaemia,EU/3/07/487,Positive,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-487
Zafiride,EMEA/H/C/004455,NGR-human tumour necrosis factor,03/06/2008,Treatment of malignant mesothelioma,EU/3/08/549,Positive,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-549
,,Human monoclonal antibody against HLA-DR,28/02/2006,Treatment of multiple myeloma,EU/3/06/358,Withdrawn,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-358
,,Human monoclonal antibody against HLA-DR,16/06/2005,Treatment of Hodgkin's lymphoma,EU/3/05/291,Withdrawn,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-291
,,Chelidonii radix,04/12/2007,Treatment of pancreatic cancer,-,Negative,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-pancreatic-cancer
,,Human monoclonal antibody against HLA-DR,24/01/2006,Treatment of chronic lymphocytic leukaemia,EU/3/05/347,Withdrawn,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-347
,,Troxacitabine,26/08/2005,Treatment of acute myeloid leukaemia,EU/3/05/311,Withdrawn,29/07/2008,29/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-311
,,artesunate,20/02/2007,Treatment of malaria,EU/3/07/430,Positive,10/07/2008,10/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-430
,,Ammonium tetrathiomolybdate,01/04/2008,Treatment of Wilson's disease,EU/3/08/539,Positive,10/07/2008,10/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-539
Akantior,EMEA/H/C/005858,Polihexanide,14/11/2007,Treatment of acanthamoeba keratitis,EU/3/07/498,Positive,02/07/2008,02/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-498
,,R-salbutamol sulfate,14/09/2007,Treatment of cutaneus forms of lupus erythromatosus,EU/3/07/481,Positive,02/07/2008,02/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-481
,,3-methoxy-pregnenolone,04/12/2007,Treatment of spinal cord injury,EU/3/07/511,Positive,01/07/2008,01/07/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-511
,,ciclosporin,14/04/2004,Treatment of atopic keratoconjunctivitis,EU/3/04/196,Withdrawn,22/01/2008,22/01/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-196
,,"4-Amino-1-[5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-ß-D-arabinofuranosyl]-2(1H)-pyrimidinone",14/09/2007,Treatment of hepatocellular carcinoma,EU/3/07/477,Positive,22/01/2008,22/01/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-477
,,Aviptadil,14/09/2007,Treatment of sarcoidosis,EU/3/07/473,Positive,22/01/2008,22/01/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-473
,,Human plasminogen,03/08/2007,Treatment of ligneous conjunctivitis,EU/3/07/461,Positive,17/01/2008,17/01/2008,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-461
,,Cisplatin,08/06/2007,Treatment of pancreatic cancer,EU/3/07/451,Positive,04/12/2007,04/12/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-451
,,Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT),17/04/2007,Prevention of corneal graft rejection,EU/3/07/445,Positive,04/12/2007,04/12/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-445
,,Human transferrin conjugated to mutant diptheria toxin,19/03/2002,Treatment of glioma,EU/3/02/090,Withdrawn,04/12/2007,04/12/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-090
,,Recombinant modified vaccinia Ankara expressing human 5T4,26/01/2007,Treatment of renal-cell carcinoma,EU/3/06/429,Positive,04/12/2007,04/12/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-429
,,capsaicin,21/09/2006,Treatment of painful HIV-associated neuropathy,-,Negative,19/07/2007,19/07/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-painful-hiv-associated-neuropathy
,,Tramadol hydrochloride,21/09/2006,Treatment of painful HIV-associated neuropathy,-,Negative,19/07/2007,19/07/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-painful-hiv-associated-neuropathy-0
,,Talactoferrinum alfa,05/06/2007,Treatment of renal-cell carcinoma,EU/3/07/448,Positive,19/07/2007,19/07/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-448
,,Mecasermin,26/08/2005,Treatment of primary growth hormone insensitivity syndrome,EU/3/05/307,Positive,04/07/2007,04/07/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-307
,,Interferon gamma,27/05/2005,Treatment of idiopathic pulmonary fibrosis,EU/3/05/281,Withdrawn,30/05/2007,30/05/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-281
,,Oregovomab,30/07/2002,Treatment of ovarian cancer,EU/3/02/109,Positive,30/05/2007,30/05/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-109
,,decitabine,14/02/2003,Treatment of myelodysplastic syndromes,EU/3/03/135,Positive,30/05/2007,30/05/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-135
Retisert; Retisert,EMEA/H/C/000787; EMEA/H/C/000787,Fluocinolone acetonide,07/03/2005,Treatment of non-infectious uveitis affecting the posterior segment of the eye,EU/3/05/261,Positive,30/05/2007,30/05/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-261
,,"5,6,7,8-Tetrahydrobiopterin",02/10/2003,Treatment of hyperphenylalaninaemia,EU/3/03/163,Positive,23/02/2007,23/02/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-163
,,Nolatrexed,02/10/2003,Treatment of hepatocellular carcinoma,EU/3/03/165,Withdrawn,23/02/2007,23/02/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-165
,,Human engineered monoclonal antibody specific for transforming growth factor ß1,04/02/2002,Treatment of systemic sclerosis,EU/3/01/080,Withdrawn,23/02/2007,23/02/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-080
,,Bryostatin-1,30/04/2002,Treatment of oesophageal cancer,EU/3/02/099,Withdrawn,23/02/2007,23/02/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-099
,,"N-3[[4-(aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4—dichloro-3-[[2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulphonyl]-(2S)-2-pyrrolidinecarboxamide, di(methanesulfonate)",23/02/2007,Treatment of moderate and severe traumatic brain injury,EU/3/04/188,Positive,23/02/2007,23/02/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-188
,,Boswellia serrata,21/10/2002,Treatment of peritumoral oedema derived from brain tumours,EU/3/02/117,Withdrawn,23/02/2007,23/02/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-117
,,aldesleukin,30/06/2003,Treatment of renal-cell carcinoma,EU/3/03/146,Withdrawn,23/02/2007,23/02/2007,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-146
Elmisol,EMEA/H/C/004330,Levamisole (hydrochloride),28/10/2005,Treatment of nephrotic syndrome,EU/3/05/324,Positive,08/08/2006,08/08/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-324
,,Vandetanib,24/01/2006,Treatment of medullary thyroid carcinoma,EU/3/05/344,Withdrawn,08/08/2006,08/08/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-344
,,E. Coli heat-shock protein 70 with bovine retinal S-antigen,24/01/2006,Treatment of autoimmune uveitis,EU/3/05/346,Positive,08/08/2006,08/08/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-346
,,"1,2-Bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine",14/12/2005,Treatment of acute myeloid leukaemia,EU/3/05/332,Positive,09/02/2006,09/02/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-332
,,"Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)",21/12/2004,Treatment of myelodysplastic syndromes,EU/3/04/254,Withdrawn,06/01/2006,06/01/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-254
,,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole,21/12/2004,Treatment of malignant gastrointestinal stromal tumours,EU/3/04/251,Positive,06/01/2006,06/01/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-251
,,"Oligonucleotide phosphorothioate (TAAACGTTATAACGTTATGACGTCAT), sodium salt",28/10/2005,Treatment of glioma,EU/3/05/327,Positive,04/01/2006,04/01/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-327
,,Beraprost sodium,18/09/2001,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,EU/3/01/053,Withdrawn,04/01/2006,04/01/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-053
Oncophage,EMEA/H/C/001072,Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex,11/04/2005,Treatment of renal-cell carcinoma,EU/3/05/270,Positive,04/01/2006,04/01/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-270
,,Biotinylated anti-tenascin monoclonal antibody,20/10/2004,Treatment of glioma,EU/3/04/232,Positive,04/01/2006,04/01/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-232
Ethyl Eicosapent soft gelatin capsules; Ethyl Eicosapent soft gelatin capsules,EMEA/H/C/001148; EMEA/H/C/001148,Ethyl Eicosapentaenoate,29/12/2000,Treatment of Huntington’s disease,EU/3/00/013,Positive,04/01/2006,04/01/2006,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-013
,,Midazolam Hydrochloride,01/03/2004,Treatment of status epilepticus,-,Negative,12/12/2005,12/12/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-status-epilepticus
,,Humanised antibody fragment (EP-CAM)-truncated Pseudomonas exotoxin A fusion protein,20/06/2005,Treatment of  Ep-CAM-YES squamous cell carcinoma of the head and neck,EU/3/05/290,Positive,12/12/2005,12/12/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-290
,,Eflornithine hydrochloride,19/02/2002,Treatment of familial adenomatous polyposis (FAP),EU/3/02/087,Withdrawn,29/11/2005,29/11/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-087
,,GM-CSF receptor antagonist,18/03/2002,Treatment of juvenile myelomonocytic leukaemia,EU/3/02/089,Withdrawn,29/11/2005,29/11/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-089
,,Mitotane,11/09/2002,Treatment of adrenal cortical carcinoma,EU/3/02/113,Withdrawn,29/11/2005,29/11/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-113
,,"Carbamic acid (common)/[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester (amelubant)",26/06/2002,Treatment of cystic fibrosis,EU/3/02/105,Withdrawn,29/11/2005,29/11/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-105
,,Deuterium oxide,20/10/2004,Treatment of pancreatic cancer,EU/3/04/239,Withdrawn,29/11/2005,29/11/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-239
,,"4-Imino-1, 3-diazobicyclo-[3.1.0]-hexan-2-one",27/07/2005,Treatment of pancreatic cancer,EU/3/05/299,Positive,29/11/2005,29/11/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-299
,,Nemorubicin hydrochloride,27/07/2005,Treatment of hepatocellular carcinoma,EU/3/05/300,Positive,27/10/2005,27/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-300
,,Sudismase,16/06/2005,Treatment of active phase of Peyronie's disease,-,Negative,27/10/2005,27/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-active-phase-peyronie039s-disease
Masipro,EMEA/H/C/004159,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole,16/11/2004,Treatment of mastocytosis,EU/3/04/242,Positive,27/10/2005,27/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-242
,,"Extract of Sorghum bicolour leaf, Pterocarpus osun stem, Piper guineense seed and Caryophylli flower",26/08/2005,Treatment of sickle cell disease,EU/3/05/302,Positive,27/10/2005,27/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-302
,,idebenone,20/11/2001,Treatment of Friedreich's ataxia,EU/3/01/062,Positive,11/10/2005,,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-062
,,Ibuprofen L-Lysinate (salt),24/06/2005,Treatment of patent ductus arteriosus in premature neonates of less than 34 week gestational age,-,Negative,11/10/2005,11/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-patent-ductus-arteriosus-premature-neonates-less-34-week-gestational-age
,,Adeno-associated viral vector containing a modified U7 snRNA gene,27/07/2005,Treatment of Duchenne muscular dystrophy,EU/3/05/297,Positive,11/10/2005,11/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-297
,,Ibuprofen L-Lysinate (salt),07/07/2005,Prevention of patent ductus arteriosus in premature neonates of less than 34 week of gestational age,-,Negative,11/10/2005,11/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-prevention-patent-ductus-arteriosus-premature-neonates-less-34-week-gestational-age
,,Aplidine,16/11/2004,Treatment of multiple myeloma,EU/3/04/245,Positive,11/10/2005,11/10/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-245
,,Pegylated arginine deiminase,20/06/2005,Treatment of hepatocellular carcinoma,EU/3/05/289,Positive,26/07/2005,26/07/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-289
,,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole,20/06/2005,Treatment of multiple myeloma,EU/3/05/286,Positive,26/07/2005,26/07/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-286
,,Humanised agonistic anti-CD28 monoclonal antibody,11/04/2005,Treatment of B-cell chronic lymphocytic leukaemia,EU/3/05/276,Positive,01/07/2005,01/07/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-276
,,Bimosiamose disodium,27/05/2005,Treatment of acute lung Injury,EU/3/05/285,Positive,29/06/2005,29/06/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-285
,,Sodium butyrate,27/05/2005,Prevention of radiation proctitis,EU/3/05/284,Positive,29/06/2005,29/06/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-284
,,Porcine lung surfactant,19/09/2001,Treatment of acute lung Injury,EU/3/01/057,Withdrawn,01/06/2005,01/06/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-057
,,Humanised anti-HM1.24 monoclonal antibody,10/05/2001,Treatment of multiple myeloma,EU/3/01/037,Withdrawn,28/04/2005,28/04/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-037
,,Histamine dihydrochloride,24/08/2004,Treatment of malignant melanoma,-,Negative,16/03/2005,16/03/2005,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-malignant-melanoma
,,acetylsalicylic acid,29/07/2004,Treatment of polycythaemia vera,EU/3/04/208,Positive,06/12/2004,06/12/2004,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-208
,,Seocalcitol,31/07/2001,Treatment of hepatocellular carcinoma,EU/3/01/052,Withdrawn,08/11/2004,08/11/2004,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-052
,,Human Milk Fat Globule 1;Yttrium (90Y) human Milk Fat Globule 1 - S p isothiocyanatobenzyl-diethylenetriaminepentaacetic acid,30/05/2001,Treatment of ovarian cancer,EU/3/01/043,Withdrawn,02/06/2004,02/06/2004,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-043
,,Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT),02/10/2003,Treatment of retinopathy of prematurity,EU/3/03/160,Positive,26/04/2004,26/04/2004,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-160
,,Alpha-1-acid glycoprotein,08/10/2009,Treatment of cocaine poisoning,EU/3/03/164,Withdrawn,26/04/2004,26/04/2004,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-164
,,Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT),02/10/2003,Treatment of neovascular glaucoma,EU/3/03/161,Positive,26/04/2004,26/04/2004,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-161
,,Prasterone,28/07/2003,Treatment of adrenal insufficiency,EU/3/03/156,Positive,07/11/2003,07/11/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-156
,,Recombinant dog gastric lipase,09/07/2003,Treatment of cystic fibrosis,EU/3/03/157,Positive,29/10/2003,29/10/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-157
,,Anti-CD 147 murine monoclonal IgM,14/11/2002,Treatment of steroid resistant graft versus host disease (GvHD),EU/3/02/123,Withdrawn,07/07/2003,07/07/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-123
Orathecin,EMEA/H/C/000608,Rubitecan,10/06/2003,Treatment of pancreatic cancer,EU/3/03/145,Positive,23/06/2003,23/06/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-145
,,Miltefosine,12/06/2002,Treatment of visceral leishmaniasis,EU/3/02/104,Positive,11/06/2003,11/06/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-104
,,Humanized anti-KSA monoclonal antibody - human interleukin-2-fusion protein,22/03/2002,Treatment of renal-cell carcinoma,EU/3/02/097,Withdrawn,23/05/2003,23/05/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-097
,,Mycobacterial cell wall complex,18/12/2002,Treatment of carcinoma in situ of the urinary bladder,-,Negative,14/01/2003,14/01/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-carcinoma-situ-urinary-bladder
,,Thymalfasin,30/07/2002,Treatment of hepatocellular carcinoma,EU/3/02/110,Positive,08/01/2003,08/01/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-110
,,chlorproguanil hydrochloride;dapsone,26/07/2002,Treatment of acute uncomplicated plasmodium falciparum malaria,-,Negative,08/01/2003,08/01/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-acute-uncomplicated-plasmodium-falciparum-malaria
,,Autologous Renal Cell Tumour Vaccine,21/10/2002,Treatment of renal-cell carcinoma,EU/3/02/116,Positive,08/01/2003,08/01/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-116
Prohippur,EMEA/H/C/004150,"Benzoic acid, sodium salt",11/09/2002,Treatment of non-ketotic hyperglycinaemia,EU/3/02/111,Positive,08/01/2003,08/01/2003,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-111
,,Recombinant glycoprotein gp350 of Epstein-Barr Virus,22/10/2002,Prevention of post-transplantation lympho-proliferative disorders,EU/3/02/118,Positive,17/12/2002,17/12/2002,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-118
